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Abstract
Many theories have been advanced to explain the development of venous ulceration in 
the lower limb. In recent years, the hypothesis of inappropriate leucocyte activation with 
the release of free radicals causing damage to the microcirculation in patients with CVD 
has gained popularity. No drug has so far been found to ameliorate these effects.
In this thesis I have investigated a series of inflammatory markers in patients with 
various CEAP stages of venous disease. The aim was to asses which, if any, 
inflammatory markers were associated with worsening stages of venous disease. I also 
used a flavonoid drug, Daflon®, in a randomised, controlled clinical trial and assessed 
the efficacy of treatment using the markers of systemic inflammation studied.
Neutrophil and monocyte activation were investigated by measuring CD lib  and 
CD62L by flow cytometry. Soluble CD62L and endothelial adhesion molecules 
(VCAM-1, ICAM-1, E-selectin & P-selectin) and vWf were measured by commercially 
available ELIS As. The cytokines (IL-la, IL-lp, IL-6 & TNF-a) and VEGF by ELISA 
and total NO using the Griess reaction were also measured. Patients’ symptoms were 
assessed by using a visual analogue scale, and the correlation of these with 
inflammatory markers was also investigated. Capillary morphology was studied using a 
capillary videomicroscope and changes were graded and correlated with the severity 
and CEAP stages of CVD.
In my study, I found evidence of a modest relationship between CEAP clinical stage 
and plasma level of VCAM-1 and neutrophil CD llb as well as monocyte CD62L data 
using multi-variate logistic regression. There was elevation of VEGF and total NO in 
patients with skin changes, although multi-variate analysis failed to show the 
significance of plasma nitrate. Capillary morphology changes were seen in the form of 
convolutions in advanced stages of venous disease. These have been classified in four 
grades. Daflon failed to down regulate plasma levels of these markers and to improve 
the symptoms.
This study demonstrates a low-grade inflammatory response to venous disease but give 
no definite clue as to the role of leucocyte in the pathogenesis of venous disease. The 
capillary morphology changes I have observed suggest that angiogenesis is upregulated 
in skin affected by chronic venous disease. This may be attributable to increased VEGF 
expression.
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Chapter 1: Introduction 
Background
Chronic Venous Disease (CVD) of lower limb is a functional defect of venous return 
due to reflux1, obstruction or both, in which walking fails to lower ambulatory venous 
pressure 2 in the distal leg veins. This ambulatory venous hypertension leads to 
oedema, tissue alterations and microangiopathy, producing typical skin changes, 
lipodermatosclerosis, white atrophy, and finally venous ulceration, even though the 
precise sequence of events remains unexplained3’4.
Diseased or functionally incompetent valves no longer offer protection against the high 
hydrostatic pressure of lower limb veins; therefore, the small veins, venules and 
capillaries are exposed to the venous hypertension. However, well before CVD reaches 
this stage, the high venous pressure is being continuously transmitted to capillary 
network, so that the crucial factor in the pathogenesis of this disease is the 
microcirculation. Identifying and documenting this microvascular changes, therefore, 
have vital importance in the management of Chronic Venous Disease.
Raised venous pressure initiates leucocyte activation, followed by margination and 
interaction of these cells within the microvascular endothelium and extra-vascular 
migration, resulting in the preferential accumulation of neutrophils in the tissue. 
Shedding of adhesion molecules (detectable in plasma) is indicative of enhanced 
leucocytes/endothelium interaction, with the release of proteolytic enzymes and free 
radicals resulting in tissue damage 5’6. An increased level of plasma endothelial growth 
factor (VEGF) has also been reported in a limited number of patients with chronic 
venous disease 7’ 8. Activated leucocytes may be releasing toxic metabolites and free 
radicals including VEGF and total NO, ultimately overcoming the natural scavenging 
mechanisms leading to tissue damage. Neutrophils taken from the legs of patients with 
lipodermatosclerosis (LDS) or ulceration produced significantly greater amounts of 
reactive oxygen species when activated ex-vivo with the bacterial chemo-attractant 
peptide FMLP 9.
In previous studies, leucocyte-endothelial activation and adhesion was investigated and 
significant rise was found with experimental venous hypertension 10, n ’ 12, 13. These
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studies have been criticised for not having age and sex matched large number of patients 
and controls, especially where many of the markers investigated had very low 
magnitude of rise in the plasma. Furthermore, those studies did not include all groups of 
patients in CEAP clinical stage and no attempt was made to investigate the role of the 
free radical production in Chronic Venous disease.
The importance of identifying the precise mechanism of leucocyte-endothelial 
activation, role of cytokines and VEGF-nitric oxide and capillary proliferation and 
morphological changes lies in the fact that various drugs and antibodies to the adhesion 
molecules can be used to counteract those influencing factors. A drug of flavonoid 
group Daflon® has been shown to down regulate ICAM-1, VC AM, VEGF and CD62L 
expression by neutrophils and monocytes in a pilot study of 20 patients 14,15,16. This is 
widely used by patients with venous disease for symptomatic relief. Animal studies 
demonstrated down-regulation of some inflammatory markers 17, 18, 19. However, if 
more is known about the subcellular events leading to skin changes and ulceration, it 
may be possible to produce drugs that are able to block specific steps and hence prevent 
the effects of venous hypertension. This may especially be useful for patients with deep 
vein incompetence where surgical correction remains a difficult problem, and 
compression treatments are difficult to tolerate by many patients.
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A brief historical review
The problems of the treatment of lower limb venous disease have been recognised since 
ancient times. The Ebers Papyrus, named after the German professor George Ebers 
(1837-1898), described possibly the first 'venous' publication from around 1550BC. 
Between 460-377BC, Hippocrates in his work, De ulceribus, documented a connection 
between leg ulcers and varicose veins and that the leg ulcers contained blood and 'evil 
humours'. Avicenna (Ibne Sina) in AD 900 still supported the Hippocratic view that 
ulcers should not be allowed to heal because they were sites from which 'evil humours' 
could escape. The famous anatomist Vesalius (1514-1564 AD) described the venous 
system in great detail but could not find the valves alluded to by Canano in AD 1546. 
However, in 1551, Amatus stated that veins contained valves. This was possibly the 
first description of a venous valve. In 1585, Salmon Alberti published the first recorded 
drawing of a valve in a vein. He noticed that they stopped retrograde flow but thought 
that they participated in the control of the ebb and flow of blood described earlier by 
Galen (AD130-200).
In 1628, the greatest physiological revolution in the history of medicine, which 
provided the foundation of our present understanding of the circulation, was published 
by William Harvey in the book Exercitatio anatomica de motu cordis et sanguini’s in 
animalibus. Biohistorians agree that the landmark work done previously by Fabricius on 
venous valves led directly to William Harvey’s discovery of the circulation. Harvey 
demonstrated that the blood circulated and made the fundamental observation that the 
valves in the veins were there to ensure unidirectional flow of blood.
In the last three decades, there have been a large number of publications on the 
treatment of venous disease and the improving of surgical techniques, surgical 
instruments, compression treatment techniques and materials. Fibrin cuff theory 
(Browse and Bumand, 1982) and more recently, the white cell trapping theory 
(Coleridge Smith et al, 1988) have been suggested as the causes of venous ulcers.
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Epidemiology
The first major study into the epidemiology of varicose veins was the US National 
Health Survey of 1935-6, which estimated that varicose veins were present in 1.75 
million of the total population of the United States. A similar study in the UK21 based 
on interviews gave a prevalence of 2.25% for varicose veins (1.41% men, 3.74% 
women). However, these surveys have been criticised on the basis of lack of statistically 
acceptable evidence.22
To determine the prevalence of CVD in the general population, recently a cross 
sectional survey23 was conducted in the city of Edinburgh among men and women aged 
18-64 years selected randomly. In 1566 subjects examined, the age-adjusted prevalence 
of trunk varices was 40% in men and 32% in women (p < or = 0.01). This sex 
difference was mostly a result of higher prevalence of mild trunk varices in men. More 
than 80% of all subjects had mild hyphen-web and reticular varices. The age adjusted 
prevalence of CVD was 9% in men and 7% in women (p < or = 0.05). The prevalence 
of all categories of varices and of CVD increased with age (p < or = 0.001). No relation 
was found with social class. In contrast with the findings in most previous studies, 
mainly conducted in the 1960s and 1970s, chronic venous insufficiency and mild 
varicose veins were more common in men than women. No evidence of bias in the 
study was found to account for this sex difference.
In another very recent cross-sectional study24 in southern California among 2408
subjects, telangiectases were present in 83% of women and 51% of men. Rates
increased with age and were highest in Caucasians and lowest in blacks. Corresponding 
rates for varicose veins were 33% and 17% with no ethnic differences. Superficial 
functional disease was found in 26% of women and 15% of men, without ethnic 
variation. Deep disease was present in 11% without gender or ethnic effects.
The clinical sequelae (oedema, liposclerotic skin changes and ulceration) of lower limb 
CVD occur in between 3% 25 and 11% of the population 26. It has also been estimated 
that the annual development of new symptoms is approximately 1% for oedema and 
0.8% for skin changes 21. The annual incidence of varicose veins in the female
population averaged at 2.6% and 1.9% in males28.
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Women were significantly more likely than men to report lower limb symptoms such as 
heaviness or tension, swelling, aching, restless legs, cramps, and itching. The prevalence 
of symptoms tended to increase with age in both sexes. In men, only itching was 
significantly related to the presence and severity of trunk varices (linear test for trend, 
P=0.011). In women, there was a significant relation between trunk varices and the 
symptoms of heaviness or tension (P=0.001), aching (P=0.001), and itching (P=0.005)
29
In the western world about 0.3% of the adult population have active venous ulcers, with 
1% of the population suffering from ulceration at some time in their lives 30, 31, 32, 25 
and the prevalence of active and healed ulcers combined is about 1% 32. The point 
prevalence estimates of ulcers present in the community vary from 1.5% in Ireland,33 to 
0.11% in Australia 34,35, to 0.15% in Scotland 36, 0.18% in England 31 and 0.30% in 
Sweden 32. In Scotland, it was estimated that the overall prevalence of lower limb 
ulceration was 3.6% among people older than 65 years 37. The Tecumseh community 
health study, a longitudinal study of a population in Michigan, has extrapolated and 
estimated that in the USA, 24 million people have significant varicose veins (prevalence 
12.9%), while 6 to 7 million people have stasis changes leg skin (prevalence 3%) and 
nearly half a million people have or have had a varicose ulcer (prevalence 0.1%)25. The 
Basel ID study 38 found a prevalence of 4.2% for severe varicose veins and 1% for 
active and healed ulcers in a highly selected population of industrial workers.
Leg ulcers can have a variety of causes with the majority being as a result of chronic 
venous disease. In a cross-sectional population study in a health district in England, a 
random sample of 100 patients (193 limbs) with leg ulcers were examined with 
ultrasound and photoplethysmography to assess the venous and arterial circulation. It 
was found that 38% had deep venous incompetence, 43% had superficial venous 
incompetence, 22% was of mixed venous and arterial aetiology and 9% was of arterial 
aetiology alone 31. Leg ulcers with liposclerotic skin changes were most commonly 
found in the gaiter area of the limb. One study showed that 88% of ulcers were located 
in the gaiter area of which 76% were on the medial side30. It has also been reported that 
patients of low social class have delayed ulcer healing 39. In general, the prognosis of 
leg ulcers is poor with only 50% healing at 4 months mentioned in a comment40, 20% 
remain open at 2 years and 8% at five years 41.
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Economic cost
The effects of lower limb chronic venous disease can also have a huge impact on the 
national economy of the country. In one study, 12.5% of patients with ulcers took early 
retirement 42and it was estimated that in England and Wales, about 500,000 working 
days are lost per year.43 In the USA, the figure is 2 million working days 43. In Brazil, 
the fourteenth most frequently quoted disease for absenteeism from work and the thirty- 
second most frequent cause of permanent disability and financial aid is lower limb 
chronic venous disease 44.
In France, the total annual cost of venous insufficiency to the health service in 1991 was 
estimated to be 14.7 billion French francs 45, representing 2.6% of the whole health 
expenditure. In the United Kingdom, it is estimated that the annual cost of venous ulcers 
is between 400-600 million pounds sterling 30, 46 and in the United States of America, 
the figure is over 1 billion dollars 47. Much of this is spent on care in the community, 
with 30% of community nursing time spent on treating leg ulcers 48. It is, therefore, 
clear that even a small improvement in healing and recurrence rates would produce 
substantial savings 49. Surgical treatment of CVD represents a substantial workload for 
the NHS, accounting for an estimated 50,000 operations each year in England and 
Wales.50
20
Review of literature
The microcirculation of skin
The term microcirculation denotes the terminal part of the circulation concerned with 
the transfer of nutrients from blood to the tissues and comprises of terminal arterioles, 
metarterioles, capillaries and post-capillary venules. The skin is an anatomically and 
physiologically specialized boundary lamina, which is of major importance in the life of 
the individual. Besides its obvious protective mechanical role, it serves many other 
important functions 51, including providing an extensive sensory surface for the 
appreciation of general sensory stimuli. It is capable of limited absorption and excretion 
and helps to conserve the moisture of underlying tissues. The blood supply to the skin is 
thus crucial not only in the provision of oxygen and nutrients but also in the central role 
it plays in the many functions of skin.
Figure 1.1: Blood supply o f  skin showing various layers o f  skin and arrangement o f  blood vessels. Blue 
is the venous network, where purplish red is arterial network. (Reproducedfrom Dormandy JD The 
dangerous red  cell. In. Eds Dormandy JD, Chien S, Progress in Clinical Haemorheology, Hoechst, 
Frankfurt, 1983. p p  29-87.)
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The structure of skin
The skin consists of a superficial layer of stratified squamous epithelium, the epidermis, 
laid on a foundation of firm connective tissue, the dermis. These two layers are of 
distinctive structure, properties and embryological origins. The interface between the 
epidermis and dermis shows a complex topology, being marked by ridge/groove 
interdigitations between the two.
The epidermis
In a typical part of the epidermis, there can be recognised a number of different strata in 
which the cells have distinctive anatomical features. Active mitotic proliferation takes 
place in the deeper layers (the stratum germinatum), the development of new cells 
leading to a gradual displacement of the older cells towards the surface. Such 
proliferative activity is intermittent and varies from one area of the skin to another at 
any particular time.
The epidermis is avascular and between the cells of the stratum germination, there are 
fine intercellular channels, which probably allow the transmission of nutrient fluids 
derived from the small blood vessels and capillaries in the subjacent dermis.
The dermis
The dermis consists of a dense felt work of connective tissue in which bundles of 
collagenous fibres predominate, mingled with a certain proportion of elastic tissue in 
superficial levels. The dermis becomes looser in texture in deeper planes and the 
transition to the subcutaneous connective tissue may be practically imperceptible. It 
contains fine plexuses of blood vessels, lymphatics and nerves, hair follicles, sweat 
glands and sebaceous glands.
Dermal papillae. The boundary between the epidermis and dermis is not evenly 
horizontal, as the latter projects up at regular intervals in the form of small vascular 
papillae. These papillae provide for a considerable extension of the area of contact 
between the vascular dermis and the avascular epidermis, so facilitating the diffusion of 
nutritive fluids from one to the other.
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Skin blood supply
The measurement of blood flow through the skin is fraught with difficulties, both 
practical and theoretical. The general conclusion to be drawn from quantitative data is 
that from the point of view of metabolic need, skin is vastly 'over-perfused' with blood; 
from available figures on the oxygen consumption of skin it has been estimated that 0.8 
ml of blood/minute/ 100ml of skin tissue would be adequate to meet its oxygen 
requirements. Yet the minimum value of blood flow measured in fingers during strong 
vasoconstriction by exposure to cold is of this order of magnitude, i.e. from 0.5 to 1.0 
ml/min/100 ml tissues 52. Even when such vasoconstriction is maintained (as in climatic 
experiments), the tissue does not necessarily become necrotic although it can become 
damaged when re-warmed. The minimum flow found in normal circumstances is thus 
more than adequate for the demands of the skin itself; the necrosis that accompanies 
peripheral vascular disease must therefore represent practically total cessation of blood 
flow due either to occlusion or complete spasm of the controlling arterioles52.
The cutaneous mean and maximum flow rates are considerably higher than the 
minimum physiological values. In the skin of the digits, the mean flow expressed for 
100 ml of tissue is 20 to 30 times greater than the minimum and the maximum flow 
during vasodilatation can be more than 100 times the minimum value. For skin 
elsewhere the mean is also many times the necessary minimum. These differences re­
emphasize the fact that cutaneous blood flow serves the entire organism and is not 
governed solely by the metabolic requirements of the skin. Such reserve of blood supply 
becomes crucial, however, when blood flow must increase in response to injury or 
repair. Blood flow to the skin can be easily made to rise to 100 times the normal level 
when the skin is scratched. The vasodilatation or triple response of Lewis serves as an 
immediate response to injury but many wounds of the skin require something more 
permanent and this is mostly provided by angiogenesis and especially by granulation 
tissue53. Ryan has also suggested that another important function of blood supply to the 
skin is the maintenance of oncotic and hydrostatic forces in a partnership with 
lymphatic drainage 54, 55. It is this that maintains the mechanical properties of the skin, 
which is an essential part of its function.
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Venule 
(m uscular)
Figure 1.2: Basic structural pattern o f the terminal cutaneous vessels. (Reproduced from  William 
Montagna & P.F. Parakkal. The structure & function o f  Skin, 3rd edition, Academic Press, London 1974. 
Page 149.)
Capillary circulation
Capillaries have been defined as those vessels in which the exchange of substances 
between blood and tissue occurs. However, other parts of the microcirculation also 
participate in nutritional exchange. Fluid and protein is exchanged in post-capillary 
venules and oxygen exchange is found to an appreciable extent in pre-capillary vessels 
56,57. Similarly, the importance of the 'arterioles' as the prime regulators of resistance to 
flow has lost momentum since the significant contributions of larger vessels have 
become recognised. Finally, even the definition of 'venules' as capacitance vessels 
cannot very well be maintained in view of their substantial participation in blood-tissue 
exchange as well as in the regulation of overall flow resistance.
c o
There is considerable individual and regional variation in capillary morphology . For 
example, arterio-venous anastomoses are numerous in the skin of the soles of feet and 
fingertips but absent in the skin of the rest of the lower limb.
Rhodin, through his study of the microcirculation overlying the thigh muscles in the 
rabbit, categorised vessels on the basis of luminal diameters, types of cells composing 
the vessel wall, and position of the vessel in relation to other segments of the vascular 
bed, into arterioles, terminal arterioles, pre-capillary sphincters, arterial and venous 
capillaries, post-capillary venules and larger collecting venules 59, 60. The blood supply 
of the human dermis, in which the arterioles and venules form two important plexuses, 
has been described 61 as an upper horizontal network in the papillary dermis from which
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the capillary loops of the dermal papillae arise and a lower horizontal plexus at the 
dermal-subcutaneous interface, formed by perforating vessels from the underlying 
muscles and subcutaneous fat. From this plexus, arterioles and venules form direct 
connections with the upper horizontal plexus as well as providing lateral tributaries that 
supply the hair bulbs and sweat glands. These two horizontal plexuses are the 
physiologically important zones in the skin and the bulk of the microcirculation resides 
in the papillary dermis.
Above the sub-papillary plexus are the terminal capillaries. These are vertical loops in 
the shape of a hairpin, which arise from the arterioles and the supply the papillae. They 
drain into the horizontal sub-papillary venous plexus, and a typical papilla contains only 
one such vessel. It is a pure capillary with no muscle and a continuous basement 
membrane, although the degree to which capillary endothelium forms a constant 
continuous lining to a vessel is still undecided. The venules in the upper and middle 
dermis are more numerous then the arterioles. They are also for the most part more 
horizontally disposed and as they originate at the first smooth muscle cell, their origin 
must be said to be most variable. The diameter of the venules ranges from 40 to 60 
picometer (pm) in the upper and mid-dermis to 100-400 pm in the deeper tissues.
The capillary loop
As already seen the capillary loop arises from terminal arterioles in the horizontal 
papillary plexus 62. It is composed of an ascending limb, an intra-papillary loop having a 
hairpin turn, and a descending limb that connects with a post-capillary venule in the 
horizontal plexus. The length of the papillary loop varies from 0.1 to 0.4 mm in 
different parts of the body63.
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Figure 1.3: Diagram showing the patternless cutaneous vascular system, the branching o f  the segmental 
arterioles into the perforator arterioles, and the latter, in turn, branching into muscular and cutaneous 
arterioles. Thus, it forms the capillary loop supplying the skin. (Reproduced from  William Montagna & 
P.F. Parakkal. The structure & function o f  Skin, 3rd edition, Academic Press, London 1974. Page 145)
Krogh 63described that the capillary loops are perpendicular to the surface of the skin 
except for those in the nail fold, where they lie parallel to the surface, each dermal 
papilla being supplied by a single capillary loop. There is an intra-papillary and an 
extra-papillary portion of the capillary loop, an imaginary line drawn between the 
deepest points of adjacent rete ridges defining these two zones. The ascending limb of 
the loop arises from the horizontal plexus and passes either directly to a papilla or 
subdivides once, twice or three times before giving rise to the final ascending limb that 
enters an individual papilla. The ascending limb of the capillary loop in its extra- 
papillary portion has the characteristics of an arterial capillary: the basement membrane 
material in its wall is homogeneous in appearance; the outside diameter of the vessel 
varies from 8 to 12 pm and the endothelial tube diameter ranges from 5 to 7.5 pm. In its 
intra-papillary portion, the outside diameter of the loop narrows to 7.5 to 10 pm and its 
endothelial tube width ranges from 3.5 to 6 pm. The endothelial tube of the crest of the 
intra-papillary descending limb is 1 to 1.5 pm wider than that of the ascending limb. 
The basement membrane material in the wall of the loop retains its homogeneous 
appearance throughout its intra-papillary course.
One capillary loop supplies approximately 0.04-0.27 mm2 of skin surface, and the 
average distance between one capillary loop and another is 50-100 pm. However, there 
are great regional differences not only in the dimensions of capillary loops, but also in 
the morphological details of the latter. For example, in the dermis of the palms and 
soles, the papillary ridges contain long and relatively straight capillary loops. Those on 
the trunk are more shallow and broader, and have more meandering, less continuously 
identifiable loops.
Capillary loop morphometry in the gaiter region of ankle and foot
The percentages of different forms of capillary loop (as seen in parallel) are as follows: 
in the vast majority of cases (88-90%) the capillary loop was in the form of a hairpin, 
consisting of parallel arteriolar and venular limbs, connected by a hairpin turn. In 2 - 3 
% of cases, the capillary loops were broader, the limbs being much further apart, and in 
another 2 to 3 %; the limbs were 'intertwined' forming a complex appearing loop. The 
remaining capillary loops had very inconstant shapes making it difficult to categorise 
them into any particular group.64
Capillary dimensions were studied by analysing those capillary loops lying in a plane 
parallel to the plane of microscopy. This allows accurate determination of the length 
capillary loop, diameters of the arterial and venous limbs, the distance and also the 
various proportions of different capillary shapes.
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Lower limb venous pathophysiology
Varicose veins are dilated, tortuous and elongated superficial veins, defined by the 
World Health Organisation as “saccular dilatations of the veins which are often 
tortuous”.65 Functionally they are veins in which the valves are incompetent. However, 
deep veins may become dilated and incompetent, but do not become varicose. Varicose 
veins may be primary or secondary to deep venous thrombosis, arterio-venous fistulae 
or any proximal obstruction, such as a pelvic tumour, that dilates the veins by 
backpressure.
The pathophysiology of chronic venous disease is influenced by changes in the 
cutaneous microcirculatory physiology as well as macrocirculatory changes. These 
changes play an important role in the venous ulcerative process with the skin and 
subcutaneous tissues in the distal third of the lower limb, mainly in the gaiter area, 
acting as the final target organs of chronic venous insufficiency. The hydrostatic and 
ambulatory venous pressures are highest in this area as a direct result of venous 
hypertension due to valvular reflux, with the high venous pressures being transmitted 
from the macrocirculation to the microcirculation, which may ultimately result in 
oedema, skin changes and venous ulceration.
Valvular reflux
This is the return of blood flow in the opposite direction from physiological flow, which 
is centripetal. This reflux may be natural, physiological or pathological. The duration of 
the reflux flow depends on the physiological or pathological state of the valvular 
apparatus. Duplex scanning of patients in the upright position in combination with 
proximal deflation of a venous-occluding blood pressure cuff to augment flow in the 
veins is the best documented non-invasive method of quantifying reflux by measuring 
reflux duration in specific axial superficial or deep venous segments 66.
Oedema
Most of the fluid that enters the tissue space by ultrafiltration from the arterial end of 
the capillary bed is absorbed back into the circulation at the venous end of that network. 
Ernest Starling, in 1896, described interstitial fluid formation and absorption in terms of 
the pressure gradients acting across the capillary endothelium, the surface area available
28
for fluid transfer and the permeability of the capillary membrane to protein. The direct 
and immediate causes of oedema are alterations in the Starling forces that lead to an 
increase in the capillary-absorption ratio and a decrease in lymphatic drainage. Any 
procedure that will facilitate venous return such as muscle activity or compression 
stockings will alleviate the condition.
Oedema in venous disease
Patients with chronic venous insufficiency often suffer from oedema of the lower limb, 
which may result from one or more of four factors: increased capillary filtration as a 
result of high intracapillary pressure due to increased venous pressure; increased 
capillary permeability to proteins due to endothelial damage; loss of the veno-arteriolar 
reflex and failure to clear interstitial fluid and proteins due to lymphangiopathy. 
Chronic venous insufficiency leads to increased capillary pressure, due to the loss of 
drop in venous pressure seen normally on exercise, resulting in the development of 
oedema. This phenomenon is thought to be important in the development of ulcers 67,68, 
69 as oedema may interfere with the normal transfer of nutrients to the tissues70 causing 
tissue ischaemia by collapse of the capillaries due to the high interstitial pressure.71 
Authors seem divided as to whether elimination of oedema 72,73 improves ulcer healing. 
Lymphatic obstruction in chronic venous insufficiency was first described by Veal and 
Hussey in 1942.74 Fagrell75 and Bollinger76 have described micro-oedema formation 
around the hairpin papillary capillaries. This is seen as a halo around the capillary and, 
if the skin is punctured with a needle, marked leakage of fluid from the halo can be seen 
with a reduction in its size. Bollinger, using fluorescein microlymphography, has also 
described microlymphangiopathy in patients with chronic venous insufficiency, with 
obliteration of parts of the superficial lymphatic network and increased permeability of 
the lymphatics.77 It would seem that oedema in patients with chronic venous 
insufficiency is multifactorial in origin, and may play an important part in the 
pathogenesis of ulceration.
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Skin changes and venous ulceration
Haemosiderosis
Venular dilatation occurs after prolonged venous hypertension resulting in extrusion of 
red blood cells through the interendothelial pores in post-capillary venules. The red 
blood cells containing haemoglobin are broken down, leaving haemosiderin as a brown 
pigment, which stains the skin mainly on the lower medial third of the lower limb. This 
staining may slowly spread around the leg to cover the entire ‘gaiter* area. The 
pigmentation may get darker and eventually look almost black78.
Lipodermatosclerosis
Lipodermatosclerosis (LDS) has been described as the progressive fibrosis of the skin 
and subcutaneous tissues induced by chronic venous hypertension resulting in skin 
pigmentation and thickening and hardening of the skin and fa t79. LDS is characterised 
by skin induration and hyperpigmentation of the legs that often occurs in patients with 
chronic venous insufficiency. One study showed that 88% of ulcers and liposclerotic 
skin changes were located in the gaiter area of which 76% were on the medial side . 
Although it has not been demonstrated that all patients with LDS have venous 
insufficiency, most authors agree that LDS appears to be highly associated with or 
restricted to the legs of patients with chronic venous insufficiency. LDS is thought to 
consist of an acute inflammatory stage followed by a chronic stage characterised by 
extensive fibrosis or sclerosis. The acute phase of LDS has the clinical features of pain 
and discomfort in the leg above the medial malleolus. The area is erythematous, scaling, 
tender and warm. At this stage, some induration is already present though the sharp 
demarcation of hardness noted in chronic LDS is usually absent80.
In chronic LDS, the skin is stiff and shiny and fixed to the hard indurated contracting 
subcutaneous tissues with a palpable edge and the skin appears brown and shiny. The 
leg appears to look like an inverted 'champagne bottle' due to the oedema of the calf 
above and the progressive contraction of the skin and subcutaneous tissues, which 
results in shrinkage of the gaiter area.
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Aetiopathogenesis of varicose veins and its sequelae
The aetiology of primary varicose veins remains unclear. Various theories have been 
postulated including primary valve failure, vein wall weakness, incompetent 
communicating veins, arterio-venous fistulae and increased venous pressure caused by 
posture, tight clothing etc. The basic abnormality seems to be weakness of the vein wall 
as a result of which the vein dilates and its valves become incompetent allowing 
retrograde flow of blood. Trendelenburg suggested that venous valves protected the 
wall of the vein distally from high pressure in the vein above, implying that valvular 
incompetence is the primary abnormality and the changes in the vein wall are secondary 
in nature.81 Patients with varicose veins have been shown to have deficient collagen 
and increased hexosamine in their non-varicose veins,82 suggesting a primary defect in 
the wall of the veins that causes them to become varicose. Other hypotheses for the 
development of varicose veins include opening up of normal arterio-venous fistulae 
during times of circulatory stress, warmth, long periods of standing, and other stresses. 
These might explain raised oxygen levels found in blood taken from varicose veins 
compared to blood taken from normal veins.83,84 However, none of these hypotheses has 
gained widespread acceptance, as they fail to explain how unilateral varicose veins, or 
varicosities in only the long or short saphenous system, develop.
Secondary varicose veins are due to certain known conditions. Destruction of the 
venous valves in the deep and communicating veins by thrombosis is the most common 
cause. Other causes include pregnancy where hormonal factors cause relaxation of the 
smooth muscle with subsequent dilatation. Direct pressure on the iliac veins by an 
enlarged uterus also acts as a contributory factor. Congenital arteriovenous fistulas 
involving the lower limb and congenital valveless syndrome are other known causes.
Superficial, perforator and deep venous incompetence in ulcers
In the nineteenth century Gay and Spender, working separately, reported that disease in 
the deep veins of the leg results in ulceration of the limb. This was confirmed by 
Homans, 85, 86 who introduced the concept of venous stasis as the cause of ulceration. 
Sethia and Darke, however, reported that 28.3% of patients with ulcers had superficial 
venous incompetence alone in a study in which venous function was assessed by 
venography and foot vein pressure measurement.87 A further study using Doppler
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ultrasound indicated that 43% of 117 ulcerated limbs had superficial venous 
incompetence; about one fifth had some deep vein reflux demonstrable as well.31 A 
more recent study 67 using colour duplex ultrasound and photoplethysmography found 
12 limbs of 59 patients (15%) had deep venous reflux alone, in 42 limbs (53%) there 
was superficial venous reflux alone and in 25 limbs (32%) there was both superficial 
and deep venous reflux. Therefore, it would appear that venous ulceration is possible in 
the presence of superficial incompetence alone.
The importance of communicating vein incompetence remains controversial, and their 
role in the development of venous ulceration remains unclear. Some authors believe 
them to be of fundamental importance in ulcer pathogenesis,88 whereas others have 
found disappointing results following their ligation, with high rates of ulcer recurrence
OQ
after venography had clearly shown the perforating veins to be incompetent. There is 
doubt about which direction of flow should be considered ‘normal’; recent work from 
our laboratory using colour duplex imaging has shown that it may be bi-directional.90
Arterio-venous shunts
For a substantial part of the earlier 20th century, it was thought that venous ulceration 
occurred as a consequence of arteriovenous shunts. Arteriovenous anastomoses have 
been recognised since 1860 when Sucquet described their morphology 91. Alfred 
Blalock 92 and several other authors reported higher oxygen tensions in venous blood in 
the legs of patients with varicose ulcers than the opposite normal leg of the same 
patient.93,94 This led to the hypothesis that venous ulceration was due to hypoxia of the 
skin as a result of blood being shunted away from the nutritional capillaries by arterio­
venous communications 83, 84, 95. Ryan 96 claimed that small arterio-venous shunts 
responsible for temperature regulation within the dermis might open up as a result of 
raised venous pressure in patients with chronic venous insufficiency. However, others 
have been unable to show increased shunting in patients with primary varicose veins 
with or without chronic venous insufficiency compared to normal controls using a 
variety of methods including venous occlusion plethysmography,97 macroaggregates98 
and microspheres." Reports continue to emerge of increased partial pressure of oxygen 
in blood taken from leg veins of patients with varicose veins compared to normal 
controls.100,101 Overall, this hypothesis for the cause of venous ulcers has fallen out of 
fashion, although one author continues to believe that this is the cause of venous
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ulceration, and that the treatment for ulceration is the identification and division of these
102anastomoses at operation.
Venous Stasis
Homans introduced the concept that stagnant flow and stasis in varicosities were 
responsible for ulceration as a result of impaired tissue nutrition. However, many studies 
have shown that the oxygen content of venous blood in patients with chronic venous 
insufficiency and ulceration is, in fact, higher than normal 83,92,93’ 10°. Blood flow and 
utilisation in patients with chronic venous insufficiency measured by Positron emission 
tomography has shown increased flow with decreased tissue extraction of oxygen in 
areas of lipodermatosclerosis and in the skin around ulcers, indicating local shunting of 
blood through an abnormal microcirculation.103 Cheatle104,105 and Belcaro 106 have also 
shown increased cutaneous blood flow using LASER Doppler fluxmetry when 
measured at 37°C. Despite this evidence, anoxia and hypo-nutrition caused by stasis is 
still discussed in relatively modem works, and the terms ‘stasis ulcer* and ‘gravitational 
ulcer’ are still used, especially in the American literature.
Fibrin cuff hypothesis
Subsequently, it has been shown in animal model that the venous hypertension caused
• • 107increased capillary permeability and increased concentration of fibrinogen in lymph. 
Extravasated fibrin has been demonstrated histologically in the skin from the gaiter area 
of patients with chronic venous insufficiency.108 Normally deposition of fibrin would 
be prevented by the interstitial fibrinolytic system. However, patients with 
lipodermatosclerosis have been shown to have reduced fibrinolytic activity.109 Based 
on these observations, Browse et al in 1982 suggested a sequence of events to explain 
skin damage in chronic venous insufficiency. Their theory is known as the ‘fibrin cuff 
hypothesis’.110 This suggests that raised venous pressure leads to widening of the pores 
between the endothelial cells lining the capillaries, increasing their permeability to large 
molecules and allowing, in particular, fibrinogen to escape into the interstitial tissue. 
This view was complimented by the observations of Landis,111 who showed that 
elevated venous pressure resulted in elevated capillary pressure and permeability, and of 
Whimster, who reported enlargement of the dermal capillaries in patients with chronic 
venous insufficiency.112 Extravasated fibrinogen then polymerises into fibrin to form 
pericapillary fibrin cuffs, which in turn are thought to act as a diffusion barrier to
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metabolites and oxygen. This would explain the high venous oxygen and the low tissue 
oxygen concentrations in patients with lipodermatosclerosis and ulceration. This 
hypothesis is illustrated in Figure 1.4.
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Figure 1.4 - The fibrin cuff hypothesis.
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There is no doubt in the existence of the fibrin cuffs, which have been observed in a 
number of histological studies.113 Although reduced fibrinolytic activity in patients 
with lipodermatosclerosis has been reported,114'116 this has not been demonstrated by all
117authors. A commercially available fibrin membrane of 1 mm thickness has been 
shown to delay the diffusion of oxygen.108 However, the concentration of fibrin used in 
this study is higher than in the pericapillary fibrin cuffs, and, based on calculations 
made by Professor Michel, pericapillary fibrin cuffs are unlikely to cause a significant 
barrier to the diffusion of oxygen.118 In addition, if this hypothesis were correct, it 
would be expected that the reduction of fibrin cuffs would result in ulcer healing. One 
study has shown that fibrin cuffs and the area of lipodermatosclerosis can be reduced 
using profibrinolytic therapy (stanozolol - Stromba®, Sterling-Winthrop, Guildford, 
UK),119 but that this drug was no better than placebo at healing leg ulcers.120 In another 
trial, the effects of stanozolol and compression therapy on LDS were studied in a 
double-blind placebo-controlled trial, which showed a 28% reduction in the area of LDS 
in the treatment group compared to 14% in the placebo group.121 However, when 
multivariate analysis of the effects of each component in the treatment was analysed, the 
effect attributable to stanozolol alone was not statistically significant. Furthermore, no 
changes in the transcutaneous oxygen tension (TCPO2) were seen in the skin of either 
group in spite of the reduction in the area of LDS.
The fibrin cuff hypothesis has also been supported by studies that have shown reduced 
levels of TCPO2 using a Clark-type surface skin electrode over liposclerotic skin of 
patients with chronic venous insufficiency.122'124 However, the technique of TCPO2 
measurement depends on the ability to cause maximal vasodilatation by heating the skin 
to 43-44°C. It has been shown that it may not be possible to cause vasodilatation in the 
area of liposclerotic skin in patients with chronic venous insufficiency to the same 
extent as normal controls using heating.105 When the TCPO2 was measured at 37°C 
instead of 43°C, the oxygenation of the skin of patients with chronic venous 
insufficiency appeared to be higher than in normal controls.125 In a more recent study, 
no difference was observed in the transcutaneous and intracutaneous oxygen tension in 
tissues with different degree of lipodermatosclerosis.126 Oxygen extraction in the skin, 
using positron emission tomography, has been found to be lower in the affected limb
•  •  • 1 fttcompared to the clinically normal limb in patients with chronic venous insufficiency, 
but this study can be criticised on the grounds that the clinically normal limb in patients
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with chronic venous insufficiency often has unsuspected abnormalities such as low skin 
TcP02 and increased venous refilling times following exercise.127 Xenon clearance has 
also been shown to be unaltered in liposclerotic skin compared to normal controls, 
suggesting there is no diffusion block to small molecules.128 These findings would 
suggest that skin hypoxia alone is not sufficient to account for skin damage and that 
other mechanisms contributing to ulcer pathogenesis must exist.
The White cell trapping hypothesis
In 1987, Moyses et al 129 reported a 15 - 20% reduction in the number of white cells 
leaving the feet in eight healthy subjects during a 45 minute period of sitting. Thomas 
et al 5 found a larger fall (of 24%) in a group of ten patients with chronic venous 
insufficiency compared to normal control subjects (5%) following 60 minutes of leg 
dependency. After the subjects were allowed to lie supine, the white cells returned to 
the circulation.
• 1 toBollinger , using capillary fluorescence microscopy, showed that there were areas of 
skin with no apparent blood flow in patients with chronic venous insufficiency, which 
was restored when elastic stockings were applied. He suggested that some of the 
capillaries were not functioning because of thrombosis.76 Using simultaneous 
fluorescence and light capillary microscopy Franzeck et al described the appearances of 
capillary loops filled with red blood cells which did not appear to be perfused, 
suggesting capillary thrombosis to be a feature of chronic venous insufficiency.131 
Coleridge Smith et al 6 also showed using video microscopy that the number of visible 
capillaries fell following a period of venous hypertension, suggesting that increasing 
venous pressure reduced the capillary perfusion pressure and hence the capillary flow 
rate.
It is well known that low capillary flow is a potent initiator of white cell adhesion132, 133, 
134 and Schmid-Schonbein has shown that the likelihood of a leucocyte adhering to a 
vessel wall is inversely related to the shear force exerted on it.135 On the basis of these 
observations, Coleridge Smith et al put forward the white cell trapping hypothesis, 
postulating that the fall in the count of capillaries in the leg skin of patients with chronic 
venous insufficiency on dependency was due to reversible adherence of white blood 
cells to the endothelium. The hypothesis postulates that an increase in venous pressure 
during standing or walking causes a reduction in capillary flow rate, resulting in
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trapping of white blood cells in the leg. The trapped white cells plug the capillaries 
resulting in areas of ischaemia, and also become activated releasing proteolytic enzymes 
and toxic metabolites (free radicals), which damage the capillaries, and chemotactic 
substances that attract more white cells. Activated white cells have been shown to be 
mediators of tissue damage in a number of organs including the heart136, 137, brain,138 
lung 139 and kidney 14°. Monocytes release the cytokines interleukin-1 (IL-I) and tumour 
necrosis factor-a (TNF-a) when activated.141 These may also activate endothelial cells 
resulting in increased vascular permeability,142 which may be the mechanism of 
fibrinogen passing into the pericapillary spaces and forming fibrin cuffs. This 
hypothesis is illustrated diagrammatically in Figure 1.5.
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Figure 1.5 - The white cell trapping hypothesis.
The first part of the hypothesis, which suggests tissue hypoxia as a result o f capillary 
plugging, seems unlikely as there is no evidence of tissue hypoxia in LDS skin (see 
above). However, there is evidence that the second part of the hypothesis, concerning 
white cell activation, may be true. Skin biopsies taken from three groups of patients 
with venous disease (no skin changes; LDS only; LDS and ulceration) showed that there 
was a low number of white cells in the skin of patients without LDS, while in patients 
with LDS but no ulceration, the number of white cells in the skin was increased eight­
fold. In patients with ulceration, there was a 40-fold increase in the number of white
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cells in the skin.143 However, neither the type of white cell nor their relationship to 
capillaries was addressed, nor this study may be interpreted as only confirmatory 
evidence of the presence of inflammation in the skin of patients with LDS and 
ulceration. A more recent study has again shown increased numbers of white cells in the 
skin of patients with LDS though the immunohistochemical features suggest that they 
are mainly macrophages and lymphocytes.144
There is some indirect evidence in support of the white cell trapping hypothesis. 
Pentoxifylline (Trental®, Hoechst, Hounslow, UK), which inhibits the effects of TNF-a 
and IL-1,145 has been shown to promote ulcer healing when used in conjunction with 
compression therapy.146 However, a later study of factorial design, permitting the 
simultaneous evaluation of alternative pharmaceutical, bandaging, and dressings 
materials performed in 200 patients with confirmed venous ulcers, pentoxifylline failed 
show any statistically significance improvement in ulcer healing 147. Pentoxifylline has 
a number of haemorrheological effects including increased red cell deformability, 
increased fibrinolysis and actions on the white cell such as inhibition of granulocyte 
aggregation and inhibition of production of oxidants, which may have influenced 
healing 148, 149, 15°. Prostaglandin E l, which prevents activation of neutrophils, has also 
been shown to be beneficial in patients with venous ulceration,151 as have free radical 
scavengers applied topically to ulcers.152 The molecular mechanism of leucocyte 
activation, leucocyte-endothelial adhesion and extravascular migration has been the 
subject of much recent study. Various adhesion molecules are expressed by circulating 
leucocytes and endothelial cells in response to diverse physiological and pathological 
stimuli, leading to firm adhesion of leucocytes to the endothelium with subsequent 
degranulation or extravascular migration.153
Experimental work to study white cell activation in venous disease was undertaken to 
show neutrophil activation by measuring the neutrophil degranulation products 
lactoferrin and elastase following experimental venous hypertension in normal subjects 
and in patients with chronic venous disease. In a series of experiments Shields et al 
showed that there was a rise in plasma lactoferrin levels in normal subjects in response 
to venous hypertension, and patients with varying severity of venous disease all had 
raised lactoferrin levels compared to age and sex matched controls.154 Similarly plasma 
elastase was noted to be higher in patients with venous disease compared to age and sex 
matched controls.155 However, no difference was found between the various patient
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groups and it was concluded that neutrophils are probably responsible for acute 
inflammatory changes and for initiating vascular endothelial damage but unlikely to 
account for the skin damage seen in patients with chronic venous insufficiency.
There was a significant rise in the plasma concentration of ELAM-1, ICAM-1 and 
VCAM-1 in normal controls and both patient groups in response to experimental 
venous hypertension. In patients with LDS basal plasma VCAM-1 and its magnitude of 
rise in response to experimental venous hypertension was significantly higher compared 
to patients with W s. There was no difference in the magnitude of change in ICAM-1 
and ELAM-1 between the two patient groups. Patients with LDS, however, had 
significantly raised plasma vWf compared to patients in the W s  group, but no 
significant change was noted in either group in response to short term experimental 
venous hypertension. 12,13,156
During the hypertensive insult there was a significant fall in both neutrophil and 
monocyte surface CD lib  and L-selectin expression, presumably because of adherence 
of leucocytes to the vascular endothelium. Following reversal of venous hypertension, 
both neutrophils and monocytes showed a significant increase in CD lib  expression 
with a concomitant fall in L-selectin expression, indicating leucocyte activation during 
the hypertensive insult. There was a rise in plasma L-selectin level confirming 
shedding of L-selectin, which precedes leucocyte activation and CD lib  expression. 
Leucocyte activation occurred in response to venous hypertension resulting in shedding 
of surface L-selectin and hence the rise seen in the plasma 12, 157. This finding is in 
keeping with the white cell trapping hypothesis and suggests that the low flow state 
induced by venous hypertension does result in increased neutrophil/endothelial 
interaction. These data suggest that venous hypertension causes neutrophil and 
monocyte activation, which in turn causes injury to the endothelium.
In another study, the median VEGF levels among patients with C3 and C4 CVD were 
81 pg/mL (interquartile range [IQR] 56 to 122) supine and 98 pg/mL (IQR 63 to 153) 
after standing for 30 minutes. Median VEGF levels among control subjects were 52 
pg/mL (IQR 35 to 71) lying supine and 60 pg/mL (IQR 39 to 105) after standing for 30 
minutes. Experimental venous hypertension caused a small rise in VEGF levels among 
the patients but not the control subjects8.
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Methods of classification and grading of lower limb chronic venous disease 
Previous classification methods
Previous methods of classification of lower limb venous disease include that of Widmer 
158, which categorised limbs, based on their clinical appearance. More recently, he 
recognised that chronic venous insufficiency must include both superficial and deep 
lesions regardless of their cause or their clinical presentation and suggested a five-stage 
chronic venous insufficiency classification21.
CEAP method of classification and scoring of lower limb chronic venous disease
In 1994, an international consensus report under the auspices of the American Venous 
Forum presented the latest method of classification and grading of lower limb chronic 
venous disease, which was as a result of significant progress made in the non-invasive 
field of investigations of venous pathology with the use of electronic and computer- 
aided technology. This system requirement was similar to those for diagnosing 
peripheral arterial disease, which had long been in use.
The CEAP method classifies lower limb chronic venous disease according to the 
clinical signs and symptoms (C), the (a)etiology (E), the anatomic distribution of the 
pathology (A) and the pathophysiologic dysfunction (P) resulting in a multi-axial 
system 159. The clinical classification differentiates telangiectases from truncal varicose 
veins, and healed ulcers from open ulcers, in a seven stage description. In addition to 
the classification of disease, the CEAP method also allows you to score the disease.
The CEAP method of classification is summarised in Table 1.1:
C for Clinical signs (grade q-6)» supplemented by (a.) for asymptomatic and (g)
for symptomatic presentation 
E for Etiologic classification (Congenital (Ec), Primary (EP), Secondary (Es))
A for Anatomic distribution (Superficial (A s), Deep (A d ), or Perforator (A P),
alone or in combination).
P for Pathophysiologic dysfunction (Reflux (P r) or Obstruction (Po), alone or in 
combination).
Table 1.1 CEAP classification o f lower limb chronic venous disease.
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Clinical classification (C 0 -6)
C is for clinical signs (grade q-6) graded in increasing order of severity according to the
objective clinical signs of disease listed in Table 1.2 below. Limbs with more severe 
signs of chronic venous disease will be placed in the higher categories and may have 
some or all of the findings defining a less severe clinical category. Each limb will be 
further characterised as symptomatic and supplemented by (g) or supplemented by (a ) 
for asymptomatic.
Therapy may alter the clinical category of a limb therefore it was recommended that 
limbs should be reclassified after any form of medical or surgical intervention at least 6 
months after.
Class 0: No visible or palpable signs of venous disease.
Class 1: Telangiectases or reticular veins.
Class 2: Varicose veins.
Class 3: Oedema.
Class 4: Skin changes ascribed to venous disease (e.g. pigmentation,
lipodermatosclerosis, venous eczema).
Class 5: Skin changes as in class 4 with healed ulceration.
Class 6 : Skin changes as in class 4 with active ulceration.
Table 1.2 Clinical classification o f lower limb chronic venous disease.
Etiologic classification ( E c , E p , or Eg)
E is for etiologic classification, that is, whether the venous dysfunction may be 
congenital, primary or secondary (table 1.3).
Congenital (Eq)
Primary (Ep) - with undetermined cause
Secondary (Eg) - with known cause
Post-thrombotic
Post-traumatic
Other
Table 1.3 Etiologic classification o f  lower limb chronic venous disease.
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Anatomic classification (As, d , p )
A is for anatomic distribution, that is, whether the vein(s) affected by venous disease is 
in the superficial, deep or perforator systems. One, two or three systems may be 
involved in any combination. Table 1.4 below lists the anatomic segments in the 
superficial, deep and perforator systems that may be involved.
Segment # Superficial Veins (Ag \ .5):
1 Telangiectases / reticular veins 
Long Saphenous Vein
2 Above Knee
3 Below Knee
4 Short Saphenous Vein
5 Non-Saphenous Vein 
Deep Veins (Ad ^ ) :
6 Inferior Vena Cava 
Iliac
7 Common
8 Internal
9 External
10 Pelvic - Gonadal, broad ligament, other
Femoral
11 Common
12 Deep
13 Superficial
14 Popliteal
15 Crural - anterior tibial, posterior tibial, peroneal (all paired)
16 Muscular - Gastrocnemial, soleal, other
Perforating veins (Apjyjg):
17 Thigh
18 Calf
Table 1.4 Anatomic classification o f lower limb chronic venous disease
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Pathophysiologic classification ( P r , o )
P is for pathophysiologic dysfunction, which may result from reflux (Pr), obstruction 
(Po) or both (Pr,o) as shown in table 1.5 below.
It is now recommended that in the investigation of patients with chronic venous disease, 
sufficient objective measurements of venous haemodynamics and anatomy by either 
invasive or non-invasive means must be carried out to adequately document the 
individual pathophysiologic changes, reflux, and/or obstruction accompanying chronic 
venous disease. Phlebographic or vascular laboratory investigations can objectively 
assess the presence of venous outflow obstruction (Po) as well as the presence of venous 
reflux (Pr) in the superficial, deep and perforating systems.
The anatomic segments that are involved with either reflux or obstruction are reported 
using the venous segments outlined in table 1.4 above, as the severity of venous 
dysfunction is influenced by the anatomic location and extent of the reflux and/or 
obstruction present160, 161.
Reflux ( P r )
Obstruction (Pq )
Reflux and Obstruction (Pr  q )
Table 1.5 Pathophysiologic classification o f  lower limb chronic venous disease.
Scoring of venous dysfunction
Another feature of the CEAP method of classification of lower limb chronic venous 
disease is the scoring system of chronic venous dysfunction that is incorporated within 
the system. This provides a numerical base for the scientific comparison of limb 
condition and evaluation of results of treatment. The scoring system is based on three 
elements:
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• The number of anatomic segments affected (anatomic score)
• Grading of symptoms and signs (clinical score)
• Disability (disability score).
This method of scoring and grading is thought to be more accurate as the grading of 
signs is objective whereas the grading of symptoms is subjective.
Clinical Score
The clinical score is the sum of the values assigned to the signs and symptoms listed in 
table 1.6 below:
Signs and Symptoms Clinical Score
Pain (0 = none; 1 = moderate, not requiring analgesics; 
2 = severe, requiring analgesics)
Oedema (0 = none; 1 = mild/moderate; 2 = severe)
Venous Claudication (0 = none; 1 = mild/moderate; 2 = severe)
Pigmentation (0 = none; 1 = localised; 2 = extensive)
Lipodermatosclerosis (0 = none; 1 = localised; 2 = extensive)
Ulcer - Size (largest ulcer) (0 = none; 1 = <2cm dia; 2 = >2cm dia)
Ulcer - Duration (0 = none; 1 = <3months; 2 = >3months)
Ulcer - Recurrence (0 = none; 1 = once; 2 = more than once)
Ulcer - Number (0 = none; 1 = single; 2 = multiple)
Table 1.6 Clinical scoring o f the signs and symptoms o f lower limb venous disease.
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Anatomical score
The anatomical score is the sum of the anatomical segments affected by either reflux, 
obstruction or both, each scored as one point, as listed in Table 1.4.
Disability score
The disability score is the sum of the values assigned to the signs and symptoms listed 
below in Table 1.7.
Score Level of disability
0 - Asymptomatic
1 - Symptomatic, can function without support device
2 - Can work 8-hour day ONLY with support device
3 - Unable to work even with support device.
Table 1.7 Disability Score.
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INVESTIGATION OF VENOUS DISEASE
History and Clinical examination
A full history and clinical examination remains the main method of investigation in 
most centres. Patients usually complain of pain, swelling or cosmetic deformity. 
Superficial venous insufficiency may cause a dull ache on standing, relieved by rest; 
deep venous insufficiency causes a more severe pain, often exacerbated by exercise. A 
history of injury or immobility should be sought, as deep vein thrombosis is often silent.
Oj
Trendelenburg test states that if the subcutaneous veins are occluded by a narrow 
tourniquet placed around the limb when the patient is lying down, rapid filling of the 
veins below the tourniquet when the patient stands indicates an incompetent 
communication between the superficial and deep systems below the tourniquet.
Non-invasive tests
There are several non-invasive methods of examining the anatomy and venous function 
of the lower limb. These have the advantages of being non-invasive, repeatable and do 
not expose the patient to ionising radiation.
Plethysmography
This was first described in 1905, 162 and includes a number of tests that detect volume 
changes in a limb or part thereof.
Strain gauge plethysmography. This relies on volume changes in the limb causing a 
proportional change in the electrical resistance of a strain gauge placed on the largest 
diameter of the calf, foot or ankle. Using strain gauge plethysmography, it is possible to 
measure venous outflow from the limb, and hence to quantify proximal venous 
obstruction, for example by deep vein thrombosis.163
Air plethysmography. This technique uses pressure changes in an air-filled bag 
applied around the leg to detect volume changes in the limb. In the currently used 
method, 164,165 a plastic sleeve is zipped around the patient's leg and filled with air to a 
pressure of 6-8 mmHg.
Foot volumetry is a variant of air plethysmography, whereby the feet of the patient are 
placed in separate water baths.
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Photoplethysmography (PPG). Photoplethysmography was originally described for 
the assessment of the arterial system.166 The principle of photoplethysmography 
depends on the variation in the light absorption of the skin caused by haemoglobin in 
the dermal venous plexuses. Infrared light (wave length 805 nm), derived from a light- 
emitting diode, is applied to the skin and the amount of light reflected is collected by a 
photoelectric detector. During high venous pressure, the dermal venous plexus is full 
and haemoglobin absorbs the light. As venous pressure falls, the venous plexus become 
less full and light absorption decreases. Using this technique, venous refilling following 
emptying of the veins of the lower limb (usually by ten dorsiflexions of the ankle joint) 
can be tested to assess venous reflux. The 95% venous refilling time is normally greater 
than 15 seconds; shorter refilling times implying venous reflux.167 The test can be 
repeated using tourniquets to compress the superficial veins and help to deduce the 
source of reflux. Photoplethysmography is widely used as a screening test to identify 
the presence of venous disease; however, its ability to differentiate between deep and 
superficial vein incompetence is not as good as duplex scanning.168
Light reflex rheography: this is a variant of photoplethysmography, using several light 
emitters shone onto the skin and the light reflected collected by a detector.
Doppler ultrasound
The Doppler effect was described by Johann Doppler, who showed that the frequency of 
sound emitted or reflected from a moving object varies with the velocity of the object. 
The use of Doppler ultrasound in the study of blood flow was first suggested by 
Franklin in 1961,169 based on the observation that a high-frequency sound wave incident 
on a moving target becomes scattered.
Duplex ultrasound scanning
The combination of a pulsed Doppler facility with real time B-mode ultrasound imaging 
using an extra transducer or a phased array of transducers provides both image and 
Doppler information. This allows defined areas of vessels to be studied to determine 
the speed and direction of flow. Thus, the presence of flow in both superficial and deep
170veins can be established, and the location of venous reflux determined accurately. 
Patients may be examined lying supine with the table tipped 20° foot down to ensure 
venous filling, when blood flow can be seen with respiration, augmented by performing
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a Valsalva manoeuvre, or standing, when forward flow can be produced by manual calf 
compression. In our laboratory, patients are examined standing, bearing weight on the 
contralateral limb to that being examined. The presence of reflux is elicited by manual 
calf compression, reflux being defined as reverse flow lasting more than 0.5 seconds.171 
Virtually all veins below the inguinal ligament can be imaged completely by this 
technique and the competence of individual valves may be assessed.172 Duplex 
scanning has been shown to correlate well with venography in the assessment of venous 
reflux and deep venous thrombosis.173 In colour duplex machines, distinct colours are 
used for forward and reverse flow so that assessment of venous reflux is simplified.
Invasive tests
Venography: Venography of the lower limb involves the injection of a contrast 
medium into a leg or foot vein and imaging the superficial and/or deep veins using X- 
rays. Venography of the lower limb can be classified into ascending venography, 
descending venography, and varicography.
Ambulatory venous pressure
Foot vein pressure permits examination of the calf muscle pump and the determination 
of superficial and deep venous incompetence, and has been proposed as the “gold 
standard” for the assessment of venous function.174 After cannulation of a foot vein, the 
patient is asked to exercise the calf muscle pump until a stable pressure is reached, 
either by walking on a treadmill or by standing on tip-toe ten times. The pressure 
reached is the “ambulatory venous pressure”. The venous system then refills, either 
from the arterial system or via reflux, if present. The time taken to return to the pre­
exercise pressure is the venous refilling time. Normally, the resting pressure is equal to 
a column of blood between the foot vein and the right atrium; during exercise the foot 
pressure falls to less than 25 mmHg, and the time taken for the pressure to return to the 
basal level after exercise is 25-30 seconds. Failure of the pressure to drop on exercise 
or a reduction in the time taken for the pressure to return to basal level implies venous 
incompetence. The test can be repeated with the use of tourniquets to determine if the 
reflux is due to incompetence of the superficial or deep systems.
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Review of recent advances in the understanding of the microcirculation:
- Adhesion molecules and its role in Leucocyte-endothelial interaction
Dutrochet first reported in 1824 that white cells became adherent to the vessel walls and 
emigrated into the tissues.175 Leucocytes express adhesion promoting receptors that 
mediate cell-cell and cell-matrix interaction. These interactions are crucial for the 
direction and control of leucocyte traffic, migration through tissues and the 
development of immune and non-immune inflammatory responses. Several families of 
adhesion receptors have been identified which are broadly divided into 3 groups - the 
Integrins, the Selectins and the Immunoglobulin superfamily. A complex interplay of 
physical, biological, and biochemical factors control and modulate leucocyte- 
endothelial cell adhesion leading to leucocyte emigration from the circulation into the 
tissues.
The Integrins
Integrins are transmembrane cell surface proteins that bind to cytoskeletal proteins and 
communicate extracellular signals.176 Each integrin consists of a noncovalently linked, 
heterodimeric a  and p chains.177 Integrins have been arranged in subfamilies according 
to the p subunits and each p subunit may have from one to eight different a  subunits 
associated with it. Within the integrin family of adhesion receptors only five members 
have so far been shown to be involved in leucocyte adhesion to endothelium; the p2 
leucocyte integrins (CDlla/CD18, CDllb/CD18 and CDllc/CD18), the pi integrin 
VLA-4 (a4/pl, CD49d/CD29), and <x4p7.178 The integrin family of CAMS serve as 
receptors for the ICAMs and VC AMs. The integrins mediate leukocyte adherence to the 
vascular endothelium or other cell-cell interactions. Different sets of integrins are 
expressed by different populations of leukocytes to provide specificity for binding to 
different types of CAMs expressed along the vascular endothelium.
P2 Integrins: The p2 leucocyte integrins share a common p chain (CD 18). Three a  
subunits are noncovalently associated with CD 18: C D lla (lymphocyte fimction- 
associated-1 or LFA- 1), CDllb (Mac-1, Mo-1) and CDllc. The expression of the p2 
integrins is restricted to leucocytes, but among subtypes of leucocytes the distribution of 
CD 11/CD 18 differs. Peripheral blood lymphocytes express primarily CD 11 a/CD 18,
whereas neutrophils, monocytes, and NK cells express all three p2 integrins.178 
Intracellular storage pools of CD 1 lb/CD 18 and CD 11 c/CD 18 are present in neutrophils 
and monocytes179 whereas there is no storage pool of CD11 a/CD 18. Surface expression 
of CDllb/ CD18 and CDllc/CD18 is increased by a variety of agonists: calcium 
ionophore, phorbol esters, FMLP, GM-CSF, C5a, TNF-a, and LTB4.180 Increased 
expression of CD1 lb/CD 18 also has been noted after neutrophil adhesion to E-
# ioi 9
selectin. Neutrophil and monocyte adhesion to endothelium relies primarily on the 
CD 11 a/CD 18 and CD 1 lb/CD 18 leucocyte integrins with only a minor role for 
CDllc/CD18.182
pi Integrins: The p i, integrins share CD29 as their common p subunit.183 This widely 
distributed family of integrins contains a series of cellular receptors for extracellular 
matrix proteins including fibronectin, collagen, laminin and vitronectin. One member 
of the pi integrins, cc4Pi(VLA-4, CD49d/CD29), has been shown to be involved in 
lymphocyte, monocyte, eosinophil, basophil, and NK cell adhesion to cytokine-activated 
endothelial cells. Because neutrophils do not express VLA-4,183 they cannot use this 
pathway to adhere to stimulated endothelium.
The Selectins
The vascular selectin family of adhesion receptors contains three monomeric 
transmembrane adhesion molecules, which share an N terminal extracellular domain 
homologous to calcium-dependent lectins 184, 185. The selectin family members, L- 
Selectin, P-Selectin, and E-Selectin, are involved in the adhesion of leukocytes to 
activated endothelium. This adhesion is initiated by weak interactions that produce a 
characteristic "rolling" motion of the leukocytes on the endothelial surface. P-Selectin 
and L-Selectin, acting in concert, have been implicated in the mediation of these initial 
interactions. Stronger interactions, probably involving E-Selectin, follow the initial 
interactions, leading eventually to extravasation through the blood vessel walls into 
lymphoid tissues and sites of inflammation.
E-selectin (CD62E) is expressed by endothelial cells, P-selectin (CD62P) by both 
endothelial cells and platelets, and L-selectin only by leucocytes.186, 187 L-Selectin, 
which has two consensus repeats is constitutively expressed on all granulocytes, 
monocytes and a sub-population of lymphocytes and is involved in leucocyte traffic in
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the systemic microcirculation.188 Upon cellular stimulation, L-selectin may transiently 
increase its ligand affinity without a concomitant increase of receptor density on the cell 
surface.189 Subsequently, L-selectin is rapidly removed from the leucocyte surface 
possibly by a proteolytic mechanism.190,191 Soluble circulating L-selectin may modulate 
leucocyte adhesion to endothelium during inflammation by partial inhibition 192. Plasma 
levels of L-selectin, shed by leucocytes upon activation, were also measured as an index 
of leucocyte activation. High levels of soluble L-Selectin have been found in plasma 
drawn from apparently normal individuals 192.
Expression of E-selectin, which has six CR domains, is induced on endothelial cells 
within 2-4 hour after treatment with interleukin-1, tumour necrosis factor or bacterial 
lipopolysaccharide (LPS).193 Endothelial cells expressing E-selectin can bind 
granulocytes, monocytes, and a subset of skin-homing lymphocytes.194, 195 While E- 
selectin expression requires protein biosynthesis,193 P-selectin is pre-formed and stored 
in a  granules of platelets and in Weibel-Palade bodies of endothelial cells.196 Surface 
expression of P-selectin is rapidly induced by treatment of endothelial cells with 
thrombin or histamine and subsides within about 10-15 min.197 The vascular selectins 
are uniquely suited for mediating the rapid cycle of attachment, detachment and 
reattachment underlying leucocyte rolling. Their flexible, monomeric structure 
combined with a very high rate of binding to natural ligand 198 has been found to be a 
prerequisite for rolling.199 Interestingly, the minimum molecular length compatible 
with leucocyte rolling is about 25 nm, which is just about reached by L-selectin. The 
cytoplasmic domain of L-selectin appears to be required for its adhesive function, to roll 
or adhere to endothelial cells.200 Cytoskeletal attachment of the vascular selectins may 
be required in order to withstand the flow forces in microvessels in vivo.
Immunoglobulin family of adhesion receptors
The Ig superfamily of adhesion molecules, including ICAM-1, ICAM-2, ICAM-3, 
VCAM-1 and MadCAM-1 bind to integrins on leukocytes and mediate their flattening 
onto the blood vessel wall with their subsequent extravasation into the surrounding 
tissue. Several immunoglobulin-like transmembrane adhesion receptors are expressed 
on endothelial cells. Of these ICAM-1 (Intercellular Adhesion Molecule-1), ICAM-2 
and VCAM-1 (vascular cell adhesion molecule-1) play key roles in adhesion and 
transmigration of blood leucocytes. While ICAM-1 expression can be increased several
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fold by treatment with cytokines such as interleukin-1 or tumour necrosis factor, ICAM- 
2 expression remains at basal levels under all conditions studied. 201 A third member of 
the immunoglobulin family of adhesion molecules is VCAM-1, which is the natural 
ligand for a pi integrin expressed on memory T-lymphocytes, very late antigen -4 
(VLA-4) or a4pl integrin.202 Interaction between VLA-4 and VCAM-1 appears to play 
a major role in binding of lymphocytes, eosinophils, and monocytes, but not neutrophils 
to activated endothelial cells. The immunoglobulin adhesion receptors do not appear to 
regulate their affinity for their integrin ligands other than by an increased surface 
expression on activated endothelial cells. The expression of both ICAM-1 and VCAM-1 
can be sustained for days after cytokine stimulation of endothelium. This pattern 
suggests a role for these molecules in chronic inflammation.203,204
Normally, VCAM-1 has a low to nominal expression on unstimulated endothelium.205, 
206 It is, however, inducible by a number of cytokines (IL-1, TNF-a, IL-4 and IL-13) 
plus ECM molecules.205, 207 When induced, VCAM-1 has the potential to play a 
significant role in migration for leukocytes that express VLA-4 (e.g., lymphocytes, 
monocytes, eosinophils, basophils). However, the actual contribution that VCAM-1 
makes may depend upon the expression and activation state of other related adhesion 
molecules. Upon exposure to TNF-a, endothelial cells upregulate the expression of 
ICAM-1, E-selectin and VCAM-1.208,209
VCAM-1, ICAM-1 and ELAM-1 exist in soluble form,210,211 and have been shown to 
be elevated in a variety of inflammatory diseases and malignancies.212, 213 The 
mechanism of release is unclear; but is probably due to proteolytic cleavage from the 
cell surface. They may also have their own biological function, as soluble ELAM-1 has 
been shown to act as a neutrophil chemoattractant.7*7 ELAM-1 expression is restricted 
to endothelial cells and elevated levels could possibly represent a specific marker for 
endothelial damage or activation.
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The adhesion cascade
The molecular mechanism of leucocyte activation, leucocyte-endothelial adhesion and 
extravascular migration has been the subject of much recent study. The molecular 
mechanism of leucocyte adhesion to vascular endothelial cells is characterised by a 
series of steps, which are shown in Figures 1.6 to 1.8. The current theory of white cell 
adhesion is a two step model.214 Normally leucocytes express L-Selectin, which bind 
loosely to receptors on the vascular endothelium resulting in marginating leucocytes to 
‘roll’ along the endothelium. This gives the circulating leucocytes a chance to examine 
the endothelium more closely although the binding is temporary and is easily broken 
down by shear stress. The participation of P-selectin and E-selectin in leucocyte rolling 
has also been reported. In the presence of endothelial damage or other local stimulus 
leucocytes shed L-selectin and express a second stage receptor the integrin CD lib , 
which then binds to counter ligands on the vascular endothelium. This allows firm 
adhesion of leucocytes to the endothelium leading to subsequent degranulation or 
extravascular migration.216 Some white blood cells are reversibly bound to the 
endothelium and re-enter the systemic circulation when venous pressure is lowered.
Low capillary flow is a potent initiator of white cell adhesion 132, 133, 134 and Schmid-
Schonbein has shown that the likelihood of a leucocyte adhering to a vessel wall is
inversely related to the shear force exerted on it.135 Various adhesion molecules are
expressed by circulating leucocytes and endothelial cells in response to diverse
physiological and pathological stimuli, leading to firm adhesion of leucocytes to the
1«
endothelium with subsequent degranulation or extravascular migration
Vascular endothelium plays a key role in regulation of the inflammatory response. 
Adhesion molecules (selectins, immunoglobulin receptors, integrins, cadherins and 
connexins) expressed on the endothelial cells surface, take part in several interactions. 
In normal circumstances, they mediate endothelial cell-matrix interactions and regulate 
vascular permeability. During the process of inflammation, the surface expression of 
adhesion molecules changes. Those receptors then participate in the interactions 
between leukocytes and activated endothelium surface, in the process of leukocyte 
activation and in their extravasation. Soluble forms of several adhesion molecules are 
released into the circulating blood. Plasma levels of soluble adhesion molecules may be 
a diagnostic marker of the systemic endothelial injury.
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The adhesion of circulating leukocytes to the vascular endothelium is essential for 
effective host inflammatory and immune responses. Adhesion proteins expressed by 
both the leukocyte and endothelial cell have been well characterised, and studies of 
these molecules have shown that both cell types are actively involved in regulating 
these binding events. In contrast, the expression and function of one type of leukocyte 
molecule, L-selectin (previously called LECAM-1), is "down-regulated” by 
inflammatory signals.
Neutrophil Elastase
Neutrophils posses two types of granules, primary and secondary, which contain various 
chemical substances. Upon activation, these are released into phagocytic vacuoles and 
some is spilled into the plasma. Lactoferrin is an iron binding glycoprotein found in 
secondary granules of neutrophils 217 and has been used as an indicator of neutrophil 
activation in several disease states including various forms of arthritis,218, 219 
pneumonia and sepsis. It is produced in response to various stimuli such as TNF-a, 
FMLP, opsonised bacteria, C5a coated bacteria/immunoglobulins and 
lipopolysaccharides, and has various functions mostly concerned with iron binding, but 
also causes increased random motility of polymorphonuclear leucocytes, which are 
primed to produce more superoxide radicals. Patients with congenital lactoferrin 
deficiency are prone to bacterial infections. Neutrophil Elastase is a 29KD protein 
which is stored in the primary granules222 and released during the process of 
phagocytosis or when neutrophils are activated by other stimuli such as soluble immune 
complexes, C5a or endotoxins.223 It is chemotactic, degrades fibrinogen224 and has been 
implicated in the tissue destruction seen in venous disease by causing endothelial cell
• • 225injury.
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Neutrophil Lymphocyte
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I E-Selectin 
(ELAM-1)
Leucocyte mediated injury 
inducesIL-1, TNF-a&  
TGF-P
Platelet Activation
VW -Factor
Figure 1.6: Chronic venous disease involves adhesion molecule expression by endothelial cells, 
leucocyte activation and local cytokine activity. Endothelial cell activation by cytokines or thrombin leads 
to increased adhesion molecule expression such as ICAM-1 (binds neutrophils/ lymphocytes), VCAM-1 
(binds lymphocytes/ monocytes) and E-selectin (ELAM-1). This can lead to MHC-II expression (T-cell 
response) and GMP- 140 (binds platelets), binding o f platelets increases the availability o f platelet 
activating factor and further accelerates the expression o f adhesion molecules. The Circulating levels o f  
many o f these molecules are known to be increased in patients with CVD.
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Leucocyte - endothelial adhesion
C D llb /C D 18
L-selectin
E-selectin
VCAM-1 ICAM-1
Figure 1.7: Surface ligands o f neutrophils and monocytes (C D llb/C D 18, L-Selectin, VLA-4) and the 
endothelial adhesion molecules with which they interact (ICAM-1, E-selectin, VCAM-1).
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Late Endothelial Changes in CVI
Macrophages T-lymphocyte
Activated endothelial cell
Capillary
Figure 1.8: The late stage o f  liposclerotic skin damage is characterized by endothelial activated, 
perivascular cuffing with fibrin and infiltration with T-lymphocytes and macrophages.
Von Willebrand Factor (vWF)
Von Willebrand Factor (vWF) is a complex multimeric adhesive glycoprotein 
synthesised by endothelial cells and megakaryocytes. Its principle, though apparently 
unrelated, functions appear to be that of a carrier/stabiliser for the pro-coagulant protein 
FVIIIiC, which circulates in serum as a non-covalently linked complex, and as an 
adhesive protein in haemostasis. vWF can bind collagen and possibly other endothelial 
structures and mediates the adhesion of platelets to the sub-endothelium through 
binding to the surface receptor glycoprotein lb. It may also play a role in the platelet- 
platelet interaction through binding to the glycoprotein Ilb/IIIa 226, 227
Increased levels of vWF antigen/activity indicate damage to the endothelium in vascular 
disease 228 and studies suggest that endothelial damage may be important in the vascular 
complications of hypertension 229. However, the short-term increases observed in vWF
  L
Fibrin cuff
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after exercise, adrenaline or DDAVP (1-deamino (8-d-arginine)- vasopressin) infusion, 
and during pregnancy 230 may indicate activation or stimulation of endothelial cells 23 *, 
rather than epithelial damage. Decreased levels are found in hypothyroidism and 
systemic lupus erythematosus and increased levels have been described in autoimmune 
disease, rheumatic vasculitis and diabetes etc 232.
CYTOKINES
Cytokines are peptides or glycoprotein mediators ranging from 6,000 to 60,000 kds 
molecular weight that act as intracellular signals. Cytokines are potent and active at
concentrations as low as 1010 to 1013 mol/L (lpg/ml). They bind to cell surface 
receptors and initiate a variety of intracellular signal transducing pathways that 
culminate in gene activation. They generally act as paracrine or autocrine signals but 
can also at times act systemically in an endocrine manner. They stimulate the growth, 
differentiation and other functions of a wide variety of target cells. Cytokines can be 
produced upon stimulation by virtually every cell type, including immune, 
inflammatory and non-inflammatory cells. A given cell type can produce many 
cytokines and also a given cytokine can activate a variety of cell types. Most cytokines 
have multiple biologic activities that overlap.233 Some cytokines act as potent inducers 
of other cytokines, resulting in cascades and networks of interacting cytokines. The 
activities of immune and inflammatory leucocytes can either be up or down regulated 
by cytokines, but cytokines also markedly influence the activities of connective tissue 
and neural, epithelial, endothelial, and other cell types engaged in tissue repair and 
restoration of homeostasis. Cytokines generally have short half-lives. Distribution to 
tissues, binding to cell receptors anticytokine antibody activity, protease activity, 
binding to serum carrier protein, aggregation and spontaneous degradation serve to 
decrease serum cytokine levels.
Endothelial-derived cytokines may be involved in haematopoiesis, cellular chemotaxis 
and recruitment, bone resorption, coagulation, and the acute-phase protein synthesis. As 
many of these processes are critical to the maturation of an inflammatory and reparative 
state, it appears likely that endothelial-derived cytokines play a crucial role in several 
diseases, including atherosclerosis, graft rejection, asthma, vasculitis, and sepsis. 
Genetic and pharmacological manipulation of endothelial-derived cytokines provides an
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additional approach to the management of chronic inflammatoiy disease. A number of 
scientific investigations support the theory that the coordinate expression of cytokines is 
paramount to the successful initiation and maintenance of inflammation. Endothelial 
cells, by virtue of their capacity to express adhesion molecules and cytokines, are 
intricately involved in inflammatory processes.
Interleukin-1 and TNF appear particularly important in that these cytokines are 
important as both proximal and distal mediators of disease. The importance of IL-1 and 
TNF during early inflammatory events is exemplified via their ability to upregulate the 
expression of adherence proteins on the endothelium and to allow inflammatory cells to 
bind to a localised area.
Induction of these cytokines in endothelial cells has been demonstrated by such diverse 
processes as hypoxia and bacterial infection. Recent studies have demonstrated that 
adhesive interactions between endothelial cells and recruited inflammatory cells can 
also signal the secretion of inflammatory cytokines. This cross talk between 
inflammatory cells and the endothelium may be critical to the development of chronic 
inflammatory states. Cytokine activation may be limited by natural inhibitors or by 
therapeutic agents such as monoclonal antibodies, recombinant proteins, and drugs that 
alter cytokine synthesis, which may be of benefit in infection, inflammation, and 
possibly atherosclerosis.
Cytokine levels correlate with outcome in certain diseases (e.g., septic shock, viral 
meningitis). Clinical evaluation is performed almost exclusively on plasma and serum 
samples, although measurements in urine, cerebrospinal fluid, joint fluids, bronchiolar 
lavage, saliva, and tissue specimens are possible. Structural (antigenic) assays such as 
enzyme-linked immunosorbent assays (ELISAs) and radioimmunoassays (RIAs) are 
reliable and can be used to follow cytokine levels in patients. ELISAs and RIAs are 
available for many cytokines. The major advantage of the RIA method that only one 
antibody preparation is needed is overshadowed by the ease of use of ELISA formats. 
The sensitivity of these assays is often on the order of 10 to 50 pg/ml, which seems to 
be adequate for patient monitoring. The specificity and reproducibility of the 
immunoassays are normally far more exacting than for bioassays. One major advantage 
of immunoassays is that given the right choice of antibody they should not be affected 
by the presence of other cytokines, inhibitors, or contaminants, which might influence a
59
bioassay target cell. A disadvantage is that a cytokine molecule might be biologically 
inactive owing to unfolding, protease action, or physical effects (temperature, pH), yet 
may preserve the immunoreactive epitope and test positive in the immunoassay. In 
practice, this event is rare.
Interleukin-1 (IL-1)
IL-1 is a cytokine produced mainly by cells of the mononuclear phagocytic system. It is 
a major mediator of the inflammatory process. There are three related molecules in the 
IL-1 family: IL-1 a  (acidic form) and IL-1 p (neutral form), which share little homology 
but have similar functions and operate through the same receptors; and an IL-1 receptor 
antagonist protein (IL-1 ra), which binds the receptors but has no biological activity.
Secreted locally, IL-1 has proinflammatory effects, promoting coagulation and 
increasing endothelial expression of adhesion molecules, an action shared by TNF-a 234. 
DL-la promotes release of IL-6 and PDGF-AA; both are potent stimulators of collagen 
production and proliferation in normal fibroblasts. IL-1, IL-6 and PDGF are of prime 
importance in activating fibroblasts to produce the extracellular matrix. IL-1 also 
induces expression of itself in newly arriving monocytes, thus reinforcing the overall 
process.235 Furthermore, IL-1 induces the expression of MMPs from resident 
fibroblasts. This can have at least two effects: first, extracellular matrix degradation can 
facilitate monocyte migration, and second, MMPs are known to degrade IL-lb, thus 
down-modulating the local inflammatory response initiated by IL-1.
IL-1 may promote thrombogenesis evidenced by the increase in factor VIII related 
antigen and also in decreased fibrinolysis. These may also activate endothelial cells 
resulting in increased vascular permeability. It is possible that this is the result of 
increased cytokine activity following white cell activation. In fact, EL-la and IL-lp are 
well recognised as local mediators of endothelial activity.
Interleukin 6 (IL-6)
The human IL-6 is a 184 amino acid protein with four cysteine residues and a predicted 
molecular weight of 21 kDa. 236 IL-6 production is generally correlated with cell 
activation. Circulating IL-6 can be found in the blood of normal individuals in the 1 
pg/mL range, 237 with slight elevations during the menstrual cycle,238 modest elevations
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in certain cancers (melanoma) (10 pg/mL),239 and large elevations after surgery (30-430 
pg/mL).240
IL-6 is a multifactorial protein produced by a variety of cells including vascular 
endothelial cells, monocytes/macrophages, fibroblasts, hepatocytes, osteoblasts, 
keratinocytes, astrocytes, lymphoid and non-lymphoid cells such as T cells, B cells, and 
various carcinomas and sarcomas including myelomas, plus bladder and renal cell 
carcinomas 241 ’242. The production of IL-6 by these various cells is regulated positively 
or negatively by a variety of signals, such as mitogenic or antigenic stimulation, 
lipopolysaccharide, IL-1, TNF, PDGF, and viruses. 243
The effects of IL-6 on different cells are numerous and varied. The effect on B cells is 
to stimulate differentiation and antibody secretion, on T cells to stimulate IL-2 
production and IL-2 receptor expression. IL-6 stimulates production of acute phase 
protein by hepatocytes, 244 and has colony stimulating activity on haematopoietic stem 
cells. 245 IL-6 has growth factor activities and will stimulate the growth of sarcomas and
 • „ „ „ „  246,247carcinomas.
IL-6, among other cytokines is of prime importance in activating fibroblasts to produce 
extracellular matrix. IL-6 has been described as both a pro-inflammatory and anti­
inflammatory molecule, a modulator of bone resorption, a promoter of haematopoiesis,
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and an inducer of plasma cell development , , . The various activities of IL-6
described above suggest that this factor has a major role in the mediation of 
inflammatory and immune responses initiated by infection or injury. Elevated IL-6 
levels have been reported to be associated with a variety of diseases, including 
autoimmune diseases,251 psoriasis,252 and malignancies such as plasmacytoma and 
myeloma. 253
Tumour Necrosis Factor (TNF)
The first suggestion that a tumour nercotising molecule existed was made when it was 
observed that cancer patients occasionally showed spontaneous regression of their 
tumours following bacterial infections. In 1975, it was shown that a bacterially induced 
circulating factor had strong anti-tumour activity against tumours implanted in the skin 
in mice.254 This factor, designated tumour necrosis factor (TNF), was subsequently 
isolated,255 cloned,256 and found to be the prototype of a family of molecules that are
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involved with immune regulation and inflammation.257 It is also known as cachectin, 254 
and tumour necrosis factor (TNF-P) also known as lymphotoxin, 258 are two closely 
related proteins that bind to the same cell surface receptors and produce a vast range of 
similar, but not identical, effects. Its primary function, however, may lie in its ability to 
initiate (along with IL-1) the cascade of cytokines and other factors associated with the 
inflammatory responses. In contrast to the similarity of their biological activities, the 
regulation of the expression and processing of the two factors is quite different. TNF-a 
is produced by neutrophils, activated lymphocytes, macrophages, NK cells, endothelial 
cells, and smooth muscle cells, while TNF-p is produced by lymphocytes. 259
Normal levels of circulating TNF are reported to be in the 10-80 pg/mL range.260, 261 
While both membrane-bound and soluble TNF-alpha are biologically active, soluble 
TNF-alpha is reported to be more potent.262 Circulating TNF-beta levels are reported to 
be about 150 pg/mL.263 TNFs play a critical role in normal host resistance to infections 
and to the growth of malignant tumours, serving as immunostimulants and as mediators 
of the inflammatory response. Many of the actions produced by the TNFs are 
functionally similar to the effects produced by IL-1. Over-production of TNF has been 
implicated in a number of pathological conditions, including cachexia, septic shock 
following infection with Gram-negative bacteria, and autoimmune disorders
TNFa may result in angiogenesis 266. Local release of TNFa causes activation of 
neutrophils and macrophages, stimulation of cytokine release (IL-1, IL-6, TNF-a itself) 
by cells of the MNP’s, and induction of expression of class II MHC molecules (this
7/^7action requiring the presence of other cytokines, such as interferon-y) . TNF-a and IL- 
1 both enhance the procoagulant activity of the endothelium268; stimulate fibroblast 
proliferation 269 and upregulate adhesion molecule expression on vascular endothelium 
and on neutrophils to enhance cell migration 270.
Vascular Endothelial Growth Factor (VEGF)
VEGF, a soluble angiogenic factor, is produced by many tumour and normal cells with 
similarity to platelet-derived growth factor271. Its high-affinity receptor tyrosine kinases 
VEGFR-1 (fins-like tyrosine kinase, Fit-1) and VEGFR-2 (Flk-1/ kinase insert domain- 
containing receptor, KDR) are expressed predominantly on endothelial cells. VEGF is a 
46-kDa heparin-binding glycoprotein and a specific mitogen for vascular endothelial
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cells in angiogenesis 272. VEGF binding to the KDR tyrosine kinase results in an 
increase in KDR gene transcription and protein expression. Thus, KDR up-regulation 
induced by VEGF may represent an important positive feedback mechanism for VEGF 
action in tumour and ischaemia-induced angiogenesis.273 The distribution of VEGF 
receptors suggests that VEGF is an important regulator of endothelial cell development 
and function.
It exists as one of four known homodimeric isoforms. The 1 6 5  amino acid isoform 
(VEGF 1 6 5 ) is secreted by a variety of normal and transformed cells. There are four 4  
transcripts encoding mature monomeric VEGF (viz. VEGF121, VEGF165, VEGF189, 
VEGF206)- VEGF121 and VEGF165 are diffusible proteins that are secreted into the 
medium. VEGF165 is the most abundant of the four isoforms in vivo and is commonly 
used in studies investigating the biological effects of VEGF. Increased expression of 
VEGF is dependent on increased mRNA and increased transcription 274.
VEGF-A is produced by different cell types, including vascular smooth muscle cells 
(VSMCs), macrophages, fibroblasts, tumour cells, and endothelial cells keratinocytes, 
and histiocytes 275, 276, 277, 278, 279. The expression of several known VEGF-A isoforms is 
induced by hypoxia; growth factors, including transforming growth factor-p, basic 
fibroblast growth factor, and platelet-derived growth factor; and cytokines, among them
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interleukin IL-lp and IL-6 , . VEGF receptors are known to be constitutively
expressed on endothelial cells, ischaemia or hypoxia, previously shown to upregulate 
transcription of endogenous VEGF mRNA, 279, 281 may also produce further 
upregulation of endothelial cell receptors for VEGF. VEGF has been established as 
critical for development ’ and maintenance of the normal vasculature, as well as 
for therapeutic 285 and tumour-induced angiogenesis 278. VEGF stimulates cell growth 
and migration in vitro 286, stimulates angiogenesis in vivo211.
VEGF is ubiquitous in wound repair, and the inflammatory process has an important 
part in the healing process. However, abnormally increased levels over a prolonged 
period can have local deleterious effects. VEGF is strongly expressed by epidermal 
keratinocytes during wound healing, in psoriasis, in skin with ultraviolet bums, and in 
bullous diseases such as erythema multiforme and bullous pemphigoid. All these 
disorders are characterised by increased microvascular permeability and angiogenesis. 
A large increase in VEGF messenger ribonucleic acid (mRNA) and protein levels is
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seen after irradiation of quiescent keratinocytes with physiologically relevant doses of 
ultraviolet B light. Over-expression of VEGF is considered dependent on de novo 
protein synthesis.274 Tissue damage in general, especially hypoxic damage can cause 
up-regulation of VEGF expression 287}279.
VEGF is a potent mitogen 277 for endothelial cells even at very low concentrations and 
markedly increases vascular permeability 288. VEGF induces increased microvascular 
permeability 289, 2,90 and monocyte migration through endothelial layers 291. VEGF is 
important in both angiogenesis and oedema formation.288 VEGF-induced endothelial 
hyperpermeability is caused by a direct action on endothelial cells 292 and is suggested to 
be mediated by enhanced transcytosis, gap formation between endothelial cells293, and 
the induction of fenestrations in nonfenestrated endothelium294.
Total NO
The role of nitric oxide (NO) as a biological signalling and effector molecule was 
virtually unknown until the late 1980s. Since 1987, when NO was determined to 
account for the biological activity of endothelium-derived relaxing factor 295, intensive 
research has revealed widespread and disparate functions of this molecule as a signal 
transducer296.
BIOCHEMISTRY OF NO
NO is a short-lived molecule (tV2=seconds) capable of diffusing across membranes and 
reacting with a variety of targets. NO has an unpaired electron, which makes it a highly 
reactive free radical species. Reaction with O2 in aqueous solutions produces the 
relatively unreactive nitrate (NO3-) and nitrite (NO2-) ions as products 29?, 298. In the 
presence of superoxide (O2-), however, NO reacts extremely rapidly to produce the very 
reactive and toxic peroxynitrite (ONOO-), which subsequently decomposes into 
additional highly reactive intermediates. NO ultimately exerts its biological effects by 
reacting either directly or through other reactive nitrogen intermediates with a variety of 
targets such as heme groups, Fe-S or Zn-S clusters, sulfhydryl groups or various other 
chemical substrates 298, 299,30°. NO and its redox forms, nitrosonium ion (NO*) and 
nitroxyl ion (NO'), react readily with sulfhydryl groups to form nitrosothiols.
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Nitric Oxide Synthases
Nitric oxide is produced by a group of enzymes called nitric oxide synthases (NOS)301, 
, . These enzymes catalyze the production of NO and L-citrulline from L-arginine,
O2 and NADPH-derived electrons. Multiple cofactors including reduced nicotinamide 
adenine dinucleotide phosphate (NADPH), flavine adenine dinucleotide (FAD), flavin 
mononucleotide (FMN) and tetrahydrobiopterin are required for enzyme activity. Two 
functional classes of the enzyme exist: constitutive and inducible. Constitutive NOSs 
require calcium and calmodulin for activity and have been isolated from neurons 
(cnNOS) and endothelial cells (ceNOS). Inducible NOS (iNOS) isoforms are generally 
calcium independent and produce high, sustained levels of NO. The names reflect 
characteristics of the activity or the original tissues in which the enzymes were first 
described, but it is now known that each of these isoforms is expressed in a variety of 
tissues and cell types.304, 305 The three main isoforms share structural similarities and 
have nearly identical catalytic mechanisms. The homodimeric form is required for NO 
production, and the subunits have molecular masses of approximately 160 (nNOS), 135 
(eNOS), and 130 kDa (iNOS).301,302,303 The inducible isoform is expressed in many cell 
types, including macrophages and vascular SMC, almost exclusively after exposure to 
cytokines and lipopolysaccharide 296.
L-arginine NO
-►NADPH — £ iNOS or eNOS or nNOS NADP
O2 L-citruline
OH’ (hydroxyl radical)
/
NO+O2’ (superoxide anion) = ONOO" (peroxynitrite) —► HOONO
NO2’ (nitrogen 
dioxide)
Figure 1.9: stages o f Nitric oxide production and its metabolism.
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Interactions between NO and reactive oxygen intermediates
Although inducible NO synthase and the phagocyte NADPH oxidase are differentially 
regulated, these systems may be co-stimulated by inflammatory stimuli (e.g. IFN-y). In 
addition to NO radical (NO') itself, potentially important NO congeners include 
peroxynitrite (OONO'), S-nitrosothiols (RSNO), nitrogen dioxide (NO2’), dinitrogen 
trioxide (N2O3), dinitrogen tetraoxide (N2O4), and dinitrosyl-iron complexes (DNIC). 
Peroxynitrite may be formed from the rapid interaction of NO' and superoxide (O2 ’) 
from the combination of hydrogen peroxide (H2O2) and nitrous acid (HNO2), which 
would exist in equilibrium with nitrite (NO2') within an acidified phagolysosomal 
vacuole, or from the interaction of nitroxyl (NO') and oxygen. The potent oxidant NO2' 
can be formed by the autooxidation of NO', or possibly by the oxidation of NO2' by 
myeloperoxidase and H2O2306.
VASCULAR BIOLOGY OF NO
Furchgott & Zawadzki described endothelium-dependent vaso-relaxation and observed 
that although intact pre-constricted rabbit aortic strips dilated in response to 
acetylcholine, strips denuded of endothelium contracted, suggesting the presence of a 
diffusible vasodilator released by endothelium307. This endothelium-derived relaxing 
factor (EDRF) was subsequently found to share many properties with NO, including 
similar half-lives, vasorelaxant properties, inhibition by haemoglobin, and potentiation 
by superoxide dismutase 295. In addition, bradykinin caused release of NO from 
endothelial cells in quantities sufficient to account for the vasodilatory effect of EDRF.
Endothelium-derived NO diffuses into subjacent SMC and activates soluble guanylate 
cyclase stimulating conversion of guanosine triphosphate to cyclic guanosine 
monophosphate (cGMP). Increased intracellular cGMP levels leads to smooth muscle 
relaxation (and hence vasodilation), by activation of cGMP-dependent protein kinases, 
which, among other activities, facilitate the extrusion of intracellular calcium via a 
membrane-associated calcium/magnesium adenosine triphosphatase pump . A family 
of phosphodiesterases inactivate cGMP by converting it to GMP.
Endothelial cell release of NO is enhanced by receptor-dependent agonists such as 
acetylcholine, adenosine triphosphate, thrombin, serotonin, histamine, substance P, and 
bradykinin, via calcium activation of ceNOS. Physical stimuli including shear stress,
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pulsatile stretching of the vascular wall, and hypoxia have also proven to be potent 
inducers of endothelial NO release and may well represent the most important 
physiologic signals for endothelium-dependent vasodilation. The NO inhibition of 
cytochrome oxidase may also be involved in the cytotoxicity of NO, and may cause 
increased oxygen radical production by mitochondria, which may in turn lead to the 
generation of peroxynitrite. Mitochondrial damage by peroxynitrite may mediate the 
cytotoxicity of NO, and may be involved in a variety of pathologies.299
NO is a key molecule that plays vital roles in signal transduction, vasodilation and the 
inflammatory response. 309 In the vasculature, NO not only functions as a vasodilator, it 
also inhibits platelet function, leukocyte adhesion to endothelial cells, and smooth 
muscle cell (SMC) proliferation. NO appears to have critical roles in cardiovascular 
homeostasis.310
L-Arginine reduces human monocyte adhesion to endothelial cells and decreases 
expression of certain endothelial cell adhesion molecules. L-Arginine was also 
associated with decreased surface expression of cell adhesion molecules and decreased 
levels of ICAM-1 mRNA, suggesting that at least some of the anti-adhesion effects of 
L-arginine may be mediated by reduced cell adhesion molecule expression.311 
Endothelium-derived NO may be an important endogenous modulator of leukocyte 
adherence and that impairment of NO production results in a pattern of leukocyte 
adhesion and emigration that is characteristic of acute inflammation.312
Nitric oxide is an important vascular mediator, released continuously by endothelial 
cells in the basal state,313, 314 and is formed by nitric oxide synthase from the 
physiological substrate L-arginine. NO modulates the expression of extracellular 
superoxide dismutase (ecSOD) in vascular smooth muscle cells in culture and seems to 
be a critical determinant of expression of vascular ecSOD in vivo. This effect of NO is 
mediated via the cGMP/protein kinase G-dependent pathway.315
Exogenous NO, such as might be secreted from activated macrophages, inhibits the up- 
regulation of endothelial adhesion molecule expression, by opposing the activation of 
NF-Kb 316, 317. However, the rapid effects of endogenous NO must be due to different 
mechanisms. Since experiments in vitro indicate that NO does not directly inhibit 
leukocyte adhesion to endothelial cells318, indirect mechanisms were proposed based on 
the ability of NO to inactivate or antagonize ROS. Both in vivo and in vitro, mast cell
67
degranulation activates leukocyte adhesion to endothelium; this process is inhibited by 
NO donor drugs and exacerbated by NO synthesis inhibitors, strongly suggesting that 
endothelial-derived NO, either directly or by inactivation of ROS, stabilizes and hence 
prevents the local release of stimulators of leukocyte adhesion.319
Isolation of iNOS was first reported in macrophages where its activity was found to be 
inducible in response to stimuli such as proinflammatory cytokines or endotoxin. 
Expression of iNOS has now been reported in a large number of cell types, and in most 
circumstances, the enzyme is inducible 304,305. The iNOS gene is under transcriptional 
control, although activity is also influenced by a variety of other control mechanisms 
that affect mRNA stability, translation and degradation of the protein, and availability 
of substrate and cofactors 303, 301, 304. This enzyme is found in the cytoplasm. The 
effect is probably mediated by a number of highly reactive nitrogen and oxygen 
intermediates. The phagocyte NADPH oxidase produces superoxide, which rapidly 
combines with NO to yield peroxynitrite and several other toxic decay products.320
VEGF and total NO
The mechanism by which VEGF causes NO release in human endothelial cells was 
shown to involve activation of tyrosine and phosphoinositide three kinases 321. In 
cultured microvascular endothelial cells isolated from coronary postcapillary 
endothelium, VEGF triggers, via kinase-derivative receptor activation, the NO synthase 
(NOS)/guanylate cyclase pathway to activate the mitogen-activated protein kinase 322.
VEGF binds to high-affinity tyrosine kinase receptors encoded by flt-1 and flk-1 genes 
323, 324 Qn vascuiaj. endothelial cells, which leads to the release of NO by the constitutive 
Ca2+ calmodulin-dependent NOS 325. However, the mechanism appears to be multi- 
factorial, complex, and more likely related to increased oxidative stress leading to 
reduced efficacy of NO or increased degradation of NO rather than an absolute decrease 
in NO concentration 326. The defect may lie in the availability of substrate for NO 
production within the endothelial cell 327, 328, in the intracellular signal transduction 
pathway that carries the message from the membrane receptors to the enzyme that 
synthesizes NO 329, in the NOS enzyme itself, or even in the breakdown of NO by 
superoxide anions in the interstitium 33°.
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VEGF-A induces angiogenesis and regulates endothelial function via production and 
release of NO, which is produced by eNOS. While the upregulation of eNOS expression 
has been shown to be mediated via VEGF receptor KDR, there is controversy about 
which of the VEGF receptors triggers the release of nitric oxide in endothelial cells. The 
VEGF receptor KDR is responsible for NO release in endothelial cells, highlighting a 
new function of KDR and further supporting the importance of KDR in the regulation of 
the vasculature.331
VEGF induction by IL-1 B was related to iNOS activity in VSMCs and NO synthesis 
augments VEGF expression in these cells and the existence of an additional, NO- 
independent regulation of VEGF synthesis. The induction of VEGF synthesis by NO 
may be of great importance in the maintenance of vascular homeostasis and in the 
response to endothelial injury. Because NO and VEGF reciprocally enhance their 
synthesis, this interaction may play a significant role in reendothelialization after 
balloon angioplasty or in the angiogenic response to ischaemia.332
These results implicate NO and prostacyclin produced by the interaction of VEGF with 
its Flk-1/KDR/VEGF-R2 receptor as mediators of VEGF-induced vascular 
permeability333. Moreover, this property appears unique to VEGF among angiogenic 
cytokines334. VEGF has been shown to induce the release of NO from rabbit, pig, 
bovine, and human vascular endothelial cells 335. It has been reported that prolonged 
VEGF exposure induced a time-dependent increase in eNOS expression; KDR 
activation mediates VEGF-induced eNOS up-regulation and activation of the PKC 
pathway was required for elevating eNOS levels
It has been demonstrated that in human cells, NO production in response to short-term 
VEGF exposure is mediated by the activation of tyrosine kinases and PI-3K; long-term 
exposure to VEGF augments NO release through increased expression of the eNOS 
protein. These observations taken together suggest that NO may be an important 
modulator of growth factor signalling in endothelial cells.321
NO decreases hypoxia-induced VEGF via a cGMP-dependent mechanism and suggest 
that NO may serve as an endogenous inhibitor of both hypoxia and non-hypoxia 
enhanced VEGF expression in vivo.337 It has recently been demonstrated that the 
physiological effects of VEGF-A are mediated in part by endothelium-derived NO. 
VEGF upregulates ecNOS enzyme and elicits a biphasic stimulation of endothelial NO
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production.338 VEGF has been shown to elevate intracellular inositol 1,4,5-trisphosphate 
and calcium levels, and to stimulate tyrosine phosphorylation and vWf release in 
cultured human umbilical vein endothelial cells339. Moreover, VEGF effects on 
permeability and vascular tone are coupled to nitric oxide (NO) production 325. NO 
dilates host vessels, causing sprout formation, and maintains blood flow in angiogenic 
vessels 340, 341. The downstream signalling cascade of VEGF-induced microvascular 
permeability also was demonstrated to involve nitric oxide (NO) as a second messenger 
287. Several studies have implicated NO in the regulation of microvessel permeability342. 
Thus, selective modulation of eNOS activity is a promising strategy for altering 
angiogenesis and vascular permeability in vivo.343 VEGF enhances the expression of 
eNOS in native and cultured endothelial cells, an effect that may be important in the 
process of VEGF-induced angiogenesis.344 VEGF stimulates proliferation of 
postcapillary endothelial cells through the production of NO and cGMP 
accumulation.345
Ku et al 325 reported that VEGF induces endothelium-dependent relaxation in canine 
coronary arteries by stimulating endothelium-derived relaxing factor/NO via a calcium- 
dependent mechanism. VEGF stimulates production of NO when applied to quiescent, 
endothelium-intact vascular segments from the thoracic aorta, pulmonary artery, and 
inferior vena cava of New Zealand White rabbits.335
This response can be blocked by competitive inhibition of NOS, suggesting that the 
putative maintenance functions of VEGF may include regulation of baseline synthesis, 
release of endothelial cell NO, or both, supporting the notion of a “survival” or 
“maintenance/repair” role for VEGF.346 Furthermore, the demonstration that VEGF is 
capable of inducing recovery of disturbed endothelium-dependent flow in the rabbit 
ischaemic hindlimb may reflect restored NO production by endothelial cells that are 
initially damaged by protracted ischaemia in the collateral-dependent limb.347
In experimental studies in animals, intravenous VEGF infusion causes hypotension,
tachycardia and vasodilatation. The hypotension is thought to be mediated by
production of nitric oxide and is reversible with appropriate blocking therapy with N-
(G)-monomethyl-L-arginine 287, 348. VEGF has been shown to stimulate NO release in
bovine, rabbit and human endothelial cells.335 It has also been shown that NO may
^  1
mediate the angiogenic effects of VEGF. The presence of nitric oxide also can
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explain the hyperpermeability induced by VEGF. Excessive release of nitric oxide can 
be caused by this mechanism. In contrast to its usual beneficial role, this free radical 
may contribute to local tissue damage. More recently, increased iNOS activity has been 
shown in the skin of venous ulcer patients 349.
NO has been shown in a number of animal models to be an important regulator of 
angiogenesis and an inhibitor of agents which promote an angiogenic response 35°. 
However, the situation may be different in human diseases and NO might have an 
angiogenic effect in chronic venous ulcers. Angiogenesis is known to occur 
coincidently with vasodilatation and hyperaemia of pre-existing microvessels . In 
addition, NO stimulates endothelial cell proliferation, migration, the release of 
proteases, and the increase of vascular permeability 352, 353, 354, all of which are factors 
which contribute to angiogenesis. VEGF, a potent angiogenic factor contributing to the 
angiogenesis in chronic venous ulcers 355, up-regulates ecNOS and so increases NO 
production by endothelial cells 338. Therefore, it was hypothesized that up-regulation of 
ecNOS in chronic venous ulcers promotes angiogenesis.349
Review of capillary morphology and density studies in CVD
In CVD, microangiopathy is characterised by the presence of enlarged, dilated, coiled and 
ramified capillaries, which are surrounded by an enlarged pericapillary spaces (halos) 
and reduced capillary numbers, microvascular thrombosis, obliterations and increased 
permeability of microlymphatics 357 depending on the severity of the CVD. Furthermore, 
capillaries can show morphological abnormalities like tortuous and elongated 
capillaries, heterogeneous distribution of capillary tufts or microvascular thrombosis. 
Venules become more evident in standing position and capillaries become larger in 
diameters in CVD.358 It has been suggested that cutaneous microangiopathy precedes 
the development of trophic skin alterations due to chronic venous congestion and the 
clinical degree of skin changes and the severity of microangiopathy are closely related
359 360 » •
Convoluted capillaries were described by Piulachs in the edges of venous ulcers using 
capillary microscopy in 1956.361 Fagrell noted that there was often a reduction in the 
actual numbers of capillaries in the gaiter area of patients with deep venous
•je
insufficiency, but those present were widely dilated, coiled and tortuous. This is 
contrary to histological studies that have shown increased numbers of capillaries in LDS
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* 112skin, though it may be that when histological sections are taken through a coiled 
capillary, it is not appreciated that there are several cuts through the same convoluted 
capillary, rather than cuts through different capillaries. Fagrell also found "halo 
formation" around them, which may correspond to the fibrin cuffs of Browse and 
Bumand. By puncturing these halos with an injection needle, he was able to 
demonstrate fluid escaping from the pericapillary space. This fluid he referred to as 
micro-oedema. Bumand et al showed histologically that capillaries proliferate when 
subjected to raised venous pressure 362. It was unclear from that work whether the 
actual number of capillary loops was increased, or if those present had become more 
convoluted and increased in length. Fagrell70 and Bollinger77 have also observed this 
phenomenon, but have not provided any quantitative data. Both of these authors have 
reported greatly increased convolution of capillaries in liposclerotic skin.
Ryan suggested that a rise in venous pressure causes dilatation of the horizontal sub- 
papillary plexus, with elongated, coiled dermal capillaries, and a reduction in the 
number of capillaries supplying the epidermis.363 Another histological study, using a 
specific monoclonal antibody for nuclei of proliferating cells (Ki-67), has shown that 
there is no evidence of capillary proliferation in patients with chronic venous 
insufficiency compared to normal controls.364 Therefore, the capillary coiling seen in 
chronic venous insufficiency is likely to be due to elongation rather than formation of 
new capillaries, which are also more widely separated owing to micro-oedema 
formation. This may result in an inability to supply enough oxygen to the tissue during 
periods of increased demand. Bumand et al. demonstrated a significant correlation 
between the number of capillaries seen on histological examination of the gaiter area of 
skin and the fall in venous pressure on exercise in patients with varying degrees of calf 
pump failure 362. They described increase number of capillaries in the skin from limbs 
with communicating vein incompetence, postphlebitic deep vein damage and 
lipodermatosclerosis histologically. Later it was found that the increase in capillary 
density was attributable to the same capillary being cut numerous times during 
histological preparation 362.
Functional capillary density is variable in both normal and diseased tissue . We only 
see the apex of skin capillary with the capillary microscope. Patients with mild CVD 
have 40-50 capillaries/mm2 in their leg skin. Increased permeability can only be shown 
by fluorescein capillaroscopy.
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In healthy control subjects, capillary density assessed by capillaroscopy (native and 
fluorescein) in supra-medial malleolar skin in young healthy subjects was 31-38/sq. mm 
respectively and dorsum of foot 36-36.2/sq. mm and shin 30-51/sq. mm. Interestingly, 
dependency did not alter the count significantly.366 On the contrary, another study 367 
showed a reduction of capillaries in controls on dependency where capillary density per 
square millimetre in controls were on supine: 29(23-33), on dependency: 26.8 (21-32) 
and in CVD they were 13.1 (6-19) and 12.9 (6-19) respectively. Capillary density has 
been found lower in patients with CVD than in controls irrespective of the position of 
the leg. Interestingly, there was a reduction of capillaries in controls on dependency, but 
not in CVD and fluorescence angiography revealed a greater number of capillaries than 
seen during native capillaroscopy. In another study, visible capillaries fell after being 
dependent for 30 minutes in CVD6.
In mild CVD, capillary density is similar to controls 368, 369 and morphologic 
characteristics are still normal; but enhanced leakage of capillaries and increased 
pericapillary halo diameters are seen using fluorescein light intensity . Minority of 
patients showed moderate dilations or increased tortuosity; mean diameter and range of 
pericapillary halos were significantly enhanced in groups with mild CVD, unlike 
controls. Enhanced transcapillary diffusion predominates, while morphological 
alterations of capillaries typical of severe CVD are yet to emerge 369. Another study 
performed in non-trophic changes group, video microscopy showed dilated tortuous 
capillaries surrounded by halo formation 37°. Franzeck et al has reported the capillary 
density in mild CVD 40-50/mm2. Recently, there has been report not to have significant 
difference in diameter of capillaries between controls and CVD. Jiinger et al presented 
the data (at the North Sea meeting of venous diseases in 2000) that the numbers of 
capillaries in healthy subjects were 40-60/mm2 and they also reported dilated capillaries 
already present in normal healthy controls.
In severe stages of CVD and ulcer patients, reduced capillary density due to capillary 
thrombosis and tortuous capillary tufts were observed ’ ’ . I n  severe SVI,
capillary density has been reported to less than 10 capillaries/mm2. Extremely tortuous 
microvessels resembling glomeruli, obliteration of vessels or avascular fields are 
frequent in severe CVD 369, 372,373. In severe CVD, capillaries are rarefied, elongated, and 
dilated with formation of glomerulus-like clusters or they may proliferate within
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granulomatous repair tissue. The peri-capillary space, which is enlarged and oedematous in 
CVD, cannot be defined anatomically.372
In patients with trophic skin changes such as lipodermatosclerosis, TcPC>2 was reduced 
significantly. Capillary density (<10/sq. mm) was reduced and in regions of atrophie 
blanche TCPO2 was zero with no capillaries seen 370. In severe CVD, a reduction of the 
capillary number can be observed, probably as a result of previous capillary
• 171 •thrombosis. Dilated, elongated winding (glomerulus) capillaries and increase in the 
pericapillary leakage diameter (halo) are seen in severe CVD.373 Avascular regions of 
atrophie blanche are bordered with enlarged tortuous capillary loops. Capillaries remote 
to areas of atrophie blanche show less altered morphology.374
Review of treatment modalities of venous disease
Surgery to varicose veins has been practised since the Roman period, by Galen who 
used a phlebectomy hook for vein avulsion 375 and Albucassis who performed partial 
internal stripping using a needle and probe to strip short sections of vein. Stripping of 
the long saphenous vein was first performed by Madelung using an incision the length 
of the vein.376 Trendelenburg popularised high ligation of the long saphenous vein,
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though with very high recurrence rates. Intraluminal stripping was first described by 
Keller in 1905,377 and extraluminal stripping the following year by Mayo.378 Homans 
noted the high recurrence rate following Trendelenburg's high ligation, and advocated 
combining this with full excision of the long saphenous vein, either by direct exposure 
or stripping.86 If there was ulceration, he reported that all scar tissue down to and 
including the deep fascia should also be excised, thus ligating any perforating veins 
beneath the ulcer. In 1938, Linton described ligation of incompetent perforating veins 
beneath the deep fascia, together with ligation of the saphenous veins if incompetent.379 
Cockett subsequently showed the association between ankle perforators and ulcers 38°. 
He deduced that the perforating veins caused the ulcers at the ankle, although this has 
not been proved but many people still believe it. He devised a better perforating vein 
operation using a much smaller incision.
Perforating veins were once thought to be the entire problem in patients with severe 
venous disease. Operations to ligate them were performed in the expectation of 
achieving long term healing of leg ulcers. This surgery was often carried out
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contemporaneously with standard varicose vein surgery. In many patients, this led to 
long term ulcer healing. In others, very poor healing or even severe post-operative 
complications would ensue with infection of the operation site and extension of the 
ulcer. It has been shown that where deep vein damage is present conventional 
perforating vein surgery does not prevent ulcer recurrence or improve venous 
physiological function in the lower limb 89, 381.
Various attempts have been made to either reconstruct damaged deep vein valves, 
transplant valves from normal vein, or use prosthetic material to produce extrinsic 
compression of the vein wall to mimic or restore normal valve function, though overall 
results have been very disappointing. 382, 383 The mainstay of treatment of deep vein 
insufficiency and ulceration has been to limit the effect of high venous pressure by 
encouraging recumbency with elevation of the leg, and provision of external 
compression. This can either be with elastic bandages or stockings, graduated to 
produce maximum compression at the ankle, or with the use of intermittent pneumatic 
compression devices. 384, 385, 386 Drug therapy is little used in the UK and studies have 
shown conflicting results on the role of pentoxifylline in ulcer healing 146,147.
Most current treatment modalities, such as surgery or external compression, are 
designed to control the macrovascular defect. However, it is the microcirculatory 
consequences of the venous hypertension that give rise to the trophic skin changes and 
ultimately to ulceration. At this microcirculatory level, pharmacotherapy may be a 
useful adjunct in the treatment of venous leg ulcers.
Medication
At present, drugs act as an adjuvant for compression therapy for venous ulcers and for 
symptoms relief in CVD with the objective of increasing venous tone 38?, 388, 389 
stimulating lymph drainage 390, 391, 392, 393 and protecting the microcirculation from 
products released by the activated leucocytes 14, 16, 15. Venous tone is modified 
pharmacologically by increasing noradrenaline activity through the inhibition of 
catecholamines-ortho-methyltransferase 394. Lymphatic transport is improved by 
stimulation of the frequency and amplitude of spontaneous lymphatic contraction 390, 
392. Microcirculatory protection may be obtained by reducing leucocyte-endothelial 
adhesion decreasing capillary hyperpermeability 395 and inflammation396, 397.
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Drugs tested in patients with venous disorders may be classified into three broad 
categories:
1) ‘Venoactive’ drugs whose indications are specific to venous disorders
2) Drugs with specific pharmacological actions, which might be expected to influence 
the microvascular events leading to ulceration or the healing process
3) Topical drugs to treat venous ulceration.
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Venoactive drugs:
Drugs, which address the symptoms of venous disease but do not influence valvular 
competence or other aspects of the macro-physiological problem, are described as 
‘venoactive drugs’. Most venoactive drugs are derived from plants. They consist of pure 
substances, plant extracts and synthetic molecules copying the plant original, 
combinations of several active substances or even a plant extract where the composition 
remains unknown. These drugs are widely used for the medical treatment of venous 
disorders and costs for drug treatment for symptoms in 1983 extrapolated to 1990 in 
France was 3.35 billion FF.45 Their main indications are symptoms (aching, discomfort, 
‘restless legs’) and oedema, which reflects the clinical presentation of patients in most 
cases.
Venoactive drugs may act at several levels of the pathophysiological pathway leading to 
clinical manifestations of CVD. They may improve venous tone, which is reflected by a
o^*7 ‘108 100decrease in the distensibility of the venous wall, expressed as compliance , ,
There are evidences that they can act on the following microcirculatory parameters to:
1. Decrease White Blood Cells (WBC) sticking and activation 400, 401
2. Decrease production of inflammatory mediators
3. Decrease capillary permeability395
4. Decrease capillary fragility 402
5. Decrease blood viscosity 403
6. Improve transcutaneous partial pressure of oxygen (TCPO2) 404
An additional effect on lymphatic pumping has also been shown 390,391,392,393.
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Flavonoids: Daflon® 1
Daflon is a micronized purified flavonoid fraction (MPFF) containing a mixture of two 
flavonoids: diosmin (90%) and hesperidin (10%). Daflon consists of 90% Diosmin (31, 
5, 7 trihydroxy -4'- methoxyflavone 7 rhamnoglucoside; C28 H32 O15) and 10% 
hesperidin flavonoids (3', 5, 7 trihydroxy -4 - methoxyflavanone 7 rhamnoglucoside; C28 
H34O15).
Symptom relief
Efficacy of this drug in symptomatic treatment of CVD is well known and has been 
documented in double blind trials in human subjects 402, 405, 406. Daflon produced a 
significant decrease in venous capacitance, venous distensibility, and venous emptying 
time (p < 0.001), in addition to the improvement in clinical symptoms and a decrease in 
the supramalleolar circumference.399
The efficacy of micronized diosmin has been demonstrated in various double blind 
studies 398,405, 407, 408. After two months treatment with micronized diosmin resulted in a 
statistically significant improvement of symptoms and signs of functional and organic 
venous insufficiency, including a reduction of supramalleolar circumference. It was also 
claimed that the drug led to disappearance or improvement in skin changes in 88% of 
micronized diosmin patients compared to 21% treated with placebo. In a randomized, 
double blind, placebo-controlled trial of 105 patients with active ulcers, Daflon was 
used as an adjunct to compression therapy and standard wound care. Patients with an 
ulcer size less than 10 cm receiving Daflon (n=14 out of 44) fared better than those 
receiving placebo (n=6 out of 47); 32% vs. 13%, (P = 0.028) with a significantly shorter 
time duration of healing (P = 0.037) in the active treatment group.409 Among the 14 
patients with ulcer size > 10 cm (Diosmin = 9, Placebo = 5) no ulcer healed. This study 
showed that a two-month course of Daflon 500 mg at a daily dose of two tablets, in 
addition to conventional treatment, is of benefit in patients with venous ulcer < or = 10 
cm by accelerating complete healing. There is no data to suggest that this drug 
influences the size or extent of varicose veins.
1 Daflon 500 mg, Detralex, Arvenum 500, Capiven, Venitol, Variton, Ardium, Servier, Courbevoie, France
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Mechanism of action
The mode of efficacy of this drug is incompletely understood. Flavonoids have several 
anti-inflammatory actions.
In a study 410 of the effects of Daflon on the microvasculature in the cheek pouch 
preparation of diabetic hamster, the flavonoid significantly inhibited the 
macromolecular permeability. Flavonoid-treated hamsters also tended to have a lower 
number of leucocytes adhering to the venular endothelium in ischaemia-reperfusion 
injury.
In another double blind, placebo controlled randomised trial, flavonoid fraction was 
found to increase the ‘capillary resistance* as evaluated by the negative suction cup 
method. This study was carried out in patients with capillary fragility who were treated 
for six weeks with significant improvement of symptoms of capillary fragility 402. 
Daflon 500mg (2 tablets daily for six weeks) also reduces the capillary permeability as 
revealed by a decrease in the retention of initially high, labelled albumin (Tc99m albumin 
test) in patients suffering from idiopathic cyclical oedema as demonstrated in a double 
blind placebo controlled study.395
Inflammatory Mediators in animal studies
In a study performed in rats 411 Daflon 100 mg per day was administered by intubation 
and an inflammatory granuloma was formed by implantation of polyurethane sponges in 
treated rats and control animals. Daflon 500 mg reduced oedema formation, inhibited 
the synthesis for PGE2 (78.5%), PGF2 alpha (45.2%) and TXB2 (59.5%) and improved 
the multiple histological aspects of acute and chronic inflammatory reaction.396
Haemorrheological
An open pilot study using 6 weeks treatment with Daflon was performed to verify the 
variations in capillary packed cell volume in comparison with the velocity in 24 patients 
with third stage CVD. Ankle skin microcirculation was evaluated by dynamic 
capillaroscopy, relative capillary packed cell volume was calculated by a densitometric 
method and the red blood cell velocity was calculated using the simplified cross­
correlation method. Daflon 500 mg significantly increased the velocity of the red blood
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cells after 4 weeks treatment and after an initial increase; Daflon ultimately decreased 
the relative intracapillary haematocrit after 6 weeks treatment, suggesting an increase in 
the deformability of red blood cells.403
Free Radicals & Oxidation in animal studies
Flavonoids have been used in the treatment of vascular endothelial damage. The values 
of their scavenging rate constants are only 30 times less active than that very potent 
endogenous NO scavenger, haemoglobin. It is speculated that NO scavenging plays a 
role in the therapeutic effect of the flavonoids. 412 In an animal model, intravenous 
injection of Daflon (25 and 50 mg/kg) reduced the hyperglycaemia induced by injection 
of alloxan in the rat.413 This effect of Daflon was linked to its ability to scavenge active 
oxygen radicals, demonstrated in vitro using human neutrophils or mouse peritoneal 
macrophages stimulated by zymosan.396 Flavonoids and many other phenolic 
compounds show a wide range of antioxidant activities in vitro. It has been shown that 
flavonoids can interact with hydroxyl free radicals. 414, 415
Xanthine Oxidase Inhibition in animal studies
Flavonoids have been demonstrated to inhibit beef heart mitochondrial succinoxidase 
and NADH-oxidase activities. Flavonoids possessing a catechol configuration exhibited 
a slow rate of auto-oxidation in buffer that was stimulated by the addition of CN\ The 
addition of superoxide dismutase (SOD) and catalase in the auto-oxidation experiments 
each decreased the rate of oxygen consumption, indicating that O2’ and H2O2 are 
generated during auto-oxidation. In the CN’ - stimulated oxidation experiments, the 
addition of SOD also slowed the rate of oxygen consumption. These findings 
demonstrate that the CNVflavonoid interaction generated O2' non-enzymatically, which 
could have biological implications.416
Effects on TCPO2 & laser Doppler parameters
The effect of Daflon on the microcirculation in man has been investigated in a study in 
which laser Doppler fluxmetry, transcutaneous oxygen and carbon dioxide levels were 
assessed in the skin 404. Patients with mild venous disease (no skin changes) were 
randomised to receive 500mg, lg or 2g of Daflon per day. Small increases in tcPC>2 and 
decreases of tcPCC>2 were observed in all groups after three months treatment, with no 
difference seen between the different dosage regimes. No changes in laser Doppler flux
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were found. Since patients without skin changes show only minor disturbances in tcP0 2  
and tcPC0 2 levels the scope for improvement in these measures of mild venous disease 
is limited. It is only in liposclerotic skin that these parameters show large changes and 
where improvement would be significantly beneficial following any treatment.
Evidence of leucocyte activation in animal studies
Studies using fluorescence intravital microscopy in the post capillary venule of the 
hamster skin fold suggested that pre-treatment with Daflon prior to the induction of 
ischaemia significantly lower the number of leucocytes adherent to the endothelium. 
The group of animals pre-treated with Daflon exhibited less neutrophil adhesion in the 
post-capillary venules at reperfusion, compared to the control group.401 This observation 
has been speculated to be linked to the protective effect of flavonoids in the treatment of 
oedema, as decreased activation is also associated with a decreased platelet and 
complement system activation, leading to a lowered release of histamine and decreased 
leucocyte-dependent endothelial damage 417. In another model of the microcirculation, 
small bowel and cremaster of rats, Korthuis showed that Daflon inhibits leucocyte 
adhesion and migration induced by ischaemia/reperfusion 17, 400. Basal expression of 
ICAM-1 was not modified, but Daflon markedly reduced the increased expression of 
ICAM-1 after 4 hours reperfusion. In contrast, post ischaemic P-Selectin expression was 
not modified by Daflon treatment.18 In a rat model of venular occlusion, treatment with 
Daflon® significantly decreased the number of rolling, adherent and migrating 
leucocytes in the rat mesentery418 Daflon reduced neutrophil expression of CD62L, 
even though CD 18 was not affected.19 Bouskela has also confirmed this in the hamster 
cheek pouch model of the microcirculation.400 These data from animal studies suggest 
that Daflon acts as an anti-inflammatory drug by reducing leucocyte adhesion.
Effect on leucocyte adhesion and endothelial activation in human studies
A recent pilot study has been conducted at the Middlesex Hospital vascular laboratory 
using Daflon®. 20 patients with chronic venous disease (CEAP clinical stage 2-4) were 
treated for 60 days with Daflon® twice daily taken orally. The expression of the 
leucocyte adhesion molecule CD62L was substantially decreased on monocytes and 
neutrophils by Daflon treatment, however, CD lib  expression was not modified. This 
finding suggests that leucocyte L-selectin interaction with endothelial selectins 
responsible for the initial stages of adhesion may be modulated by Daflon, reducing the
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likelihood of leucocyte adhesion and presumably acting as an anti-inflammatory 
treatment.
Significant down regulation of plasma levels of VCAM-1 and ICAM-1 activity 
following therapy was also noticed indicating that endothelial damage in venous disease 
is mitigated by Daflon treatment. In this study the plasma VEGF levels decreased in 
patients with stage C4 chronic venous disease after treatment with Daflon (98-57 
pg/ml), but not in patients with stages 2 and 3.15 These findings may suggest possible 
mechanisms by which Daflon exerts an effect and improves venous ulcer healing 409. In 
any case, it is further evidence of mitigation of the inflammatory responses in CVD by 
MPFF. Further investigation is needed to confirm these findings in a randomised 
double blind placebo controlled study in different groups of patients.
Hydroxyethylrutosides (Oxerutins, Paroven®2)
Hydroxyethylrutosides is a standardised mixture of semisynthetic flavonoids, mainly 
mono-, di-, tri-, and tetra hydroxyethylrutosides, which acts primarily on the 
microvascular endothelium to reduce hyperpermeability and oedema. This drug and 
troxerutine have also been used with variable effects on CVD symptoms.
Adverse effects of flavonoids:
Reported adverse events with drug therapies are nausea, headache, gastric pain/cramps 
and insomnia. They do not appear to be significant differences between agents in the 
frequency of side effects, although certain adverse events are more common with 
certain drugs.
Calcium dobesilate, a synthetic venotonic, has been tried in various clinical trial with 
certain efficacy and Horse chestnut extract, Coumarine rutine, Dihydroergotamine, Red 
vine leaf extract (RVLE) have also been used with limited success in some symptoms 
relief.
These have been summarised in the table 1.8.
2 Novartis Consumer health
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Non-Venoactive drugs:
A variety of other systemic drugs have been used in patients with venous disorders 
especially for ulcers.
Diuretics for oedema, Antimicrobials, Zinc, Fibrinolytic agent stanozolol, Defibrotide, 
Haemodialysate, Naftidrofuryl (Praxilene®3), Flunarizine, Aspirin, and Various 
medicated dressings have also been evaluated in ulcer healing in various trials with very 
limited efficacy.
Drugs those modify leucocyte metabolism
Disappointment with existing pharmacological treatments has led to the search for 
alternative lines of drug treatment on venous skin damage. The discovery of the 
involvement of leucocytes in the development of venous ulceration has opened new 
avenues of investigation in this area. Two drugs, which modify white cell activation 
prostaglandin El (PGEi) and the prostacyclin analogue Iloprost 4 did not show any 
convincing benefits in ulcer healing.
Pentoxifylline (Trental®5)
Pentoxifylline has been used for the treatment of claudication for a number of years, 
with moderate success 419. It has been shown that it actually has a potent effect on 
inhibition of cytokine-mediated neutrophil activation, which appears to be independent 
of other known activators of neutrophils such as TNFa 145. They also showed it to 
reduce white cell adhesion to endothelium and to reduce the release of superoxide free 
radicals produced in the so-called respiratory burst characteristic of neutrophil 
degranulation.
In a rigorous multi-centre placebo-controlled double blind prospective study 146 of 80 
patients with venous ulcers, pentoxifylline has been shown to result in statistically 
significant better healing rates of ulcers than placebo. A randomised, double blind 
placebo controlled trial, parallel group study of factorial design, permitting the 
simultaneous evaluation of alternative pharmaceutical, bandaging, and dressings
3 Merck-Lipha Pharmaceuticals, UK
4 Schering, Berlin
5 Hoechst Marion Roussel, UK
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materials was performed by the same authors in 200 patients with confirmed venous 
ulcers using Pentoxifylline 400 mg three times daily or placebo. It showed complete 
healing occurred in 65 of the 101 (64%) patients receiving pentoxifylline and 52 of the 
99 (53%) patients receiving placebo. The difference in the healing rates between patients 
taking pentoxifylline and those taking placebo did not reach statistical significance. 147 
The difference that they found (64% healing with pentoxifylline v 53% healing with 
placebo) would probably be clinically useful in view of the high material and labour 
cost of continuing treatment with pressure bandaging and the unpleasantness of leg 
ulcers. The study described only had a 30% power to detect this magnitude of 
difference. To have an 80% power to detect this difference would require a study with 
332 in each group.
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Table 1.8. Drugs used for relief of venous symptoms.
Symptoms Drug with efficacy shown in 
clinical trial
Heaviness Diosmin 398, Coumarine rutine, 
Dihydroergocristine420, Rutosides421, 
Calcium dobisilate
Discomfort Calcium dobisilate
Cramps Calcium dobisilate, Rutosides, 
Dihydroergocristine, Coumarine 
rutine
Pain and aching Micronized Diosmin 398, Calcium 
dobisilate, Dihydroergocristine, 
Coumarine rutine, Tribenoside 
(better than Diosmin)422
Sensation (subjective symptoms) of swelling Rutosides
Tightness and paraesthesiae Dihydroergocristine 420
Restless leg syndrome Calcium dobisilate
Paraesthesiae Calcium dobisilate, Coumarine 
rutine
Fatigue, tiredness and tenderness Rutosides
Sensation of warmth Dihydroergocristine
Global symptoms Ruscus asculteatus 423 for 8 weeks, 
calcium dobesilate for 4 weeks, 
Daflon 500mg 424 bd for 4 weeks, 
hydroxyrutosides in skin changes 
group (Widmer class 2)
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Summary review of microcirculation in CVD: capillary circulation, endothelium, 
angiogenesis and free radicals
Although the exact pathogenesis of skin damage in chronic venous disease is unclear, 
the currently favoured theory is the ‘white cell trapping hypothesis’ which postulates 
that venous hypertension leads to inappropriate leucocyte activation with release of 
toxic metabolites and free radicals resulting in skin damage. In recent years, it has been 
recognised that the capillaries and other small vessels in the tissues play an extremely 
important role in many conditions, including inflammation, immunity, tumours and 
ischaemia. In fact, the endothelium is one of the most important factors in determining the 
progress of many diseases. Researchers, by examining the mechanisms at work in the 
microcirculation of the skin in patients with CVD, have attempted to explain the 
development of venous leg ulcers.
The microcirculation of the skin has been studied by histological methods 108 and by 
capillary microscopy 425. Observation of capillaries during ambulatory venous 
hypertension shows that they dilate and that there is a considerable reduction in their flow 
velocity. These factors combine to reduce the shear rate in the microcirculation, an 
important factor influencing leucocyte adhesion. 135 A reduction in shear rate favours 
neutrophil adhesion, which probably occurs in the post-capillary venule. The trapped 
leucocytes become activated releasing free radicals and proteolytic enzymes resulting in 
endothelial injury. Over a long period, this damages the microcirculation.
Many factors remain to be fully explained. The progress from the chronic inflammatory 
state to actual ulceration is difficult to investigate and there is no animal model. A 
possible answer is that an initiating stimulus causes massive activation of the peri­
vascular macrophages resulting in extensive tissue and blood vessel destruction. This may 
be a spontaneous event such as thrombosis of one of the capillary loops, which has been 
observed using capillary microscopy 426. Alternatively, minor trauma to the region may 
set in motion the series of events, which leads to ulcer formation.
It seems likely that VEGF may account for at least some of the vascular proliferation seen 
in the skin of patients with venous disease. This growth factor is also responsible for 
increased vascular permeability to large molecules, a feature of the skin microangiopathy 
that has been reported from capillary microscopy studies 425. The mechanism of 
stimulation of epidermal VEGF production is unclear at present. The median plasma
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VEGF levels among patients with C3/C4 CVD have been found statistically 
significantly higher than control subjects 8. The source of the plasma VEGF increase 
cannot be deduced from this study, however, there remains the possibility that this may 
be one of the factors leading to vascular proliferation in the skin of patients with venous 
disease.
The studies referred to above suggest that a number of events are involved in the 
development of the microangiopathy of the skin which accompanies chronic venous 
disease of the lower limb. Endothelial adhesion is a normal physiological activity of 
neutrophils and monocytes. The chronic changes seen in liposclerotic skin may be the 
response to sustained, low-grade endothelial injury by neutrophils and monocytes over 
months or years. The perivascular infiltration of vessels in the papillary dermis by 
macrophages and T-lymphocytes may simply be a tissue response to the chronic 
inflammatory processes referred to above. A consistent pathological feature in patients at 
risk of venous ulceration is the development of vascular proliferation in the skin, and 
liposclerotic skin change. Whether this is simply an associated phenomenon or crucial to 
subsequent ulceration remains unclear at present. VEGF is probably one of the angiogenic 
factors involved in the development of this change.
Ischaemia allows the breakdown of the normal mechanisms of defence against free 
radical injury. The neutrophils cause occlusion of capillaries in re-perfused tissues 136. 
When they are activated and producing free radicals they become even more difficult to 
deform and adhere to the endothelium occluding the capillaries. Two major groups of 
compounds called the selectins and the integrins are responsible for this adhesion 
process and elsewhere are important in the adhesion of cells to one another. When 
activated, neutrophils are able to increase the amount of the integrin CD 1 lb/CD 18 on 
their surface by a considerable amount. This greatly increases the tendency of 
neutrophils to adhere to capillary endothelium.
The capillary endothelium is responsible for the production of a wide range of 
vasoactive compounds. In health, it produces prostacyclin, which favours vasodilation 
and inhibits neutrophil adhesion. It also produces endothelium derived relaxing factor 
(EDRF) i.e. nitric oxide 295. This is a vasodilator and also inhibits neutrophils adhesion. 
Thromboxane A2 (TXA2) and leukotriene B4 (LTB4) are produced by ischaemic 
endothelium. The TxA2 is strongly chemo-attractant to neutrophils and is released
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following an ischaemic stimulus. LTB4 is bound specifically on the surface of 
neutrophils and enhances expression of surface adhesion molecules, favouring the 
accumulation of neutrophils in ischaemic tissues.427 The neutrophils are attracted by 
and activated by these compounds resulting in triggering of the ‘respiratory burst’ with 
further release of free radicals. This process compounds the damage already caused and 
produces further endothelial injury to the microcirculation.
In one study, levels of plasma nitrate in the patients of systemic sclerosis correlated 
significantly with levels of sVCAM-1 and sE-selectin and approached a significant 
correlation with sICAM-1, suggesting that activated endothelial cells may produce
AJO
plasma nitrate. Inflammatory processes are regarded as important in the pathogenesis 
of skin changes seen in CVD 12. Increased leucocyte activity can damage the skin and 
the vein wall itself leading to valvular failure. In the chronic stages, there is a reparative 
tissue response that exists alongside the inflammatory response.429 Many growth factors 
including VEGF are involved in the reparative response 43°. It has recently been found 
that VEGF may induce the production of iNOS that may, in turn, result in the 
production of damaging amounts of the free radical NO. In addition, the cytokines TNF- 
a, IL-ip, and INF-y synergistically activate iNOS expression in the liver, and the 
human iNOS gene was first cloned from cytokine-stimulated hepatocytes.304 This may 
be a key factor in leading to skin damage in patients with venous disease.
8 8
Hypotheses:
1. Venous disease is associated with a systemic inflammatory response.
2. The severity of the response is associated with the severity of venous disease.
3. The inflammatory response can be assessed from markers of inflammation 
reflecting leucocyte activation, endothelial cell damage and free radical 
production.
4. The capillary microscope can be used to quantify the severity of venous disease.
5. The severity of capillary convolution seen through the microscope correlates 
closely with the CEAP clinical stage of venous disease.
6. Venous reflux assessed by photoplethysmography and skin changes in venous 
disease measured by tissue tonometry correlate with the CEAP clinical stage of 
venous disease.
7. The flavonoid drug Daflon which influences oedema and symptoms of venous 
disease exerts its effect by acting as an anti-inflammatory drug, reducing the 
systemic response to venous disease reported previously by a number of authors.
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Chapter 2
M E T H O D O L O G Y
Enzyme Linked Immuno Sorbent Assay (ELISA)
Principles
Plasma selectins and integrins, VEGF and cytokines were measured using antigen 
capture ELISA or sandwich ELISA. The wells of standard 96 well ELISA plastic plates 
are pre-coated with a specific monoclonal antibody against an interested antigen. Test 
samples are added and the relevant antigen in the samples is captured by the antibody in 
the well. Unbound antigen in the sample is then washed out and the polyclonal 
antibody against another epitope of the same antigen conjugated to an enzyme is added 
to bind to the antigen. Unbound antibody is then washed out and a chromogen substrate 
is added to react with the enzyme on the bound antibody to produce a colour product. 
The enzymatic reaction is then stopped at a certain o f time. The optical density (OD) is 
measured by ELISA reader. A series of different known concentrations of specific 
antigen are assayed within the same run with the test samples and their OD are used to 
create a standard curve, which is the curve plotting between concentration and OD. The 
concentration of the specific antigen in the samples is read off from the curve using 
their OD. (Figure 2.1)
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Figure 2.1: Principles of sandwich ELISA. See text for detail. (From Stites 1994)
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ASSAYS FOR FOLLOWING THE BIOLOGICAL PARAMETERS have been 
described in appendix 3.
• sIC AM-1 (ng/ml)
• sVCAM-1 (ng/ml)
• sP-selectin (ng/ml)
• sE-selectin (ng/ml)
• Von Willebrandt factor (IU/ml)
• sL-selectin (ng/ml)
• IL la (pg/ml)
• ILlp (pg/ml)
• TNFa (pg/ml)
• EL-6 (pg/ml)
• VEGF (pg/ml)
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FLOW CYTOMETRY 
Principles
Flow cytometry is the analysis of cellular or particle characteristics in a fluid suspension 
as they pass singly through a beam o f light. The scattered light (both forward or low 
angle and side or 90° angle) and fluorescence intensity are measured by a set of 
photodetectors. The data collected by these detectors is transferred into a computer for 
further processing, analysis and display of the results. There are four basic 
compartments to a flow cytometer: the fluid system, the optic system, the detector 
system and the data processing system. The function of the fluid system is to create a 
stream of single particles flowing through the flow cell or flow chamber from sample 
tube through to waste tank. This is achieved by hydrodynamic focusing, in which the 
sheath fluid is wrapped around the test sample and both are pumped together in the 
same direction along a tiny tube then ejected directly through the flow chamber. The 
sheath fluid acts as a fluid ring singly escorting the sample particles through the flow 
cell (Figure 2.2). The flow rate can be adjusted to allow between less than a hundred to 
over a thousand particles passing through the flow cell per second. The function of the 
optic system is to bring the laser beam into intersection with the particles passing 
through the flow cell. Light detectors placed downstream and at 90' to the beam detect 
size-dependent forward scatter and granularity-dependent side scatter of the beam. 
Additionally, further detectors record any fluorescence from antibody-conjugated 
fluorochromes that may have bound to specific membrane components on the cells 
under analysis (Figure 2.3). Finally, the function of the data processing system is to 
integrate all signals collected and display them as frequency distribution plots or 
histograms. Histograms may be displayed as single parameter (one parameter versus 
count) or as two parameter dot plots where the relationship of two parameters to each 
other is displayed with count as the Z-axis (Figure 2.4). The computer workstation 
allows the operator to reanalyse previously stored data sets using different gate and 
histogram assignments. Flow cytometry is much more powerful than light or 
fluorescent microscopy on a blood smear because of the higher number of cells 
analysed, which can be as many as 50,000 cells within a few minutes. The limitation of 
flow cytometry is that the samples have to be free particles suspended in fluid, so the 
solid tissues have to be digested into single cells before analysis.
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Figure 2.2: Flow cell of Coulter Epics XL-MCL flow cytometer (From Beckman Coulter Epic XL- 
MCL instruction manual. Beckman Coulter, Inc. P.O. Box 3100, CA 92834-3100, USA.)
The process begins with the flow of isotonic saline solution called the sheath. The 
sheath enters the flow cell from beneath and flows upward. The test sample, which 
contains particles in suspension, also flows upward, contained within the sheath. 
Particles are constrained with the core of the sheath by hydrodynamic forces and 
therefore pass very precisely through the centre of the laser beam. Particles interact with 
the beam, producing scatter and fluorescence signals, which are sent to the processing 
electronics via the light detectors.
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Figure 2.3: Optical system of Coulter Epics XL-MCL flow cytometer (From Beckman Coulter Epic 
XL-MCL instruction manual). PMT: Photo Multiplier Tube; FL: fluorescent channel; SS: side scatter; 
FS: forward scatter; DL: Dichroic long pass Filter; BK: Blocking filter; BP: Band Pass.
The optical system includes forward scatter (FS), side scatter (SS), fluorescent detectors 
FITC (FL1 for 525 nm) and PE (FL2 for 575 nm) respectively. The signals are 
transferred to a computer for further processing and display of results.
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Figure 2.4: Two types of flow cytometric histograms used in our study (From left—>right) Single­
parameter histogram, Double-parameter histogram
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Figure 2.5: Appearance of Coulter Epics XL-MCL flow cytometer (From instruction manual o f  
Beckman Coulter, Epics XL-MCL, USA).
The Coulter Epics XL-MCL has 4 major parts: Work station (a computer controlling all 
functions, processing and display of results both via the monitor and print out from a 
printer), Cytometer (flow cytometer), Multi-tube carousel loader (MCL) and Power 
supply (supplying both electric current and positive pressure).
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Procedure for C D llb  and CD62L assay
Blood collection
Samples of peripheral blood were collected from a foot vein into a citrate anticoagulated 
bottle. All samples were stored at ambient temperature and analysed within two hours 
of collection. Granulocytes (neutrophils) and monocytes were selected by value of their 
forward and side scatter properties. CD1 lb and CD62L expression were measured using 
CD1 lb FITC and CD62L PE antibody conjugates (Beckman-Coulter).
Staining
Samples were challenged with the chemotactic peptide FMLP and a diluent control. 
Briefly, 50 pi of whole blood was added into each of 4 tubes and to half of the tubes 5 
pL of FMLP (final concentration 100 nMol in Dulbecos PBS) (Sigma F-3506) was 
added to half of the samples and other half was prepared with same amount of diluent. 
Samples were incubated at 37 °C for 10 minutes. All samples were then brought to O’C 
on ice. To each tube, 5ul of appropriate antibody was added. Anti CDllb (MO-1) was 
added into two 2 tubes and anti CD62L (TQ-1) into 2 tubes and incubated on ice for 40 
minutes. At the end of this time, cells were treated using the immunoprep system 
(Beckman-Coulter) to remove red cells from the sample by hypotonic lysis.
Flow Cytometry
A Coulter Flow Cytometer (Coulter Epics ELITE, Coulter Electronics Ltd, UK) was set 
up such that PMT3 measured PE and PMT2 FITC fluorescence.
Instrument voltage and gain parameters were as follows:
Forward scatter Side scatter PMT2 PMT3
Volts 181 174 910 760
Gain 5 1 1 1
The contribution of cell aggregates was excluded electronically (by pulse integral/ 
height analysis). Fluorescent signals were collected at 525 +/- lOnm for CD l ib  FITC 
& 575 +/- lOnm for CD 62L PE. A gate was placed on the neutrophil and monocyte 
populations on the forward/side scatter dot plot. At least of 5000 Monocyte events and 
>10,000 Neutrophil events were collected. Data was expressed on a logarithmic single 
parameter histogram and the mean cell fluorescence (MCF) recorded in arbitrary units.
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All data obtained was standardised by ratioing the fluorescent values against standard 
fluorescent microparticles (Beads).
Data calculation technique
Data was expressed as % up or down regulation using this formula:
[(Post-stimulated value -  pre-stimulated value)/pre-stimulated value] * 100 
= % Up regulation of basal level.
In addition, absolute basal values for CD1 lb and CD62L were calculated using the 
following formula:
MCF (-FMLP)*(reference calibration bead value)/(Test bead value))
Their unit was expressed as Fluorescent unit.
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The Griess Reaction
PRINCIPLE OF THE ASSAY
The transient and volatile nature of NO makes it unsuitable for most convenient 
detection methods. However, since most of the NO is oxidised to nitrite (NO2- ) and 
nitrate (NO3- ), the concentrations of these anions have been used as a quantitative 
measure of NO production. After the conversion of NO3- to NO2-, the 
spectrophotometric measurement of NO2-  is accomplished by using the Griess 
Reaction. The interaction of NO in a system is measured by the determination of total 
nitrate and nitrite concentrations in the sample. Serum and plasma samples must be 
filtered through an ultra-filter with MW cut-off at 30 kDa to avoid interference from 
coloured proteins, for example bilirubin and haemoglobin, since there is no washing 
step.
Assay of Total NO was performed using a colourimetric Griess reaction. A kit supplied 
by R&D systems (R&D Systems Europe, Abingdon, Oxon, UK; Catalogue Number 
DEI600) was used. Plasma levels were read from standard curves obtained by means of 
plotting mean absorbance for standards.
This assay determines total nitric oxide based on the enzymatic conversion of nitrate to 
nitrite by nitrate reductase. The reaction is followed by a colourimetric detection of 
nitrite as an azo dye product of the Griess Reaction. The nitrite is coupled to Griess 
reagent 1 (sulphanilamide) and Griess reagent 2 [N-(l-Naphthyl) ethylenediamine] to 
form a deep purple azo-product. The Griess Reaction is based on the two-step 
diazotization reaction in which acidified N02- produces a nitrosating agent, which 
reacts with sulfanilic acid to produce the diazonium ion. This ion is then coupled to N- 
(1-naphthyl) ethylenediamine to form the chromophoric azo-derivative, which absorbs 
light at 540 nm.431 The optical intensity (OD) of the final product is directly correlated 
with the concentration of total nitric oxide metabolites (Nox or nitrates plus nitrites). 
Serial dilution of known nitrite concentration solutions and their OD are used to create a 
standard curve. The concentration of Nox in the samples is read off from the curve 
using their OD.
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Figure 2.6: Principles of the Griess Reaction. See text for detail. (From Cayman Chemical, NO assay 
instruction manual)
Reproducibility: (Data supplied by the manufacturer)
Intra-assay Precision (Precision within an assay): Three samples of known 
concentration were assayed eight times on one plate to assess intra-assay precision. 
Inter-assay Precision (Precision between assays): Three samples of known 
concentration were assayed in eight separate assays to assess inter-assay precision.
Sample
Intra-assay Precision Inter-assay Precision
1 2 3 1 2 3
n 8 8 8 8 8 8
Mean (pmol/L) 20.9 50.9 68.5 18.7 48.8 68.2
Standard
Deviation
1.1 1.6 0.8 1.3 2.0 2.3
CV (%) 5.3 3.1 1.2 7.0 4.1 3.3
The average percentage recovery of nitrate spiked into EDTA plasma sample was 96%, 
range 90 - 102%.
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Capillary videomicroscope
The CAM1 Capillary Anemometer has a high resolution (752x582 pixel) monochrome 
charge-coupled device [CCD] video camera. Four ultra-bright light emitting diodes 
(LEDs) epi-illuminate the skin at a wavelength of 525 nm (green). A microscope is 
attached to a heavy support to allow 3 dimension adaptations to the skin surface. The 
image is magnified by 6.3 times to give an overall magnification of about 1.23 
um/pixel. The standard CCIR video signal is digitised and displayed by a Matrox 
Pulsar frame grabber in the PC at 25 frames per second. Gain and offset of the video 
input signal can be adjusted by the CapiScope software to maximise the use of the 8 bit 
dynamic range of the frame grabber. Single images or video sequences can be captured 
and saved to disc by the CapiScope software for later analysis. Analysis functions 
available include velocity, automatic diameter, capillary number density and capillary 
area density. This was manufactured by KK Technology, UK.
Conventional capillary microscopy is of limited use in the skin of the leg. It is usually 
employed in the nail fold where capillary loops run horizontally in the skin. Elsewhere 
the nutritional capillaries pass from deep to superficial, running perpendicularly to the 
skin surface, which has implications on flow velocities. A device termed capillary 
video-microscope was used through which capillary loops can be visualised and skin 
capillaries can be counted.
Using capillary microscopy it is possible to study the nutritional capillaries in the skin 
directly and non-invasively. In this way, abnormalities in morphology can be observed, 
and capillary blood velocity measured,432 although only in certain sites such as the nail 
fold, and only a small sample of capillaries can be studied at a time. A significant 
problem in human subjects is that of movement, although various systems attempt to 
eliminate or compensate for this. In spite of its limitations, microscopy is still regarded 
as the "gold standard" for measuring nutritive capillary blood flow 433 In fact, 
capillaroscopy demonstrated to have the highest sensitivity in finding out the 
pathological alterations in patients with CVD complaining of symptoms but with 
normal Doppler ultrasonographic findings when compared with clinical examination 
and infrared photoplethysmography 434
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Capillary density and morphology
I assessed both the capillary density [number of capillaries per unit area] as well as the 
complexity of the capillary morphology. All clearly identifiable capillary loops in a 
field were considered to be part of the total capillary count for that area. These were 
considered to be ‘visible capillaries’. Due to the fact that not all parts of every capillary 
were in focus or within the image, not all of the visible capillaries could be evaluated 
for their morphology. Only those capillaries, which were clearly visible, were 
considered to be ‘evaluable’. The total number of visible capillaries was counted in a 
2.4mm region, where one field is 0.6 mm . Within each capillary, the number of 
convolutions was also counted. Capillary density was determined by counting the 
number of capillaries (as shown in figure 2.7a) seen in an area of 1 mm2 of skin. 
Morphology was assessed by counting the number of ‘convolutions’ or loops per 
evaluable capillary. We counted a 180-degree reversal o f direction as a capillary loop. 
Each of these was counted as a convolution (as shown in figure 2.7b), the number of 
convolutions for each evaluable loop scored 1 - 1 0  and >10 when more complex 
capillaries contained more than 10 loops.
Figure 2.7: a)A single capillary loop and b) multiple convolutions arising from a single capillary. 
Arrows indicate the loops and convolutions.
The measurements were repeated with the subjects standing supported for 10-20 minutes 
(enough time to be allowed for the venous pressure to rise), using a high stool to maintain 
comfort and balance. Recordings were made in the same region of the limb as before.
I obtained the capillary counts in the ankle region over the gaiter area or most affected 
part of the leg with skin changes, and also count the number of capillary loops and thus 
morphology by counting the loops of capillary in controls, and subjects with varicose 
veins in supine and dependency.
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Figure 2.8: Pictures o f capillary microscope set up and showing the investigator studying the supramalleolar
region in a seated patient.
Photoplethvsmographv
Protocol for venous reflux test by photoplethysmography (PPG)
The model PPG13 Vasculab® Photoplethysmograph (PPG) (Medasonics, Mountain 
View, California) was used in this study. It serves as a preamplifier and power supply 
and was used with the model PH77 PHOTOPULSE® Photoplethysmograph sensor.
PROCEDURE
The subject was examined in the sitting position with the lower limbs dependent and 
with the transducers attached using a double-sided tape 5cm proximal to the medial 
malleolus. A stable trace was established, and the subject was asked to perform a series 
of 10 dorsiflexions and plantar flexions at the ankle to activate the calf muscle pump. 
This produced an emptying phase in which the falling content of haemoglobin resulted 
in increased amounts of light reaching the photo detector. The subject was then asked to 
rest and the refilling phase recorded. Tests were repeated three times.
The time taken for the trace to return to the baseline level was referred to as the PPG 
refilling time. It was measured by placing the start cursor at the end of the exercise 
phase and the end cursor at the end of the refilling phase where the trace started to level 
off. In normal subjects, this refilling time is greater than 20 seconds whereas abnormal 
subjects with incompetent veins will have refilling times of less than 20 seconds.
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Protocol to measure skin compliance test by Tissue Tonometry 
The Middlesex Hospital tonometer
A durometer has been used to determine the degree of induration in LDS by Romanelli 
and Falanga 435 based on previous work done on the assessment of skin hardness in 
patients with systemic sclerosis (scleroderma) by Falanga and Bucalo 436. An instrument 
to record the depth and rate of pitting in lymphoedematous arms objectively was also 
developed by Bates et al in London 437 based on the Clodius tonometer. A mathematical 
model the Kelvin-Hooke model was proposed to analyse the pitting curves obtained 
from the instrument and to determine the spring and dashpots constants. Subsequently, a 
tissue tonometer has been developed into the Vascular Laboratory at the Middlesex 
Hospital to measure skin compliance in lipodermatosclerosis. It is based on the 
tonometer designed by Bates et a l437
The tissue tonometer, a simple, non-invasive device, which consists of a plunger, may 
be loaded by different weights. The plunger (4 mm diameter) is attached to a caunti- 
lever bar, which pivots and is connected to a linear variable differential transformer 
(LDVT), a position sensing device. This device senses the movements of the plunger, 
which is placed on the skin and then released by a cable release mechanism and allowed 
to sink into the tissues by under the force of a weight applied to the plunger. The signals 
obtained by the LVDT in the tonometer are converted by an analogue to digital (A/D) 
converter in the computer into the traces displayed on the computer screen.
The tissue tonometer can be positioned on the gaiter area of the lower extremity by 
contouring one end around the calf and resting the other end on the medial malleolus. 
The gaiter region is the area most characteristically affected by pigmentation, 
lipodermatosclerosis and ulceration as a consequence of venous disease. The contoured 
edge provides stability of the tonometer in the area of interest.
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Procedure:
The subject is asked to lie in the supine position with the body weight distributed on the 
lateral aspect of the limb to be investigated with the knee slightly flexed, resulting in the 
lateral condyle of the knee and the lateral malleolus resting against the couch, thus 
making the tissue tonometer more stable. To improve equipment stability during 
measurements, a Velcro cuff is placed around the calf so that the contoured end of the 
tonometer rests on it to prevent it from sliding or falling off.
The tonometer is calibrated prior to each measurement. After calibration, the tissue 
tonometer is placed on the subject's lower limb as described above and the plunger 
positioned above the area of interest and gently lowered onto the skin by means of a 
knob control on the tonometer until the plunger is just touching the skin, without 
causing any indentation. The tonometer is allowed to settle on the subject's lower limb 
for 5 minutes to ensure that the ends of the tonometer have stabilised to prevent any 
further sinking into the tissues during recording.
The plunger with a 30 g weight in place is allowed to drop under gravity on to the skin 
by releasing it with the cable release mechanism. The plunger is allowed to sink into the 
skin for 5 minutes under gravity. The first 10 seconds, the fast phase, is recorded in a 
faster mode (x 10) to obtain enough data points for analysis of the skin compliance, 
since this initial stage happens rapidly, within 1 second. After the first 10 seconds, the 
plunger steadily sinks into the skin and the recording mode then automatically switches 
to normal speed to record the lower subsequent stage. Specially written software is used 
on the IBM compatible PC to record and analyse the traces.
The traces were divided into three phases: phase I, phase II and phase IE.
Phase I occurs within the first second to reflect the initial rapid indentation phase. The 
start cursor is placed at the site indicating where the plunger is released unto the tissues 
and the end cursor is placed at the end of the straight line just before the start of the 
creep phase. The distance between the start and end cursors will give the distance 
travelled in mm during phase I.
It was necessary to subdivide the subsequent slower indentation phase or creep phase 
into phases II and ID with the former lasting from 1 to 10 seconds and the latter lasting
from 10 to 300 seconds because a mono-exponential regression line did not fit the 
whole of this part of the trace and it was better to use two exponential regression lines. 
For phase II, the start cursor is placed at the beginning of the creep phase and the end 
cursor is placed at the 10 second mark, which is shown on the computer screen. The 
specially written software then plots a mono-exponential regression line to provide the 
distance parameter in mm and the rate constant parameter (-1/tau in seconds'1), which is 
the slope of the line.
For phase III, the distance and rate constant parameters are calculated from a mono­
exponential regression line after the start and end cursors are placed at the 10 second 
mark and 300 second mark respectively.
The tissue tonometer had been adapted to cope with the change in speed between the 
initial fast indentation phase and the subsequent slower indentation phase with the 
recording mode in the first ten seconds of indentation, the rapid indentation phase, set at 
40 samples per second which automatically switched to a slower speed of 4 samples per 
second to record the relatively slower subsequent indentation phase in the last 290 
seconds.
Five minutes of recording following release of the plunger was selected for all 
measurements using the tissue tonometer after it was observed in preliminary 
measurements that the trace levelled off before 5 minutes had elapsed and that five 
minutes recording was reasonable before patient fatigue and/or restlessness sets in 
which may introduce ‘noise’ into the data.
Chapter 3: STUDIES
Patients and Volunteers
The studies below include a large cohort of patients with venous disease being treated in 
the vascular clinic at The Middlesex Hospital. The data from these patients are included 
in chapters 1, 4, 5 and 6 . A further series of patients with venous disease was included 
in the group studied in chapters 2 and 3. A separate set of volunteers has also been 
investigated and their data from investigations on this group has been included in 
chapters 1, 3 and 4. Patients were recruited according to the internationally agreed 
CEAP classification, rather than on the basis of duplex ultrasonography, which was 
used to confirm that venous reflux was present in the patient groups. The control groups 
did not undergo duplex examination but were classified clinically according to the 
CEAP criteria, I acknowledge that there is the possibility that some of the control 
subjects may have had venous reflux in the absence of any obvious symptom or clinical 
sign. The reason for reporting the data in separate studies is to facilitate the task of 
understanding the very large amount of data accumulated during these investigations.
Study 1:
Leucocyte-endothelial activation markers, vWf, cytokines and VEGF in the blood 
of healthy controls and patients with chronic venous disease
Rationale
Leucocyte activation, endothelial injury and free radical damage have been 
hypothesised as the possible causes for the skin changes seen in advanced stages of 
CVD. Previous studies have shown leucocyte adhesion occurs in the lower limb in 
response to experimental venous hypertension 12,13. This process results in modulation 
of leucocytes regulation and is exaggerated in patients with venous disease compared to 
normal controls. Local release of cytokines in the microcirculation is thought to be the 
initiating factor.
Vascular endothelial cells commonly express the adhesion molecules E-selectin, ICAM- 
1 and VCAM-1 and their expression is known to be inducible by a number of cytokines
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(IL-1, TNF-a etc) plus ECM molecules 205,438,207’208,209. Monocytes release IL-I and 
TNF-a when activated 141 and IL-6 is produced by a variety of cells including vascular 
endothelial cells, monocytes/macrophages 241 ’ 242. The expression of several known 
VEGF-A isoforms is also induced by cytokines such as IL-lp and EL-6 280. There has 
been no study to explore the role of cytokines in various stages of chronic venous 
disease.
The proliferation of the capillary endothelium in the skin of patients with CVD has not 
been fully explained, although production of VEGF in the epidermis has been 
demonstrated by immunohistochemistry7 as well as found to be elevated in the plasma 
of certain patients group (C3/C4)8.
Venous disease results in many different symptoms. The Edinburgh Vein Study 29 found 
little relationship between the symptoms reported by the patient and the severity of 
venous reflux detected by duplex ultrasonography. Perhaps this variation is attributable 
to the difference in inflammatory response to venous disease.
The aim of this study was to investigate the soluble leucocyte-endothelial adhesion 
molecules in the blood of a superficial vein in the leg of patients with venous disease as 
compared to healthy controls. As a measure of activation, I assessed cell surface 
expression of the integrin CD lib  and the selectin CD62L on neutrophils and 
monocytes. Plasma levels of soluble E-selectin, P-selectin, sICAM-1, sVCAM-1 and 
vWf and L-selectin were also measured as an index of leucocyte-endothelial adhesion.
I also investigated the plasma cytokines such as IL-la, EL-lp, IL-6 and TNF-a and 
plasma VEGF levels in the microcirculation of legs of the healthy controls and in all 
stages of patients with CVD. The patients’ symptoms were recorded using a visual 
analogue scale and correlated with various markers in different disease groups.
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Material and Methods
Patients considered for the entry into the study were those of attending The Middlesex 
Hospital Outpatient for the management of venous disease. Those suitable for the 
inclusion in the study were canvassed by a letter of explanation indicating the nature of 
the study. Patients with CEAP clinical class C2 (varicose veins), C3 (oedema), C4 (skin 
changes) and C5 (healed ulcer) were considered. Thirty normal healthy volunteers acted 
as control subjects (CO), This group comprised of the members of the department of 
Surgery and Haematology, patients treated for unrelated conditions at London Foot 
Hospital and normal healthy volunteers from general public. They had no symptoms or 
signs of arterial or venous disease of the lower limb.
Selection/inclusion criteria
■ Either sex,
■ Age above 18 years old and any race,
■ Having given their written informed consent,
■ Patients affected with stage C2 to C5 according to the CEAP clinical 
classification (for stage C5 healed ulcer for at least 4 weeks),
■ Having the diagnosis and extent of venous disease been confirmed by duplex 
ultrasonography and photoplethysmography,
Exclusion criteria
History of alcohol or drug abuse,
CVD of stage Cl or C6 according to CEAP clinical classification,
Diabetes mellitus,
Connective tissue disorders including rheumatoid arthritis,
Blood disorders,
Arterial disease (ankle-brachial index < 0.9),
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Infection within the previous 6 weeks,
Patient with concomitant acute or chronic disease that may interfere with the 
results (particularly inflammatory and/or infectious disease),
Recent deep venous thrombosis (less than 1 year),
Recent superficial venous thrombosis (less than 15 days),
Skin grafting,
Sclerotherapy, Stripping or any surgery for varicose veins in previous 3 
months
Excluded medications
■ Non steroidal anti-inflammatory agents,
■ Corticoids,
■ Salicylates,
■ Vit A, Vit C, Vit E and derivatives,
■ Pentoxyfilline, Naftidrofuryl,
■ Any kind of anticoagulant treatment,
■ Any medication known to alter white blood cell activity,
Patients and volunteers fulfilling the entry criteria and giving informed written consent 
were studied further. Approval for the study was obtained from UCL Medical School 
Committee for medical ethics.
All patients were assessed clinically by a vascular surgeon skilled in the management of 
venous diseases to assign the patient to the appropriate clinical grade of the CEAP 
classification. A medical history was taken and clinical examination performed, 
including assessment of the lower limbs. This included a systemic as well as venous 
examination. Patients included in the study underwent standard vascular laboratory 
investigation including duplex ultrasonography and measurement of 
photoplethysmography venous refilling times. The numbers of patients and controls
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studied and their age and sex distribution including their duplex findings in various 
groups of CEAP are summarised in Tables 3.1 and 3.2.
Procedure
The study was conducted in an environmental chamber at 22°C (room temperature). All 
the patients and control subjects were acclimatised for 10-20 minutes whilst lying supine 
before the start of the experimental protocol to minimise venous pressure in the leg. A 
23-gauge canula (Venisystems ™ Butterfly®, Abbott, Ireland) was placed in the distal 
long saphenous vein or dorsal foot vein of the most affected leg. 5 ml of blood was 
collected into a citrated tube and 8 ml of blood was collected into two tubes containing 
EDTA (EthyleneDiameneTetraacetic Acid) Vacutainer, Becton Dickinson Vacutainer 
Systems Europe, BP No 37-38241, France).
A full blood count, including a differential white cell count was performed on all 
subjects. Plasma from the samples were separated by centrifugation at 20,000 rpm for 
10 minutes at 4°C within one hour of collection which was promptly frozen at -84°C 
before analysis of ELISA. ICAM-1, VCAM-1 were assayed using the commercially 
available kit manufactured by Diaclone and E-selectin, P-selectin, L-selectin, VEGF 
and cytokines: IL-la, high sensitive kits of IL-lp, TNF-a and IL-6 were measured by 
commercially available ELISA kits manufactured by R & D Systems Europe, UK. Von 
Willebrand factor was measured using the kit manufactured by Shield diagnostics, 
Aberdeen, UK. The assay protocols are described in Appendix 3. The separate citrated 
samples were analysed for leucocyte surface CD lib  and CD62L expression by whole 
blood assay using fluorescent-labelled monoclonal antibodies in a flow cytometer.
The VEGF kit used enables detection of 25% of VEGF protein activity in the plasma. In 
contrast, detectable levels in serum are 100%. Thus, absolute levels of VEGF165 are 
about four times the levels depicted herein. However, detection in both serum and 
plasma is equally reliable and the manufacturer confirms that this kit is suitable for use 
with plasma samples.
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Symptom severity
The symptoms of venous insufficiency (pain, cramps, heaviness, paraesthesiae and 
oedema) were assessed by the investigator with the patient using a visual analogue scale 
(VAS). The scale was marked 0 to 10 cm, severe symptoms were graded 10 where 
absence of symptoms were marked as 0. I measured pain, cramps, heaviness, 
paraesthesiae and oedema using VAS of 10 cm. This has been shown in appendix 6.
Analysis of data
The Statistical Package for the Social Sciences (SPSS, Chicago, Illinois, USA) was used 
to analyse the data. Non-parametric tests of significance for paired and unpaired data 
(Wilcoxon matched pairs signed rank test and Mann Whitney U test) were used. The 
difference between medians and 95% confidence interval were calculated using 
Wilcoxon method Confidence Interval Analysis (British Medical Journal, London). All 
results are described as median (interquartile range, IQR). Where multiple statistical 
tests of significance had been carried out and there was doubt as to the validity of such 
testing, SPSS was used to investigate the relationship between CEAP clinical stage and 
several of the parameters measured during this investigation by univariate and 
multivariate logistic regression.
Correlation coefficient (r) was also calculated using Microsoft Excel programme.
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Results
The subjects in each of the groups were of similar age and sex distribution for each 
analysis. The number of patients with the superficial and the deep venous incompetence 
among the study groups has been summarised in the table 3.1.
For Flowcytometric analysis of CDllb and CD62L, 15 healthy volunteers (6M: 9F, 
median age 53 years, range 49-59 years) and for enzyme linked immunosorbent analysis 
of all others, 30 healthy volunteers (13M: 17F, median age 53 years, range 47 - 56 
years) were recruited. 132 patients (60M: 72F, median age 53 years, range 45-64 years) 
with chronic venous disease were included.
Stage & 
number
Sex
distribution
Age (years, 
mean value 
and range)
No. with 
superficial 
venous 
insufficiency
No. with 
deep and 
superficial 
venous 
insufficiency
Flow
cytometry: 
C D llb  & 
CD62L
Controls
(n=15)
6M: 9F 53 (49-59)
ELISA Controls
(n=30)
13M, 17F 53 (47-56)
ELISA & 
flow
cytometry
Patients
(n=132)
60M, 72F 53 (45-64) 8 1 + 9
(Deep vein not 
visualised)
42
C2 (n=47) 12M, 35F 52 (44-59) 35 11
C3 (n=18) 3M, 15F 52 (42-61) 13 4
C4 (n=44) 30M, 14F 60 (42-66) 23 18
C5 (n=23) 15M, 8F 53 (44-64) 13 9
Table 3.1: demographic data and duplex findings o f patients for the study o f  leucocyte-endothelial 
activation study.
Patients in whom VEGF was measured:
Stage & 
number
Sex
distribution
Age (years, 
mean value 
and range)
No. with 
superficial 
venous 
insufficiency
No. with deep 
and superficial 
venous 
insufficiency
Patients
(n=108)
47M, 61F 53 (44-61) 72 +(6)** 29
C2 (n=47) 13M, 34F 52 (43-59) 34 + (2)** 11
C3 (n=16) 3M, 13F 50(41-55) 12 +(1)** 3
C4 (n=29) 20M, 9F 55 (49-66) 16+(2)** 10
C5 (n=16) 11M, 5F 47 (43-62) 10+(1)** 5
** Deep vein not visualised are in parenthesis
Table 3.2: demographic data and duplex findings o f patients for the study o f VEGF study. 
The results are summarised in the following tables.
1 1 4
Flow cytometry results:
Absolute values of leucocyte C D llb & CD62L (Median (inter-quartile range) 
fluorescent units) and soluble L-selectin
CEAP stage Controls C2/C3
(n=24)
C4/C5
(n=31)
C4
(n=17)
C5
(n=14)
C D llb
Neutrophils
37
(21-44)
36
(30-53)
48
(37-55)
44
(35-51)
51
(43-56)
Diff. bet. 
medians & 
95% Cl
3
(-9-16)
11
(-1-22)
8
(-21-5)
16
(3-27)
CD62L
neutrophils
277
(240-323)
317
(275-362)
319
(292-376)
334
(296-376)
310
(291-361)
Diff. bet. 
medians & 
95% Cl
39
(-6-101)
47
(-3-100)
51
(-2-114)
43
(-8-99)
C D llb
monocytes
45
(27-72)
57
(38-73)
65
(54-75)
65
(52-73)
66
(60-75)
Diff. bet. 
medians & 
95% Cl
8
(-11-25)
18
(-1-31)
18
(-35-2
23
(2-37)
CD62L
monocytes
225
(157-288)
262
(243-299)
261
(214-289)
266
(214-298)
262
(215-284)
Diff. bet. 
medians & 
95% Cl
51
(-3-105)
32
(-18-77)
41
(-20-92)
31
(-24-92)
sL-selectin
(ng/ml)
796
(656-894)
915
(723-1120)
822
(664-990)
830
(650-1057)
820
(743-905)
Diff. bet. 
medians & 
95% Cl
137
(5-258)
40
(-48-139)
50
(-62-180)
24
(-120-71)
Table 3.3: Absolute values o f surface C D llb  & CD62L on neutrophils and monocytes and soluble 
CD62L o f  various CEAP stages. Values are in median fluorescent units for surface CD1 lb  & CD62L and 
in nanograms/ml for soluble L-Selectin with upper and lower quartile ranges in parenthesis. Median 
difference with controls and 95% confidence interval are also shown. Median differences were calculated 
using the Wilcoxon method.
C2/C3 data presented together because of smaller sample of C3 patients and C5 data 
separated from C4 to show the only significant data found in C5 even though it has 
smaller number of patients.
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Percentage u p  regulation of CD llb & down regulation of CD62L following FMLP 
stimulation (Median (IOR) %)
Controls C2 C3 C4 C5
C D llb
Neutrophils
365
(395-162)
185
(250-139)
213
(258-155)
188
(250-141)
207
(221-146)
Diff. bet. 
medians & 
95% Cl
122
(14-221)
108
(-53-211)
122 
(12- 209)
141 
(-6- 221)
JCD62L
neutrophils
60
(28-64)
57
(53-62)
59
(52-67)
60
(51-66)
64
(56-67)
Diff. bet. 
medians & 
95% Cl
1 (-7-14) 5 (-5-24) 3 (-4-21) 8 (-7-24)
C D llb
monocytes
116
(204-64)
78
(113-45)
93
(127-51)
70
(86-54)
79
(98-53)
Diff. bet. 
medians & 
95% Cl
56 
(-2 -109)
40
(-31-106)
51
(2-125)
-45
(-119-12)
JCD62L
monocytes
18 
(14- 27)
40
(33-45)
32
(27-44)
37
(24-45)
42
(34-45)
Diff. bet. 
medians & 
95% Cl
20 (12 - 27) 15 (6-28) 17 (7-27) 20 (7 - 28)
Multi-variate
logistic
regression
analysis
Multivariate logistic regression analysis shows a mod 
statistically significant relationship between CEAP clinic; 
neutrophil CD1 lb data (p=0.018) as well as with monoc;
data (p=0.002). (Results are in appendix 5)
est but 
al stage and 
yte CD62L
Table 3.4: Percentage up-regulation o f surface C D llb  & down-regulation o f surface CD62L on 
neutrophils and monocytes o f various CEAP stages. Values are in median fluorescent units for surface 
C D llb  & CD62L with upper and lower quartile ranges in parenthesis. Median difference with controls 
and 95% confidence interval are also shown. J Marked values o f CD62L indicate down regulation 
following FMLP stimulation o f leucocytes, (minus sign has been omitted for clarity). The median 
differences are between control and respective groups o f patients as shown in the respective column.
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Figure 3.1: Graph showing absolute values o f surface CD1 lb on neutrophils and monocytes in controls 
& various CEAP stages; median fluorescent units with error bars indicating the interquartile range (IQR). 
Y axis shows values o f CD1 lb in fluorescent units and X axis shows various CEAP stages.
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Figure 3.2: Graph showing absolute values o f surface CD62L on neutrophils and monocytes in controls 
& various CEAP stages; median fluorescent units with error bars indicating the interquartile range (IQR). 
Y axis shows values o f CD62L in fluorescent units and X axis shows various CEAP stages.
117
ELISA results:
sVCAM-1 shows significant elevations in all CEAP stages of CVD patients when 
compared with controls. These have been illustrated in the table 3.5 and graphs 3.3, 
3.4, 3.5, 3.6, 3.7, 3.8 below.
All results are described as median (interquartile range, IQR) ng/ml
Controls C2 C3 C4 C5
VCAM-1
(ng/ml)
*724
(599-886)
1270
(968-1566)
1265
(1066-1868)
1229*
(1059-1561)
1163
(893-1477)
ICAM-1
(ng/ml)
**453
(418-532)
545
(435-656)
550
(392-627)
**626
(453-732)
563
(439-646)
E-selectin
(ng/ml)
*34
(28-49)
43
(34-60)
39
(28-49)
t 4 6
(37-57)
40
(33-50)
P-selectin
(ng/ml)
107
(87-130)
116
(90-140)
98
(76-137)
111
(91-138)
89
(78-106)
VWf
(IU/ml)
1.19#
(1.05-1.29)
1.32
(1.02-1.72)
1.37
(1.17-1.60)
1.29#
(1.07-2.01)
1.29
(1.10-1.53)
Median diff. Vs 
controls (95% Cl) * 518(373-681); ** 114 (25-201); t  10 (2-18); 
# -0.14 (-0.36-0.04)
Multi-variate 
logistic regression 
analysis
Only sVCAM-1 reaches statistical significance with CEAP 
clinical stage (Logistic regression OR 1.015 95% Cl 1.00306 - 
1.02798)
(Results in appendix 5)
Table 3.5: Values o f  soluble adhesion molecules VCAM-1, ICAM-1, E-selectin, P-selectin (in ng/ml) 
and vW f (in IU/ml) in various CEAP stages. Values are in median with upper and lower inter-quartile 
ranges in parenthesis. Median difference between control and disease group (marked with same 
symbol) and 95% confidence interval o f the median difference calculated using the Wilcoxon method 
are also shown.
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Figure 3.3: Graph showing values o f VCAM-1 in plasma o f control subjects & patients with various 
CEAP stages; median (ng/ml) with error bars indicating the interquartile range (IQR). Vertical axis 
shows values o f  sVCAM-1 in ng/ml and horizontal axis shows the various CEAP stages.
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Figure 3.4: Graph showing values o f ICAM-1 in plasma o f control subjects & patients with various 
CEAP stages; median (ng/ml) with error bars indicating the interquartile range (IQR). Vertical axis 
shows values o f sICAM-1 in ng/ml and horizontal axis shows various CEAP stages.
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Figure 3.5: Graph showing values o f sE-selectin in plasma o f control subjects & patients with various 
CEAP stages; median (ng/ml) with error bars indicating the interquartile range (IQR). Y axis shows 
values o f  sE-selectin in ng/ml and X axis shows various CEAP stages.
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Figure 3.6: Graph showing values o f sL-selectin o f control subjects & patients with various CEAP 
stages; median (ng/ml) with error bars indicating the interquartile range (IQR). Axis is similar as in 
previous graphs.
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Figure 3.7: Graph showing values o f sP-selectin o f control subjects & patients with various CEAP 
stages; median (ng/ml) with error bars indicating the interquartile range (IQR). The CEAP stages are 
shown on the horizontal axis and vertical axis shows values o f sP-Selectin in ng/ml.
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Figure 3.8: Graph showing values o f vW f in plasma o f control subjects & patients with various CEAP 
stages; median (IU/ml) with error bars indicating the interquartile range (IQR). Axis is similar as in 
previous graphs.
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Cytokines
The values of the all cytokines analysed were lower than the ‘normal’ ranges quoted 
by the manufacturers for human plasma. IL-6 was increased in patients as compared 
to control subjects, but the values as a whole were in lesser magnitude. TNF-a was 
lower in the patient groups than the controls. IL-la and IL-lp were immeasurable in 
many patients and IL-la showed similar levels in the control and patient groups.
The results are summarised in Table 3.7.
Control C2 C3 C4 C5
TNF-a 2.5 1.1 2.2 1.9 1.4
(pg/ml) (1.9-3.2) (0.6-2.3) (1.0-13.9) (0.9-9.6) (0.9-2.3)
Median diff. Vs 1.2 0.2 0.4 1.1
controls (95% Cl) (0.7-1.7) (-1-10.8) (-1.2-1.1) (0.4-1.7)
IL -la 0 0 0.0 0.0 0.0
(pg/ml) (0-0) (0-0.7) (0-1.6) (0-1.0) (0.0-0.4)
IL-ip 0 0.3 0.3 0.4 0.2
(pg/ml) (0-0.2) (0.2-0.9) (0.2-1.1) (0.2-2.3) (0.1-0.3)
Median diff. Vs 0.2 0.2 0.2 0.1
controls (95% Cl) (-0.4-0) (-0.42-0) (0.3-0) (0.2-0)
IL-6 1.3 2.2 2.5 3.0 2.3
(pg/ml) (0.9-2.7) (1.2-2.8) (1.5-3.4) (2.2-4.0) (1.5-3.3)
Median diff. Vs 0.4 0.7 1.44 0.7
controls (95% Cl) (-0.1-1.0) (0.1-1.5) (0.62-2.08) (0.1-1.4)
^Median differences calculated using the Wilcoxon method.
Table 3.7: Values o f basal resting plasma cytokines in patients with various CEAP stages o f  chronic 
venous disease, expressed as Median (Interquartile range, IQR, ranges in parenthesis) pg/ml. Median 
difference with controls and 95% confidence intervals o f  the median differences are also shown.
1 2 2
IL-la IL-lp TNF-a IL-6
Controls 26 14 Nil Nil
C2 35 2 6 Nil
C3 10 1 1 Nil
C4 31 1 2 Nil
C5 17 1 1 Nil
Table 3.6: shows number o f patients’ samples, which had undetectable values. I counted them as ‘0’ in 
my assay calculation.
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Figure 3.9: Graph showing values o f TNF-a in plasma o f control subjects & patients with various CEAP 
stages; median (pg/ml) with error bars indicating the interquartile range (IQR). The CEAP stages are 
shown on the horizontal axis and vertical axis shows values o f TNF-a in pg/ml.
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Figure 3.10: Graph showing values of IL-6 in plasma o f control subjects & patients with various CEAP 
stages; median (pg/ml) with error bars indicating the interquartile range (IQR). The CEAP stages are 
shown on the horizontal axis and vertical axis shows values o f IL-6 in pg/ml.
VEGF
VEGF was consistently raised in all CEAP stages of CVD, but only in C5 did it reach a 
statistically significant level. Data from our control subjects (56 pg/ml lying) is very 
close to that of the manufacturer (62 pg/ml, R&D Systems) for control subjects.
The median plasma VEGF165 levels (pg/ml) for controls and patients are shown in Table 
3.8.
Controls C2 C3 C4 C5
56 (38-85) 86 (39-133) 94 (38-118) 83 (51-161) 88 (67-135)
Median diff. Vs 
controls (95% Cl)
25 (0-52) 25 (-10-59) 26 (0-54) 32.5 (8-61)
Multi-variate 
regression analysis
VEGF retains statistical signi 
stage (logistic regression OR 
1.025101)
(Results are in appendix 5)
ficance with C 
1.015446 95°/
lAP clinical 
'0 Cl 1.00264 -
Table 3.8: Values o f basal resting plasma VEGF in patients with various CEAP stages o f chronic venous 
disease, expressed as Median (Interquartile range, IQR, ranges in parenthesis) pg/ml. Median difference 
with controls and 95% confidence interval are also shown.
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Figure 3.11: Graph showing values o f VEGF in plasma o f control subjects & patients with various CEAP 
stages; median (pg/ml) with error bars indicating the interquartile range (IQR). The CEAP stages are 
shown on the horizontal axis.
Symptom severity
Symptoms score were compared in different stages of CVD and it has found that 
advanced stages are relatively less symptomatic and recurrent disease is more 
symptomatic than primary disease. Detail results have been shown in the table 3.9 and 
graphs 3.12, 3.13,3.14, 3.15,3.16 below.
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Pain Heaviness Cramps Paraesthesiae Oedema
C2 (n=48) 2.8 (0.1-5) 2.6 (0.3-5) 2.8 (0-6.4) 0.2 (0-2.8) 0 (0-1.5)
C3 (n=18) 4.5 (3.4-5.5) 4.2 (0.8-5) 1.6 (0-4.5) 0 (0-1.2) 5 (3-5.9)
C2/C3
(n=61)
3.3 (0.6-5)€ 3.4 (0.2-5) 
1
2.5 (0-5) 0 (0-2.5) 0.7 (0-5)
C4 (n=43) 0.5 (0-3.0) 1.4 (0-5) 4.4(0.4-7.8) 0 (0-2.6) 1.5 (0-5)
C5 (n=23) 0 (0-4) 0 (0-1.3) 0 (0-6.3) 0 (0-1.8) 0 (0-2.0)
C4/C5
(n=66)
0 (0-3) € 0.1 (0-4.8) If 3 (0-7) 0 (0-2) 1 (0-3)
SVI
C2/C3
(n=48)
3.4 (0.1-5) 3.5 (0.8-5)
§
1.5 (0-4.6) t 0 (0-3.9) 1 (0-5) t
DVI
C2/C3
(n=15)
3.1 (0.8-5.4) 2 (0.2-4.9) § 4.4 (0.8-7) J 0 (0-1.6) 0.5 (0-2.3) f
SVI
C4/C5
(n=33)
0.0 (0-3.0) 0.6 (0-5) 3 (0-7) 0 (0-1.8) 1.3 (0-4)
DVI
C4/C5
(n=27)
0.0 (0-3) 0 (0-2.2) 3.25 (0-6.4) 0.1 (0-3.8) 0.8 (0-2.6)
Primary
C2/C3
(n=35)
3 (0.1-5) * 3 (0-5) 2.4 (0-6.7) 0.02 (0-3.1) 0.1 (0-3)#
Recurrent
C2/C3
(n=31)
4.5 (0.7-5) * 3.5 (1.4-5) 2.8 (0-4.6) 0 (0-2.5) 1 (0-5.1)#
Primary
C4/C5
n=32
0.2 (0-5) 0.5 (0-5) 2.0 (0-7.0) 0.1 (0-3.5) 1.5 (0-5.5)
Recurrent
C4/C5
n=34
0 (0-2) 0 (0-2.98) 4.3 (0-6.5) 0 (0-0.5) 0.2 (0-2.5)
€ Difference between medians: 1.8 & 95% Cl: 0.1 to 2.8 
U Difference between medians: 0.9 & 95% Cl: 0 to 2
§ Difference between medians: 0.4 & 95% Cl: -1 to 2.4 
t  Difference between medians: 0 & 95% Cl: -0.4 to 1.9 
j  Difference between medians: 1.4 & 95% Cl: -0.2 to 3.8
* Difference between medians: -0.5 & 95% Cl: -2 to .9
# Difference between medians: -0.2 & 95% Cl: -1.5 to 0
Table 3.9: symptoms score in VAS in patients with various CEAP stages and other groups o f patients 
with CVD, expressed as Median (Interquartile range in parenthesis) cm. Number o f  patients studied in 
each group is also in parenthesis. Median difference with controls and 95% confidence interval calculated 
using the Wilcoxon method are also shown.
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Figure 3.12: Graph showing score o f pain in VAS in cm in patients with various CEAP stages; median 
(cm) with error bars indicating the interquartile range (IQR). The CEAP stages are shown on the 
horizontal axis.
HEAVINESS
10 
£  8
I  6
* 2
T *  T 1tI 1 L , ,-^t—
C2 C3 C4a C4b C5
Figure 3.13: Graph showing score o f heaviness in VAS in cm in patients with various CEAP stages; 
median (cm) with error bars indicating the interquartile range (IQR). The CEAP stages are shown on the 
horizontal axis.
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Figure 3.14: Graph showing score o f cramps in VAS in cm in patients with various CEAP stages; median 
(cm) with error bars indicating the interquartile range (IQR). The CEAP stages are shown on the 
horizontal axis.
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Figure 3.15: Graph showing score o f paraesthesiae in VAS in cm in patients with various CEAP stages; 
median (cm) with error bars indicating the interquartile range (IQR). The CEAP stages are shown on the 
horizontal axis.
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Figure 3.16: Graph showing score o f oedema in VAS in cm in patients with various CEAP stages; 
median (cm) with error bars indicating the interquartile range (IQR). The CEAP stages are shown on the 
horizontal axis.
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The association of symptoms with biological markers was also investigated. Two 
measures of association are shown in table 3.10.
Symptoms Severity 
distribution 
in VAS
Number in
asymptomatic
vs.
symptomatic
group
Age Parameters Values in
asymptomatic
vs.
symptomatic
Correlation
coefficient
Pain 0 (0 -  0.1) vs. 
5 (3.3-5.5)
n=63 in each 
group
56 (45-68) 
vs.
53 (46-62)
L-Selectin 799 (663-1004) 
vs.
944(771-1105)
0.1
s VC AM-1 1189 (926- 
1453) vs. 1289 
(1045-1569)
0.1
Heaviness 0 ( 0 - 0 .2 )  vs. 
5 (3.5-6.4)
n=66 in each 
group
57 (48-69) 
vs.
52 (42-59
L-Selectin 820 (663-1055) 
vs.
901 (732-1088)
0.1
VEGF 61 (35-111) vs. 
78 (35-126)
0.01
Cramps 0 (0-0.5) vs. 
6.5 (4.4-8.5)
n=66 in each 
group
53 (41-61) 
vs.
54 (47-65)
VEGF 57 (34-116) vs. 
72 (38-123)
0.1
Paraesthesiae 0 (0-0) vs. 
3.1 (0.7-5)
n=71 in 
asymptomatic 
group vs.
61 in
symptomatic
group
54 (47-64) 
vs.
53 (43-64)
VEGF 79 (43-124) vs. 
51 (31-111)
0.12
L-Selectin 790 (658-949) 
vs.
982 (798-1310)
-0.11
Oedema 0 (0-0) vs. 
5 (2.5-6)
n=70 in 
asymptomatic 
group vs.
64 in
symptomatic
group
55 (44-66) 
vs.
53 (46-63)
VEGF 54 (31-104) vs. 
85 (40-147)
0.2
Diff.
between
medians:
20
95% Cl:
(5 to 44)
Table 3.10: Association o f symptoms (score in VAS in cm) with various biological markers in patients 
with various CEAP stages o f CVD. At first, the symptom data was separated in to upper and lower 
halves. The median symptom score (IQR) is shown for these two halves in the second column. The 
associated median biological marker values are also calculated in the two data halves, and are shown in 
the sixth column.
For most biological markers there is a slight trend towards a higher value in the half of 
patients with the higher symptom score. For the ‘oedema symptom’ group the VEGF 
levels are much higher in the patients with the higher symptom scores, which reached 
significant level. The correlation coefficient (r) has also been calculated for the 
relationship between symptoms and biological markers. The value of this is universally 
low, indicating the lack of correlation between symptoms and biological markers.
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Discussion:
Previous studies have been reported limited numbers of patients when discussing 
leucocyte activation in CVD. In this investigation a substantial number of patients (132) 
have been investigated and compared to significant number (30) of control subjects. A 
number of technical problems (namely human errors in ELISA analysis and flow 
cytometer machine malfunctions) and the introduction of enhanced measurement 
methods (i.e. using high sensitivity ELISA kits for cytokines) during this investigation 
meant that not all measurements could be made in all subjects, accounting for the 
differences between patients for different parameters. My greatly increased patient 
cohort ensured that my measurements are reliable when considering that, in venous 
disease, relatively small changes of inflammatory mediator levels have been sought. 
Considerable care was taken to exclude any patient from the study where any disease 
process or medication may have interfered with the measurements. A further factor 
which may confound studies of this type is the tendency for age differences to arise 
between patients with varicose veins (C2) and those with skin changes and healed ulcers 
(C4, C5). In this cohort of patients the age of the control and patients groups is very 
similar, which were not the case in previous studies.
In the study, absolute values of neutrophil and monocyte CD1 lb fluorescence are raised 
in patients of CEAP clinical stage C5 compared to controls (table 3.3) based on 
confidence interval analysis. Neither C4/C5 data taken together nor the other stages of 
CVD reach a statistically significant level. In addition, all data including C5 have wide 
error bars (figs 3.1 and 3.2). The changes in expression of surface CD lib  following 
FMLP stimulation (table 3.4) show that in all patients there is a trend towards reduced 
upregulation in neutrophils and monocytes compared to controls. Multivariate logistic 
regression shows that this reaches statistical significance for neutrophil CD lib  data. 
This implies that either these cells have a reduced ability to express CD l ib  or are 
already in a state of upregulation. The extent of shedding of CD62L in neutrophils is the 
same in patients and control subjects. However, monocytes from patients show 
decreased CD62L shedding following stimulation with FMLP compared to controls 
with multivariate logistic regression confirming this relationship (table 3.4). This may 
arise because in patients with venous disease monocytes are already activated and have 
partially shed their CD62L, limiting the extent of further shedding in response to FMLP
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stimulation. There was no difference between the patients of different CEAP clinical 
stages. This may indicate that the activation of monocytes is part of the inflammatory 
response in all stages of chronic venous disease. The author acknowledges that the 
changes he has observed reflect a mild inflammatory response, which was just 
detectable in the numbers of patients studied in this investigation.
sVCAM-1 shows a increased trend compared to controls in all CEAP stages of CVD 
compared to that of controls (table 3.5). Multi-variate logistic regression analysis 
shows that only sVCAM-1 increases with CEAP clinical stage. sICAM-1 and sE- 
selectin show elevated trends in patient groups compared to controls but multi-variate 
logistic regression fails to find statistical significance here. These results indicate that 
there is low-grade endothelial activation in all stages of venous disease.
Low plasma concentrations of IL-6 were observed in all patients and controls. 
Significantly raised elevations were seen in C3 -  C5 patients compared to controls 
(table 3.7). No statistically significant differences were observed between patient 
groups. TNF-a levels were similar in patient and control groups. Attempts have been 
made by some investigators to detect TNF-a by immunohistochemistry in liposclerotic 
skin, but were not detected by this technique 144. IL-la did not show any difference 
between controls and patients, but many undetectable values were encountered whilst 
performing the assays. In retrospect, the methodology used in my investigation was 
unable to assess changes in these cytokines in venous disease.
The importance of IL-1 and TNF is their ability to up-regulate adhesion molecule 
expression on vascular endothelium and to enhance migration neutrophils and to allow 
inflammatory cells to bind to a localised area. It is thought that TNF-a may mediate 
angiogenesis 266 and local release of TNF-a causes activation of neutrophils and 
macrophages and stimulation of cytokine release (IL-1, IL-6, TNF-a itself). Since 
plasma levels of IL-la and TNF are normal in patient groups in this study, it may mean 
that the significantly raised adhesion molecules especially sVCAM-1 found in CVD are 
not secondary to a chronic inflammatory response stimulated by these cytokines. 
However, my data should be interpreted cautiously since there may be little relationship 
between the plasma levels of the cytokines I have measured and the tissue 
concentrations at the site of inflammatory processes. Stimulation of endothelial cells 
with IL-1B is known to increase monocyte adhesion to endothelial cells 439 and to induce
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endothelial cell surface expression of ICAM-1, VCAM-1 and E-selectin 440, 438. 
Although IL-lp was raised in my study, because of many ‘O’ values we do not think 
they are significant.
IL-6 production is generally correlated with the cell activation and it plays a major role 
in the mediation of inflammatory and immune responses initiated by infection or injury. 
Increased IL-6 in my study may play a role in maintaining the induced endothelial 
damage.
In this study, levels of VEGF were higher in patients group than in controls, which 
reached statistical significant level by uni & multi variate regression analyses. This has 
been more pronounced in the C5 patients. The levels of VEGF among patients are 
similar in those with skin changes (C4, C5) as those without skin changes (C2, C3). 
While it is thought that VEGF may contribute to the capillary proliferation seen in 
advanced CVD 8, it is not clear whether it is hypoxia induced or directly related to 
capillary proliferation or both. Therefore, ‘cause and effect’ could not be established 
with this study. It is also known that the capillary density is reduced in advanced forms 
of CVD (C4, C5), although capillary convolution and proliferation are remarkable 
features 368, 37°. Cutaneous capillary proliferation may either be in response to hypoxia 
via VEGF pathway or some other unknown mechanisms. The trend towards elevated 
VEGF levels seen in the C2 and C3 patients is unlikely to reflect capillary proliferation 
in the skin, since this is not normally a feature of uncomplicated venous disease. The 
explanation for this observation remains unclear. The origin of VEGF measured in 
patients from the C5 group remains unknown. If it is epidermal origin then it may 
contribute to skin damage via VEGF-NO pathway or it may simply be a response to 
local reparative and increased angiogenic process or act simply as vascular permeability 
factor.
I was surprised to find that C2 and C3 group patients reported far more severe 
symptoms than those with patients in the C4 and C5 groups (table 3.9). Pain and 
heaviness scored most highly in the patients of the C2 and C3 groups. The ‘cramp’ 
score was highest in the patients with C4 disease, who produced low scores for pain and 
heaviness. Patients with healed venous ulcers (C5) had very few symptoms. It must be 
remembered that although the scores were recorded objectively, the individual 
experience of patients with the same disease varies widely, and the perception of
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symptoms is extremely subjective. Patients with varicose veins may find the symptoms 
from these troublesome since they find the appearance of their varices unpleasant. 
Patients with healed venous ulcers may compare their present situation to their 
symptoms when the ulcer was open. Since venous ulceration may be associated with 
severe pain, they may find a healed ulcer very easy to live with.
Table 3.9 also shows the influence of whether symptoms were associated with primary 
or recurrent venous disease. Minor differences in the pattern of symptoms are shown, 
but none reaches statistical significance. The data has also been shown according to 
whether symptoms are attributable to superficial or deep vein incompetence. Again, this 
does not affect the severity of symptoms recorded by the patients.
Correlation of symptoms with biological markers was also investigated (table 3.10). 
This was done because it has been observed that there is a poor correlation between the 
severity of physiological abnormality of the venous system and the resulting symptoms. 
I observed only weak associations with correlation coefficients of about 0.1 or less for 
the majority of combinations of symptoms and biological markers. The only slight 
exception to this was the association between the symptom of ’oedema’ and plasma 
VEGF levels. Here a weak positive correlation was observed (r=0.2). The symptom of 
paraesthesiae showed a slight negative correlation with VEGF levels. sL-selectin also 
showed a weak correlation with several symptoms. The low values for the correlation 
coefficients demonstrate that none of the factors investigated here correlates well with 
any of the symptoms measured by VAS. I have to conclude that the extent of the 
systemic inflammatory response as indicated by the biological markers presented here 
explains the variability in symptoms reported by patients with venous disease.
Implications o f these findings have been explained and summarised in chapter 4 as a 
seneral discussion.
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Study 2:
Increased total Nitric Oxide (NO) in the plasma of patients with severe chronic 
venous disease
Rationale
Despite the demonstration of increased leucocyte activation and sequestration, a 
demonstrable microangiopathy and up-regulation of VEGF expression, the exact chain 
of events leading to skin ulceration in CVD remains unknown. Skin damage in CVD 
may be partially attributable to free radical injury. It is possible that macrophages, 
which have been found in liposclerotic skin release nitric oxide (NO) via inducible 
nitric oxide synthase (iNOS). I hypothesise that raised nitric oxide (NO) production is 
one of the main causes of free radical damage of skin. NO when present at high 
concentrations acts as a free radical and is involved in many pathological conditions 
including vascular and inflammatory disorders. The aim of this study was to determine 
whether there is evidence of increased plasma NO levels in patients with venous disease 
leading to skin changes compared to control subjects.
Methods, patients and materials
Patients considered for the entry into the study were those of attending The Middlesex 
Hospital Outpatients Department for management of venous disease. Those suitable for 
the inclusion in the study were canvassed by a letter of explanation indicating the nature 
of the study. Patients with CEAP clinical class C2 (varicose veins), C3 (oedema), C4 
(skin changes) and C5 (healed ulcer) were considered. Thirteen healthy volunteers acted 
as control subjects. This group comprised of the members of the department of Surgery 
and Haematology, patients treated for unrelated condition at the London Foot Hospital 
and normal healthy volunteers from the general public. They had no symptoms or signs 
of arterial or venous disease of the lower limb. Patients and volunteers with systemic 
inflammatory disorders (diabetes, rheumatoid disease, recent infection) were excluded 
from this study. Patients and volunteers fulfilling the entry criteria and giving informed 
written consent were studied further. Approval for the study was obtained from UCL 
Medical School Committee for medical ethics.
Plasma nitrate levels are dependent on the systemic production of NO and on dietary
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intake of nitrates. It is impossible to avoid nitrogen altogether in diets and also at the 
same time to fulfil other inclusion and exclusion criteria. All patients and control 
subjects were on identical comparable diets containing low nitrogen containing food. 
Possible causes of raised or altered plasma levels of nitrates are listed in table 3.11.
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High Nitrate containing diet 
(List is exhaustive)
Most foods contain nitrate and nitrite
Vegetables, in particular, green leafy vegetables;
Lettuce, spinach, potatoes, carrots, cauliflower and onions
Meat products
Poultry
Eggs
Beverages
Beer
Salty food
Post meal
Chronic hypoxia Severe asthma, COAD
Cardiovascular diseases Peripheral vascular diseases
Recent IHD
CVA
Heart failure
Hypercholesterolaemia
Hypertension
Drugs NSAIDs
Steroid
Adriamycin, bleomycin 
(3 receptor antagonist 
Calcium antagonist
Vitamins E, C, A, D and other antioxidants
Patients treated with other vasoactive drugs
Medication known to alter white cell activity
Nitrate or vasodilator therapy
Blood disorders Any blood disorders, Iron deficiency anaemia
Connective tissue disorder Rheumatoid Arthritis & others
Gastrointestinal disorders Crohn's disease, celiac diseases
Neurological diseases Huntington's and Parkinson's disease
Miscellaneous Deep venous thrombosis within the past 12 months 
Superficial venous thrombosis within 15 days
Pregnancy
Diabetes mellitus 
Renal impairment
Infection within the previous six weeks
Acute/ chronic inflammatory or infectious disease
Active malignancy
Stress or exercise
Obesity
Alcoholism
Table 3.11: diet and conditions causing altered Total NO
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Patients and volunteers in whom any of the above conditions may have influenced their 
plasma NO levels were excluded from further investigation. All subjects studied were 
investigated during the morning and had fasted for at least 6 hours before the study 
began.
All patients were assessed clinically by a vascular surgeon skilled in the management of 
venous diseases to assign the patient to the appropriate clinical grade of the CEAP 
classification. Patients included in the study underwent standard vascular laboratory 
investigation including duplex ultrasonography and measurement of 
photoplethysmography venous refilling times.
Table 3.12 shows the numbers of patients and controls studied and their age and sex 
distribution. In all, 13 control subjects and 44 patients with venous disease were 
investigated. The subjects in each of the groups were of similar age and sex distribution. 
The number of patients with the superficial and the deep venous incompetence among 
the study groups is proportionately distributed.
Procedure
The study was conducted in an environmental chamber at 22 ° C (room temperature). All 
the patients and control subjects were acclimatised for 10-20 minutes whilst lying supine 
before the start of the experimental protocol to minimise venous pressure in the leg. A 
foot vein of the more severely affected side was canulated with a 23-gauge canula 
(Venisystems ™ Butterfly®, Abbott, Ireland) and 10 ml blood was collected with the 
volunteer lying supine. EthyleneDiameneTetraacetic Acid (EDTA) was used as the 
anticoagulant. The specimens were spun within one hour of collection at 20,000 rpm for 
10 minutes at 4°C to separate the plasma and which was promptly frozen at -84°C 
before analysis.
Assay of Total NO was performed using a colourimetric Griess reaction. A kit supplied 
by R&D systems (Oxon, United Kingdom) was used. Details procedures are in 
appendix 4.
Data analysis
The Statistical Package for the Social Sciences (SPSS, Chicago, Illinois, USA) was used 
to analyse the data using univariate and multivariate logistic regressions analysis to
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detect a relationship between CEAP clinical stage and plasma NO. Non-parametric tests 
of statistical significance for paired and impaired data (Wilcoxon matched pairs signed 
rank test and Mann Whitney U test) were used. The differences between medians and 
95% confidence interval were calculated by the Wilcoxon method using a computer 
program (CIA, BMA Publishing, London).
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Results
Stage & 
number
Sex
distribution
Age (years, 
mean value 
and range)
No. with superficial 
venous insufficiency
No. with deep and 
superficial 
venous insufficiency
Controls (n=13) 7F, 6M 50 (43-55)
C2, C3 (n=20) 18F, 2M 50 (40-55) 16 (C2= 8, C3=8) 4 (C2= 2, C3= 2)
C4 (n=13) 3F, 10M 57 (41-65) 9 (C4a=5, C4b= 4) 4 (C4a=2, C4b=2)
C5, A.B. (n=ll) 5F, 6M 53 (48-64) 8 3
All data: median (inter-quartile range)
Table 3.12. Distribution of subjects according to age, sex and clinical, etiologic, 
anatomic, pathologic (CEAP) stage
The median plasma total NO levels for controls and patients are shown in Table 3.13.
CEAP stage CO C2 C3 C4 C5
Plasma total
NO um/1 (IQR)*
43 
(41 -  50)
45
(41-49)
39 
(28 -  50)
53
(44-58)
55
(51-64)
Median differenceT vs. controls (95% Cl) 
Combining C4 & C5 (n=24): 9 (2-15)
6
(-1 -1 4 )
12
(5 -22 )
Univariate
regression
analysis
Univariate logistic regression analysis shows no relationship 
between CEAP clinical stage and plasma NO. (Full analysis in
appendix 5).
* Values in parentheses are interquartile range.
^Median differences calculated using the Wilcoxon method.
Table 3.13. Median plasma levels of total nitric oxide (pmol/L)
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Diff: 12 umol/l (95% Cl: 5 - 22)
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Figure 3.17: Graph showing values o f total NO (pmol/L) in controls and in various CEAP stages of  
CVD. Vertical (Y) axis shows values o f total NO and the horizontal (X) axis shows various CEAP stages. 
Median value is shown by horizontal bar. It also shows 95% Confidence Interval.
In my study, levels of total NO were similar amongst the control group and patients 
with venous disease without skin changes (C2, C3). In the patients with healed ulcers 
and atrophie blanche levels of total NO were approximately 27% higher than in 
controls. The patients in the C4 group (skin changes) showed a similar median total NO 
to those in the C5 group. Combining the data in the C4 and C5 patients results in a set 
of data significantly different from control subjects (median difference 9 and 95% C.I. 
2-15), but logistic regression failed to show a relationship between CEAP clinical stage 
and plasma nitrate levels. In summary, a trend towards higher levels of nitrates is 
present in the more severe stages of venous disease but this is only a modest elevation 
and a statistically significant relationship between clinical stage and plasma nitrate level 
was not established.
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Discussion
Dietary intake of nitrates in foods may provide a confounding source of nitrates in 
clinical studies, obscuring changes due to disease (Table 3.11). In this investigation, we 
only studied those patients and volunteers in whom this had been avoided by careful 
selection and by investigating fasting subjects. Other medical conditions, which might 
alter or give rise to elevated plasma nitrates were regarded as exclusion criteria.
The disease groups vary in their composition of men and women. Women predominate 
in the C2 (varicose veins) group, but men are more numerous in the more severe disease 
groups. In the control, group men and women are evenly distributed. When combined 
all stages of CVD together had similar sex distribution to that of controls. These sex 
differences reflect a weakness in the data, but consider that where statistical differences 
have been found (between C4, C5 patients and controls) the sex distribution is similar. 
The median total NO levels among my control subjects were similar to those measured 
by the manufacturer of the analysis kit with human control subjects, and I believe that 
these levels reflect those in a population of healthy subjects. In fact, I did not find any 
significant differences in the basal total NO between men and women in our study. 
Again, I did not have a large number of patients to compare in each group because of 
exhaustive exclusion criteria.
Logistic regression failed to show a relationship between CEAP clinical stage and 
plasma nitrate levels.
Implications o f these findings have been explained and summarised in the chapter 4 as 
seneral discussion in the context o f others.
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Study 3:
Capillary morphology changes in patients with CVD of lower limbs and healthy 
volunteers using the capillary videomicroscope: reproducibility and reliability of 
inter-observer analysis
Rationale
Capillaries form part of the microcirculation, which is responsible for nutritional 
delivery in all tissue. This includes the area of skin, which is commonly affected by 
ulceration in CVD. Microangiopathy of CVD has been demonstrated histologically 362 in 
the early eighties. In CVD, microangiopathy is characterised by the presence of enlarged, 
dilated, coiled and ramified capillaries, which are surrounded by an enlarged pericapillaiy 
spaces (halos) 356 and reduced capillary numbers, microvascular thrombosis, obliteration of 
and increased permeability of microlymphatics 357 depending on the severity of the CVD.
Although capillary morphological changes have been detected in CVD for decades, no 
attempts have been made to grade these findings by quantitative measurement. In 
addition, there is no uniform agreement among the authors of various centres about the 
description of capillary morphology in CVD, nor they have been quantified in 
descriptive terminology based on the severity of the disease. I think that the skin 
capillaries become gradually more abnormal as the disease progresses, especially with 
morphology changing promptly and the numbers slowly.
The aim of my study was to summarise, verify and grade the distribution of capillary 
morphology in different groups of patients of CVD using capillary microscopy. The first 
step was to assess the reliability of the technique of analysis of recorded picture; 
therefore, I measured the inter-variability between examiners in assessing capillary 
density and capillary morphology analysis.
Methodology
Approval was obtained from UCL Medical School Committee for medical ethics for the 
study. Patients with chronic venous disease were recruited from the vascular clinic at 
The Middlesex Hospital and volunteers comprised of the members of the staff, patients
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treated for unrelated conditions and normal healthy volunteers from the general public. 
A medical history was taken and clinical examination was performed. Patients who 
gave informed written consent were studied further and were assigned to appropriate 
CEAP clinical stages by a surgeon experienced in the management of venous disease. 
All patients underwent a venous Duplex examination and photoplethysmography to 
establish venous reflux and to localise it anatomically.
In total 132 patients were studied, among them only 95 patients were analysed finally 
and the rest were excluded because of poor quality images. We subdivided CEAP 
clinical stage C4 patients into C4a with haemosiderosis and venous eczema and C4b with 
lipodermatosclerosis. 10 healthy subjects (CO) without any history of previous venous 
disease were studied.
The inclusion criterion for the study was age above 18 years.
Table 3.14: Exclusion criteria for the study 
Patients treated for venous disease within 3 months 
Diabetes mellitus
Any concomitant active disease (judged as clinically significant by the investigator)
Patients treated with vasoactive drugs
Deep venous thrombosis within the past 12 months
Superficial venous thrombosis within 15 days
Significant peripheral vascular diseases (ABPI<0.8)
Infection or inflammation in legs
Procedure
The study was conducted in an environmental chamber at 22°C. Patients and controls 
acclimatised for 10-20 minutes before the start of the experimental protocol lying supine. 
A small amount of liquid paraffin wiped over the examination area to reduce specular 
reflection from the skin surface. In each patient and volunteer the supra-malleolar skin 5
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cm proximal to the medial malleolus or the region most severely affected by 
lipodermatosclerosis in patients with venous disease was investigated. This was done first 
with the volunteer lying supine. Following this, subjects were asked to sit on a stool with 
their legs dependent for 10-20 minutes before taking further images. At least 4 
representative areas of capillaries were studied in each limb. Images of the capillaries 
were recorded digitally for subsequent morphometric analysis by two observers.
Each capillary image was analysed and scored for the morphology by two different 
examiners with varying degrees of expertise in the field with their results remaining 
unknown to each other. Observer bias during the capillary microscopy has also partially 
been overcome by the use of a computerised recording system and a second 
independent observer who confirmed the capillary loop counts. Observer 1 is the main 
investigator and the author of the thesis who examined and analysed the data on two 
separate occasions. Observer 2 is the consultant surgeon experienced in capillary 
microcirculation and supervisor.
The data from two observers were examined and the kappa statistic calculated to 
measure the agreement between the two observers.
We assessed both the capillary density [number of capillaries per unit area] as well as the 
complexity of the capillary morphology. All clearly identifiable capillary loops in a field 
were considered to be part of the total capillary count for that area. These were considered 
to be ‘visible capillaries’. Due to the fact that not all parts of every capillary were in focus 
or within the image, not all of the visible capillaries could be evaluated for their 
morphology. Only those capillaries, which were clearly visible, were considered to be 
‘evaluable’. Morphology was assessed by counting the number of ‘convolutions’ or loops 
per evaluable capillary. We counted a 180-degree reversal of direction as a capillary 
loop. The number of convolutions for each evaluable capillary loop were counted and 
when more complex capillaries contained more than 10 loops, they were recorded as 
>10 (figure 3.18).
In a number of preliminary studies, I agreed the criteria that would be applied in the 
capillary counting with the other observer. We found that we could easily reach agreement 
on the number of convolutions per capillary detailed in the methodology in chapter 2. We 
then embarked on the study to confirm the agreement between independent observations.
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Figure 3.18: Single and multi-looped capillaries. I counted each loop as a convolution o f that capillary where 
it changes direction by 180° or more.
Statistical analysis
The data descriptors used here are at the median and interquartile ranges for all parameters.
The kappa measure of agreement is used for analysis of agreement between observers. 
The maximum value of kappa is 1, which represents perfect agreement, and kappa will 
take the value zero if there is only chance agreement. Method of calculating the Kappa 
measure of agreement between different examiners using the capillary loop counts in 
each evaluable capillary of each patient of lower limb chronic venous disease is 
described in appendix 4. In order to undertake kappa analysis it was necessary to 
categorise the number of loops per capillary. The independent assessor and I categorised 
our findings as follows: Grade 1= 1-2 loops; Grade 2 = 3-5 loops; Grade 3 = 6-10 loops; 
Grade 4 = >10 loops.
As an index of the agreement of capillary counts (both ‘visible’ and ‘evaluable’) the 
coefficient of variation has been calculated. The formula for coefficient variance (CV): 
CV (%) = V [{(Stdeva)2 + (Stdevb)2}/2]/(mean) where Stdeva and Stdevb are the standard 
deviations of the capillary count observations of observers a and b respectively and 
‘mean’ is the overall mean capillary count.
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Results:
Table 3.15 shows the CEAP distribution of all patients studied.
Table 3.15. Distribution of subjects according to age, sex and clinical, etiologic, 
anatomic, pathologic (CEAP) stage
Stage & 
number
Sex
distribution
Age (years, mean 
value and range)
No. with superficial 
venous insufficiency
No. with deep and
superficial
venous insufficiency
CO (n=10) 6F, 4M 43 (32-56)
Cl (n=15) 13F, 2M 56 (53-61)
C2 (n=20) 14F, 6M 53 (47-60) 16 4
C3 (n=15) 12F, 3M 50 (41-59) 11 4
C4a(n=15) 5F, 10M 52 (40-67) 8 7
C4b (n=15) 5F, 10M 64 (55-68) 9 6
C5 (n=15) 5F, 10M 50 (44-65) 7 8
Patients group had similar age distribution, although C l, C2 and C3 had more female 
dominance than C4 and C5.
I have shown increased number of convolutions with the advanced form of CVD. This 
has been detailed in the table 3.16,3.19 below.
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M edian num ber o f  loops per 
evaluable capillary
G rade as defined
CEAP Patient no O bserver 2 O bserver 1 O bserver 2 O bserver 1
CO 1 1 1 1 1
2 1 1 1 I
3 1 1 1 1
4 1 1 1 1
5 1 1 1 1
6 1 1 1 1
7 1 1 1 1
8 1 1 1 1
9 1 1 1 l
10 1 l 1 1
Cl 11 1 1 1 1
12 1 1 1 1
13 1 1 1 1
14 1 1 1 1
15 1 1 1 l
16 1 1 1 1
17 1 1 1 1
18 1 1 1 1
19 1 1 1 1
20 1 1 1 1
C2 21 1 1 1 1
22 l i
23 1 1 1 1
24 1 1 1 1
25 1 1 1 1
26 1 1 1 1
27 1 1 1 1
28 1 1 1 1
29 1 1 1 1
30 1 1 1 1
C3 31 1 1 1 1
33 I 1 l 1
34 2 1 1
35 1 1 1 1
36 1 1 1 1
37 2 1 1 1
38 1 1 1 1
39 1 1 1 1
40 1 1 1 1
C4a 41 4 2 2
42 2 2 1 1
43 4 2 2
44 5 5 2 2
45 4 2 2
46 1 1 1 1
47 4 2 2
48 2 3 1 2
49 4 2 2
50 2 2 1 1
C4b 51 4 2 2
52 6 3 3
53 5 5 2 2
54 3 3 2 2
55 15 15 4 4
56 8 3 3
57 5 6 2 3
58 13 13 4 4
59 15 18 4 4
60 15 15 4 4
C5 61 15 15 4 4
62 6 3 3
63 10 10 4 4
64 10 10 4 4
65 14 14 4 4
66 10 10 4 4
67 11 12 4 4
68 11 11 4 4
69 5 5 2 2
70 5 5 2 2
Table 3.16: Inter-variability o f the capillary loop counts in each evaluable capillary o f  each patient o f  
lower limb venous disease between different examiners.
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n 70
Observer 1
Observer 2 Grade 1 Grade 2 Grade 3 Grade 4 Total
Grade 1 42 1 0 0 43
Grade 2 1 11 0 0 12
Grade 3 0 1 3 0 4
Grade 4 0 0 0 11 11
Total 43 13 3 11 70
Kappa statistic 0.95
Table 3.17: Contingency table allowing calculation o f the kappa measure o f  agreement between the 
different observers.
There was near perfect agreement between examiners A and B regarding the capillary 
loops counts.
Number of visible capillaries and evaluable capillary numbers:
Number of visible capillaries and evaluable capillary numbers were also assessed for 
variability between the two observers by calculating the coefficient of variation (CV). 
CV for number of visible capillaries between observers were 14% and for evaluable 
capillaries 16%. Table 3.18 shows the agreement between two observers for capillary 
count and evaluable capillaries.
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Patient num ber C apillaries count E valuable capillaries
Observer 1 Observer 2 Observer 1 Observer 2
1 14 14 14 10
2 23 20 15 14
3 5 8 5 5
4 7 8 7 T
5 7 7 6 6
6 12 14 9 11
7 15 15 12 10
8 15 17 13 13
9 16 16 15 15
10 15 15 13 13
11 7 9 7 7
12 22 25 14 13
13 7 7 7 6
14 18 17 12 12
15 14 16 10 9
16 18 18 11 10
17 17 24 15 15
18 23 28 15 15
19 19 18 11 11
20 15 21 14 14
21 15 15 11 11
22 12 12 9 9
23 9 10 8 8
24 15 13 11 9
25 18 19 11 11
26 15 16 8 S
27 12 10 7 7
28 16 14 13 12
29 12 12 6 6
30 12 13 7 7
31 13 13 9 11
32 14 15 11 11
33 6 6 4 4
34 16 16 12 12
35 10 10 7 7
36 14 14 10 11
37 18 17 11 10
38 16 19 11 11
39 10 14 10 10
40 8 9 3 4
41 12 12 7 8
42 15 20 12 12
43 10 10 3 3
44 8 8 7 7
45 11 11 10 10
46 7 7 6 6
47 10 10 9 8
48 7 7 7 7
49 14 14 11 11
50 13 13 9 10
51 3 3 3 3
52 24 24 12 13
53 13 15 10 10
54 1 1 1 1
55 6 5 3 3
56 5 5 3 3
57 2 2 2 2
58 2 3 1 2
59 3 2 2 l
60 7 7 5 5
61 7 7 5 5
62 8 8 6 6
63 7 7 6 6
64 7 7 5 5
65 5 5 4 4
66 7 7 4 4
67 1 1 1 1
68 5 6 5 s
69 6 6 4 4
M ean (Stdev) 1 1 (6 ) 1 2 (6 ) *(4) 8 (4 )
Table 3.18: Agreement between two observers for capillary count and evaluable capillaries.
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I also compared visible capillaries, evaluable capillaries and loops per capillary in each 
patient on dependency. I did not find any statistically significant difference between 
supine and dependent counts for evaluable capillary numbers or loops (see table below).
CEAP Supine Dependency
Loops per 
capillary
Evaluable capillary 
count
Loops per 
capillary
Evaluable capillary 
count
CO 1 11 1 8
1 8 1 3
1 5 1 7
1 8 1 10
1 8 1 12
1 3 1 5
1 14 1 5
1 14 1 14
1 10 1 10
1 5 1 5
Median (IQR) K i - i ) 8(6-11) K i - i ) 8(5-10)
C l 1 4 1 4
1 7 1 8
1 6 1 6
1 7 1 7
1 8 1 8
1 9 1 9
l 12 1 12
1 7 1 7
1 5 1 4
1 4 1 4
1 3 1 3
1 12 l 12
l 9 1 9
1 7 1 6
1 9 1 9
Median (IQR) i (i-D 7(6-9) 1(1-1) 7(5-7)
C2 1 8 1 5
1 6 1 10
1 6 1 6
1 3 1 6
1 3 1 9
1 3 1 8
l 4 i 2
1 6 l 7
1 3 l 2
1 4 l 10
1 3 l 4
1 14 2 12
1 13 1 11
1 13 1 7
2 10 3 7
2 8 4
“ T 10 3 19
i 4 1 15
2 9 3 20
2 10 2 13
3 7 3
7 2 7 2
3 8 2 9
1 4 1 7
4 4 3 6
1 9 1 12
“ T 3 3 6
5 5 2 5
4 IS 4 18
Median (IQR) 1 ( 1 - 2 ) 6(4-9) 7(5-11)
C3 1 9 1 4
1 3 1 7
1 8 1 11
1 11 1 13
1 7 1 13
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1 is 2 11
1 4 1 5
1 11 2 13
1 1 12
1 7 1 8
1 2 9
2 7 1 6
1 7 2 10
1 5 2 11
2 15 2 13
2 5 5 6
4 3 4 3
2 15 2 13
M edian (IQ R) 1 (1-2) 8(6-11) i ,1-2) 11 (6-13)
C4a 3 10 2 22
1 14 2 13
1 10 1 9
1 5 1 6
3 12 4 8
4 5 2 5
2 2 7
1 3 1 6
2 10 2 7
3 5 2 6
2 7 1 10
5 4 4 3
6 2 5 4
3 4 2 8
4 3 4 3
M edian (IQ R) 3(2-4) 5(4-10) 2(2-3) 7 (6 -9 )
C4b 3 3 3 2
2 2 4 7
4 10 5 10
3 5 2 4
6 3 6 4
3 13 4 18
4 4 2
3 3 4 6
7 1 11 3
10 2 8 6
2 13 4 9
5 1 4 4
3 7 3 9
IS 1 16 1
16 1 20 1
13 2 9 8
16 1 7 9
M edian (IQ R) 4 (3-10) ..  J. u _ - -‘ I - * * ' .  - l ! 6 (3-9)
C5 7 3 5 7
4 5 8
14 3 8 11
6 3 7 5
20 1 IS 1
7 10 13 5
7 3 9 2
8 1 7 1
7 0
10 3 10 6
6 3 10 4
4 4 5 3
9 2 4 4
4 5 4 3
4 3 0
8 4 17 5
M edian (IQ R) -  ______ ...m -ii....... 8 (5-10) 4 I2.’5! .............
Table 3.19: showing the number evaluable capillaries and loops per capillary in each patient summarised 
by median and IQR for each o f  the CEAP stages in both the supine and dependent positions.
152
Discussion
This study confirms that the capillary microscopy is reliable in analysing the density of 
skin capillaries and in assessing their morphological changes with regard to the 
interpretation of photographs obtained at one site by one observer. Independent 
assessment of both capillary density counts and morphological changes showed good 
agreement with little inter-observer variation. The independent observer and I based our 
definition of a capillary convolution on the simple basis that this was a change of 
direction of the capillary loop of 180° or more. This was sufficient to allow a count to 
be established between skilled observers. This strategy may be successful in replacing 
the ambiguity of various types of terminology that has been used by previous authors. 
Clearly, very complex capillary formations required simplification in order to reflect the 
need to agree on a classification. It is often difficult to establish whether a capillary 
‘glomerulus’ has 20 or 25 convolutions. Our simple solution to this was to establish a 
grading system based solely on the number of convolutions.
Grade 1= 1-2 loops 
Grade 2 = 3-5 loops 
Grade 3 = 6-10 loops 
Grade 4 = >10 loops
This allows sufficient latitude for all of our observations to be included and the Grades 
also comply with our observations made in different clinical stages of venous disease. 
In grade 1, normal capillaries in most patients without skin changes can be included. 
Grades 2 and 3 show moderate or early stages of convolution seen in patients with mild 
skin changes. Grade 4 capillary convolution is usually only seen in patients with 
lipodermatosclerosis (C4b) or healed ulcers (C5).
We could have added a further stage to our classification to include areas of atrophie 
blanche where no capillary loops are visible. We did not include such areas in this 
reproducibility study but for more complete description of skin changes this could be 
added.
When I compared the images recorded with the volunteers supine to those obtained with 
the limb dependent, I did not find any statistically significant difference in capillary 
count or capillary morphology. I did find a difference in evaluable capillary count 
between these two positions in the patient group but not in normal healthy group. The 
improved venous filling of capillaries seen by capillary microscopy on moving the limb
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to the dependent position may well be due to a change in size rather than to an actual 
increase in numbers.
In one study, the mean capillary numbers on supine in controls were 28.5 with standard 
deviation of 4.9 and on dependency were 26.8 with standard deviation of 5, in Chronic 
Venous Insufficiency on supine was 13.1 with standard deviation of 7.4 and 
dependency was 12.9 with standard deviation of 6.9 367. Capillary density has been 
found lower in patients with CVD than in controls irrespective of the position of the leg.
In this study, evaluable capillary counts are lower among patients in comparison with 
normal healthy controls, which are consistent with other previous researchers.367 
Occasionally, branching venules or flower shaped tortuosity of sub-dermal papillary 
plexus is seen without any defined capillary loops.
This method of classification of capillary morphology could be used for quantitative 
measurement of capillary study among various centres, having the advantage of being 
based on counting capillary convolutions rather than on assessing subjective features of 
capillary loops.
In this investigation one observer recorded the images but two independent observers 
analysed the recorded data to assess the variability of the methodology as used in this 
research. It could be argued that each observer should have recorded and analysed his 
own images. This would have increased the complexity of the study but would have 
made the conclusions more generally applicable. This might be done in an extension of 
this research. However, the main aim of the work was to allow me to analyse my 
images reliably, which I have achieved. This research sampled four areas from the 
target limb in order to give a reasonable representation of the skin microcirculation 
without resulting in an excessive amount of data to analyse. I consider that this was 
sufficient to represent the condition of the skin of target limb. For this to be a clinically 
useful tool it would have to be shown that measurements taken by different observers 
from different sites on the same leg, and at different times, were reproducible. 
Therefore, from the present study we do not advocate this technique as a clinical 
method of assessment for general clinical use in day to day practice yet.
Implications o f these findings have been explained and summarised in chapter 4 as a 
general discussion in the context o f other findings.
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Study 4:
Correlation of the clinical severity of the CVD based on the CEAP method of 
classification with the capillary morphology changes of lower limb observed by 
capillary microscope
Rationale
The CEAP system of classification was introduced because there was a need for 
uniform diagnosis and meaningful scientific communication between research centres. 
The CEAP classification presents a new level of diagnosis in lower limb chronic venous 
disease, although it has been criticised for being too complex due to its requirements for 
detailed analysis of the disease involving several tables 159. This provides a numerical 
basis for the scientific comparison of limb condition and evaluation of results of 
treatment based on the number of anatomic segments affected (anatomic score), grading 
of symptoms and signs (clinical score) and disability (disability score).
The microcirculation of the skin has been studied by histological as well as capillary 
microscopic techniques during the last 20 years. Previous works using the 
capillaroscopy on the toenail folds has been reported based on the Widmer's 
classification 441. None of them has been validated for CEAP classification. In addition, 
capillary morphology in CVD has not been quantified based on the severity of the 
disease. I hypothesized that the skin capillaries become gradually abnormal as the 
disease progresses, especially with morphology changing promptly and the numbers 
slowly.
The aim of this study was to clarify the correlation between the extent of abnormalities 
of the nutritional capillaries and the degree of severity of CVD based on the CEAP 
classification. I intended to compare the capillary density and morphology of capillaries 
in each CEAP clinical stage.
Some patients with venous disease develop skin changes and leg ulcers, whilst others do 
not. It has been shown that uncomplicated varicose veins develop increased endothelial 
cell density and complicated varicose veins then lose elastin. 442 The authors of this 
observation have also suggested that the venous morphology predicts the progression of 
CVD. On the other hand, operating on varicose veins before skin changes have
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developed has not been shown to reduce the incidence of venous ulceration compared 
with a strategy of postponing surgery until the early skin changes of chronic venous 
insufficiency becomes apparent . It has also been suggested that cutaneous 
microangiopathy precedes the development of trophic skin changes due to chronic 
venous disease and the clinical degree of skin changes and the severity of 
microangiopathy are closely related 359}360. Therefore, it would be beneficial to detect 
the group of patients at risk of developing skin changes and ulceration at the earliest 
possible stage. It would then be possible to prioritise treatment to prevent further 
complications. At present, there is no measure to indicate which of the patients with 
C2/C3 disease will develop skin changes (C4).
I hypothesise that a subgroup of patients amongst those with uncomplicated varicose 
veins (C2/C3) are at risk of developing clinical skin changes as the disease progresses. 
This sub-group may show microangiopathic changes detectable by capillary microscope 
long before the development of skin changes.
The aim of this study was to assess the typical capillary morphology quantitatively in 
each of the CEAP stages and to detect patients with uncomplicated venous disease 
(C2/C3) who exhibit capillary morphology changes typical of clinically advanced 
disease (C4/C5). The association of biological markers of inflammation with capillary 
morphology was also assessed.
Methodology
Permission to conduct the study was obtained from UCL Medical School Committee for 
medical ethics. Patients with chronic venous disease were recruited from the vascular 
clinic at the Middlesex Hospital and volunteers comprised of the members of the staff 
and normal healthy volunteers from the general public. A medical history was taken and 
clinical examination was performed. Patients who gave informed written consent were 
studied further and were assigned to appropriate CEAP clinical stages by a surgeon 
experienced in the management of venous disease. All patients underwent a venous 
Duplex examination and photoplethysmography to establish venous reflux and to 
localise it anatomically. In total 147 patients and 10 healthy volunteers were studied. 
The final analysis for the first part of the study included only 95 patients from whom 
good quality images were obtained for analysis. I subdivided patients of CEAP clinical 
stage C4 into C4a with haemosiderosis and venous eczema and C4b with
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lipodermatosclerosis. In the second part of the study, a further group of 66 patients with 
CEAP clinical stage C2 & C3 disease were investigated. Forty eight patients had 
varicose veins without oedema and trophic changes (C2), 18 patients had varicose veins 
and oedema (C3).
The inclusion criterion for the study was age above 18 years.
Table 3.20: Exclusion criteria for the study
Patients treated for venous disease within 3 months 
Diabetes mellitus
Any concomitant active disease (judged as clinically significant by the investigator)
Patients treated with vasoactive drugs
Deep venous thrombosis within the past 12 months
Superficial venous thrombosis within 15 days
Significant peripheral vascular diseases (ABPIO.8)
Infection or inflammation in legs
Procedure
The study was conducted in an environmental chamber at 22°C with subjects lying supine. 
Patients and controls acclimatised for 10-20 minutes before the start of the experimental 
protocol to minimise venous pressure in the leg. A small amount of liquid paraffin 
wiped over the examination area to minimise specular reflection from the skin surface. 
In each patient and volunteer the supra-malleolar skin 5 cm proximal to the medial 
malleolus or the region most severely affected by lipodermatosclerosis in patients with 
venous disease was investigated. At least 4 representative areas of capillaries were studied 
in each limb. Images of the capillaries were recorded digitally by a computer for 
subsequent morphometric analysis.
I assessed both the capillary density [number of capillaries per unit area] as well as the 
complexity of the capillary morphology. Morphology was assessed by counting the 
number o f ‘convolutions’ or loops per capillary. I counted a loop as a 180-degree reversal 
of direction. The number of convolutions for each evaluable capillary loop were
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counted and when more complex capillaries contained more than 10 loops, they were 
recorded as > 1 0 .1 followed the method of assessment as standardised in previous study 
(study 3).
During the first part of the study I observed a small number of patients who appeared to 
have some convoluted capillary loops without any skin changes. For the second part of 
the study, 1 subdivided a group of patients with CEAP C2 & C3 stage venous disease 
more than two (i.e. grade 2 as validified in previous study) convolutions per capillary. I 
named these the ‘atypical’ group in order to differentiate them from those of the same 
CEAP stage exhibiting capillaries without convolutions. These have been illustrated in 
figure 3.27.
Figure 3.19: shows simple loop of capillaries commonly seen in control subjects as well as in patients 
o f  CEAP clinical stages C l, C2 and C3.
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Figure 3.20: This picture shows early capillary convolutions with variable number o f  loops usually seen 
in C4a patients, but sometimes seen in patients o f  the C2 & C3 groups.
Figure 3.21: shows convoluted tortuous capillaries seen in CEAP stages C4b and C5.
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Figure 3.22: typical glomeruli shaped capillary seen in lipodermatosclerosis and healed ulceration 
(C4b and C5). Here multiple proliferation o f  single capillary has formed a ‘glomerulus’.
A 23-gauge canula (Venisystems™ Butterfly®, Abbott, Ireland) was placed in the 
distal long saphenous vein or dorsal foot vein of the most affected leg of the C2, C3 
patients. 5 ml o f blood was collected into a citrated tube and 8 ml o f blood was 
collected into two tubes containing EDTA (EthyleneDiameneTetraacetic Acid) 
Vacutainer, Becton Dickinson Vacutainer Systems Europe, BP No 37-38241, 
France). Plasma from the samples were separated by centrifugation at 20,000 rpm for 
10 minutes at 4°C within one hour of collection which was promptly frozen at -84°C 
before analysis of ELISA. ICAM-1, VCAM-1 were assayed using the commercially 
available kit manufactured by Diaclone® and E-selectin, L-selectin, VEGF and 
cytokines: TNF-a and IL-6 were measured by commercially available ELISA kits 
manufactured R & D Systems Europe, UK, once all samples were collected. Von 
Willebrand factor was measured using the kit manufactured by Shield diagnostics, 
Aberdeen, UK. The separate citrated samples were analysed for leucocyte surface 
CD l ib  and L-selectin expression by whole blood assay using fluorescent-labelled 
monoclonal antibodies in a flow cytometer. The assay protocols are described in 
Appendix 3. The symptoms of pain, cramps, heaviness, paraesthesiae and oedema 
were assessed with the patient using a visual analogue scale (VAS of 10 cm). Scale 
was marked 0 to 10 cm, severe symptoms were graded 10 where absence of 
symptoms were marked as 0.
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Statistical analysis
Descriptors used to represent the data are the median and interquartile ranges for the 
capillary analysis and biological markers.
Differences between medians were calculated using the Wilcoxon method.
Results
The subjects in each of the groups for analysis were of similar age distribution.
Stage & 
number
Sex
distribution
Age (years, mean 
value and range)
No. with 
superficial 
venous 
insufficiency
No. with deep & 
superficial 
venous insufficiency
First part of the study:
CO (n=10) 6F, 4M 43 (32-56)
Cl (n=15) 13F, 2M 56 (53-61)
C2 (n=20) 14F, 6M 53 (47-60) 16 4
C3 (n=15) 12F, 3M 50 (41-59) 11 4
C4a (n=15) 5F, 10M 52 (40-67) 8 7
C4b (n=15) 5F, 10M 64 (55-68) 9 6
C5 (n=15) 5F, 10M 50 (44-65) 7 8
Second part of the study:
C2 (n=48) 35F, 13M 52 (44-59) 37 11
C3 (n=18) 15F, 3M 52 (42-61) 14 4
Atypical
C2
(n=12) 7F, 5M 56 (52-66) 10 2
C3
(n=2) IF, 1M 47 (44-50) 2 0
Table 3.21. Distribution o f subjects according to age, sex and clinical, etiologic, anatomic, pathologic 
(CEAP) stage
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Capillary count decreases with the severity of the CVD, but capillary convolutions 
increase as the disease progresses. This has been illustrated in the table below and in 
the figures 3.23 and 3.24.
Patient supine. All data: median (inter-quartile range)
CEAP
stage
CO Cl C2 C3 C4a C4b C5
Capillary
count
15
(8-15)
18
(14-19)
15
(12-15)
14
(11-16)
10
(8-12)
4
(2 -1 1 )
7
(4 -7 )
No. of
evaluable
capillaries
13 
(8 -14 )
T12
(10-14)
9
(8-11)
10
(8-11)
7
(6-10)
3
(2 -8 )
+5
(4 -5 )
Convolut­
ions per 
capillary
1
(1 -1 )
*1
(1 -1 )
1
(1 -1 )
1
(1 -1 )
4
(2 -4 )
7
(5 -1 4 )
J10(>10)
(7-11)
Classifica 
tion grade
1
(1 -1 )
1
(1 -1 )
1
(1 -1 )
1
(1 -1 )
2
(1 -2 )
3
(2 -4 )
4
(3-4)
Diff. between medians: *11 capillaries (95% Cl: 5 -  17), *9 convolutions (95% Cl: 5 
-11 ) Wilcoxon.
Table 3.22: shows number o f countable capillaries, evaluable capillaries and number o f  loops per 
evaluable capillary in various CEAP clinical stages o f CVD. Classification grade o f capillary loops 
has also been summarised based on my proposition in the previous study. Difference between medians 
o f Cl and C5 and 95% Cl for the differences between medians were calculated using the Wilcoxon 
method.
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Figure 3.23: This graph shows the number o f visible capillaries per field in the six CEAP stages 
studied. The CEAP stages are shown on the horizontal axis and the number o f  capillaries on the 
vertical axis. The horizontal bar shows the median number o f  capillaries. Difference between medians 
o f C l and C5 and 95% Cl for the differences between medians were calculated using the Wilcoxon 
method.
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Figure 3.24: This graph uses similar axes to those o f the previous one. This time the vertical axis 
shows the number o f  convolutions per capillary in the six CEAP stages. Difference between medians 
o f C 1 and C5 and 95% Cl for the differences between medians were calculated using the Wilcoxon 
method.
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Capillary count and convolutions per capillary of the ‘atypical* patients has been 
shown in the table below. Comparison has been made with or without including 
those so-called ‘atypical’ groups of patients in their corresponding CEAP stages.
All data: median (inter-quartile range)
CEAP
stage
C2
(Including
atypical
group)
n=48
C3
(Including
atypical
group)
n=18
C2
(Excluding
atypical
group)
n=36
C3
(Excluding
atypical
group)
n=16
Atypical
group
alone
n = 
12+2=14
Median no. 
of
evaluable
Supine 6.0
(4 -9 )
7.5
(5 -11 )
4
(3 -8 )
8
(7 -1 0 )
8
(4.3 -1 0 )
capillaries Dependency 7.0 10.5 7 11 6
(5-11) (6-13) (6-10) (7.3-12.8) (4.3-14.5)
Convolutions 
per capillary
Supine 1 1 3
(1 - 2 .2)
11.3
d - 1.6)
§1
(1 - 1.1)
§ 1.2
d - 1 .3 )
1§3.1 
(2.2-4.0)
Dependency 1 1-4 1 1-5 1 1.4 t  2.6
(1-2.5) (1.1-1.9) (1 -1 .4 ) (1.1 - 1.6) (2.3-3.8)
•  1  Difference between medians of ‘C2/C3 including atypical group* and ‘atypical group
alone* in supine: 1 3 5  & 95% Cl: 1-2.4
•  § Difference between medians of ‘C2/C3 excluding atypical group* and ‘atypical group
alone* in supine: 2 & 95% Cl: 1.2- 2.9
•  t  Difference between medians of ‘C2/C3 including atypical group* and ‘atypical group 
alone* on dependency: 1.2 & 95% Cl: 0.7-1.8
Table 3.23: number o f evaluable capillaries and number o f loops per capillary on supine and on 
dependency in C2/C3 & “atypical” group o f patients. Difference between medians and 95% Cl for the 
differences between medians o f similarly symboled groups were calculated for convolutions only 
using the Wilcoxon method. Data was analysed considering C2/C3 together.
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C onvolutions per capillary loop •  C2
•  C3
Medians
•  Atypical
C2 C3 Atypical
Figure 3.25: This graph shows the number o f convolutions per capillary for the second part o f  the study 
i.e. C2, C3 and ‘atypical’ groups studied. The CEAP stages are shown on the horizontal axis and the 
number o f  convolutions on the vertical axis. The horizontal bar shows the median number o f  
convolutions.
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Various markers were correlated between atypical and C2/C3 (exclusive atypical), 
which did not show any statistically significance and has been illustrated in the table 
3.24 below.
C2/C3 including 
atypical
C2/C3 excluding 
atypical group
Atypical group Difference bei 
medians
& (95% Cl)
Number 66 52 14
Age 52 (42-59) 51 (41-59) 54 (51-65)
Neutrophil 
CD lib 185 (139-258) 202 (152-258) 137(106-256) 20 (-24-62)
Neutrophil
CD62L 58 (63-53) 58 (64-53) 56(60-53)
0 (-4-5)
Monocytes
CDllb 79(47-116) 79(50-117) 86(41-101) -5 (-32 to 25)
Monocytes
CD62L 40 (45-30) 38(46-30) 41(42-34) 2 (-8-11)
VEGF 84 (35-125) 104(37-106) 60(48-116) 12 (-11 to 53)
TNF-a 1.3 (0.7-5.5) 1.3 (0.6-9.2) 1.4 (.8-1.9) -.5 (-.4-0.9)
IL-6 2.2 (1.3-3) 2.2 (1.3-2.8) 2.1 (1.4-2.9) -1 (-0.7-0.5)
sL-selectin 915(723-1120) 1052 (796-1202) 671 (612-915) -106(-274-69)
sE-selectin 40 (30-58) 39 (28-52) 46 (36-57) 4 (-20-17)
sIC AM-1 547 (431-646) 547 (394-630) 585 (442-701) -18 (-129-24)
sVCAM-1 1268 (996-1567) 1270(1039-1584) 1159 (868-1554) 2.5(-224-250)
vWf 1.3 (1.0-1.7) 1.3 (1.0-1.6) 1.4 (1.2-1.8) -0.2 (-0.5-0.1)
Capillary
count 13 (10-18) 12 (9-16) 16 (10-22)
-3 (-7-0)
Pain 3.3 (1-5) 3 (1-4.9) 2.8 (0-5.4) -1.5 (-2.9-0)
Heaviness 3.4 (0-5) 3.5 (0-5) 1.9 (.1-4.6) 0 (-1.9-1)
Cramps 2.5 (0-5) 2.5 (0-4.7) 3.2 (0-7) -1.95 (-3.6-0)
Faraesthesiae 0 (0-2.5) 0.3 (0-2.8) 0 (0-0 .2) 0 (0-.5)
Oedema 0.7 (0-5) 0.7 (0-4.5) 0.8 (0-5) 0 (-1.5-0.3)
Table 3.24: Associations o f inflammatory markers and symptoms with the groups o f patients studied. 
Difference between medians and 95% Cl for the median differences between column three and four i.e. 
‘normal C2/C3 excluding atypical’ and ‘atypical group’ were calculated using the Wilcoxon method. 
Patient supine. All data: median (inter-quartile range). CD62L values refer to down regulation.
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Discussion
In this study, I have demonstrated good correlation of the various CEAP stages of CVD 
with the capillary morphology classes explained in the previous study. I also found that 
the number of capillary loops per unit area decreased with the advancing severity of 
disease. There was considerable overlap in capillary density between the different 
CEAP stages and, therefore, reduced capillary density observed using this technique 
might not be strongly related to the severity of skin changes. In contrast, capillary 
morphology assessed by counting the number of loops per capillary showed 
considerable changes in the more severe CEAP clinical stages. Capillary convolution is 
strongly associated with skin damage and can be reliably assessed by capillary 
microscopy.
Only the apex of skin capillaries is seen with the capillary microscope. Density of skin
• • • i r ecapillaries varies between publications . Browse et al described an increased number 
of capillaries on histological sections of the skin from limbs with communicating vein 
incompetence, postphlebitic deep vein damage and lipodermatosclerosis. Later it was 
found that the increase in capillary density was attributable to the same capillary being 
cut numerous times during histological preparation 362.
Assessing the absolute capillary count was not the main purpose of our study. This has 
been done by a number of previous authors and is subject to a number of errors. Native 
capillaroscopy shows only the capillary loops, which are perfused or contain red blood 
cells. Not all capillaries are open at any time and the count varies depending on the 
circumstances of the observations. This can be seen from a range of publications 
mentioned in “Review of capillary morphology and density studies in CVD” in chapter- 
1 365,366,367,368,369.1  concede that capillary counting did not count all capillaries present 
but I conducted my observations under standardised conditions, which were the same 
for all subjects. I concentrated in assessing the capillary morphology in the seven CEAP 
clinical stages described above. I have demonstrated in previous study (study 3) that if 
the analysis is confined to capillaries, where good quality images have been obtained, 
there is good agreement between independent observers on the grade of morphological 
change. In this study, I have demonstrated considerable differences between the lesser 
stages of CVD.
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It has been shown that there was a significant difference in the skin circulation between 
the group of C4 patients with pigmentation alone and no palpable evidence of 
induration as compared to other group of C4 patients with liposclerotic skin changes 
with palpable induration. In this study subdivided the group C4 patients into C4a and 
C4b to differentiate between the skin microcirculation in these two groups.
The definition of CEAP C4 stage was, therefore, changed from:
Class 4 Skin changes ascribed to venous disease (e.g., pigmentation, venous 
eczema, lipodermatosclerosis)
To:
Class 4a: Early skin changes such as haemosiderosis, venous eczema
Class 4b: Advanced skin changes such as lipodermatosclerosis
A rise in venous pressure has been suggested to cause dilatation of the horizontal sub- 
papillary plexus, with elongated, coiled dermal capillaries, and a reduction in the 
number of capillaries supplying the epidermis.363 Figures 3.23 and 3.24 emphasise the 
value of this subdivision. The capillary density and convolution in patients of C4a 
overlaps with those of C2 and C3. For patients of stage C4b these parameters show 
greatest similarity to those of C5 patients.
While exploring the correlation of various stages with capillary morphology changes, I 
have detected a group of patients who exhibit various degrees of abnormally great 
convolution of their cutaneous capillaries in the leg in CEAP stages of C2/C3. These 
patients have class 2 changes of their capillary morphology (3-5 convolutions per 
evaluable capillary). Several of them had class 3 changes of capillary morphology (i.e. 
6-10 convolutions per capillary). The absolute numbers of patients identified with these 
abnormalities in this study is small (only 14 patients in all). It is unlikely that 
statistically significant differences will be apparent with this number of patients. This is 
bom out in table 3.24, where although some trends emerge (e.g. sL-selectin and VEGF) 
none is of large enough magnitude to reach statistical significance. Some trends were 
seen in the symptoms resulting from venous disease with respect to heaviness and 
cramps.
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I have found that 21% of my C2 and C3 patient group may have capillary morphology 
of those with more severe venous disease. 25 -  30% of the population has varicose 
veins but only 2 - 5% have skin changes or ulceration, a proportion of 10 -  20%. I 
speculate that this group of patients are prone to develop clinical skin changes. Further 
studies are required to investigate the association my findings with the progression of 
venous disease in a larger number of patients.
I conclude that distinct capillary morphology changes detected by capillary microscopy 
are seen in the different clinical stages of the CEAP classification. In addition, an 
‘atypical’ group of patients exists who have a more advanced form of capillary 
morphology changes than their CEAP clinical stage. This group may be the target for a 
further study to assess the long term outcome and likelihood of development of skin 
changes.
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Study 5:
Photoplethysmographic and tissue tonometric parameters correlate with the 
severity of CVD in different stages of CEAP classification
Rationale
The most frequent causes of CVD are primary abnormalities of the venous wall and the 
valves and secondary changes due to previous venous thrombosis that can lead to 
reflux, obstruction, or both. Because the clinical examination will not always indicate 
the nature and extent of the underlying abnormality (anatomic extent, pathology, and 
cause), a number of diagnostic investigations have been developed that can elucidate 
whether there is calf muscle pump dysfunction and determine the anatomic extent and 
severity of obstruction or reflux 443. Non-invasive tests for the evaluation of CVD 
include quantitative photoplethysmography (QPG), air plethysmography, and duplex 
ultrasonography measurement of valve closure time (VCT), which have been shown to 
identify accurately the presence of CVD, define the disease and locate the involved 
segments. However, the correlation of non-invasive assessment of CVD with the 
clinical severity (Society for Vascular Surgery/ International Society for Cardiovascular 
Surgery staging) of the disease was not able to distinguish these groups by available 
non-invasive methods such as PPG 444.
A series of studies has been published using PPG to study patients with venous disease 
to assess its role and efficacy. PPG has been shown to be a sensitive method of 
detecting reflux, but the specificity was poor and refilling times could not accurately 
predict the location of reflux 445. Quantitative PPG provides an accurate estimate of 
ambulatory venous pressure (AVP) in patients with suspected chronic venous 
insufficiency 446. The application of calibrated photoplethysmography in conjunction 
with induced changes in leg hydrostatic pressure proved to be an effective physiological 
method non-invasively to quantify venous haemodynamics in normal control subjects, 
patients with venous valvular insufficiency, venous obstructive disease, or both 447.
No published study, which has measured venous reflux using PPG in patients with 
venous disease classified according to the CEAP system. On the other hand, 
lipodermatosclerosis has been described as a spectrum of disease characterised by skin
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induration and hyper-pigmentation 80. It has been previously shown that there is a 
correlation between the healing of venous ulcers and the degree of induration 448. There 
is a significant reduction in skin compliance in patients with clinically severe LDS as 
compared to normal controls and patients with pigmentation alone or oedema without 
any clinical evidence of skin change. Tissue tonometer has been used in various 
diseases in other clinical disciplines to measure the skin hardness and compliance 435, 
436^  437^ 449^  450^  45i^  452^  ^ut -g nQ pUbiished study using the tissue tonometer in 
CVD. Variations in skin compliance have not been assessed in patients with venous 
disease classified according to the CEAP system.
In this study, the purpose of the investigation was to establish the relationship between 
the severity of the venous disease indicated by the clinical classification (CEAP) and 
photoplethysmographic and tonometric methods of investigating functional and 
mechanical properties of lower limb skin changes to assess the skin compliance of the 
venous disease.
We also correlated the PPG refilling times with the tonometric phase 1 to explore the 
relationship between these two parameters.
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Materials and Methods
Patients considered for the entry into the study were those of attending The Middlesex 
Hospital Outpatient for management of venous disease. Those suitable for the inclusion 
in the study were canvassed by a letter of explanation indicating the nature of the study. 
Patients with CEAP clinical class C2 (varicose veins), C3 (oedema), C4a (skin changes 
such as eczema and haemosiderosis), C4b (lipodermatosclerosis) and C5 (healed ulcer) 
were considered.
Selection/inclusion criteria
■ Either sex,
■ Age above 18 years old, any race,
■ Having given their written informed consent,
■ Patients affected with stage C2 to C5 according to the CEAP clinical
classification (for stage C5 healed ulcer for at least 4 weeks),
■ Having the diagnosis and extent of venous disease been confirmed by duplex 
ultrasonography,
Exclusion criteria
CVD of stage CO, Cl or C6 according to CEAP clinical classification,
Diabetes mellitus, Connective tissue disorders 
Peripheral oedema due to non-venous cause 
Arterial disease (ankle-brachial index < 0.9),
Recent deep venous thrombosis (less than 1 year),
Recent superficial venous thrombosis (less than 15 days)
Support stockings initiated or modified 6 weeks before the study
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Patients fulfilling the entry criteria and giving informed written consent were studied 
further. Approval for the study was obtained from UCL Medical School Committee for 
medical ethics.
All patients were assessed clinically by a vascular surgeon skilled in the management of 
venous diseases to determine the clinical severity of the venous disease and assign the 
patient to the appropriate clinical grade of the CEAP classification. A medical history 
was taken and clinical examination performed. This included a systemic as well as 
venous examination. Patients included in the study underwent standard vascular 
laboratory investigation, as part of their routine management for venous disease, 
including duplex ultrasonography. 132 patients with various CEAP stages of chronic 
venous disease were included in this study.
Procedure
The study was conducted in an environmental chamber of 22°C (room temperature). All 
the patients were acclimatised for 10-20 minutes before the start of the experimental 
protocol to minimise venous pressure in the leg.
Duplex examination was performed by the experienced and trained employed technician 
and the details of the technique have been considered out of the scope of this study. We 
analysed the data based on the duplex findings dividing them into superficial (SVI) and 
deep venous incompetence (DVI).
PPG and tonometry measurements were made using the procedure mentioned in the 
methodology section in chapter 2.
Analysis of data
The difference between medians and 95% confidence interval were calculated using 
Wilcoxon method. The software used was Confidence Interval Analysis (British 
Medical Journal, London). All results are described as median (interquartile range, 
IQR).
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Results
The number of patients studied and their age and sex distribution including their duplex 
findings in various groups of CEAP are summarised in Table 3.25.
Stage & number Sex
distribution
Age (years, 
mean value 
and range)
No. with SVI No. with DVI & 
SVI
Patients (n=132) 60M, 72F 53 (45-64) 81 (+9) ** 42
C2 (n=47) 12M, 35F 52 (44-59) 35 11
C3 (n=18) 3M, 15F 52 (42-61) 13 4
C4 (n=44) 30M, 14F 60 (42-66) 23 18
C4a (n=24) 17M, 7F 54 (42-66) 11 11
C4b (n=20) 13M, 7F 65 (56-68) 12 7
C5 (n=23) 15M, 8F 53 (44-64) 13 9
** Deep vein not visualised are in parenthesis
Table 3.25: demographic data and duplex findings for PPG and tonometry study.
In keeping with previous studies, the PPG refilling time reduces with increasing severity 
of venous disease. The distance parameter measured by the tonometer in first second 
after application of loading to the probe decreases in the more severe stages of venous 
disease. This is illustrated in the table and graphs below.
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CEAP stages PPG refilling time (in seconds) Tonometry phase 1 Distance 
parameter (mm)
C2 14.1 (8.7-17.8) t 2.2 (1.5 -2.6) t
C3 11.6 (8.5-21.6) 1.7 (1.5- 2.7)
C4a 9.4 (7.7-14.7) 1.6 (1.2-1.8)
C4b 9.6 (8.1-12.4) 1.1 (0.9-1.5)
C5 9.1 (7.2-10.7) t 1.4 (0.7-1.9) %
■(■Difference between medians of C2 & C5: 3.9 sec (95% Cl: 0.63 -  7.1)
JDiff. between medians of C2 & C5: 0.73 mm (95% Cl: 0.3 -  1.09)
Table 3.26: Values o f PPG refilling time in seconds and tonometry phase 1 distance parameter (X0) in 
mm in patients with various CEAP stages o f CVD, expressed as Median (Interquartile ranges, IQR, in 
parenthesis). Median differences and 95% confidence interval are also shown. Median differences 
calculated using the Wilcoxon method.
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Figure 3.26: PPG refilling times in various stages o f  CVD. PPG refilling times in seconds are shown on 
Y-axis and various CEAP clinical stages on X-axis. Difference between medians o f  C2 and C5: 3.9 sec; 
95% Cl for the differences between medians: 0.63 to 7.1. Median differences calculated using the 
Wilcoxon method.
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Figure 3.27: Tonometer phase 1 distance parameter (X0) in various stages o f  CVD. Initial distance 
travelled in mm is shown on Y-axis and various CEAP clinical stages on X-axis. Difference between 
medians o f  C2 and C5: 0.725 mm; 95% Cl for the differences between medians: 0.30 to 1.09. Median 
differences calculated using the Wilcoxon method.
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I did not find any difference in PPG refilling times or tonometry parameters between 
patients with superficial or deep venous incompetence in any CEAP clinical stage of 
CVD.
I also calculated the correlation coefficient between the PPG refilling times and phase 1 
distance of all categories of patients. There was weakly negative correlation between 
PPG refilling times and the phase 1 distance (r= - 0.1).
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Discussion
PPG refilling time reflects the severity of venous reflux and is widely accepted as a 
method of measuring the physiological disturbance in patients with venous disease. 
Correlation with refilling times measured by direct foot vein pressure measurements has 
been shown. 453 It is generally accepted that venous refilling in normal subjects takes 17 
-  20 seconds or greater 167•4:>4. PPG readings have been shown to be reproducible and 
remain useful in the assessment of venous dysfunction 167.
Observations were not made on control subjects in my study since such data have been 
widely published previously. PPG refilling times decrease with the more advanced 
stages of venous disease, but there is overlap between observations in the different 
CEAP clinical groups. Median PPG refilling times in C2, C3, C4a, C4b and C5 disease 
are 14.1 sec, 11.6 sec, 9.4 sec, 9.6 sec and 9.1 seconds respectively. The difference 
between the C2 and C5 measurements reaches statistical significance but the 
measurements in the C3, C4 and C5 groups are very similar and do not account for the 
clinical differences between such patients. Van Bemmelen found a poor correlation 
between the results of PPG measurements and duplex ultrasonography. 455 PPG is a 
functional and not an anatomical test, therefore poor correlation might have been 
expected between these investigations. Van Bemmelen found that shorter venous 
refilling times were encountered in patients in whom duplex ultrasonography showed 
more incompetent segments, but precise identification of patients with superficial and 
deep venous reflux was not possible. My findings confirm that PPG refilling times did 
not differ between patients of the same clinical stage with deep or superficial venous 
reflux. I expected to find a substantial difference between the different CEAP clinical 
stages. However, patients with stages C3 -  C5 have very similar measurements. This is 
surprising since it is widely assumed that the severity of venous reflux is an important 
factor in determining the outcome of venous disease. My observations suggest that 
patient with leg oedema, skin changes of any type and those with healed ulcers have a 
similar amount of venous reflux. Some other factor may be more important in 
determining which patients suffer venous ulceration and which experience only ankle 
oedema.
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Tonometry validation or reproducibility was not the purpose of this work. The 
technique of tonometry to assess the skin of the lower limb has been evaluated in detail 
previously with good reproducibility 457, 456. It has been shown that the parameter 
evaluated here (phase 1 distance) has a coefficient of variation of 8% when evaluated in 
control subjects on different occasions. This has shown considerable differences 
between normal skin and liposclerotic skin and is therefore a useful objective measure 
of the severity of lipodermatosclerosis. We revisited this area to correlate this parameter 
with the disease severity and PPG refilling time.
In regard to tonometry, I only measured the initial distance travelled by the weighted 
plunger in first second. This measurement has been shown to be a repeatable assessment 
reflecting the severity of skin induration 457. Subsequent phases of the tonometer trace 
did not show any significance between the different stages of CVD. In my study, initial 
distance phase (Do) in C2, C3, C4a, C4b and C5 disease are 2.2 mm, 1.7 mm, 1.6 mm, 
1.1 mm and 1.4 mm respectively, showing a clear progression with advancing severity 
of venous disease (table 3.26). These findings are consistent with previously published 
data using this technique.456, 457 As a whole C2/C3 disease has 2.4 mm distance 
travelled in phase 1 and C4/C5 has 1.65 mm in its phase 1. In keeping with previous 
work 457 using this technique, patients without lipodermatosclerosis (C2, C3, C4a) have 
similar displacement of the plunger during phase I, but those with LDS (C4b and C5) 
have reduced plunger travel. This reflects the clinical presence of LDS. No correlation 
was found with the PPG refilling times, confirming that the severity of venous disease is 
not predicted by PPG measurements.
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Study 7:
Effect of Oral Micronized Flavonoid Therapy (Daflon®) on patients with CVD in a 
double blind randomised placebo controlled clinical trial
Rationale
Pharmacological treatment is widely used to ameliorate the symptoms of venous disease 
in many European countries. In Scandinavian countries and in the UK this class of drug 
is infrequently used. One reason for these discrepancies is the lack of controlled 
scientific trials establishing the role of these compounds. A purified micronized 
Flavonoid fraction (Daflon® 500, Servier Laboratories, France) has been used in 
Europe and other parts of the world for the treatment of CVD for several years. Daflon 
consists of 90% Diosmin and 10% hesperidin flavonoids. A double blind randomised 
trial published in 1994 had shown its efficacy in treating the clinical symptoms of CVD 
without any significant side effects 405. Placebo controlled study 458, 409 has 
demonstrated an improvement in ulcer healing.
Animal studies have demonstrated the ability of Daflon® 500 mg to reduce the number 
of adherent leucocytes to the venular endothelium in a dose dependent way 401. This was 
accompanied by a down-regulation of endothelial ICAM-1 expression. Other studies 
have also shown the protective effect of Daflon® 500 mg against the leakage of 
macromolecules 459, 460, 17.
A pilot study performed on a cohort of 20 patients showed that many markers of the 
systemic inflammatory response to venous disease were significantly reduced by 
Daflon® treatment 14, 16. These included the leucocyte markers CD lib , L-selectin, the 
endothelial markers sE-selectin, sICAM and sVCAM and the angiogenesis factor 
VEGF.
A placebo controlled, randomised, double blind study on a larger number of patients 
was required to verify these findings. To investigate the dose response of any findings it 
was decided to evaluate the effect of Daflon® 500 mg at two different dosages (lg/day 
and 3g/day).
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The aim of my study was, therefore, to assess the effects of micronized purified 
flavonoid fraction (S5682, Daflon® 500 mg, Servier, France) treatment for two months 
on the microcirculation in CVD.
MATERIAL & METHODS
This was a single-centre, placebo-controlled, randomised, double blind and parallel 
group study. Stratification of the groups was made according to the severity of the 
disease (absence of skin changes CEAP stage C2-C3 or presence of skin changes CEAP 
stage C4-C5). In each group (Daflon® 500 mg lg/day; Daflon® 500 mg 3g/day and 
placebo), there were same numbers of patients with skin changes as without skin 
changes. This stratification is based on previous observations showing that some 
inflammatory mediators are more elevated in patients with skin changes, compared to 
those with uncomplicated venous disease. The study was conducted under the terms of a 
clinical trials exemption certificate obtained from the Medicine Control Agency by the 
manufacturers. The study was considered and approved by the UCL Medical School 
committee on medical ethics.
PATIENTS: Patients considered for the study were those attending the vascular clinic 
at The Middlesex Hospital for management of venous diseases. In this clinic, patients 
routinely undergo venous duplex examination to assess the extent of nature of their 
venous disease, allowing suitable volunteers to be identified for inclusion in the study. 
Those patients who gave the written informed consent were considered further for this 
investigation. All patients were examined by a surgeon experienced in the management 
of venous disease and allocated to the correct CEAP clinical stage.
Selection/inclusion criteria
- Either sex,
- Age above 18 years old, any race,
- Having given their written informed consent,
- Patients affected with stage venous disease CEAP clinical stage C2 to C5 
(for patients presenting with stage C5 healed ulcer for at least 4 weeks),
- Having the diagnosis and extent of venous disease been confirmed by duplex 
ultrasonography and photoplethysmography,
- Patients who are psychologically stable and well motivated.
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Exclusion criteria
■ History of alcohol or drug abuse,
■ Known history of allergy or intolerance to diosmin or any other venotonic agent,
■ CVD of stage CO, Cl or C6 according to CEAP clinical classification,
■ Diabetes mellitus,
■ Connective tissue disorders including rheumatoid arthritis,
■ Blood disorders,
■ Arterial disease (ankle-brachial index < 0,9),
■ Impaired hepatic function (ALAT or ASAT 3 x upper limit of normal)
■ Impaired renal function (serum creatinine >120 pmol/1),
■ Any concomitant active disease or abnormality in laboratory test, judged as 
clinically significant by the investigator,
■ Infection within the previous 6 weeks,
■ Patient with concomitant acute or chronic disease that may interfere with the
results (particularly inflammatory and/or infectious disease), according to 
investigator's opinion,
■ Recent deep venous thrombosis (less than 1 year),
■ Recent superficial venous thrombosis (less than 15 days),
■ Concomitant medications:
• Non steroidal anti-inflammatory agents,
• Corticoids,
• Salicylates,
• Vit A, Vit C, Vit E and derivatives,
• Pentoxyfilline, naftidrofuryl,
• Any kind of anticoagulant treatment,
• Any medication known to alter white blood cell activity,
• All venotropic drugs are non authorized treatments for 15 days prior 
to inclusion into and duration of the study,
■ Support stockings should not be initiated or modified during the course of the 
study,
■ Skin grafting,
■ Sclerotherapy,
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■ Vein stripping operations,
■ Predictable poor compliance to treatment,
■ Participation of the patient in an other clinical trial during the previous 3
months,
■ Pregnant or breastfeeding women, or women of childbearing age without active 
contraception (oestro-progestative treatment, intrauterine contraceptive device) 
or wishing to become pregnant.
Treatments: The drugs and placebo used in the study were prepared by the 
manufacturer and were of identical appearance. All volunteers took two tablets three 
times per day to ensure that the randomisation was not apparent to investigator or 
patient. The randomisation was established by the manufacturer and remained unknown 
to the investigator and patients until the study had been completed. Compliance to
treatment was established by asking volunteers to return the remaining tablets at the end
of the treatment period and calculating the percentage consumed.
Investigation schedule
Scale has been shown in appendix 6.
At D-15 visit, the study was explained to patients and written information sheets were 
provided. Volunteers agreeing to take part in the study gave their written consent. The 
patient information sheet and consent form are shown in appendix 7 & 8. Then they 
were screened for the suitability for the study by taking history, clinical examination 
and taking a blood sample for full blood count and urea, electrolytes and liver function 
tests. They would also have duplex scanning this had not been done within previous 6 
months. A PPG venous refilling test was also done to confirm the severity of venous 
reflux.
At the DO visit, inclusion and exclusion criteria were reviewed and if the patients were 
found suitable then they had blood taken for the study parameters described below; 
tissue tonometry and capillary microscopy would be performed. Volunteers also 
received their study medication with instructions at this visit.
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At the D60 visit, in addition to blood taken for specific biology, tissue tonometry and 
capillary microscopy, compliance and acceptability and adverse effects were assessed.
METHOD OF SAMPLING
At DO and D60: All the patients were acclimatised for 10-20 minutes in an 
environmental chamber of 22 ° C (room temperature) whilst lying supine before the 
start of the experimental protocol to minimise venous pressure in the leg. A 23-gauge 
canula (Venisystems ™ Butterfly®, Abbott, Ireland) was placed in the distal long 
saphenous vein or dorsal foot vein of the most severely affected leg. 8 ml of blood was 
collected into two tubes containing EDTA (EthyleneDiameneTetraacetic Acid) 
Vacutainer, Becton Dickinson Vacutainer Systems Europe, BP No 37-38241 Meylan 
Cedex, France) and 4 ml of blood was collected into a citrated tube.
Each sample was divided into 3 parts: Full blood count, including a differential white 
cell count, whole blood assay for leucocyte adhesion molecules (citrated sample), 
plasma separated by centrifugation at 20,000 rpm for 10 minutes at 4°C within one hour 
of collection which was promptly frozen at -84°C for analysis of soluble endothelial and 
leucocyte adhesion molecules and cytokines by ELISA. Detailed methods of analysis 
are described in appendix 3.
Efficacy criteria
The outcome of treatment was assessed using measurements of inflammatory mediators. 
All efficacy criteria are assessed at DO and D60.
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Main criteria sIC AM-1 (ng/ml)
sVCAM-1 (ng/ml)
Secondary Neutrophil CD1 lb (FU/ml)
criteria Monocyte CD1 lb (FU/ml)
Neutrophil CD62L (FU/ml)
Monocyte CD62L (FU/ml)
sP-selectin (ng/ml)
sE-selectin (ng/ml)
Von Willebrandt factor (IU/ml)
sL-selectin (ng/ml)
Cytokines ELI a  (pg/ml)
ILlp (pg/ml)
TNFa (pg/ml)
IL-6 (pg/ml)
VEGF (pg/ml)
Tonometry parameters Distance constant (mm) for 
initial, middle and final phases
Time constant(s) for middle 
and final phases
Capillary microscopy Capillary density (number of 
capillaries/mm2)
Morphological description of 
capillaries
Symptoms of chronic venous Pain
insufficiency (VAS of 10 cm) Cramps
Heaviness
Paraesthesiae
Oedema
Global efficacy of treatment
Table 3.27: efficacy criteria assessed at DO and D60 visits. FU = Fluorescent Unit. All specific biology 
criteria were studied as (D60-D0) variation.
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Safety criteria
Vital signs (weight, blood pressure, heart rate),
■=> Adverse events.
Statistical analysis
The difference between medians and 95% confidence interval were calculated using 
Wilcoxon method Confidence Interval Analysis (British Medical Journal, London). All 
results are described as median (interquartile range, IQR).
RESULTS
The number of patients studied and their age and sex distribution including their duplex 
findings in various groups of CEAP are summarised in Table 3.28 below.
Stages & number Sex
distribution
Age 
(years, 
mean value 
and range)
No. with 
superficial 
venous 
insufficiency
No. with 
deep & 
superficial 
venous 
insufficiency
Patients
(n=132)
60M, 72F 53 (45-64) 81 (+9) 42
C2, C3 C2 (n=47) 12M, 35F 52 (44-59) 35 11
(n=66) C3 (n=18) 3M, 15F 52 (42-61) 13 4
C4, C5 C4 (n=44) 30M, 14F 60 (42-66) 23 18
(n=66) C4a (n=24) 17M, 7F 54 (42-66) 11 11
C4b (n=20) 13M, 7F 65 (56-68) 12 7
C5 (n=23) 15M, 8F 53 (44-64) 13 9
** Deep veins not visualised are in parenthesis
Table 3.28: demographic data and duplex findings o f the all patients included for the study in various 
CEAP stages.
All three treatment groups had a similar distribution of factors, which may have 
influenced the outcome of the study assays. These include age, CEAP stages, SVI, DVI 
and recurrent status. These are shown in the table below.
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Stage & number Placebo lg  Daflon 3g Daflon
Patients (n=102 out of 132) 32 35 35
C2 (n=41 out of 48) 13 14 14
C3 (n=14 out of 18) 2 6 6
C4 (n=31 out of 44) 11 10 10
C5 (n=18 out of 23) 5 7 6
Median age 55 (41-66) 55 (50-66) 52 (45-61)
Sex (M: F) 21: 14 10: 25 16: 19
SVI 22 23 24
DVI 8 13 10
Primary 14 20 19
Recurrent 17 17 18
Smokers 25 29 15
Non smokers 6 13 25
Positive family history 24 25 23
Without family history 10 15 17
Table 3.29: demographic data o f various determinants and duplex findings o f completed patients in 
individual treatment group o f the trial.
In following pages, I have summarised the findings of my study. Table 3.29 presents the 
data of all patient groups, Table 3.30 of C2/C3 and table 3.31 of C4/C5 CEAP stages of 
CVD in three different treatment doses showing the pre and post treatment results of 
various markers and symptoms.
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Placebo Daflon lg Daflon 3g
All patients Before After Before After Before After
treatment treatment treatment treatment treatment treatment
Neutrophil 216 216 191 #161 207 189
CD l ib  (FU) (156-283) (140-316) (126-228) (106-205) (163-256) (131-284)
Neutrophil
CD62L (FU)
61 (65 -55) 59 (6 9 -4 8 ) 60 (65 - 54) 58 (6 3 -4 7 ) 63 (6 6 -5 5 ) 61 (68 - 54)
M onocytes 73 74 78 67 70 87
C D llb  (FU) (52-100) (45-140) (47- 96) (53- 87) (52-117) (40- 127)
M onocytes
CD62L (FU)
43 (48 - 5) 33 (45 -16) 3 9 (4 3 -2 8 ) 28 (44 - 17) 40 (46 - 32) 3 8 (5 3 -3 1 )
VEGF (pg/ml) 57 (34-115) If 47 (70-30) 64 (35- 130) 59 (89-37) 83 (38- 127) § 63 (102-35)
TNF-a (pg/ml) 1.4 (0.8-5.2) 1.5 (0.6-5.7) 1.4 (0.8-2.9) 1.4 (0.8-4.5) 0.9 (0.6-1.7) 0.9 (0.4-1.7)
IL -la  (pg/ml) 0.0 (0.0-1.4) 0.0 (0.0-2.1) 0.0 (0.0-0.6) 0.0 (0.0-0.0) 0.0 (0.0-1.2) 0.0 (0.0-0.0)
IL-13 (pg/ml) 0.3 (0.9-0.2) 0.2 (0.8-0.1) 0.2 (0.6-0.1) 0.3 (0.9-0.2) 0.3 (0.7-0.1) 0.3 (0.9-0.1)
IL-6 (pg/ml) 2.3 (2.7-1.6) 2.7 (3.6-1.6) 2.2 (3.7-1.4) 2.7 (3.9-1.7) 2.4 (3.2-1.5) f l .6  (3.0-1.3)
sL-selectin 903 879 779 800 852 899
(ng/ml) (753-1078) (737-1061) (644-1087) (620-1067) (705-1058) (755-1059)
sE-selectin 41 41 49 43 44 40
(ng/ml) (32-49) (30-50) (34-63) (34-60) (33-56) (28-53)
sP-selectin 93 98 114 109 97 87
(ng/ml) (75-115) (76-113) (88-137) (90-141) (85-143) (72-106)
SICAM-1 577 520 630 637 605 582
(ng/ml) (470-645) (436-647) (455-725) (474-685) (535-724) (462-680)
SVCAM-1 1302 1328 1361 1320 1223 1239
(ng/ml) (1175-1589) (1087-1635) (1141-1579) (1069-1528) (995-1443) (1008-1386)
VW f (IU/ml) 1.3(1.1-1.9) 1.4(1.1-1.8) 1.4 (1.2-1.7) 1.5 (1.2-1.7) 1.3 (1.0-1.6) 1.4 (1.0-1.6)
Pain (cm in VAS) 2(0-5) 2(0-4) 1(0-4) t 0  (0-3) 1 (0-5) 1(0-4)
Heaviness 2 2 3 0 1 * 0
(cm in VAS) (0-5) (0-4) (0-5) (0-4) (0-4) (0-3)
Cramps 1 0 4 0 1 0
(cm in VAS) (0-5) (0-3) (0-7) (0-2) (0-6) (0-3)
Paraesthesiae 1 0 0 0 0 0
(cm in VAS) (0-3) (0-1) (0-0) (0-0) (0-2) (0-1)
Oedema 1 0 0 0 1 1
(cm in VAS) (0-3) (0-2) (0-3) (0-2) (0-5) (0-3)
All data: median (inter-quartile range).
# Difference between medians of pre & post treatment markers: 27 & 95% Cl: -14 to 63 
Difference between medians of pre & post treatment markers: 15 & 95% Cl: -5 to 51
§ Difference between medians of pre & post treatment markers: 19 & 95% Cl: -5 to 48 
t  Difference between medians of pre & post treatment markers: 0.2 & 95% Cl: -.3 to 1 
|  Difference between medians of pre & post treatment markers: 0 & 95% Cl: 0 to 1.9
* Difference between medians of pre & post treatment markers: 0 & 95% Cl: 0 to 1.1
Table 3 JO: Study outcome measures (biological & symptoms) in different dose groups before and after 
the treatment in all patients group. Values o f CD62L mean down regulation following FMLP stimulation 
o f  leucocytes, minus sign has been omitted to avoid too many parenthesis in the IQR line. Median 
differences calculated using the Wilcoxon method. Difference between medians and 95% Cl for the 
differences between medians o f pre and post treatment markers have also been analysed with appropriate 
indicators. None reached statistically significant level.
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C2, C3 Placebo Daflon lg Daflon 3g
Before After Before After Before After
treatment treatment treatment treatment treatment treatment
Neutrophil 239 229 181 164 205 186
CD l ib  (FU) (171-307) (178-3520 (109-245) (115-203) (150-252) (143-262)
Neutrophil 61 63 60 61 57 62
CD62L (FU) (65- 53) (70- 43) (63- 54) (66- 40) (63- 54) (66-55)
Monocytes 71 71 84 61 102 91
CD l ib  (FU) (45-92) (43-109) (50-103) (44-93) (55-139) (44-115)
Monocytes 43 43 39 26 43 38
CD62L (FU) (49- 28) (46- 6) (42- 28) (44- 20) (46- 38) (50- 20)
VEGF (pg/ml) 114(48-126) 51 (34-90) 62 (33-142) 57 (33-114) 81 (36-114) 64(34-111)
TNF-a (pg/ml) 0.8 (0.5-2.0) LI (0.4-2.7) 1.8 (0.8-9.2) 1.9 (0.8-3.3) 0.8 (0.6-3.9) 0 .7 (03-1 .5 )
IL -la  (pg/ml) 0.0 (0.0-2.2) 0.2 (0.0-2.4) 0.0 (0.0-1.2) 0.0 (0.0-1.9) 0.0 (0.0-1.1) 0.0 (0.0-0.1)
IL-10 (pg/ml) 0.3 (0.2-1.1) 0.3 (0.2-1.0) 0.3 (0.1-0.6) 0.3 (0.2-1.0) 0.2 (0.2-0.6) 0.3 (0.2-2.6)
IL-6 (pg/ml) 2.2 (1.2-2.5) 2.3 (1.2-2.9) 2.1 (1.3-3.2) 2.4(1.1-3.7) 2.2(1.4-3.1) 1.5 (1.2-3.1)
sL-selectin 945 958 767 800 979 969
(ng/ml) (828-1144) (619-1152) (626- 1395) (616- 1332) (812-1104) (814-1091)
sE-selectin 43 41 36 34 42 38
(ng/ml) (36-53) (36-53) (27-62) (26-58) (35-60) (32-58)
sP-selectin 96 101 120 133 120 92
(ng/ml) (89-113) (79-120) (104-138) (105-145) (84-145) (81-153)
sICAM-1 537 496 639 621 581 539
(ng/ml) (455-613) (419-610) (452-774) (489-721) (485-653) (386-624)
sVCAM-1 1389 1223 1378 1359 1214 1256
(ng/ml) (1113- 1560) (1079- 1610) (1044-1750) (976-1618) (1143-1538) (1112-1405)
VW f (IU/ml) 1.3 (1.0-1.6) 1.3 (1.0-1.6) 1.5(1.3-1.8) 1.6 (1.4-1.8) 1.3 (1.0-1.5) 1.2 (0.9-1.8)
Pain (cm in VAS) 4 (2 -5 ) 3(1-4) 3(0-4) 0 (0-2) 3(0-5) 1(0-4)
Heaviness 4 3 3 0 3 2
(cm in VAS) (1-5) (2-5) (0-4) (0-3) (1-6) (0-4)
Cramps 3 1 3 0 1 0
(cm in VAS) (0-5) (0-3) (0-5) (0-3) (0-7) (0-2)
Paraesthesiae 1 0 0 0 0 0
(cm in VAS) (0-4) (0-2) (0-2) (0-1) (0-2) (0-1)
Oedema 0 0 1 0 1 1
(cm in VAS) (0-2) (0-2) (0-4) (0-3) (0-5) (0-3)
Table 331 : Study outcome measures (biological & symptoms) in different dose groups before and after 
the treatment in C2/C3 patients group. Values o f CD62L mean down regulation following FMLP 
stimulation o f leucocytes; minus sign has been omitted to avoid too many parenthesis in the IQR line. 
Median differences calculated using the Wilcoxon method. None o f them reached a statistically 
significant level. All data: median (inter-quartile range).
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C4, C5 Placebo Daflon lg Daflon 3g
Before After Before After Before After
treatment treatment treatment treatment treatment treatment
Neutrophil 213 235 181 164 213 205
CD l ib  (FU) (161-274) (131-301) (109-245) (115-203) (180-245) (102-285)
Neutrophil 63 57 60 61 66 61
CD62L (FU) (67- 57) (65-48) (63- 54) (66- 40) (69- 64) (68- 49)
Monocytes 81 90 84 61 64 71
CD l ib  (FU) (65-109) (49-149) (50-103) (44-93) (52-74) (33-157)
Monocytes 43 31 39 26 38 38
CD62L (FU) (46-38) (43-17) (42-28) (44-20) (45-21) (54-33)
VEGF (pg/ml) 46 (34-75) 41 (32-66) 62 (33-142) 57 (33-114) 94 (50-154) #64(37-101)
TNF-a (pg/ml) 2.0 (0.9-5.2) 1.9(1.1-5.7) 1.8 (0.8-9.2) 1.9 (0.8-13.3) 1.2 (0.6-1.7) 0.9 (0.7-1.7)
IL -la  (pg/ml) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-1.2) 0.0 (0.0-1.9) 0.0 (0.0-1.4) 0.0 (0.0-0.0)
IL-13 (pg/ml) 0.3 (0.1-0.6) 0.2 (0.1-0.7) 0.3 (0.1-0.6) 0.3 (0.2-1.0) 0.3 (0.1-0.6) 0.3 (0.1-0.6)
IL-6 (pg/ml) 2.3 (1.7-3.0) 3.0 (2.3-3.8) 2.1 (1.3-3.2) 2.4(1.1-3.7) 2.7(1.7-3.2) 1.7 (1.3-2.9)
sL-selectin 854 830 767 800 802 790
(ng/ml) (744-921) (754-965) (626-1395) (616-1332) (638-886) (635-909)
sE-selectin (ng/ml) 37 (30-46) 41 (27-46) 36 (27-62) 34 (26-58) 45 (31-52) 40 (24-53)
sP-selectin (ng/ml) 86 (68-119) 87 (62-105) 120(104-138) 133 (105-145) 94 (86-117) 75 (64-92)
sICAM-1 621 594 639 621 635 648
(ng/ml) (482-667) (478-659) (452-774) (489-721) (551-759) (539-747)
s VC AM-1 1296 1328 1378 1359 1259 § 1232
(ng/ml) (1210-1706) (1076-1635) (1044-1750) (976-1618) (923-1427) (972-1418)
VWf (IU/ml) 1.3(1.2-2.0) 1.4 (1.3-1.9) 1.5 (1.3-1.8) 1.6 (1.4-1.8) 1.3 (1.0-1.5) 1.4 (1.0-1.5)
Pain (cm in VAS) 0(0-3) 1 (0-3) 3(0-4) 0 (0-2) 0 (0-2) 1 (0-3)
Heaviness 0 0 3 0 0 0
(cm in VAS) (0-3) (0-3) (0-4) (0-3) (0-2) (0-0)
Cramps 0 0 3 0 3 1
(cm in VAS) (0-6) (0-5) (0-5) (0-3) (0-5) (0-4)
Paraesthesiae 0 0 0 0 0 0
(cm in VAS) (0-2) (0-1) (0-2) (0-1) (0-2) (0-2)
Oedema 2 0 1 0 0 0
(cm in VAS) (0-3) (0-3) (0-4) (0-3) . (0-3) (0-2)
TMedian differences calculated using the Wilcoxon method.
# Difference between medians of pre & post treatment markers: 31 & 95% Cl: -12 to 93 
§ Difference between medians of pre & post treatment markers: - 26.5 & 95% Cl: -287 to 285
Table 3 3 2 : Study outcome measures (biological & symptoms) in different dose groups before and after 
the treatment in C4/C5 patient group. Comparison o f mean visual analogue symptom scores in all patients 
before and after 60-day treatment. Values o f CD62L mean down regulation following FMLP stimulation 
o f leucocytes; minus sign has been omitted to avoid too many parenthesis in the IQR line. Difference 
between medians and 95% Cl for the differences between medians o f  pre and post treatment markers 
have also been analysed with appropriate indicators. None reached statistically significant level. All data: 
median (inter-quartile range).
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Tonometry parameters (distance constant in mm for initial, middle and final phases and 
time constants for middle and final phases in seconds) and capillary microscopy 
parameters (capillary density per mm2 and morphology) did not show any changes 
whatsoever in any treatment group of patients.
In contrast to the pilot study conducted using an identical protocol, none of the 
indicators of efficacy reached statistical significance. The data show wide variance and 
this may conceal any difference attributable to drug treatment. Therefore, global 
efficacy of treatment was insignificant.
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Discussion
I have failed to demonstrate any down regulatory effect of the treatment on any markers 
in this randomised controlled trial. Many of the measurements show large variance and 
this may account for my failure to find differences attributable to the treatment. Care 
was taken at all stages of blood taking and testing to ensure that the effect of handling of 
samples was minimised. Blood was taken without the use of a tourniquet in order to 
avoid inducing venous hypertension with the tourniquet. Samples were immediately 
prepared for processing. Those blood samples, which were to be analysed by flow 
cytometry were immediately taken to the lab and immuno-staining commenced 
immediately. The flow cytometer was maintained and operated by a skilled scientist 
fully conversant with the complexities of this technique. Blood for ELISA assays was 
centrifuged and plasma frozen within one hour of venesection. All assays for the same 
patient were conduced using the same 96 well assay plate. This meant that one sample 
for each patient had to remain frozen for 60 days longer than the other. However, I can 
find no evidence of sample deterioration of assays during frozen storage from published 
literature. The assays were conducted with the assistance of skilled scientists fully 
conversant with the use of this technique. I believe that the data reported here are 
correct and reliably reflect the outcome of flavonoid treatment in patients with venous 
disease.
The assays reported in study 1 were performed contemporaneously with the data 
reported here. These show a clear difference for many parameters between control 
subjects and those with venous disease. Patients with venous disease have clear 
evidence of low-grade systemic inflammatory response. This was unaltered by 
flavonoid treatment in this study.
In several previous studies, detailed in the review chapter (chapter 1), this drug has 
shown to be effective in alleviating symptoms in CVD 399,402,405,406,407,408. Flavonoid
• • • • 17 18 19treatment has also been to down regulate leucocyte adhesion in animals studies ’ ' ’ 
4oo, 40i, 417,418 ^  more recenjiy jn a pilot study this has shown to down regulate CD62L,
sVCAM-I , and sICAM-1 and VEGF 14,15, 16. Many of these studies were not well 
designed. The results of the pilot study may have been fortuitous due to the small 
sample size. In my study in a much larger cohort of patients no effect of the trial drug 
was seen on either the markers of inflammation or on the symptoms. This is certainly a
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curious finding since a number of previous double-blind studies have reported an effect 
on the symptoms of venous disease. Analysis of possible confounding factors such as 
compliance with the trial drug and variations in demographic data do not appear to be 
responsible for my failure to observe any effect of the treatment.
In conclusion, I could not show any effect of the trial medication on any of the 
parameters measured. The means by which Daflon® exerts it effect has not been 
clarified by this investigation.
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Chapter 4
GENERAL DISCUSSION
A number of previous authors have published data addressing the role of inflammatory 
processes in venous disease 10, 12, 13, 156, 157. These indicate the general type of 
inflammatory response but report a limited range of parameters. I set out to study a 
much larger cohort of patients with venous disease (n = 132 in total) and to assess in 
considerable detail a wide range of indicators of inflammation in comparison to a 
substantial group (n=30) age and sex matched control subjects.
Patients were categorised according to the internationally agreed CEAP classification, 
rather than on the basis of duplex ultrasonography, which was used to confirm that 
venous reflux was present in the patient groups. It is possible that some of the control 
subjects may have had venous reflux in the absence of any obvious sign or symptom of 
venous disease, as we did not routinely perform duplex scanning for our controls 
subjects. The basis of inclusion of control subjects in this study was on clinical criteria 
in order that they could be assigned to the CO group of the CEAP clinical stage. I 
acknowledge that there is the possibility that some of the control subjects may have had 
venous reflux in the absence of any obvious symptom or clinical sign. This would not 
have altered their CEAP clinical stage since this is based on clinical criteria alone. The 
data obtained from the studies in this thesis shows most differences lie between the 
control subjects and patients, confirming that the control group comprised a different 
cohort from the patients.
This work has provided me with a detailed assessment of the inflammatory mechanisms 
at work in chronic venous disease. In comparison to the studies of previous authors, I 
calibrated the flow cytometer to allow assessment of absolute levels of surface antigens, 
as well as assessing the response of leucocytes to FMLP stimulation. Absolute 
expression of CD lib  or CD62L on neutrophils and monocytes were similar in control 
subjects and patients of all CEAP stages. However, multivariate logistic regression 
analysis shows a modest but statistically significant relationship between CEAP clinical 
stage and neutrophil CDllb data (p=0.018) as well as with monocyte CD62L data 
(p=0.002) following FMLP stimulation. Plasma levels of soluble CD62L were 
measured by ELISA in concert with flow cytometry so that the amount of leucocyte
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CD62L shed into the plasma could be assessed. A modest elevation of this adhesion 
molecule was seen in CEAP stages C2 and C3 compared to controls, but no increase 
was seen in the more severe stages of disease (C4 & C5), in table 3.3. These apparent 
contradictory findings do not support our hypothesis of leucocyte activation to 
corroborate the severity of venous disease.
In keeping with published data from other authors 12, 13 plasma levels of sVCAM-1 
were elevated in all patient groups compared to controls. Multi-variate logistic 
regression analysis showed a positive association between CEAP clinical stage and 
sVCAM-1 levels. Simple analysis showed raised sICAM-1 levels in C4 patients but no 
relationship with CEAP clinical stage was found on multi-variate logistic regression 
analysis., sP-Selectin and sE-Selectin showed no elevation in association with 
increasing CEAP clinical stage.
In this study, I also assessed plasma levels of cytokines and found that TNFa was 
reduced and IL-6 was modestly elevated in the patients group compared to controls. EL- 
l a  and EL-lp were found at very low levels in the plasma and IL-la showed no 
difference between control and patient groups, although IL-lp was raised in patients 
group. I had arranged for these (IL-la and IL-lp) assays to be performed using high- 
sensitivity ELISAs since relatively low plasma levels of these markers were observed in 
initial investigations. VEGF was also found to be elevated in all patients compared with 
controls. Logistic regression analysis confirmed a relationship between plasma VEGF 
level and increasing severity of venous disease.
In summary, I found differences between control subjects and patient groups in keeping 
with previously reported data, but the indices of leucocyte activation were not greatly 
perturbed in the patient groups. This may have masked some of the changes in our 
measurements. The soluble endothelial adhesion molecules and cytokines showed little 
reflection of the severity of venous disease in the measurements from patients. This 
tends to suggest that my measurements made in the blood do not reliably reflect the 
actual situation in the tissues of the lower limbs. A limitation of the design of this study 
is that it only reflects the events in the circulating cells and soluble plasma factors. It 
does not measure the precise mechanisms in the region where skin changes occur in the
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leg. Clearly a substantial change in design of the study would be required to achieve 
this. A complication in measuring the state of priming or activation of leucocytes is the 
extent to which the circulating cells reflect the overall picture. Many leucocytes will be 
adherent to the wall of post-capillary venules throughout the body and these will not be 
included in samples taken from peripheral blood. The marginated cells may also be the 
most active. There are, therefore, several different interpretations, which might be put 
on the data I have obtained. Perhaps the inflammatory changes are much greater in the 
tissues than reflected by measurements from the peripheral blood and the most active 
cells remain sequestered in the regions of tissue damage. Alternatively, the modest 
differences between patients and controls reflect a mild inflammatory response to the 
venous disease.
My data show that patients with venous disease demonstrate a low-grade inflammatory 
response to venous disease but give no definite clue as to the role of leucocyte in the 
pathogenesis of venous disease. This study has failed to show any major difference 
between patients with the mild stages of venous disease and those with skin changes 
(C4, C5) in any of the parameters that have been measured to assess the inflammatory 
response. This may suggest that the inflammatory processes are not involved in the 
pathogenesis of venous disease, but I believe that my methodology of using blood tests 
to assess disease processes happening at a cellular level may be too crude and 
simplistic. I was limited in this study in being obliged to study patients (rather than an 
animal model) in whom more invasive testing was considered inappropriate. For some 
parameters (neutrophil CD lib  and monocyte CD62L expression, soluble VCAM and 
VEGF) multivariate logistic regression did show a weak relationship with CEAP 
clinical stage. Examination of the data shows that the principal differences lie between 
control subjects and those with venous disease.
I recorded the symptoms of patients in some detail using visual analogue scale (VAS). 
Visual analogue scale is widely used in many aspects of medicine and the VAS used in 
this study has been employed in many previous studies. 461, 462 This has been used in a 
previous study in the evaluation of symptoms arising from venous disease and this has 
been published recently. 463 However, the visual scale I used was simple and may not 
have been fully validated, as is the case with other health questionnaires. These data 
themselves contain some interesting features. Patients of CEAP clinical stages C4 and
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C5 report low scores for pain and heaviness, whereas those with less severe disease (C2 
and C3) reported much higher scores. For the symptoms of cramps, C4 patients report 
far more severe symptoms than those with stage C5 (healed ulcers). In fact, patients of 
this group report very few symptoms at all. The authors of the Edinburgh Vein Study 29 
reported that they could find no correlation between the severity of venous disease 
detected by clinical examination and duplex ultrasonography and the extent of the 
symptoms reported by the patients. This was widely interpreted as saying that the 
symptoms of venous disease were unrelated to the venous incompetence. In my study 
the paradox of the patients with the more severe clinical disease reporting fewest 
symptoms almost certainly reflects the subjective nature of the individual patient 
experience. Those patients with moderate varicose veins are annoyed by them, those 
with skin changes are grateful that they do not have an ulcer, which were once very 
painful.
In an attempt to assess the role of the inflammatory processes in producing patients’ 
symptoms, I attempted to assess the association of severity of disease with the 
inflammatory markers recorded in the same patients (table 3.10). This table shows no 
relationship between the majority of markers of disease and the resulting symptoms. 
This may simply reflect the wide spread of data with small differences between control 
and patient groups. Interestingly, the symptom of oedema (or swelling) was associated 
with VEGF levels (with correlation coefficient = 0.2; but significant difference between 
medians), even though these were very similar among all patients groups.
In the next study (study 2) simple analysis suggested that there is a modest elevation in 
the plasma nitrates in patients with the more severe stages of venous disease (C5). 
Logistic regression failed to show a relationship between CEAP clinical stage and 
plasma nitrate levels. In study 3, I investigated whether or not it was possible to 
quantify the morphological changes reported in skin capillaries seen by capillary 
microscopy. These have been reported by a number of previous authors 365,367’369,370,371 ’ 
374 but without any attempt to quantify the changes. The proliferation of skin capillaries 
is a feature, which is well known to be associated with the more severe stages of venous 
disease. I found that by following a carefully defined scoring system, two independent 
observers could achieve remarkably similar scores for the severity of capillary 
convolution in a wide range of images and clinical CEAP stages.
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This work allowed me to study patients with a wide range of venous disease and assess 
the correlation with capillary convolution (study 4). This investigation confirmed that 
the capillary microscopy could be used to quantify the severity of capillary convolution 
in patients with venous disease., The aim of the study was to verify our use of the 
technique and not to prove its reproducibility as a clinical method of assessment for 
day-to-day clinical practice. However, this also allowed me to identify a group of 
patients with mild venous disease (C2, C3) who showed increased capillary 
convolution. This phenomenon was seen by a previous investigator (H Pardoe, MSc 
Thesis, University of London) using histological examination. I studied the 
haematological data to assess whether any significant differences lay between the 
patients with mild venous disease combined with capillary convolution and the 
remainder of the patients. Table 3.24 shows this analysis but fails to show any 
significant difference. My hypothesis here is that patients who show capillary 
microscopy evidence of early capillary convolution are at risk of developing skin 
changes and leg ulceration in later life. So far I have found no definite evidence to 
support this suggestion, but clearly a very long term study would be required to 
establish the significance of capillary convolution.
Study 5 addresses measures of the severity of venous disease. Photoplethysmography 
refilling times have long been used to assess venous reflux in patients with varicose 
veins and chronic venous disease. My finding showed more rapid refilling (shorter 
venous refilling times) in the more severe groups (table 3.26). However, there was 
considerable overlap between groups. This has been seen in a number of previous 
studies using other measures of venous function as well as PPG assessments of venous 
refilling. Although the variability of PPG measurements contributes to this, the severity 
of the clinical disease suffered by patients is clearly dependant on factors in addition to 
the degree of venous reflux. The tonometry measurements reflect the severity of skin 
induration and are clearly more severely abnormal in patients with healed ulcers and 
palpable induration of the skin. There was less overlap of data between groups for these 
measurements than for PPG measurements. Investigation of the correlation between the 
PPG refilling time and tonometry parameter showed a veiy poor correlation coefficient 
as might be expected from cursory examination of the data. Clearly many additional
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factors are responsible for the severity of the venous disease than simply the severity of 
venous reflux.
In the final study (study 7) I assessed the efficacy of the flavonoid drug Daflon on all 
the parameters previously measured. This drug is widely used in continental Europe in 
the management of the symptoms of venous disease. It has been shown to improve the 
subjective experience of venous disease as well as to moderate oedema of the lower 
limb. In my study I was unable to demonstrate any significant effect on any factor. This 
was most surprising in view of the fact that a pilot study had shown efficacy in this 
respect 14, 15, 16. Previous studies have reported an influence of this drug on the 
symptoms of venous disease but this was not seen in my data. An analysis of subsets of 
data, based on the CEAP classification also failed to reveal any effect. I have to 
conclude that Daflon® has no effect on the elevated inflammatory markers seen in 
venous disease, despite the previous studies showing influence in this area.
To summarise the findings from all above studies, I have shown increased plasma levels 
of sVCAM-1 in all CEAP clinical stages compared to controls. Multi-variate logistic 
regression shows a modest relationship between CEAP clinical stage and plasma level 
of this adhesion molecule and neutrophil CD1 lb as well as monocyte CD62L data. In a 
previous study the greatest rise of plasma sVCAM-1 occurred in patients with LDS in 
response to experimental venous hypertension 12.
As we know, E-selectin (CD62E) is expressed by endothelial cells, P-selectin (CD62P) 
by both endothelial cells and platelets, and L-selectin only by leucocytes 186,187. Our 
normal levels of P-selectin suggest that platelets are probably not involved in this 
disease process. As VCAM-1 is the counter ligand for VLA receptors expressed by 
monocytes, it appears that although neutrophils may be important in the initial phase, 
monocyte infiltration of the tissues may be more important in patients who go on to 
develop skin changes.
The median basal plasma level of IL-6 was higher in patients with varicose veins 
compared to controls. These findings suggest that IL-6 may be implicated in the 
microcirculatory changes seen in chronic venous disease, although it is not at all clear 
whether endothelial and leucocyte activation in such patients are induced by these
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cytokines. While ICAM-1 expression can be increased several fold by treatment with 
cytokines such as IL-1 or TNF. The expression of both ICAM-1 and VCAM-1 can be 
sustained for days after cytokine stimulation of endothelium. This pattern suggests a 
role for these molecules in chronic inflammation 203,204. Endothelial injury may be the 
consequence of free radical release from activated leucocytes, although the mechanism 
is unclear.
I observed proliferation of vessels in the skin in patients with CVD. This correlates with 
the severity of clinical skin damage. Until recently the growth factors, which mediate 
this process, have remained unknown. It has been reported that VEGF and platelet- 
derived growth factor expression is increased in the skin of patients with venous disease 
and may be the cause of vascular proliferation. The skin changes of 
lipodermatosclerosis involve an injury phase (neutrophil mediated) as well as a 
reparative phase (growth factors, collagen). The data from one study show that both 
groups of patients (C3 and C4) had similar elevations in plasma VEGF level compared 
to controls 8. In my study, all I found a positive relationship between CEAP clinical 
stage and plasma VEGF levels by logistic regression analysis. This may reflect the fact 
that this growth factor is induced in patients with venous disease to repair tissue damage 
caused by venous hypertension typically seen in healed ulcer (C5). However, 
measurement of plasma levels may not reliably reflect the actual tissue levels expressed 
in the region of tissue repair. Epidermally derived VEGF is likely to be a factor in the 
angiogenesis of CVD especially lipodermatosclerosis. This increased expression of 
VEGF has not particularly been seen in ‘atypical* group; rather this was lower in this 
‘capillary proliferative' group. VEGF seems to act both in the short term (over a few 
minutes) and in the long term (over a few hours) to increase microvascular permeability 
464. Furthermore, raised VEGF (in our study) in symptomatic oedema as well as C3 
group signifies this role. This is likely to promote extravasation of fibrinogen and 
deposition of fibrin in the tissues. This may represent a mechanism for formation of the 
perivascular cuffs characteristically found in chronic venous disease.465
In addition, leucocyte-mediated tissue damage might directly release VEGF from depots 
in the intima or intercellular matrix. Activated platelets or macrophages at the site of 
injury may release peptide factors that in turn stimulate VEGF release. The abundant 
macrophages in skin exposed to chronic venous disease also are a potential source of
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VEGF. Excessive neovascularization with hyperpermeable vessels might contribute 
directly to the skin changes that occur with chronic venous disease. Increased 
production of nitric oxide is a possible mechanism of local tissue damage. VEGF has 
also been associated with stimulation of NO production 348, 287. VEGF up-regulates 
endothelial nitric oxide synthase and so increases NO production by endothelial cells338. 
Recently, it has been reported that the up-regulation of eNOS in chronic venous ulcers 
promotes angiogenesis and increased iNOS activity has also been demonstrated in the 
skin of venous ulcer patients 349. Moreover, Nitric Oxide stimulates endothelial cell 
proliferation, migration, the release of proteases and the increase of vascular 
permeability352, 353, 354, all of which contribute to angiogenesis.
Large amounts of NO is produced by the induction of iNOS, interact with oxygen free 
radicals derived from polymorphonuclear cells (PMNs) and macrophages to form 
peroxynitrite 466. Peroxynitrite is a potent oxidant that can attack many types of 
biological molecules and has strong oxidizing and cytotoxic properties causing tissue 
damage 467,468. NO, either alone or when combined with other oxygen or nitrous free 
radicals, could result in the tissue damage associated with severe chronic venous 
disease. Moreover, excessive vasodilatation may damage the endothelium of the 
microvasculature, causing increased permeability and oedema 469. Increased VEGF in 
CVD with oedema in our study may be explained by this mechanism. My own 
investigation failed to show any relationship between plasma nitrate levels and CEAP 
clinical stage. However, the extent to which plasma nitrate levels reflect activity at the 
tissue level is unclear and more detailed investigation of NO in the development of skin 
changes in venous disease would be required before it could be eliminated as a 
significant factor.
Implications for pharmacological treatment
Although bandaging and stockings have been used effectively in the treatment of 
chronic venous insufficiency for many years, modem pharmacological science may 
provide assistance in healing venous ulcers. Drugs, which reduce white cell activation, 
may be useful in healing venous ulcers, assuming this mechanism is important in the 
perpetuation of ulceration. Pentoxifylline reduces the likelihood of white cell activation 
by an effect, which appears to be independent of other known activators of neutrophils 
such as TNFa, resulting in much lower likelihood of endothelial adhesion l45. Recent
2 0 1
randomised, double blind placebo controlled trial using Pentoxifylline or placebo in 200 
patients with confirmed venous ulcers did not show any statistically significant 
difference. 147 I used an oral purified flavonoid fraction known to influence white cell 
activity in animals. After sixty days therapy, there was no significant modulation of any
( f tmarkers in any group following the treatment in comparison with placebo. Daflon 
failed to produce any benefit in reducing the inflammatory factors measured in my study. 
The data comparing control subjects with patients showed very modest differences 
between controls and patients for most inflammatory mediators. Against this 
background any effect of Daflon may not have been detected. Alternatively, Daflon may 
act by an entirely different mechanism, which was not investigated during my studies.
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CONCLUSIONS
The studies I have completed and described above have investigated the inflammatory 
mechanisms in venous disease. These have confirmed that there is a mild systemic 
inflammatory response in patients with venous disease compared to control subjects. 
However, I was unable to show an unequivocal relationship between any inflammatory 
marker and the severity of venous disease. Almost all indicators of inflammation were 
equally elevated in all patient groups. However, I did not include any patient with active 
venous ulceration in my work.
My work with the capillary microscope has shown that it is possible to quantify the 
morphological changes of the skin capillaries of patients with venous disease. I showed 
that this objective measure was clearly related to the severity of venous disease. None of 
the markers of systemic inflammation showed a good correlation with the capillary 
morphological changes. A subgroup of patients with mild venous disease show capillary 
convolution similar to that in the more severe venous disease groups. I propose that this 
subgroup may be at risk of developing skin changes and ulceration. Further work would 
be required to investigate this hypothesis.
I compared a measurement of venous reflux, the PPG refilling time with the clinical 
severity of venous disease, and found some correlation. However, there was 
considerable overlap of venous function between clinical groups indicating that a 
number of other factors are also involved in the development of skin changes. Tissue 
tonometry proved capable of demonstrating the changes in skin compliance in venous 
disease.
I undertook a randomised, double blind study to investigate the efficacy of a flavonoid 
drug, Daflon®, on the systemic inflammatory processes in venous disease. 
Disappointingly, I found no influence of this drug on any factor measured. Recent 
literature undertaken in animal models of vascular disease suggests influences of 
Daflon® on leucocyte-endothelial adhesion. These could not be confirmed in patients 
with venous disease.
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Future Perspectives
Studies that measure the expression of VEGF mRNA levels might more conclusively 
prove the actual site of origin of the protein. The precise origin of the moderately 
increased plasma NO measured in this study has not been established by our 
investigation. Further study is required to measure the levels of cGMP both in 
circulating cells and platelets to corroborate the findings described, since soluble 
guanylate cyclase is the intracellular target of NO. In addition, it will be essential to 
measure the expression of NOS isoforms protein or mRNA in circulating cells and 
plasma peroxynitrite to correlate their levels to disease severity.
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Chapter 5: Appendices
Appendix 1 
Abbreviation
CVI: chronic venous insufficiency 
CVD: chronic venous disease 
LDS: Lipodermatosclerosis 
VEGF: Vascular endothelial growth factor 
ALAT: Alanine aminotransferase 
AS AT: Aspartate aminotransferase 
ELISA: Enzyme-linked immunosorbent assay 
ICAM: Intercellular adhesion molecule 
VCAM: Vascular cell adhesion molecule 
TNF-a: Tumour necrosis factor
CEAP: Clinical, etiological, anatomical, pathological classification 
Ab: Antibody
FMLP: Formyl-methionyl-leucyl-phenylalanine
FITC: Fuorescein-isothiocyanate
FACS: Fluorescence activated cell sorting
EDTA: Ethylene-diamine-tetracetic acid
F VIE: Factor eight
PE: Phycoerytherin
HRP: Horse radish peroxidase
NO: nitric oxide
eNOS: endothelial nitric oxide synthase 
iNOS: inducible nitric oxide synthase 
nNOS: neuronal nitric oxide synthase
KDR: kinase-insert domain containing receptor (i.e., VEGF receptor-2); 
Fit-1: fins-like tyrosine kinase-1 (i.e., VEGF receptor-1)
PBS: phosphate-buffered saline
vWf: von Willebrand Factor
aFGF, bFGF =acidic, basic fibroblast growth factor
GM-CSF =granulocytemacrophage-colony stimulating factor
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D-NAME =N-nitro-D-arginine methyl ester 
L-NAME =N-nitro-L-arginine methyl ester 
P AF =platelet-activating factor 
PDGF-BB =platelet-derived growth factor-BB 
TGF-6 transforming growth factor-6
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Appendix 2
ELISA kits with their parameters
Sensitivity Measuring range Normal range
L-selectin <0.3 ng/ml 0.3 - 60 ng/ml 660-1250 ng/ml in 201 serum
E-selectin <0.1 ng/mL 0.1-10 ng/ml 29.1 - 63.4 ng/ml in serum or 
heparinised plasma
P-selectin <0.5 ng/mL 0.5- 50 ng/ml 22 - 44 ng/ml in 23 samples
ICAM-1 <0.1 ng/ml 0.1 -8 .0  ng/ml 219 - 1042 ng/ml in serum 
detected in 77 normal human
VCAM-1 <0.6 ng/ml 0.6 -  50 ng/ml 80 - 1502 ng/ml in serum of 80 
normal human
VEGF <5.0 pg/mL 5 -  2000 pg/ml ND-115 pg/ml in thirty-seven 
samples
VWf 1-200  IU/ml Results for EDTA plasma will be 
approximately 10% higher
VWf: The conversion factor for IU/ml to % activity is: 1 IU/ml = 100% activity.
180 citrated plasma samples from apparently healthy Caucasian volunteers aged 
between 18 and 71 were assayed for vWF activity using the Shield Elisa kit. 90% of 
values were >50%.
% Activity 
Range
No. of Samples % Samples
<30 2 1.1
>30 - 50 16 8.9
>50 - 60 17 9.4
>60-180 133 74.0
>180 12 6.6
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Cytokines:
Unit: pg/ml IL -la IL-lp high 
sensitive kit
IL-6 High 
sensitive kit
TNF-a High 
sensitive kit
Sensitivity <1.0 pg/ml <0.1 pg/ml <0.094 pg/ml <0.18 pg/ml
Measuring
range
1.0-250 © i oo © 0.01 -10.0 0.18-32
Normal
range
<3.9
Forty serum 
samples
ND-1.633 ND -11.5 
(n=76)
ND - 4.12
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Appendix 3
ELISA KITS AND ASSAY PROCEDURES
sL-Selectin
ASSAY PROCEDURE
Bring all reagents and samples to room temperature before use. It is recommended that 
all samples, Standards and the sL-Selectin Control be assayed in duplicate.
1. Prepare all reagents, samples, and sL-Selectin Control as directed.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, reseal.
3. Add 100 pL Standard, sL-Selectin Control, or sample to each well. Ensure sample 
addition is uninterrupted and completed within 15 minutes.
4. Cover the plate with a plate sealer provided and incubate at room temperature for 1 
hour.
5. Add 100 pL sL-Selectin Conjugate to each well with sufficient force to ensure 
mixing.
6. Cover the plate with a new plate sealer and incubate at room temperature for 30 
minutes.
7. Aspirate or decant each well and wash, repeating the process five times for a total of 
six washes. Wash by filling each well with Wash Buffer (400 pL) using a multi-channel 
pipette, manifold dispenser or auto washer. Complete removal of liquid after each wash 
is essential to good performance. After the last wash, remove any remaining Wash 
Buffer by aspirating or decanting. Invert the plate and blot it against clean paper 
towelling.
8. Add 100 pL Substrate to each well. Cover the plate with a new plate sealer and 
incubate at room temperature for 30 minutes (/l.5 hours for sE-selectin/15 minutes for 
sP-selectin).
9. Add 100 pL of Stop Solution to each well. The Stop Solution should be added to the 
wells in the same order as the Substrate.
10. Determine the optical density of each well within 30 minutes, using a microplate 
reader set to 450 nm. If wavelength correction is available, set to 620 or 650 nm. If 
wavelength correction is not available, subtract readings at 620 or 650 nm from the 
readings at 450 nm. This subtraction will correct for optical imperfections in the plate. 
Readings made directly at 450 nm without correction may be higher and less accurate. 
♦Samples and the sE-Selectin Control require dilution.
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CALCULATION OF RESULTS
Calculate the mean absorbance values for each set of duplicate Standards. Create a 
standard curve by reducing the data using computer software capable of generating a 
four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by 
plotting the mean absorbance for each Standard on the Y-axis against the concentration 
on the X-axis and draw a best fit curve through the points on the graph. Determine the 
concentration of each unknown sample by calculating the concentration of sL-Selectin 
corresponding to the mean absorbance from the standard curve. For samples and the sL- 
Selectin Control, the concentration determined from the standard curve must be 
multiplied by the dilution factor. It is recommended that the user run the sL-Selectin 
Control in each assay. If the values obtained are not within the expected range, as stated 
on the sL-Selectin Control vial label, the assay results may be invalid.
A standard curve should be generated for each set of samples assayed.
Note: Values in heparin and citrate plasma have been found to be comparable to paired 
serum samples. Values in EDTA plasma have been found to be slightly decreased 
compared to paired serum or heparin and citrate plasma samples probably because sL- 
Selectin is a Ca 2+ -dependent molecule.
RECOVERY
The recovery of sL-Selectin, spiked to three different levels ranging from 475- 3784 
ng/mL in various matrices, was evaluated.
Average % Recovery Range in Serum* (n=5) 103 (88 -  114)% and in EDTA plasma* 
(n=5) 102 (93 -  109)%
SPECIFICITY
This assay recognizes both recombinant and natural human sL-Selectin. No cross 
reactivity was found with recombinant human sP-Selectin or recombinant human sE- 
Selectin.
sE-Selectin
Same as sL-selectin
CALCULATION OF RESULTS
Same as before 
TYPICAL DATA
Same as before
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Note: Values in citrate plasma have been found to be slightly decreased compared to 
paired serum or heparin plasma samples. The use of EDTA plasma samples in this kit is 
not recommended, since sE-Selectin is a Ca 2+ -dependent molecule.
RECOVERY
The recovery of sE-Selectin spiked to three different levels in 10 serum samples was 
evaluated. Mean % Recovery: 101.6% (97.4% -100.2%)
sP-Selectin
Same as sL-selectin 
CALCULATION OF RESULTS
Same as before
TYPICAL DATA
Same as before
RECOVERY
The recovery of sP-Selectin, spiked to three different levels throughout the range of the 
assay in various matrices, was evaluated.
Average % Recovery Range: Serum (n=7) 101 (84 -119%)
EDTA plasma (n=7) 94 (78 - 107%)
Heparin plasma (n=7) 100 (77 - 114%)
All samples were first diluted 20-fold with Sample Diluent as directed by the assay 
procedure.
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sICAM-1
ASSAY METHOD
a) Before use, mix all reagents thoroughly without making foam.
b) Determine the number of microwell strips required to test the desired number of 
samples, plus appropriate number of wells needed for running blank standards and 
controls. Each sample, standard, blank and control samples should be assayed in 
duplicate. Remove sufficient microwell strips from the pouch.
c) Add 100 pi of appropriate standard diluent to standard wells Bl, B2, Cl, C2, Dl, 
D2, E l, E2, FI, F2. Reconstitute standard vial with the appropriate volume as 
described in the chapter reagents preparation. Pipette 200 pi of standard into wells 
A1 and A2 (see Plate Scheme below). Transfer 100 pi from A1 and A2 to Bl and 
B2 wells. Mix the contents by repeated aspirations and ejections. Take care not to 
scratch the inner surface of microwells. Repeat this procedure from the wells Bl, 
B2 to wells Cl, C2 and from wells Cl, C2 to Dl, D2 and so on creating two parallel 
rows of sICAM-1 standard dilutions ranging from 8 to 0.25 ng/ml (for VCAM-1 50 
to 1.56 ng/ml). Discard 100 pi from the content of the last microwells used (FI, F2). 
Alternatively, these dilutions can be done in separate tube and diluted standard 
pipetted directly into wells.
d) Add 100 pi of appropriate standard diluent to the blank wells (G1-G2).
e) Add 100 pi of sample to sample wells and lOOpl of reconstituted control vial to 
control wells (HI, H2).
f) Preparation of biotinylated anti-sICAM-1: Dilute the biotinylated anti-sIC AM-1 
240 pi with the 6360 pi biotinylated antibody diluent in a clean glass vial 96. Add 
50 pi of diluted biotinylated anti-sICAM-1 to all wells.
g) Cover with a plate cover and incubate for 1 hour at room temperature (18°C- 25°C).
h) Remove the cover and wash the plate as follows:
i. Aspirate the liquid from each well;
ii. Dispense 0.3 ml of washing solution into each well;
iii. Aspirate again the content of each well;
iv. Repeat steps 2) and 3) two times.
i) Prepare Streptavidin-HRP solution just before use: Add 0.5 ml of HRP diluent to a 
5 pi vial of Streptavidin-HRP. Dilute immediately before use.
j) Distribute lOOpl of Streptavidin-HRP solution to all wells, including blank wells.
k) Cover and incubate 30 min at room temperature.
1) Remove the cover and empty wells. Wash microwell strips according to step i).
Proceed immediately to the next step, 
m) Pipette 100 pi of ready-to-use TMB substrate solution into all wells, including the 
blank wells and incubate in the dark for 15-20 minutes at room temperature. Avoid 
direct exposure to light by wrapping the plate in aluminium foil, 
n) Incubation time of the substrate solution is usually determined by the ELISA reader 
performances: many ELISA readers record absorbance only up to 2.0 O.D. The
O.D. values of the plate should be monitored and the substrate reaction stopped 
before positive wells are no longer properly readable (maximum 20 minutes), 
o) The enzyme-substrate reaction is stopped by quickly pipetting 100 pi of H2SO4: 
stop reagent into each well, including the blank wells, to completely and uniformly 
inactivate the enzyme. Results must be red immediately after the addition of H2SO4: 
stop reagent, or within one hour, if the microwell strips are stored at 2-8°C in the 
dark.
p) Read absorbance of each well on a spectrophotometer using 450 nm as the primary 
wavelength and optionally 620 nm (610 nm to 650 nm is acceptable) as the 
reference wavelength.
DATA ANALYSIS
Generate a linear standard curve by plotting the average absorbance on the vertical axis 
versus the corresponding sICAM-1 standard concentration on the horizontal axis. The 
amount of sICAM-1 in each sample is determined by extrapolating OD values to 
sICAM-1 concentrations using the standard curve.
sICAM-1 ELISA
2 .5-1
2 .0 -
1.5 -
d
o  1.0-
0 .5 -
0 . 0 - f
0 82 4 6
sICAM-1 (ng/mL)
Typical sICAM-1 standard curve ranging from 0.25 to 8 ng/mL
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LIMITATIONS OF THE PROCEDURE
Do not extrapolate the standard curve beyond the 8 ng/ml standard curve point. The 
dose-response is non-linear in this region and good accuracy is difficult to obtain. 
Concentrated samples (> 8 ng/ml) have to be diluted with standard diluent or with your 
own sample buffer. During analysis, multiply results by the appropriate dilution factor. 
The influence of various drugs, aberrant sera (haemolysed, hyperlipidemic, jaundiced) 
has not been investigated. The rate of degradation of native sICAM-1 in various 
matrices has not been investigated.
PERFORMANCES AND CHARACTERISTICS 
Precision
Intra-Assay Inter-Assay
Sample n Mean
(ng/mL)
SD CV% Sample n Mean
(ng/mL)
SD CV%
A 8 7.82 0.081 1.03 A 22 8.05 0.317 3.93
B 8 1.17 0.033 2.82 B 22 1.03 0.084 8.15
01/1
sVCAM-1
Assay procedures
Same as sICAM-1
PERFORMANCES AND CHARACTERISTICS 
Precision
Intra-Assay Inter-Assay
Sample n Mean
(ng/mL)
SD CV% Sample n Mean
(ng/mL)
SD cv%
A 8 48.79 0.221 0.45 A 28 49.69 0.720 1.44
B 8 5.81 0.132 2.27 B 28 5.95 0.354 5.94
0 1  ^
von Willebrand Factor (Shield Diagnostics)
PROCEDURE
Preparation for the Assay
1. Allow all reagents and microtitre foil pack to warm to 18...25°C for a minimum 
of 30 minutes prior to use. Mix liquid reagents by gentle inversion.
2. Prepare working strength vWF Wash Buffer by pouring the contents of the vial 
of Wash Buffer Concentrate into a clean vessel and adding 375ml 
distilled/deionised H2O. Mix thoroughly.
3. Prepare working strength vWF Diluent by pouring the contents of the vial of 
Diluent Concentrate into a clean vessel and adding 100ml distilled/deionised 
H2O. Mix thoroughly.
4. Reconstitute 1 vial of Calibrator and 1 vial of Controls 1 and 2 each with 0.5ml 
of distilled/deionised H2O. Swirl contents gently and ensure all particulate 
material is in solution. Do not vortex. Allow to stand for 30 minutes at 18...25°C 
with intermittent gentle swirling, before dilution.
5. Dilute the reconstituted Calibrator 1 in 10 (1 part Calibrator + 9 parts working 
strength Diluent). The value for this 1 in 10 dilution is equivalent to twice the 
value quoted on the Calibrator label, i.e. if the Calibrator value (quoted) = 0.85 
IU/ml (85%), then the value for this Calibrator at a 1 in 10 dilution =1.7 IU/ml 
(170%). From the 1 in 10 stock, prepare a series of doubling dilutions using 
working strength Diluent to give a decreasing range of Calibrator values. Use 
working strength Diluent as the Zero Calibrator.
6. Dilute both reconstituted Controls 1 in 20 by pipetting 50pl of Control and 
adding 950pl of working strength vWF Diluent. Mix gently.
7. Dilute patient samples 1 in 20 (and 1 in 100 if further dilutions are required) by 
pipetting:
(i) 50pl sample + 950pl working strength vWF Diluent (1 in 20). Mix 
gently.
(ii) 200pl of the 1 in 20 dilution and 800pl of working strength vWF 
Diluent (1 in 100). Mix gently.
8. Prepare working strength TMB Substrate 5-10 minutes before required by 
diluting the x5 Concentrate 1 in 5 with Substrate Buffer according to the table
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below. PROTECT FROM LIGHT. USE WITHIN 30 MINUTES OF 
PREPARATION.
No. of Strips Volume of x5 
TMB
Volume of Substrate 
Buffer
6 1.5ml 6.0ml
12 2.5ml 10.0ml
9. Calculate the number of microtitre strips required for the current assay, and 
retain these in the microtitre strip holder. Return surplus strips to the foil pack, 
and store in the re-sealable plastic bag, with desiccant, at 2...8°C until required. 
Ensure that all strips are securely held within the microtitre strip holder.
Users may wish to number each strip along the top edge as a further aid to 
identification. Retain the microtitre strip holder for further use.
ASSAY PROTOCOL
1. Reference the wells of the microtitre strips to allow identification of the kit 
Calibrators, Controls and patient samples.
2. Pipette in duplicate lOOpl of each vWF Calibrator dilution into the appropriate 
wells.
3. Pipette lOOpl of each prediluted patient sample (at 1/20) and Controls (at 1/20) 
into the remaining wells. Should further dilutions of patient samples be required, 
a 1/100 dilution is recommended.
Note: All Calibrators, Controls and samples should be added in a continuous 
operation, remembering to change pipette tips between samples. The additions 
from start to finish should not exceed 10 minutes for any one set of Calibrators.
4. After all Calibrators, Controls and samples have been added incubate for 60 + 
10 minutes at 18...25°C.
5. Decant the contents of the strips by quick inversion over a sink suitable for 
disposal of biological materials. Firmly blot the inverted strips with absorbent 
paper towels to remove excess liquid.
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6 . Using an automatic pipette or plate washer, add a minimum of 200pl of working 
strength vWF Wash Buffer to each well. Decant the liquid by quick inversion 
over the sink and blot firmly.
7. Repeat step 6 times 4 and blot firmly as before.
8. Add lOOpl of the vWF Conjugate to each well.
9. Incubate for 15 + 2 minutes at 18...25°C.
10. Decant the contents of the strips by quick inversion over the sink. Firmly blot 
the inverted strips with absorbent paper towels to remove excess liquid.
11. Using an automatic pipette or plate washer, add a minimum of 200pl of working 
strength vWF Wash Buffer to each well. Decant the liquid by quick inversion 
over the sink.
12. Repeat step 11 times 4 and blot firmly as before.
13. Add lOOpl of working strength Substrate to each well.
14. Incubate for 15+2 minutes at 18...25°C.
Note: The plate reader should be switched on at this time to allow adequate “warming
up” time.
15. Add lOOpl of Stop Solution to each well at approximately the same rate as the 
Substrate Solution was added, and tap the plate gently to mix the contents of 
each well.
16. The plate should be read using an appropriate microtitre plate reader fitted with 
a 450 nm filter within 30 minutes.
CALCULATION OF RESULTS
Each vWF assay is to be considered separately when calculating and interpreting 
results. Calculate the mean absorbance value of each Calibrator and linear plot against 
Calibrator activity or concentration on suitable graph paper. Alternatively, a suitable 
computer and curve fitting programme may be used. The following standard curves 
have been evaluated:
8 point: 7 doubling dilutions of the Calibrator from 1 in 10 to 1 in 640, plus a 
zero standard.
5 point: dilutions of the Calibrator of 1 in 10,1 in 20,1 in 40 and 1 in 160, plus 
a zero standard.
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The vWF activity for each of the dilutions can be calculated from the vWF activity 
printed on the Calibrator label using the following formula:
Activity of diluted Calibrator =
vWF activity printed on Calibrator label x 20
Dilution factor
The following curve-fitting programmes have been found to be suitable:
Smoothed Spline; 4 parameter logistic; 5 parameter logistic; log/logit; lin/linit. 
Sample/Control activities can then be read by interpolation from the Calibrator curve.
The activity for samples/Controls should be calculated from the 1 in 20 sample/Control 
dilution result. DO NOT CORRECT FOR THIS DILUTION FACTOR. If the activity 
for the samples at a 1/20 dilution is greater than the top Standard, results can be 
calculated from the 1/100 dilution if this has been included in the assay run. Results 
calculated using the 1/100 dilution must be multiplied by 5 to correct for this further 
sample dilution.
1 IU/ml = 100% activity.
The standard curve illustrated in Figure 1 is for reference purposes only and should not 
be used for interpretation of results.
Figure
1.6
E
e
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TNF-g
AMPLIFICATION SYSTEM
The Quantikine HS Immunoassay kit uses an amplification system in which the alkaline 
phosphatase reaction provides a cofactor that activates a redox cycle leading to the 
formation of a coloured product (34 - 36). In this amplification system, alkaline 
phosphatase dephosphorylates the reduced form of nicotinamide adenine dinucleotide 
phosphate, NADPH (Substrate), to reduced nicotinamide adenine dinucleotide, NADH. 
The NADH subsequently serves as a specific cofactor that activates a redox cycle 
driven by the secondary enzyme system consisting of alcohol dehydrogenase and 
diaphorase (Amplifier). In the reaction catalyzed by diaphorase, NADH reduces a 
tetrazolium salt (INT-violet or iodonitrotetrazolium violet) to produce an intensely 
coloured formazan dye and NAD +. NAD + in turn is reduced by ethanol, in an alcohol 
dehydrogenase-catalyzed reaction, to regenerate NADH which can then re-enter the 
redox cycle. The rate of reduction of the tetrazolium salt and thus the amount of 
coloured product formed are directly proportional to the amount of TNF-a bound in the 
initial step.
ASSAY PROCEDURE: for all cytokines and VEGF
Bring all reagents and samples to room temperature before use. It is recommended that 
all samples and standards be assayed in duplicate.
1. Prepare all reagents and working standards as directed.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, reseal.
3. Add 50 (100 for IL-ip & VEGF) pL of Assay Diluent to each well.
4. Add 200 (150 for IL-lp & & 100 for VEGF) pL of Standard or sample per well. 
Cover with the adhesive strip provided. Incubate for 14 - 20 hours (2 hours for IL-la & 
VEGF) at 2 - 8° C (room temperature for IL-lp & IL-la & VEGF).
5. Wash
Notes on washing
• Excessive drying of the wells can lead to poor assay performance and imprecision.
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Subsequent reagents should be added immediately after washing the plate, and the wells 
not allowed to dry completely. Also avoid prolonged exposure of the wells to vacuum 
aspiration apparatus.
• After removal of the adhesive strip prior to washing, the strip can be adhered to the 
underside of the wells to avoid the possibility of wells becoming dislodged during the 
decanting and rapping operations.
• Inclusion of a 30 second soak between each addition of Wash Buffer and decanting the 
plate contents will improve the precision of the assay.
Wash Procedure
a. Remove liquid from the wells by inverting the plate and decanting the contents.
b. Remove excess liquid by grasping the plate firmly and smartly rapping the inverted 
plate on a clean paper towel at least 5 times.
c. Fill each well with 400 pL of Wash Buffer using a squirt bottle, multi-channel pipette 
or manifold dispenser.
d. Remove liquid from the wells by inverting the plate and decanting the contents.
e. Repeat steps b, c, and d 3 times for a total of 4 washes. After the last wash, smartly 
rap the inverted plate on a clean paper towel at least 10 times to remove excess Wash 
Buffer.
6 . Add 200 pL of TNF-a Conjugate to each well. Cover with a new adhesive strip. 
Incubate for 3 hours (6 hours for IL-6 & 2 hours for IL-la & VEGF) at room 
temperature.
7. Repeat the wash as in step 5.
8. Add 50 pL (200 pL for IL-la & VEGF) of Substrate Solution to each well. Cover 
with a new adhesive strip. Incubate for 60 (45 for IL-lp & 20 min for IL-la & VEGF) 
minutes at room temperature. Do not wash the plate.
[For TNF-a, IL-6 and IL-ip only: 9. Add 50 pL of Amplifier Solution to each well. 
Cover with a new adhesive strip. Incubate for 30 (45 for IL-ip) minutes at room 
temperature. Note: Addition of Amplifier Solution initiates colour development.]
10. Add 50 pL of Stop Solution to each well. Addition of Stop Solution does not affect 
colour in the wells.
11. Determine the optical density of each well within 30 minutes, using a microplate 
reader set to 490 nm. If wavelength correction is available, set to 650 nm or 690 nm. If 
wavelength correction is not available, subtract readings at 650 nm or 690 nm from the
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readings at 490 nm. This subtraction will correct for optical imperfections in the plate. 
Readings made directly at 490 nm without correction may be higher and less accurate.
CALCULATION OF RESULTS
Average the duplicate readings for each standard and sample and subtract the average 
zero standard optical density. Plot the optical density for the standards versus the 
concentration of the standards and draw the best curve. The data can be linearized by 
using log/log paper and regression analysis may be applied to the log transformation.
To determine the TNF-a concentration of each sample, first find the absorbance value 
on the y-axis and extend a horizontal line to the standard curve. At the point of 
intersection, extend a vertical line to the x-axis and read the corresponding TNF-a 
concentration. If samples have been diluted, the concentration read from the standard 
curve must be multiplied by the dilution factor.
TYPICAL STANDARD CURVES
The following standard curves are provided for demonstration only. A standard curve 
should be generated for each set of samples assayed.
RECOVERY
The recovery of TNF-a was determined by spiking to levels throughout the range of the 
assay in various matrices.
Recovery Range in Serum 95 (81 - 105%) and in EDTA plasma 96 (86 - 105%)
IL-1B
AMPLIFICATION SYSTEM 
Same as TNF-a
ASSAY PROCEDURE 
Same as TNF-a
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IL-6
CALCULATION OF RESULTS
Same as TNF-a
TYPICAL STANDARD CURVES
Same as TNF-a 
RECOVERY
The recovery of IL-6 was determined in various matrices by mixing high dose samples 
with low dose samples in ratios of 1:2, 1:1, and 2 :1.
Average % Recovery Range in Serum 110 (100 - 123%) and in EDTA plasma 103 (90 - 
112%).
IL-la
ASSAY PROCEDURE 
Same as TNF-a
CALCULATION OF RESULTS
Average the duplicate readings for each standard, control, and sample and subtract the 
average zero standard optical density. Create a standard curve by reducing the data 
using computer software capable of generating a four parameter logistic (4-PL) curve- 
fit. As an alternative, construct a standard curve by plotting the mean absorbance for 
each standard on the y-axis against the concentration on the x-axis and draw a best fit 
curve through the points on the graph. The data may be linearized by plotting the log of 
the IL-la concentrations versus the log of the O.D. and the best fit line can be 
determined by regression analysis. This procedure will produce an adequate but less 
precise fit of the data. If samples have been diluted, the concentrations read from the 
standard curve must be multiplied by the dilution factor.
TYPICAL DATA
These standard curves are provided for demonstration only. A standard curve should be 
generated for each set of samples assayed.
RECOVERY
The recovery of IL-la spiked to levels throughout the range of the assay in various 
matrices was evaluated. Average % Recovery Range: Serum (n=6) 107 (74 - 127%) 
EDTA plasma (n=6) 104 (84 - 121%).
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VEGF
The test is used to measure levels of VEGF165. This is one of the four transcripts that 
encode mature monomeric VEGF (VEGF121, VEGF165, VEGFi89, and VEGF206). 
VEGF121 and VEGF165 are diffusible proteins secreted into the medium. The other two 
are mostly bound to heparin-containing proteoglycans in the matrix. Results obtained 
for naturally occurring human VEGF and the recombinant VEGF121 showed linear 
curves parallel to the standard curves obtained with the Quantikine kit standards.
ASSAY PROCEDURE 
Same as above
CALCULATION OF RESULTS
Average the duplicate readings for each standard, control, and sample and subtract the 
average zero standard optical density. Create a standard curve by reducing the data 
using computer software capable of generating a four parameter logistic (4-PL) curve- 
fit. As an alternative, construct a standard curve by plotting the mean absorbance for 
each standard on the y-axis against the concentration on the x-axis and draw a best fit 
curve through the points on the graph. The data may be linearized by plotting the log of 
the VEGF concentrations versus the log of the O.D., and the best fit line can be 
determined by regression analysis. This procedure will produce an adequate but less 
precise fit of the data. If samples have been diluted, the concentration read from the 
standard curve must be multiplied by the dilution factor.
RECOVERY
The recovery of VEGF spiked to three different levels in five samples throughout the 
range of the assay in various matrices was evaluated.
Average % Recovery Range: Serum 102 (92 - 115%), EDTA plasma 97 (82 - 113%) 
LINEARITY
To assess linearity of the assay, five samples were spiked with high concentrations of 
VEGF in various matrices and diluted with the appropriate Calibrator Diluent to 
produce samples with values within the dynamic range of the assay.
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Appendix 4:
Griess reaction for total NO 
Total NO
PRINCIPLE OF THE ASSAY
This assay determines total nitric oxide based on the enzymatic conversion of nitrate to 
nitrite by nitrate reductase. The reaction is followed by a colorimetric detection of nitrite 
as an azo dye product of the Griess Reaction. The Griess Reaction is based on the two- 
step diazotization reaction in which acidified NO2* produces a nitrosating agent, which 
reacts with sulfanilic acid to produce the diazonium ion. This ion is then coupled to N- 
(1-naphthyl) ethylenediamine to form the chromophoric azo-derivative, which absorbs 
light at 540 nm.
Plasma levels were read from standard curves obtained by means of plotting mean 
absorbance for standards. The kit used enables the detection of total NO in the plasma. 
Since most of the NO is oxidised to nitrite (NO2’) and nitrate (NO3'), the concentrations 
of these anions have been used as a quantitative measure of NO production. After the 
conversation of NO3' to NO2’, the spectrophotometric measurement of NO2’ is 
accomplished by using the Griess Reaction. The detection of total nitrite is then 
determined as a coloured azo-dye product of the Griess reaction that absorbs visible 
light at 540nm.
INTERFERENCE
The Griess Reaction involves an oxidation and a nucleophilic reaction. Buffer or sample 
components that interfere with the oxidation and nucleophilic reaction may interfere 
with colour formation. Examples of nucleophiles and antioxidants are azide, ascorbic 
acid, compounds containing sulphydryl groups such as cysteine, glutathione, DTT, and 
_-mercaptoethanol. If concentrations of these materials are in excess of 10 jiM in the 
sample, the recovery of nitrite should be determined using the nitrate standard provided 
with the kit. To determine the recovery, nitrate at concentrations similar to those used 
for the standard curve should be added to the buffer containing the suspected interfering 
compound, and to a similar buffer without the suspected interfering compound. If there 
is a significant change in the total nitrite concentration found in the buffer containing
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the interfering compound, the effect should be determined and the suitable corrections 
made.
Nitrate Reductase converts nitrate to nitrite. Any sample or buffer component that may 
interfere with this enzyme will lower the conversion of sample nitrate to nitrite and 
therefore result in lower estimates of total NO.
The nitrate salt content should be considered when choosing a tissue culture media. 
Some media may contain relatively high levels of nitrate, which may interfere with 
sensitive detections. Media that contain phenol red as a pH indicator do not interfere 
with the Griess Reaction as the indicator is typically yellow coloured under the 
conditions of the Griess Reaction.
ASSAY PROCEDURE
The reconstituted NADH and Nitrate Reductase should be kept on ice throughout the 
duration of the assay. Bring all other reagents to room temperature before use. It is 
recommended that all samples and standards be assayed in duplicate.
1. Prepare all reagents, working standards, and samples as directed in the previous 
sections.
2. Remove excess microplate strips from the plate frame, return them to the storage bag.
3. Add 200 pL of Reaction Buffer (IX) to the Blank wells.
4. Add 50 pL of Reaction Buffer (IX) to the zero standard wells.
5. Add 50 pL of Nitrate Standard or sample* to the remaining wells.
6. Add 25 pL of NADH** into all standard and sample wells.
7. Add 25 pL of Nitrate Reductase** into all standard and sample wells. Mix well by 
tapping the side of the plate gently and cover with the adhesive strip provided.
8. Incubate for 30 minutes at 37° C.
9. Add 50 pL of Griess Reagent I to all wells except the Blank wells.
10. Add 50 pL of Griess Reagent II to all wells except the Blank wells. Mix well by 
tapping the side of the plate gently.
11. Incubate for 10 minutes at room temperature.
12. Determine the optical density (OD) of each well using a microplate reader set at 
540 nm.
♦Samples must be diluted and ultrafiltered.
**NADH and Nitrate Reductase must be diluted.
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CALCULATION OF RESULTS
Average the duplicate readings for each standard and sample and subtract the average 
zero standard optical density.
Create a standard curve by reducing the data using computer software capable of 
generating a linear curve-fit. As an alternative, construct a standard curve by plotting 
the mean absorbance for each standard on the y-axis against the total nitrite 
concentration on the x-axis. Since samples have been diluted, the concentration read 
from the standard curve must be multiplied by the dilution factor.
TYPICAL DATA
This standard curve is provided for demonstration only. A standard curve should be 
generated for each set of samples assayed.
SENSITIVITY
The sensitivity of the total Nitric Oxide assay is typically less than 1.35 pmol/L. It was 
determined by adding two standard deviations to the mean absorbance value of sixteen 
zero standard replicates and calculating the corresponding concentration.
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Appendix 5
UNIVARIATE LOGISTIC REGRESSIONS
In all analyses p_c refers to the CEAP clinical group, 
ncdl lb  = neutrophil CD1 lb
. logistic p_c ncdllb
Logit estimates
Log likelihood = -42.25686
Number of obs 
LR chi2(1)
Prob > chi2 
Pseudo R2 =
146
12.16
0.0005
0.1257
p_c | Odds Ratio Std. Err. z P>Iz| [95% Conf. Interval]
ncdllb | .9923116 .0022923 -3.341 0.001 .9878289 .9968147
ncd621 = neutrophil cd62L 
. logistic p_c ncd621
Logit estimates Number of obs = 146
Log likelihood = -44.75788
LR chi2(1)
Prob > chi2 = 
Pseudo R2
7.15
0.0075
0.0740
p_c | Odds Ratio Std. Err. z P>|z| [95% Conf. Interval]
ncd621 | .946703 .0188999 -2.743 0.006 .9103753 .9844803
mcdllb = monocyte CDllb 
. logistic p c mcdllb
Logit estimates Number of obs 145
Log likelihood = -44.850938
LR chi2(1)
Prob > chi2 = 
Pseudo R2
6.75
0.0094
0.0700
p_c | Odds Ratio Std. Err. z P>Iz| [95% Conf. Interval]
mcdllb | .9922271 .0031832 -2.432 0.015 .9860076 .9984858
mcd621 = monocyte cd62L 
. logistic p_c mcd621
Logit estimates Number of obs 146
Log likelihood = -40.399657
LR chi2(1)
Prob > chi2 = 
Pseudo R2 =
15.87
0.0001
0.1642
p_c | Odds Ratio Std. Err. z P>Iz| [95% Conf. Interval]
mcd621 | .9310537 .0179663 -3.702 0.000 .896498 .9669414
228
MULTIVARIATE LOGISTIC REGRESSION
. logistic p_c ncdllb ncd621 mcdllb mcd621
Logit estimates
Log likelihood = -28.178411
Number 
LR chi2 
Prob > 
Pseudo
of obs 
!(4)
chi2 = 
R2
145
40.10
0.0000
0.4157
p_c | Odds Ratio Std. Err. z P> 1 z I [95% Conf. Interval]
ncdllb | .9894006 .0044588 
ncd621 | .9336058 .0297228 
mcdllb | .9915151 .0057915 
mcd621 | .9194543 .0252146
-2.365
-2.158
-1.459
-3.062
0.018
0.031
0.145
0.002
.9806999
.8771304
.9802287
.8713392
.9981784
.9937174
1.002931
.9702264
PLASMA: UNIVARIATE LOGISTIC REGRESSIONS
In all analyses p_c refers to the CEAP clinical group.
vegf = plasma vegf 
. logistic p c vegf
Logit estimates
Log likelihood = -72.114 94 9
Number of obs = 
LR chi2(1)
Prob > chi2 
Pseudo R2 =
162
11.02
0.0009
0.0710
p_c | Odds Ratio Std. Err. z P>|z| [95% Conf. Interval]
vegf | 1.014797 .0052566 2.836 0.005 1.004546 1.025152
si sel = soluble L-selectin 
. logistic p c si sel
Logit estimates
Log likelihood = -76.101383
Number of obs = 
LR chi2(1)
Prob > chi2 
Pseudo R2 =
161
2.64
0.1045
0.0170
p_c I Odds Ratio Std. Err. z P>|z| [95% Conf. Interval]
sl_sel | 1.001071 .0007076 1.514 0.130 .9996847 1.002458
. logistic p_c sl_sel
Logit estimates
Log likelihood = -76.101383
Number of obs = 
LR chi2(1)
Prob > chi2 = 
Pseudo R2
161
2.64
0.1045
0.0170
p c I Odds Ratio Std. Err. z P> 1 z | [95% Conf. Interval]
sl_sel | 1.001071 .0007076 1.514 0.130 .9996847 1.002458
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se_sel = soluble e-selectin 
. logistic p_c se_sel
Logit estimates
Log likelihood = -75.659122
Number of obs 
LR chi2(1) 
Prob > chi2 
Pseudo R2
162
3.93
0.0474
0.0253
p _ c I Odds Ratio
-4-
Std. Err. z P>|z| [95% Conf. Interval]
se_sel I 1.022361 .0120855 1.871 0.061 .998946 1.046324
sp_sel = soluble p-selectin 
. logistic p_c sp_sel
Logit estimates
Log likelihood = -77.411285
Number of obs 
LR chi2(1) 
Prob > chi2 
Pseudo R2
161
0 . 0 2
0.8990
0 . 0 0 0 1
p_c I Odds Ratio Std. Err. z P> 1 z 1 [95% Conf. Interval]
sp_sel 1 .9994716 .0041442 -0.127 0.899 .991382 1.007627
slcam_l - ICAM-1 
. logistic p_c slcam_l
Logit estimates
Log likelihood = -76.266982
Number of obs 
LR chi2(1) 
Prob > chi2 
Pseudo R2
162
2.72
0.0994
0.0175
p_c | Odds Ratio Std. Err. z P> 1 z | [95% Conf. Interval]
slcam_l | 1.001541 .0009705 1.589 0.112 .9996403 1.003445
svcam_l = VCAM-1 
. logistic p_c svcam_l
Logit estimates
Log likelihood = -57. 68034
Number of obs = 
LR chi2 (1)
Prob > chi2 
Pseudo R2
162
39.89
0.0000
0.2569
p_c I Odds Ratio Std. Err. z P> 1 z | [95% Conf. Interval]
svcam_l | 1.004027 .0008329 4.845 0.000 1.002396 1.005661
vwf = von Willibradt factor (vWF) 
. logistic p_c vwf 
Logit estimates
Log likelihood = -76.91688
Number of obs = 
LR chi2(1)
Prob > chi2 = 
Pseudo R2
162
1.42
0.2341
0.0091
p_c | Odds Ratio Std. Err. z P> 1 z | [95% Conf. Interval]
vwf | 1.646365 .7130747 1.151 0.250 .7044549 3.847682
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PLASMA: MULTIVARIATE LOGISTIC REGRESSIONS 
ALL VARIABLES
. logistic p_c vegf sl_sel se 
Logit estimates
Log likelihood = -51.033809
sel sp_sel slcam_l svcam_l vwf
Number of obs 
LR chi2(7)
Prob > chi2 
Pseudo R2 =
160
52.36
0.0000
0.3390
p_c I Odds Ratio Std. Err. z P> 1 2 1 [95% Conf. Interval]
vegf | 1.015446 .0063571 2.448 0.014 1.003062 1.027982
sl_sel | 1.000652 .0009285 0.703 0.482 .998834 1.002473
se_sel | 1.003995 .0150526 0.266 0.790 .9749218 1.033936
sp sel | .9882203 .0058767 -1.993 0.046 .976769 .9998058
slcam_l | .9983391 .0016866 -0.984 0.325 .9950389 1.00165
svcam_l | 1.004493 .001066 4.225 0.000 1.002406 1.006585
vwf | .7575712 .4541107 -0.463 0.643 .233985 2.452782
JUST SIGNIFICANT VARIABLES
. logistic p_c vegf svcam_l 
Logit estimates
Log likelihood = -53.966809
Number of obs = 
LR chi2(2)
Prob > chi2 
Pseudo R2
162
47.32
0.0000
0.3048
p_c | Odds Ratio Std. Err. z P> 1 2 1 [95% Conf. Interval]
vegf | 1.013809 .0057299 2.426 0.015 1.00264 1.025101
svcam_l | 1.003857 .0008272 4.672 0.000 1.002237 1.00548
NITRIC OXIDE: UNIVARIATE LOGISTIC REGRESSION
no = plasma nitric oxide 
. logistic p_c no
Logit estimates
Log likelihood = -31.984814
Number of obs = 
LR chi2(1)
Prob > chi2 = 
Pseudo R2
65
1.08
0.2981
0.0166
p_c I Odds Ratio Std. Err. z P>|z| [95% Conf. Interval]
no | 1.030846 .031023 1.009 0.313 .9718003 1.093479
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The kappa measure of agreement
This method is used in study 3 to assess the agreement between three different 
observers in assessing the ease of use of the application of the CEAP method of 
classification and scoring of lower limb chronic venous disease.
The method for the kappa measure of agreement is as follows. The observed measure of 
agreement, Io, and the corresponding expected measure, Ie, are defined as follows:
n = total no of 
observations
Examiner A
Examiner B/C positive negative
positive a b
negative c d
Io= a + d , 
n
L, = (a + c) (a + bl + (b + dHc + dl , 
n2
Kappa is defined as the difference between observed and expected agreement as a 
fraction of the maximum difference: 
k - Io- Ie 
1 - I e
The maximum value of kappa is 1, which represents perfect agreement, and kappa will 
take the value zero if there is only chance agreement.
Fleiss et al, recommended that kappa values exceeding 0.75 represents excellent 
agreement, values between 0.40 and 0.75 represents fair to good agreement and values 
less than 0.40 represents poor agreement.
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Appendix 6
VISUAL ANALOG SCALE
10 cm
Absence of symptom Greatest seventy of symptom
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Appendix 7
Participant information sheet
We would like to invite you to take part in a study to try some tablets called Daflon® 
500 mg. This improves the symptoms that you get in your legs due to your varicose 
veins. We would also like to measure any changes in the blood after treatment with 
these tablets. Daflon® 500 mg is widely used in Europe, but not in the UK, for the 
treatment of patients like you with troublesome veins. It has been taken by many 
thousands of patients and is very safe and causes few side effects. Occasionally tummy 
upsets and headaches occur, but these are not dangerous or severe.
Before the study starts, we would like to check that you are suitable for the study by 
examining you and by doing an ultrasound scan to test blood flow in the veins. We 
would also like to take some blood from the arm. This visit will take about one hour.
If you are suitable for the study, we would like you to take Daflon® 500 mg 6 tablets 
per day (2 tablets in the morning, 2 at midday and 2 in the evening) or an identical 
placebo tablet (containing no active drug), every day for 2 months. Just before you start, 
and again at the end of treatment we would like you to come for some more blood tests 
and an examination of the skin of the leg using gadgets placed on the skin. These tests 
take about an hour, and this time we shall take the blood from a vein at the ankle.
While you are in the study, the only request we make is that you avoid taking a number 
of other types of tablets, which might interfere with our measurements. A list of those to 
avoid will be given to you. All proposals for research using human subjects are 
reviewed by an ethics committee before they can proceed. This proposal was reviewed 
by the Joint UCL/UCLH Committees on the Ethics of Human Research.
The Company, which is sponsoring the research project, Servier UK Ltd, has agreed to 
abide by the Association of British Pharmaceutical Industry Guidelines on 
Compensation 1991 (where the subject is a patient). In effect, this means that in the 
circumstances set out in the Guidelines, the Company will pay compensation on a 
voluntary basis in the event of your suffering a serious injury of an enduring and 
disabling nature, which is caused by the product under research or a procedure carried
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out purely because of the research project. A copy of these Guidelines will be provided 
on request.
You do not have to take part in this study if you do not want to. Your decision whether 
or not to take part will not affect your medical management. You may withdraw from 
the study at any time without giving a reason and without affecting your normal care 
and management.
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Appendix 8
PATIENT CONSENT FORM 
Patient Consent form
1. Have you read the information sheet about this study YES/NO
2. Have you had an opportunity to ask questions and discuss this study? YES/NO
3. Have you received satisfactory answers to all your questions YES/NO
4. Have you received enough information about this study? YES/NO
5. Which doctor have you spoken to about this study? Dr.................................
6. Do you understand that you are free to withdraw from this study
• at any time
• without giving a reason for withdrawing
• without affecting your future medical care
7. Do you agree to take part in this study? YES/NO
Signed.........................................................................Date:......................................
Name in Block Letters:.............................................................................................
Doctor........................................................................................................................
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Appendix 9
Presentations at the learned societies
■ ‘Capillary morphology in the leg skin of patients with chronic venous disease’- 
Venous forum, The Royal society of Medicine, October 2000, Chester.
■ ‘Capillary morphology in the leg skin of patients with chronic venous disease’- 
Surgical Research Society (SRS), April 2001, Birmingham.
■ ‘Increased Total Nitric oxide in the plasma of patients with chronic venous disease’- 
British Microcirculation Society, March 2001, Southampton and International 
Union of Angiology, Cologne, 24 May 2001.1 was awarded the first prize.
■ ‘Leucocyte activation in the microcirculation of the resting leg in patients with 
various stages of chronic venous disease’ - 14th World UIP (Union of International 
Phlebology) Congress, 7th to 11th September, Rome
■ ‘Endothelial activation in the microcirculation in patients with chronic venous 
disease’ - 14th World UIP Congress, 7th to 11th September, Rome
■ “Relationship of plasma vascular endothelial growth factor (VEGF) to CEAP 
clinical stage and symptoms in patients with chronic venous insufficiency (CVI)” - 
the world congress of International Union of Angiology (IUA) at New York, 8 April 
2002.
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Appendix 10
Publications out of this thesis
Full publications
=> Howlader MH, Coleridge Smith PD. Increased plasma total nitric oxide among 
patients with severe chronic venous disease. Int Angiol. 2002 Jun;21(2): 180-6.
=> Howlader MH, Coleridge Smith PD. Microangiopathy in chronic venous 
insufficiency: quantitative assessment by capillary microscopy. Eur J Vase 
Endovasc Surg. 2003 Sep;26(3):325-31.
=> Howlader MH, Coleridge Smith PD. Symptoms of chronic venous disease and 
association with systemic inflammatory markers. J Vase Surg. 2003;38(5):950-4.
=> Howlader MH*, Coleridge Smith PD. Relationship of plasma vascular endothelial 
growth factor to CEAP clinical stage and symptoms in patients with chronic 
venous insufficiency. Eur J Vase Endovasc Surg. 2004 Jan;27(l):89-93.
Abstracts:
=> Howlader MH*, Coleridge Smith PD. Capillary morphology in the leg skin of 
patients with chronic venous disease (abstract). British Journal of Surgery, vol 88, 
suppl. 1, May 2001.
=> Howlader MH*, Coleridge Smith PD. Increased Total Nitric oxide in the plasma 
of patients with chronic venous disease (abstract). International Angiology, March 
2001;vol20:suppl 1 issue 1: 22.
Accepted for publication
=> Howlader MH*, Coleridge Smith PD. Chronic venous insufficiency and venous 
ulcer: pharmacological approach. Accepted for publication in ‘Vascular 
Medicine*.
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Appendix 11 
Raw data 
Study 1: 
IN CONTROLS: FLOWCYTOMETRY
un/down regulation absolute
NEUTROPHILLS MONOCYTES NEUTROPHILLS M ONOCYTES
CD l ib CD62L C D llb CD62L C D llb CD62L C D llb CD62L
374 -64 200 -38 42.1 353 42.1 309.5
663 -60 462 -16 21.3 379.4 24.6 288.1
205 -60 208 -19 40.4 322 41.6 168.5
365 -61 195 -27 23.8 318.4 26.6 263.9
612 -68 225 -21 15.4 326 19.5 224.5
13 -31 19 -13 148 120.8 103.2 155.3
304 -71 116 -51 33.4 315.2 53 219.3
31 -22 31 2 116.9 93.1 90 103.8
219 -64 57 -15 58.2 245.8 75.8 151.2
381 -25 78 -18
568 -64 215 -43 21.1 268.2 48.8 157.6
406 -64 199 -28 20.3 244.1 26.7 247.6
385 -58 114 -2 13.6 229 22.3 135.4
29 -15 -4 -16 42.9 284.7 48.8 288.4
118 -21 71 -2 40.5 363.5 34.2 321.9
n 15 15 15 15
M edian 365 -60 116 -18 37 300 42 222
UQ 395 -28 204 -14 43 325 52 282
LQ 162 -64 64 -27 21 245 27 156
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Controls: ELIS As
VEGF TN Fa ILlalpha ILlbeta IL6 sL sclectin sE selcctin P selectin sICAM-l sVCAM-l VWF
45 2.46 0.00 0.00 1.20 895 14 110 434 646 1.17
88 2.45 0.00 0.07 5.39 607 40 113 513 699 1.15
184 3.38 5.00 0.00 2.99 1004 52 120 599 830 2.77
35 3.13 0.00 0.00 1.06 877 21 76 516 746 0.66
36 1.60 0.00 0.21 0.73 751 46 85 461 675 1.05
75 1.60 0.00 0.00 0.99 798 29 86 471 905 1.06
42 1.15 0.00 0.00 0.92 735 28 93 773 772 1.21
23 1.52 0.00 0.08 0.40 841 28 134 532 722 1.23
52 1.92 0.00 0.33 1.31 768 36 93 419 642 0.84
131 5.93 1.96 0.08 1.82 1319 29 155 639 1588 3.17
12 3.25 0.00 0.00 1.30 642 16 103 357 436 1.42
109 6.23 5.01 0.55 0.92 950 57 122 441 596 1.14
17 2.75 0.00 0.64 0.81 838 33 119 356 501 1.26
72 2.37 0.00 0.18 2.01 560 20 134 489 941 1.66
131 4.28 0.00 0.12 0.87 2085 50 345 545 1351 0.98
59 2.02 0.00 0.80 0.82 794 31 101 453 818 1.23
125 1.92 0.00 0.00 2.48 623 53 156 386 770 1.30
37 1.74 0.00 0.00 1.05 653 35 102 410 611 0.63
81 3.62 7.22 0.29 3.31 1320 68 165 520 950 1.22
79 5.43 0.00 0.44 3.63 915 99 147 450 912 0.94
86 2.35 0.00 0.02 1.66 474 41 125 418 537 1.15
90 10.71 0.00 0.43 17.63 728 30 132 388 588 1.30
54 2.68 0.00 0.00 2.71 891 75 107 662 1731 1.99
41 1.57 0.00 0.00 3.96 342 9 61 396 400 0.87
67 1.96 0.00 0.12 2.93 804 25 42 575 943 1.08
52 3.17 0.00 0.12 1.54 715 68 108 645 705 1.08
2 1.67 0.00 0.00 2.21 1011 34 88 448 726 1.00
74 2.58 0.00 0.00 1.16 665 20 79 427 514 1.24
39 2.82 0.00 0.00 0.58 864 43 78 UR 734 1.57
4 2.18 0.00 0.00 0.37 634 29 59 319 431 1.25
n 30 30 
median 56 2.45 0.00 0.04 1.31 796 34 107 453 724 1.19 
UQ 85 3.23 0.00 0.20 2.65 894 49 130 532 886 1.29 
LQ 38 1.92 0.00 0.00 0.92 656 28 87 418 599 1.05
240
C2
NEUTROPH
ILLS
MONOCYT
ES VEGF
TNF
a IL-la IL-lb IL-6
sL-
Selectin
sE-
Selecti
sP-
selecli slC A M -l
sVCA
M -l vWF
capillary
density
symptoms
CD11 
b
CD62
L
CD11
b
CD62
L pg/ml pg/ml pg/ml pg/ml pg/ml ng/ml ng/ml ng/ml ng/ml ng/ml lU/ml supine dep pain
heavin
ess cramps
parest
hesia edema
264 -47 132 -24 25 10.2 1.5 0.9 2.1 1441 34 78 550 754 1.32 19
not
done 0.1 1.4 1 0.3 0.3
336 -54 204 -44 23 10.7 1.4 1.2 1726 42 59 601 1039 1.53 15 16 2.1 0 0 0.5 0
183 -51 37 -36 32 21.9 2.1 0.9 1805 36 102 596 1268 1.26 22 12 0.6 2.6 0 0.7 0
247 -54 142 -43 31 15.3 1.9 65.3 1303 19 121 580 858 2.00 30 22 0.7 2.4 0.3 0.2 0.6
142 -64 47 -40 52 11.8 1.5 1.3 1347 39 240 643 1170 1.92 17 25 0.1 0.9 0.3 0.3 0.4
261 -63 93 -31 25 9.0 1.8 0.4 1379 28 80 396 911 1.55 17 15 3 3.2 0.2 1.6
265 -55 116 -29 55 2.5 0.0 0.0 807 48 117 183 461 1.25 6 8 2.5 4 0.5 6.5 2.4
16 -60 -66 38 12.4 1.9 0.5 1701 22 112 648 852 1.78 27 20 2.5 0.2 2.4 0.3 0.1
205 -56 39 -37 76 84.2 0.0 176.1 1201 76 146 180 1263 0.78 18 16 1.3 0.3 8.4 0.5 0.7
181 -49 80 -18 140 0.7 0.0 18.6 1097 43 138 168 1160 1.05 9 6 0 0 0 0 0
138 -53 73 -31 6.5 0.0 47.4 803 34 129 146 788 0.54 12 15 8 7 0 0 0
239 -65 81 -48 57 0.0 0.0 0.0 860 93 75 193 1389 1.06 30 35 5 5.3 3.1 2.5 0
314 -64 139 -46 37 0.0 0.0 255.7 1064 35 181 187 920 0.88 21 26 0 6.4 4 2 0
314 -64 139 -46 114 0.0 0.0 9.9 915 48 93 192 981 0.63 7 6 5 7 9.8 7.2 0
184 -59 79 -38 162 7.1 0.0 5.4 1261 70 85 544 1770 0.83 8 9 3 4 0 0 0
140 -61 46 -45 60 0.0 0.0 14.0 1087 15 65 58 1398 0.82 9 17 5.4 4.3 0 1.5 4.5
118 -48 46 -14 104 1.2 0.0 0.2 1089 69 119 917 2365 0.95 10 10 3 3 5 4 3.5 0
301 -63 78 -41 34 2.2 0.0 0.1 609 106 97 868 3626 2.50 14 11 0 6 9 0 8
73 -46 50 -41 197 0.8 0.0 0.1 769 65 227 699 1361 2.25 19 22 0 4 0.2 4.8 0
182 -57 58 -44 85 0.7 0.0 0.0 944 58 145 626 1625 1 40 11 14 7.5 7.6 7.6 5.3 5.4
118 -53 15 -27 282 1.3 0.0 0.3 n/a 50 232 811 1187 1.25 22 21 18 1.8 5 1.5
164 -57 52 -40 151 2.3 0.0 0.1 628 27 138 1149 2236 1.33 13 18 0 0 7 3 0
199 -51 112 -37 86 0.6 0.0 0.1 790 26 126 682 1570 0.86 16 17 7 7.5 0 0 0
203 -60 93 -42 52 0.7 0.0 0.0 620 26 109 682 1673 1.41 16 10 1.8 10 0 0
222 -58 101 -35 39 1.1 3.8 0.2 723 71 108 703 1391 2.10 20 16 5.5 7.5 1.2 0 0
166 -53 142 -40 32 0.8 1.4 0.2 1098 57 98 850 1271 1.25 11 10 0 1 0 5.2 0
67 -45 13 -28 28 0.6 0.0 0.1 1069 94 123 630 1089 1.16 16 14 5 4 4 2.5 1
126 -54 44 -39 116 2.1 0.0 0.3 689 51 136 707 1551 2.06 16 14 0 0 0 0 0
130 -48 39 -43 101 0.7 0.0 0.3 387 49 166 457 915 1.28 8 12 6.5 5 6.5 7 0
185 -65 83 -62 185 0.8 9.0 1.2 817 72 120 562 1271 1.96 11 10 5 5 5 0 0
145 -66 40 -46 113 0.8 0.0 0.1 1120 44 169 582 2111 2.53 10 12 5 8 0 2 0
230 -62 105 -55 170 1.7 0.0 0.2 1055 35 131 1030 2080 1.70 18 23 5 0 2.5 0 6.5
101 -53 21 -13 147 0.0 0.0 0.3 641 35 145 545 1075 1.42 10 12 5 0 0 6
432 -74 168 -51 172 0.8 5.6 0.3 955 43 114 624 1555 1.08 11 27 5 3.5 0 7.5 5
121 -57 89 -36 51 1.6 0.0 0.2 539 114 151 1168 1567 1.78 29 32 7 6.5 7 5 0
268 -67 71 -30 120 1.7 0.0 0.3 443 28 96 387 1392 1.04 13 8 2 0 3 0 0
93 -59 7 -22 25 2.0 0.0 0.3 1055 18 58 408 823 1.44 18 21 7 0 8 0 1.5
206 -48 111 -38 160 0.5 0.0 0.3 879 65 70 531 1142 0.96 8 12 0 3.5 4 0 0
144 -55 86 -45 56 1.2 0.0 0.2 747 84 96 437 1174 1.43 9 11 0 1.5 0 0 0
93 -38 41 -33 63 1.7 0.0 0.4 508 38 113 429 470 1.20 10 11 2 2 7 0 0
157 -55 28 -54 107 0.5 2.2 0.2 935 37 90 476 1738 0.69 9 13 0.5 0 4.5
301 -61 55 -55 126 0.5 0.0 0.1 1068 55 68 510 1660 1.49 13 21 3.5 2.5 3.5 0 2
171 -62 135 -51 357 0.0 0.0 0.2 607 24 148 445 774 0.96 16 26 2 0 3.5 0 0
217 -56 139 -40 124 0.9 0.0 0.3 537 51 51 476 1165 1.34 8 18 3.2 2 8 0 3
230 -44 119 -37 142 1.5 0.0 0.4 893 35 147 519 929 0.67 11 13 0 5 4 0 7
299 -64 153 -42 120 1.3 0.0 0.3 653 39 118 455 1289 2.18 12 15 3 0 4 0 1.5
139 -61 73 13 125 0.3 0.0 0.2 1162 34 91 537 1566 1.77 8 9 4.4 4 7 0 0
275 -63 55 -60 27 0.7 0.0 0.2 636 26 69 488 1352 1.33 11 22 0 0 0 0 0
n 48 47 48 47
median 185 -57 79 -40 86 1.13 0.0 0.3 915 43 116 545 1270 1.32 13 IS 2.75 2.55 2.75 0.20 0.00
UQ 250 -53 114 -33 133 2.25 0.3 0.9 1097 60 140 656 1566 1.72 18 21 5.00 5.00 6.43 2.75 1.50
LQ 139 -62 46 -45 38 0.64 0.0 0.2 671 34 90 435 968 1.02 10 11 0.10 0.28 0.00 0.00 0.00
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capillarosco
py: density
symptoms
C D llb CD62L C D llb CD62L pg/ml , v ,  m l
Pg/
ml P V  m i
Pg/
ml ng/ml
ng/
ml
ng/
ml
ng/
ml
ng/
ml IU/ml supine dep pain
lieav
ines
s
era
mps
pare
sthe
sia
ede
ma
94 -46 52 -41 39 9.7 1.2 2.9 2.5 1869 61 129 914
143
5 1.53 19 21 3.4 3 2.8 0 2.1
258 -59 127 -44 25 14.0 1.7 0.3 7.8 1632 16 60 605 929 1.31 20 19 6.3 8.2 6.9 0.5 1
221 -55 96 -28 13.7 1.7 0.4 2.0 1766 24 106 521
139
4 1.46 24 18 3.3 5.1 4 0.1 3
258 -45 51 -26 29 16.5 2.2 1.6 3.6 1088 12 112 454
104
0 2.22 16 16 4.5 4.9 1.6 1.4 3
155 18 14.1 1.9 0.5 2.7 1394 29 73 499
126
2 1.43 22 21 8.1 4.8 3 5 5
155 -59 93 -53 34 36.0 1.0 403.0 2.5 873 64 139 168
120
5 0.51 10 9 5 0 0 0.3 5.2
79 -59 50 -31 82 50.2 1.2 150.0 4.5 1533 74 86 200
198
1 1.30 8 8 4.5 3.5 4.8 0 0.5
182 114 -32 120 2.3 0.0 0.0 2.6 456 44 68 370 458 1.58 11 28 5 4.5 4.5 5.5
239 -52 174 -32 106 1.1 0.0 0.5 1.2 717 47 148 615
240
0 2.16 16 24 5.5 0 0 8.5
180 -52 101 -40 115 1.6 0.0 0.0 1.4 794 60 160 327 536 0.86 3 7 0 0 0 0 6.5
122 -71 -69 341 0.7 0.0 0.2 1.5 1052 37 245
102
4
266
4 1.90 16 18 6 9 8.5 7 6.5
273 -55 148 -27 47 0.9 2.7 0.1 1.5 1013 50 88 713
114
4 1.22 26 26 5 3.5 0 0 5
559 -77 575 -80 21 0.0 0.0 0.2 1.8 728 23 115 372 825 1.61 7 13 0 5 0 0 5.5
401 -69 151 -52 118 0.3 0.0 0.0 4.2 896 39 64 606
152
8 1.99 7.5 15 5 5 1.2 0 4.5
219 -70 35 -22 225 2.0 0.0 0.2 1.3 765 28 150 743
206
9 0.90 8 20 3.5 3 0 0 5
323 -65 60 -21 118 2.4 0.0 0.2 2.4 1203 41 89 631
237
9 0.89 10.6 13 0 0 0 0 3
98 -67 38 -23 73 0.9 0.0 1.1 1.2 586 37 54 551
126
9 1.16 24 25 8 5 7 7 7
207 -63 65 -30 111 1.3 0.0 0.3 6.4 820 39 90 550
122
3 1.20 16 19 3.4 0 1.4 0 6
n 16 17 17 18
med
ian 213 -59 93 -32 94 2.15 0.0 0.3 2.5 954 39 98 550
126
5 1.37 16 19 4.50 4.15 1.60 0.00 5.00
UQ 258 -54 127 -27 118 13.93 1.6 1.0 3.4 1346 49 137 627
186
8 1.60 20 21 5.50 5.00 4.50 1.18 5.88
LQ 155 -68 51 -44 38 0.96 0.0 0.2 1.5 773 28 76 392
106
6 1.17 9 14 3.40 0.75 0.00 0.00 3.00
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: density
Symptoms: cm
C D llb
CD62
L C D llb C D
pg/m
pg/ml pg/ml n: I’"- 111 ng/ml ng/ml ng/m ng/ml ng/m' IU/m! supine ,1,-| pain
heavin
ess cramps
paresth
esia edema
172 -29 88 -24 14.8 1.4 2.4 3.5 2169 102 180 1821 2377 2.39 6 6 3.3 6 0.1 0.2 7.5
188 -17 86 -3 20.0 1.3 0.9 3.0 1757 32 146 697 1701 2.29 20 29 5.1 0.5 0.6 0.7 0.8
120 54 40 45.0 3.3 22.7 6.8 1414 71 181 1157 1628 2.29 21 21 0.2 1.7 6.4 4.4 0.3
134 -69 64 -47 29 14.8 1.4 0.5 2.5 1668 52 327 648 1543 3.24 29 34 2.1 2.9 0.2 0.1 2.7
131 54 21.3 3.3 166.8 3.7 1580 44 113 469 925 1.29 25 43 5 2.7 4.4 0.1
169 -48 31 -28 15.9 2.0 0.8 3.1 1145 50 180 455 1160 2.15 25 24 0.5 0.2 0.2 0.2 0.2
120 -46 32 -4 64 13.3 1.7 0.4 3.0 1329 56 270 753 1190 2.43 20 20 0.7 0.8 9.8 0.5 3.5
173 72 14.6 2.3 0.4 3.5 1180 69 247 776 1085 1.25 19 15 0.6 0.4 1.9 2
200 -65 34 -25 29 0.0 0.0 88.8 2.0 1047 50 127 142 1218 0.57 23 25 3.6 8 8.5 0
162 -60 35 -45 234 14.2 0.0 13.7 2.7 1057 34 192 140 1095 1.00 14 14 0.5 4 9.7 4 2.6
197 -39 68 -19 284 0.0 0.0 2.3 2.5 522 57 125 172 887 0.54 20 24 7 0 3.1
270 -58 80 -29 3.2 0.0 2.5 4.2 649 56 123 442 741 1.05 13 14 0 3.5 3.5 2.5
171 -59 70 -24 791 4.8 0.0 75.4 3.2 852 40 155 148 904 0.96 13 23 0.7 0 6.2
99 56 23.1 0.0 5.6 2.8 799 68 109 215 1579 1.20 20 20 0 5.1 0
366 -57 191 -50 40 31.9 0.7 1417.3 2.3 1020 23 37 136 877 0.90 29 30 0 0 0
259 -59 79 -35 177 1.9 0.0 29.5 5.3 974 69 99 194 1114 1.03 16 13 10 3.5 9.5 3.5 7.5
172 -49 75 -28 174 5.9 0.0 65.2 7.9 1077 33 143 193 1513 1.77 4 6 6.5 9.7 4.4 9 7.5
234 -67 59 -38 106 0.3 0.0 0.1 1.1 603 51 106 539 1290 2.37 23 23 0 0 0
132 -71 64 -59 0.8 0.0 0.0 1.0 914 78 32 672 2374 2.53 15 17 8.4 9 5
231 -66 108 -56 0.7 118 0.3 1.4 629 55 127 451 1051 1 48 5 8 o S
241 -75 114 -55 161 0.7 0.0 0.1 0.9 1056 72 104 630 1847 1.38 11 7 7.5 10
255 -76 87 -49 0.7 0.0 0.1 1.2 776 55 94 623 1311 0.68 16 18 0 j
172 -56 47 -44 57 1.1 0.0 0.1 1.3 867 42 79 485 1240 1.26 a 4 5.4 8.5 0.5 5.5
79 1.9 0.0 0.2 3.1 651 38 142 796 1066 1.47 15 10 0 2.9
256 -59 66 -29 85 0.6 0.0 0.3 2.2 738 46 126 645 1720 1.25 11 11 5.4 5 9 1.5
313 -64 1 -6 83 1.0 0.0 0.1 2.5 847 45 111 735 1410 1.27 10 9 5.3 10 4.5
147 -65 23 -44 1.8 0.0 0.2 4.8 558 20 nh 760 1375 2.01 5 6 0 5 1.5
207 -61 70 -48 96 0.6 0.0 0.0 0.9 1820 70 91 557 1497 0.86 4 9 4 8.5
280 -57 61 -42 51 2.0 0.0 0.3 5.7 620 48 116 626 862 1.09 : ./. 8 1.4 1.5
79 -55 59 -40 47 4.1 0.0 1.8 1.2 718 24 115 408 583 1.08 7 9 5 7 5.5
293 -65 112 -37 35 1.5 0.0 0.4 3.3 824 36 95 729 1333 0.69 8 8 0 0 3.5 2.5
246 -66 129 -30 64 4.0 0.0 0.1 13.9 770 49 94 456 458 2.07 3 4 9 5 2.5
21 -84 3 -43 1.1 0.0 0.2 3.8 958 38 92 702 1591 1.26 5 3 5 6
286 -67 174 -45 3.4 0.0 0.1 6.3 573 37 112 474 1237 2.00 12 9 0 5.5
79 -41 52 -8 59 0.7 0.0 0.3 3.7 498 21 72 644 915 1.39 6 17 0 1.5
229 -64 177 -41 33 3.8 0.0 0.1 2.7 848 24 51 868 3614 1.18 2 3 0 0
90 -66 73 -58 183 1.9 0.0 0.4 2.0 746 42 92 592 1774 2.02 3 7 0 0.5
187 -56 73 -23 123 3.5 0.0 0.2 61.0 646 42 81 746 1187 1.80 6 9 7 2
267 -57 145 -48 63 1.6 0.0 0.5 5.7 612 62 70 681 1192 1.37 1.5 1.5 0 0 0
206 -71 77 -33 105 0.2 8.9 0.3 3.2 830 46 88 837 1229 1.50 3 2 0 0 0
218 -60 78 -39 88 1.2 0.0 0.7 5.7 665 30 86 646 1088 1.62 12 19 0 0 0
158 -62 79 -62 239 2.6 14.2 0.3 2.1 730 69 116 517 2168 1.02 8 10 0 5 3
275 -72 122 -38 1.5 0.0 0.5 3.0 649 16 53 756 935 1.25 5 6 1.8 2.5 5 0
m e d a
n 193 -61 71 -39 83 1.9 0.0 0.4 3.0 830 46 111 626 1229 1.29 12 10 0.50 1.40 4.40 0.00 1.50
UQ 253 -57 87 -28 161 9.6 1.0 2.3 4.0 1057 57 138 732 1561 2.01 20 20 3.00 5.00 7.75 2.55 5.00
LQ 150 -66 55 -47 51 0.9 0.0 0.2 2.1 650 37 91 453 1059 1.07 5 7 0.00 0.00 0.35 0.00 0.00
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201 -62 76 -37 3.7 0.0 21.8 2.4 941 47 67 159 1258 1.28 6 4 0 0 0 0 0
244 -43 123 -36 0.0 0.0 2.5 8.8 990 40 114 185 1237 1.56 11 9 8.8 1 10 10 9
115 -46 48 -26 9.8 2.7 11.8 2.5 907 39 62 143 861 1.49 4 3 10 5 7 5 0
256 -71 70 -43 77 0.1 0.8 0.9 n/a 1030 80 62 626 2787 1.48 4 7 5.4 0 4.3 0 0
216 -70 54 -44 111 1.0 0.0 0.0 1.7 903 32 138 666 1477 1.89 5 9 3 0 0 2.5 1.5
87 -62 215 -42 3.7 0.0 0.3 4.6 886 72 112 486 1011 1.72 3 6 0 0 6 0 0.3
208 -68 79 -49 1.3 0.0 0.0 1.5 820 51 83 470 1445 2.01 5 8 0 0 0.5 0 0
153 -65 46 -25 0.9 0.0 0.1 6.1 635 36 94 597 1546 1.27 5 5 0 2.2 0 0 2
231 -49 109 -4 2.3 0.0 0.0 1.0 604 45 100 337 404 1.28 8 9 5 0 0 1.5 2
350 -64 52 -45 150 0.7 5.1 0.1 3.0 1919 45 123 759 1519 1.25 9 7 0 0 0 0 3
323 -57 160 -40 79 1.1 0.0 0.3 1.9 779 57 129 775 1163 0.59 3 5 0 0 9.5 0 2
227 -70 83 -51 53 1.4 0.0 0.2 2.1 785 31 89 539 925 0.98 8 13 2 1.5 6.5 0 0
137 -59 90 -44 96 3.4 0 .0 0 .2 4.5 862 49 114 810 1916 1.48 3 5 0 0 0 0 0
125 -65 50 -33 63 1.6 2.2 0.3 3.2 740 79 81 679 804 1.29 24 12 0 0 3 0 0
140 -52 87 -43 104 0.7 0 .0 0 .2 1.7 861 18 75 389 1138 1.57 3 8 0 3 0 0 0
213 -67 96 -48 165 2.4 14.9 0.3 2.7 988 30 97 576 1477 1.66 3 2 0 0 0 0 5
189 -66 64 -56 170 1.5 0 .0 0.1 1.2 820 45 84 555 1054 1.10 6 6 0 0 0 0 8
207 -44 92 -12 154 1.4 16.5 0.1 3.4 617 70 93 563 1123 1.37 7 6 5 5 8.5 5.5 0
211 -55 100 -46 71 9.4 0 .0 2 .0 3.0 663 15 68 617 1234 1.29 5 na 0 0 7 0 0
101 -63 58 -40 49 0.0 0 .0 0.2 1.0 746 34 81 408 649 0.96 2 9 5 8.5 0 0 0
164 -67 107 -35 68 1.5 0 .0 0.2 L9 790 27 53 568 1478 1.11 5 12 0 0 0 0 0
151 -69 37 -42 46 0 .8 0 .0 0.2 1.4 760 34 80 563 821 0.72 5 5 0 0 0 2 1.5
214 -64 26 -3 130 1.7 0 .0 0.2 1.2 663 40 89
OCo00 776 0.96 6 5 1.3 0 0 6 0
N 23
med
ian 207 -64 79 -42 88 1.4 0.0 0.2 2.3 820 40 89 563 1163 1.29 5 7
0.0
0 0.00 0.00 0.00
0.0
0
UQ 221 -56 98 -34 135 2.3 0.4 0.3 3.2 905 50 106 646 1477 1.53 7 9
4.0
0 1.25 6.25 1.75
2.0
0
LQ 146 -67 53 -45 67 0.9 0.0 0.1 1.5 743 33 78 439 893 1.10 4 5
0.0
0 0.00 0.00 0.00
0.0
0
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Pain
NEUTRO NEUTRO MONOCYT MONOC VEGF TNFalpha IL-la IL-Ib IL-6 sL- sE- sP- sICAM- sVCAM- vWF symptoms
C D llb CD62L C D llb CD62L oe/ml oe/ml be/ml De/ml oe/ml he/ml ne/ml ne/ml ne/ml ne/ml HJ/ml pain
181 -49 80 -18 146 6> 0.0 IX 0 1M 1097 43 1 3 X 168 1160 1.05 0
180 -52 101 -40 115 1 0 0.0 0.0 1.4 794 60 160 327 536 0.86 0
301 -63 78 -41 34 2.2 0.0 0.1 .3.6 609 106 97 868 3626 2.50 0
73 -46 50 -41 197 o x 0.0 ().! 769 65 227 699 1361 2.25 0
164 -57 52 -40 151 0.0 0.1 1.1 628 27 138 1149 2236 1.33 0
166 142 -40 32 0.8 1.4 0.2 2.2 1098 57 98 850 1271 1.25 0
126 -54 44 -39 I 10 2 ! 0.0 0 7 o.o 08 9 51 : m 707 1551 ?.Q6 0
206 -48 111 -38 160 0.0 0.3 879 70 531 1142 0.96 0
559 -77 575 -80 21 0.0 0.0 0.2 1.8 728 23 115 372 825 1.61 0
144 -55 86 -45 56 1.2 0.0 0.2 1.3 747 84 90 437 1174 1.43 0
230 -44 119 -37 142 1.5 0.0 0.4 4.9 893 35 147 519 929 0.67 0
2 7 5 -63 55 MMj 27 6 " 0.0 0.2 030 26 69 488 1352 1.33 0
323 -65 60 -21 118 2.4 0.0 0-2 2.4 1203 41 89 031 2379 0.89 0
197 -39 68 -19 284 0.0 0 .0 2.3 2.5 5 2 2 57 125 172 887 0.54 0
2 7 0 -5 8 80 -29 3.2 0.0 2.5 4.2 646 50 123 442 741 1.05 0
99 56 2 7 0.0 799 68 109 215 1579 1.20 0
366 5” I'M Ml 40 51 » 0.7 1417 3 2.3 1020 37 136 877 0.90 0
201 -62 7 -37 Q.O 21.8 2.4 941 47 67 159 1258 1.28 0
234 -67 59 -38 106 0.3 0.0 0,1 14 603 51 106 539 1290 2.37 0
241 -75 114 -55 161 0.7 0.0 0.1 0.9 1056 72 104 030 1847 1.38 0r-oo -62 2 1 5 -42 3.7 0.0 o ; 4.6 880 72 112 486 1011 1.72 0
79 1.9 0.0 0.2 3-1 05! 38 142 796 1066 1.47 0
208 -68 79 -49 1.3 0.0 0.0 1.5 820 51 83 470 1445 2.01 0
313 -(.4 1 -(. 83 1.0 o.o 0.1 2.5 847 4.x 111 735 1410 1.27 0
153 -65 46 -25 0 .9 o.o 6 1 0.1 035 -M 94 1546 1 27 0
350 -(,4 -M' "  ■ 54 0.1 3-Q 1919 45 123 759 1519 1.25 0
323 -57 160 -40 79 1.1 0.0 0-3 1.9 779 57 129 775 .. .Mi 72 9 >9 0
79 -55 54 -40 4" 4.1 1 1.8 1.2 718 24 115 408 583 1.08 0
137 -59 90 -44 96 3.4 0.0 0.2 4.5 862 49 114 810 1916 1 -;x 0
293 -65 M2 -37 35 1.5 0.0 0.4 3-3 824 36 95 729 0.69 A
125 -65 50 -33 63 1.6 2-2 0.3 3.?, 740 79 81 679 Si M i 29 0
140 -52 87 -43 104 0.7 no 0.2 1.7 801 18 75 389 1138 1.57 0
213 -67 96 -48 165 2.4 14.9 0-3 2.7 988 30 97 5 7 6 1477 1.66 0
246 -66 129 -30 64 4.0 0.0 0.1 13.9 770 49 94 456 458 2.07 0
21 -84 5 -43 1.1 0.0 0.2 3.8 958 38 92 702 1591 l.?6 0
286 -67 174 -45 3.4 0.0 Q.l 6.3 573 37 112 474 12 M 2.QQ 0
79 -41 52 -8 39 0.7 0 0 0-3 3-7 498 21 M2 644 915 1.39 0
229 -94 t - -41 5.8 66 0.1 2.7 848 24 51 868 3614 1.18 0
189 -Oh 64 -5< 171 1 5 66 6 i 1.2 820 45 84 555 1054 1.10 0
90 -66 73 -58 183 1.9 0.0 0.4 2.0 746 42 92 592 1774 2.02 0
267 -57 145 -48 63 1.6 0.0 0.5 5.7 612 62 70 681 1192 1.37 0
211 -55 100 -46 71 9.4 Q.O 2.0 3.0 66'- 15 ox 617 1234 i ’■ 0
206 -71 77 -33 103 0.2 8.9 0-3 3.2 x M0 40 XX 537 ___i 2 2 'J : 0
218 -6 0 7X -37 XX 81 0-0 0 .7 6 6 M 646 1088 1.62 0
158 -62 79 -62 239 2.6 14.2 0-3 2.1 730 69 116 517 2168 : "2 0
164 -67 107 -3 5 68 1.5 0.0 0.2 1.9 790 27 5 3 568 1478 1 0
151 -o*> 37 M2 46 ox 6 7 1.4 760 o-l 80 563 821 Q.72 0
264 -47 1 52 -24 2 5 10.2 1.5 6 9 2.1 1441 34 78 550 754 1.32 0.1
142 -64 47 -40 32 11.8 1.5 1,3 2-3 1 347 39 240 6 9- 1170 1 M 0.1
120 54 40 45.0 3.3 22.7 6.8 1414 71 181 1157 1628 2.29 0.2
169 -48 51 -28 |X6 2 6 0.8 3.1 1 MM 50 180 455 1160 2.15 0.5
162 -60 35 -45 234 14.2 0.0 13.7 2.7 1057 34 192 140 1095 1.0Q 0.5
185 -51 37 -36 32 21.9 2.1 0.9 2.7 1805 36 102 596 1268 1.26 0.6
173 72 14.6 2.3 0.4 3-5 1180 69 247 776 1085 1.25 0.6
247 -54 142 -43 31 15.3 1.9 6 6 ; 1303 19 .  .M XX') X X X 9.7
120 -46 32 -4 64 13.3 1.7 0.4 3-Q 1329 56 270 753 1190 2-43 0.7
171 -59 70 -24 791 4.8 0.0 75.4 3.2 852 40 155 148 9 . )4 0 99 0.7
205 -56 39 -37 76 84.2 0.0 176.1 3.0 1201 76 146 180 1263 0.78 1.3
214 -64 26 -3 1,30 1.7 6.6 6.7 1.2 6 6 3 40 x- 868 776 0.96 1.3
118 -53 15 -27 2X2 1.3 0-0 0.9 n/a 50 ____M2 r ..  >M 1187 1.25 1.8
275 -72 122 -38 1.5 0 0 0 x 3.0 649 16 53 . M2 935 1.2,5 1.8
268 -67 71 -30 120 1.7 0.0 0.7 2.0 443 3x 96 387 1392 1.04 2
93 -38 41 -33 63 1.7 Q.O 0.4 2-7 508 38 113 429 470 1.20 2
171 -62 r - -51 357 0.0 0.0 0.2 2.8 607 24 148 445 7 7 4 ( 1 9 9 2
227 -70 83 -51 53 1.4 0.0 0.2 2.1 785 31 89 539 925 0.98 2
280 -57 61 -42 51 2.0 0.0 0.3 5.7 620 48 116 626 862 1.09 2
336 -54 204 -44 23 10.7 1,4 1,2 2-2 1726 42 5 9 601 1039 : ' 2.1
134 -69 64 -47 29 14.8 1.4 0.5 2.5! 1668 52 327 648 1543 3.24 2.1
265 -55 116 -29 55 O.o 0.0 6.6 807 4X 117 183 461 1.25 2.5
16 -60 -66 38 12.4 1.9 0.5 34 1701 22 112 648 852 1.78 2.5
261 -63 93 -31 25 9.0 1.8 0 4 1 . 5 1379 28 80 396 911 1.55 3
184 -59 79 -38 162 7.1 0.Q 5.4 0.1 1261 70 . 544 1770 0.83 ... ._ 3
118 -48 46 -14 104 1.2 00 1' 10X9 69 1 19 9M 2365 Q.9,5 3
299 -64 153 -42 126 ! M 0.0 o ; I 053 39 118 455 1289 2.18 3
216 -70 54 -44 111 1.0 0-0 0.0 1.7 903 32 1 3x 666 1477 1.89 3
2 5 i . . a : . -  M9 0 . 7 o.o 0.1 1.2 776 55 94 623 1311 0.68 3
245
172 -56 47 -44 57 1.1 0.0 0.1 1.3 867 42 79 485 1240 1.26 3
147 05 23 -44 1.8 0.0 0.2 4.8 558 20 n/a 760 1375 2.01 3
187 -56 7 ; -2 3 123 3.8 0.0 0.2 Ql.Q 646 42 81 746 1187 1.80 3
217 -56 139 -40 124 0.9 0.0 0-3 1.9 537 51 51 476 1165 1.34 3.2
221 -55 96 -28 13.7 17 0.4 2.0 1766 24 106 8? i 1394 1.46 3.3
172 -29 88 -24 14.8 1.4 2.4 3.5 2169 102 180 1821 2377 2.39 3.3
94 -4o 52 -41 39 9.7 1.2 2.9 2.5 1869 61 129 914 1435 1.53 3.4
207 -63 65 -30 111 1.3 0.0 0.3 6.4 820 39 90 550 1223 1.20 3.4
301 55 -55 120 0.5 Oi 0 1 2.6 1 06 S 5.8 OSr- SU) 1660 1.49 3.5219 ■-< 35 -22 22.8 2 .' 0 . 0 0.2 1.3 765 28 150 743 2069 0.90 3.5
200 -65 34 -25 29 0.0 0.0 88.8 2.0 1047 50 127 142 1218 Q.57 3.6
139 -61 73 13 125 0.3 0.0 Q.2 2.3 1162 34 91 537 1566 1.77 4.4
258 4 5 51 -26 29 16.5 2.2 1.6 3-0 1088 12 112 454 1040 2.22 4.5
79 50 -31 82 50.2 1.2 150.0 4.5 1533 74 86 200 1981 1.30 4.5
239 -65 81 -48 57 0.0 0.0 0.0 2.5 860 93 75 193 1389 1.06 5
155 -59 93 -53 34 36.0 1.0 403-0 2.5 873 64 139 168 1205 0.51 5
314 -(,4 139 -46 1 14 no 0.0 9.9 0.7 915 48 93 192 981 1)03 5
273 -55 148 -27 47 0.9 2.7 0.1 1.5 1013 50 88 713 1144 1.22 5
67 -45 13 -28 28 0.6 0.0 0.1 1.0 1069 94 123 630 1089 1 IQ 5oo - 83 -62 185 0.8 9.0 1.2 0.9 817 72 120 562 1271 i on 5
145 -66L -46 11.3 OS 0.0 0.1 1.4 1120 44 166 582 2111 5
230 -62 105 -55 170 1.7 0.0 0.2 4.9 1055 35 131 1030 2080 1.7Q 5
432 -74 168 -51 172 0.8 5.6 0-3 2.7 955 43 114 624 1555 1.08 5
401 -69 151 -52 118 0.3 0.0 0.0 4.2 896 39 64 606 1528 1.99 5
131 54 21.3 3-3 16Q.$ 3-7 1580 44 113 469 925 1.29 5
231 -66 108 -56 0.7 11.8 0.3 1.4 629 55 127 451 1051 I.4S 5
231 -49 109 -4 2.3 0.0 0.0 1.0 604 45 100 337 404 1.28 5
207 -61 70 -48 96 0.6 0.0 0.0 0.9 1820 70 91 557 1497 OSO 5
207 -44 92 -12 154 1.4 16.5 0.1 3.4 617 70 93 563 1123 1.37 5
101 58 -4(1 46 _ .. "0 0.0 i o 746 34 8i 8-8 649 0.96 5
188
_ .
-17 8Q -3 20.0 1.3 0.9 3.0 1757 32 146 697 1701 2.29 5.1
140 46 -45 60 0.0 0.0 14.0 2.0 1087 1-8 65 8 8 1308 -  S3 5.4
256 -71 70 -43 77 0.1 0.8 0.9 n/a 1030 80 62 626 2787 1.48 5.4
256 - 66 -29 85 0.6 0.0 0.3 2.2 738 46 126 045 1720 1 25 5.4
239 -52 174 -32 106 1.1 Q.Q 0-5 1.2 717 47 148 615 2400 2.16 5.5
222 -58 101 -35 39 1.1 3.8 0.2 1.2 723 71 108 703 1391 2 10 5 .5
122 -71 -69 341 0.7 Q.O Q.2 1.5 1052 37 245 1024 2664 1.90 6
258 -59 127 -44 14.0 1-7 0.3 7.8 1632 16 60 605 929 1,31 6.3
130 -48 39 -43 101 0.7 O.Q 0-3 2.0 387 49 166 457 915 1.28 6.5
172 -49 3 5 -28 174 5.9 0.0 (•8 2 o.o 1077 33 143 193 1 -8 1 ^ 1 6 .5
199 -51 112 -37 86 0.6 0.0 0-1 1.0 790 26 126 682 1570 Q?0 7
121 -57 89 -36 51 1.6 0.0 0.2 4.0 539 114 151 1168 1567 1.78 7
93 - 7 -22 25 2.0 0.0 0.3 3-0 1055 18 58 408 823 1.44 7
182 58 -44 85 0.7 Q.O Q.Q 0.6 944 58 145 626 102.5 ; - 7.5
138 -53 73 -31 6.5 Q.O 47.4 4.4 803 34 129 146 788 0.54 8
98 -67 38 -23 73 0.9 0.0 1.1 12 586 37 54 551 1269 1.16 8
132 -71 64 -59 0.8 Q.O 0.0 l.Q 914 78 32 672 2374 8
155 18 14.1 1.9 0.5 2 7 1394 29 73 499 1262 1.43 8.1
244 -43 123 -36 0.0 0.0 2-3 8.8 990 40 114 185 1237 1 80 8.8
259 -59 79 -35 177 1.9 0.0 29.5 3-3 974 69 99 194 1114 1.03 10
115 -46 48 -26 9.8 2.7 11.8 2,5 907 39 62 143 80 1 1 40 10
246
Heaviness
NEUTRO NEUTRO MONO MONO VEGF TNFalnha IL-la IL-lb IU-6 sL- sE- sP- slCAM- sVCAM- vWF
C D llb CD62L C D llb CD62L De/ml De/ml De/ml o e /m l De/ml ne /m l ne /m l ne /m l n e /m l ne /m l IlJ/ml heaviness
336 -54 204 -44 23 10.7 1.4 1.2 2.2 1726 42 59 601 1039 1.53 0
181 s o -18 140 0.7 0.0 18.6 1.7 1097 43 138 168 1160 0
155L_ ±'> 93 -53 34 3 0 . 0 I 0 403.1 873 64 1 168 1205 0.51 0
314 -64 139 -46 37 0.0 0.0 235.7 3-5 1064 35 181 187 920 0.88 0
239 -52 174 -32 106 1.1 0.0 0.5 1.2 717 47 148 615 2400 2.16 0
180 0 0 -44 115 1.6 0.0 O.O 1 4 7 94 60 lo o m SO -Ss 0
164 -57 52 -40 151 2.3 0.0 0.1 1.1 628 27 138 1149 2236 1.33 0
126 -54 44 -39 116 2.1 0.0 0.3 0.6 689 51 136 707 1551 2.00 0
230 -62 105. -55 170 1.7 0.0 0.2 4.9 1055 35 131 1030 2080 1.70 0
268 -67 71 7 i 2! 1.7 0 . 0 2. 0 443 28 90 48" 1392 1.04 0
93 -59 7 -22 25 2.0 0.0 0.3 3.0 1055 18 58 408 823 1.44 0
171 -62 1 - -51 357 0.0 O.o 0.2 2.8 607 24 148 445 774 0.96 0
299 -(>4 1 53 -42 120 1.3 0.0 0.3 2.2 653 39 118 455 1289 2.18 0
275 -63 55 -60 2 7 0.7 0.0 0.2 2.3 636 26 69 488 1352 1 - 0
323 -65 6, -21 1 IS 2.4 0 . 0 n.2 2.4 1 203 4 1 SO 0 8 ' 2379 0 89 0
207 -63 65 -30 1C 1.3 0.0 0.3 6.4 820 39 90 550 1223 1.20 0
270 -58 80 -29 3.2 0.0 2.5 4.2 649 56 123 442 741 1.05 0
171 L -24 791 4.s 0 0 4 40 L77 1 • 8 ___ 094 0.96 0
99 56 23.1 0.0 5.6 2.8 799 68 109 215 1579 1.20 0
366 -57 191 -50 40 31.9 0.7 1417.3 2.3 1020 23 37 136 877 0.90 0
201 -62 76 -37 3.7 0.0 21.8 ■4 941 47 67 159 1258 1.28 0
256 -"1 77 0.1 o s 0.9 s so o2 o2o 2 "8 " 1.48 0
234 -67 59 -38 106 0.3 0.0 0.1 1.1 603 51 106 539 1290 2.47 0
216 -70 54 -44 111 1.0 0.0 0 0 1 7 903 32 138 666 1477 1.89 0
231 -oo 108 -56 0.7 11.8 0.3 1.4 629 55 127 451 1051 1.48 0
255 87 -49 0. 7 0 0 9 1 77< 55 94 623 1311 0.68 0
87 -f'1 5 7 4 2 00 0 3 4.6 _ 7'7' 112 486 I'M ; 1.72 0
79 1.9 0.0 0.2 3 1 651 38 142 796 1066 I 47 0
208 -„x 79 4' : • OO 00 1 7_  s o , 51 8 3 470 1445 0
231 -44 109 -4 2.3 0.1) o n 1 0 604 45 100 4 3 " 404 ! 28 0
147 -65 23 -44 1.8 0.0 0.2 4.8 558 20 n/a 760 ; 2.01 0
350 -64 52 -45 150 0.7 5 1 ' 0 1919 45 123 :7 i - 1 28 0
323 -57 160 -40 79 1.1 O.o 0.3 1 9 779 57 129 775 1163 0.59 0
137 -59 90 -44 96 3 4 0.0 4 7 862 4" i 14 ' 3 1910 1.48 0
293 -65 I : 7 -37 35 1.5 0.0 0.4 3.3 824 36 95 "2o 1 v 3 0
125 -65 50 -33 63 1.6 2 2 (, 7 3 2 740 79 81 079 -■> 0
213 -(,7 0„1 -4 s Ho 2 4 14.9 o.; 2.7 988 97 5 7o 1477 1.66 0
286 -67 174 -45 3.4 0.0 0.1 6.3 573 37 112 474 U s 7 2.00 0
79 -4] 5 2 -8 7 0 - 0  0 0. 3 3 ' 498 21 7’ 644 9' 0
229 -64 177 -41 33 3.8 Q.Q 0.1 2.7 848 24 51 868 3614 1.18 0
189 -66 64 -56 17C 1.5 0 0 0.1 1.2 820 45 84 5.8 5 Kiss 1.10 0
90 -66 73 -58 183 1.9 0 0 0.4 2,0 746 42 92 592 1774 7 02 0
267 -57 144 -48 63 1.6 O.o 0.5 5.7 612 62 70 OS! 1197 1 9; 0
211 -55 100 -46 71 9.4 0.0 2.0 3.0 663 15 68 617 1234 1.29 0
206 -71 77 -33 105 0.2 8.9 0.3 3.2 830 46 88 837 1229 1.50 0
218 -60 78 -3» 88 1.2 0.0 0.7 5.7 665 91 86 040 OKS 1 02 0
164 .. .  O '7 -35 os 1.5 0 0 0.2 1.9 790 27 53 _.7os 1478 1.11 0
151 -69 37 -42 46 0.8 0 0 0-2 1-4 760 34 80 563 821 0.7?, 0
214 -64 26 -3 13C 1.7 0.0 0.2 1.2 663 40 89 868 776 0 90 0
16 -00 -66 38 12.4 1.9 0.5 3.1 1701 22 112 O S S 882 i 7S 0 2
169 -48 31 -28 15.9 2.0 0.8 3.1 1145 50 180 455 1160 2.15 0.2
205 -56 39 -37 76 84.2 0.0 176.1 3.0 1201 76 146 180 1263 0 7 8 0.3
173 72 14.6 0.4 3.5 1180 09 247 7701 : 1 is 8 ! 2 8 0.4
157 -55 28 -54 107 0.5 2.2 0-2 1,2 935 37 90 476 1738 0.09 0.5
188 -17 84 -3 20.0 1.3 0 . 9 3.0 1757 32 146 097 1701 2.29 0.5
120 - 4 6 4 2 -4 04 13 7 1 7 OS 3. 0 1329 56 270 753 1190 2 44 0.8
142 -64 47 -40 52 11.8 1„5 1.3 2.3 1347 39 240 643 1170 1.92 0.9
166 -53 142 -40 32 0.8 1.4 0.2 2.2 1098 57 98 850 1271 1.25 1
244 -43 123 -36 0.0 0.0 2.5 8.8 990 40 114 185 1237 1.56 1
264 -47 132 -24 25 10.2 1,5 0.9 2.1 1441 34 78 8 8!! 7 5 S 1.4
280 -57 61 -42 51 2.0 0.Q 0-3 5-7 620 48 116 626 862 1.09 1.4
144 -55 86 -45 56 1.2 0.Q 0.2 1-3 747 84 96 437 1174 1.43 1.5
227 -70 83 -51 53 1.4 0 0 0.2 2 . 1 785 31 89 ^  5 50 92 8 9 9' 1.5
120 54 40 45.0 3.3 - 7 6.8 1414 71 181 1157 1628 2.29 1.7
118 -53 15 -27 282 1.3 0.0 0.3 0.9 n/a 50 232 811 1187 1 28 1.8
203 -60 93 -42 52 0.7 0 0 0 0 1,0 620 26 109 682 1673 1.41 1.8
93 -38 41 -33 63 1.7 0.0 0.4 2.7 508 38 113 429 470 1.20 2
217 -56 139 -40 124 0.9 0 0 0.3 1.9 537 51 51 470 1108 : 44 2
153 -65 46 -25 0.9 0.0 0.1 6,1 635 36 94 597 1546 1 7 2.2
247 -54 142 -43 31 15.3 1.9 65.3 3.2 1303 19 121 580 858 2.00 2.4
301 -4 ; 55 -55 l2 o 0 5 Oil (| i loos 55 ,  77 2:9 1660 1.49 2.5
275 -72 122 -38 1.5 0 0 0.5 3.0 649 16 53 756 935 1-25 2.5
185 -51 37 -36 32 21.9 2.1 0.9 2.7 1805 36 102 596 1268 1.26 2.6
131 54 21.3 3-3 166.8 3.7 1580 44 113 469 925 1.29 2.7
134 -69 64 -47 29 14.8 1.4 0.5 2-5 1668 52 327 048 1 54 8 3 24 2.9
94 -46 52 -41 39 9.7 1.2 2.9 1 869 61 129 914 14 5.: 1 87 3
219 . 2-4 2 2 .. 2.0 no 0 2 : 763 2 8 - . " 4 5 7 9 9 9 0.90 3
247
140 -52 87 -43 104 0.7 0.0 0.2 1.7 861 18 75 389 1138 1.57 3
261 _.i,3 .. 1' -31 25 4 ! 1.8 0.4 1.5 1379 28 80 396 911 1.55 3.2
7 9 _____  -5'< ; ; 82 50.2 1 2 1 5 0 . 0 4 . 5 1 533 74 86 200 1981 1.3Q 3.5
118 ■4S 4 6 - 1 4 1041 12 0.0 0.2 1.0 1089 69 119 917 2365 0.95 3.5
273 148 -27 4 7 0.9 2.7 Q.J 1.5 1013 50 88 713 1144 1.22 3.5
432 ■;4 168 -51 172 1 ' 8 5.6 0 .3 2.7 955 43 114 624 1555 1.08 3.5
2 0 6 -4 8 111 -38 160 0.5 0.0 0.3 2.3 879 65 70 531 1142 0.96 3.5
2 5 9 - 5 9 7 6 -35 1 7 7 1.9 0.0 29.5 5 3 974 69 99 194 1114 1.03 3.5
265 " i 16 -2< - 2.6 0.0 0.0 6.6 807 48 117 183 461 1.25 4
184 -59 79 -38 162 7.1 o.q 5.4 0.1 1261 70 85 544 1770 0.83 4
73 • !'• 5< -41 197 0.8 0.0 0.1 3.5 769 65 227 699 1361 2.25 4
67 -45 : - 28 28 4 6 0.0 0.1 1.0 1069 94 123 630 1089 1.16 4
139 -61 73 L ' 125 I K) 4.2 2 . 3 1162 34 91 537 1566 1.77 4
162 -60 3 5 -45 234 14.2 0.0 i ’.7 2.7 1057 34 192 140 1095 1.00 4
2 0 7 7 -48 4( 4 6 0.0 0.4 0.9 1820 70 91 >57 1497 0.86 4
140 -61 46 -45 60 0.0 0.0 14.0 2.0 1087 15 65 58 1398 0.82 4.3
155 i 8 14.1 1.9 0.5 2.7 1394 29 73 499 1262 1.43 4.8
258 -45 51 -26 29 16.5 2 .?. 1.6 3.6 1088 12 112 454 1040 2.22 4.9
182 114 -32 12C 2.3 0.0 0.0 2.6 456 44 68 370 458 1.58 5
130 -48 39 -43 101 0.7 0.0 0.3 2.0 387 49 166 457 915 1.28 5
185 -65 S3 - 6 2 - 0.8 9.0 1.2 0.9 817 72 120 562 1.96 5
101 21 -13 147 0.0 0.0 Q. 3 1.0 641 35 145 545 1075 1.42 5
559 " S77 -Si 21 0.0 0.0 0.2 1.8 728 23 115 372 825 1.01 5
401 i- i -52 118 0 .3 0.0 0.0 4.2 896 39 64 606 1528 1.99 5
230 -44 ! i'> -37 142 1.5 Q.O 0.4 4.9 893 35 147 519 929 0.67 5
98 . . _ -'.7 8 -23 5 0 4 4 4 1.1 1.2 586 37 54 551 1269 1.16 5
115 -46 48 -26 9.8 2-7 11.8 2,5 907 39 62 143 861 1.49 5
256 -5‘> 6 6 - 2 0 8 5 4  6 0.0 0 .3 2.2 738 46 126 645 1720 1.25 5
79 L _ 51'u  ^ 4' 4.1 4 4 i.s 1.2 718 24 115 408 583 1.08 5
21 -84 5 -43 1.1 0.0 0.2 3-8 958 38 92 702 1591 1.26 5
207 -44 '4' - 1 2 1 5 4 1.4 16.5 0.1 3.4 617 70 93 563 1123 1.37 5
158 -'■2 7 ' 47 2 3 0 2 . 6 1 4 . 2 4.3 2.1 730 69 116 517 2168 1.02 5
221 -5 5 96 -28 13.7 1-7 0.4 2.0 1766 24 106 521 1394 1.46 5.1
239 . .  -'-5 8 1 - 4 8 5 7 <>i 4 4 4.4 2.5 860 93 75 193 1389 1.06 5.3
313 i -6 83 1.0 Q.O Q? 2,5 847 45 111 735 1410 1.27 5.3
172 4 ~ - 4 4 5 7 ! i 4  4 4.1 1,3 867 42 79 485 1240 1.26 5.4
301
.
-6 3 78 -41 34 2.2 O.Q Q.l 3-6 609 106 97 868 3626 2.50 6
172 -29 ss - 2 4 1 4 . 8 : : 2.4 2169 102 180 1821 2377 2,39
121 ' , 84 -36 51 1.6 0.0 0.2 4.0 539 114 151 1168 1567 1.78 6.5
138 -5 3 73 -31 6.5 Q.Q 47.4 4.4 803 34 129 146 788 Q.54 7
314 -64 139 -46 114 0.0 Q,Q 9.9 Q-7 915 48 93 192 981 0.63 7
197 68 -19 2 8 4 0.0 0.0 2,,3 2,5 522 57 125 172 887 Q.54 7
187 -56 73 -23 123 3.5 QQ Q-2 61.0 646 42 81 746 1187 1.80 7
199 -51 m -37 86 0.6 Q.Q Q.l l .Q 790 26 126 682 1570 0.86 7.5
222 ... 101 3 0 1 ! 7 . 8 4 . 2 1.2 723 71 108 7 0 3 1391 2 K! 7.5
241 1 14 ,8 s 161 4  - 4 . 4 0.1 0.9 1056 72 104 630 1847 1 38 7.5
182 -57 58 -44 85 0.7 Q.Q O.Q Q.6 944 58 145 626 1625 1.40 7.6
145 7.41 ■46 1 1 ; 0 .8 n n 4.1 1.4 1120 44 169 582 2111 2.53
200 - 6 5 34 -25 29 0.0 Q.O 88-8 2.0 1047 50 127 142 1218 0.57
258 -59 ; r 4-1 2.6 14.0 1.7 0.3 7.8 1632 16 60 605 929 1.31 S .2
132 -71 64 -59 0.8 QQ O.Q 1.0 914 78 32 672 2374 2.53 8.4
101 5 8 - 4 4 4 0 m 4 . 4 4 . 2 1.0 746 34 81 4 0 8 649 n w i , 8 5
122 -71 -69 341 0.7 Q.O Q.2 1.5 1052 37 245 1024 2664 1.90
246 1 2 4 . 3 0 (.4 4.0 4 4 0.1 13.9 770 49 94 456 458 2.07 9
17.2 -49 75 -2 8 174 5 - 9 0.0 65.2 7. 9 107 7 33 1 4 3 193 . 1 5 1 3 1.77 9.7
248
Cramps
NEUT NEUT MON MON VEGF TNF a IL-la IL-lb IL-6 sL- sE- sP- sICA sVCA vVVF
C D llb CD62I. C D llb CD62L De/ml De/ml De/ml De/ml De/ml ne/ml ne/ml ne/ml ne/ml ne/ml IU/ml cramos
336 -54 204 -44 23 10.7 1.4 1.2 2.2 1726 42 59 601 1039 1.53 0
185 51 37 -36 32 21.9 2.1 0.9 2.7 1805 36 102 596 1268 1.26 0
181 - 4 0 8 0 - 1 8 140 0.7 o.q 18.6 1.7 1097 43 138 168 1160 1.05 0
138 - 53 73 .. 5 1 6.5 0.0 47.4 4.4 803 34 129 146 788 0.54 0
155 - 5 9 m 5 ' ' 4 o , n 1 ' 403 . 0 2.5 8 Ms 64 139 168 1205 0.51 0
184 - 5 9 79 -38 162 7.1 0.0 5.4 0.1 1261 70 85 544 1770 0.83 0
140 -61 46 -45 O' 0.0 0.0 14.0 2.0 1087 15 65 58 1398 0.82 0
180 52 l o ! - 4 0 MS 1.6 0.0 0.0 1.4 794 60 160 327 536 0.86 0
199 -5 1 112 - 3 " Sf Of, n , n 1 1.0 ■700 2 6 126 682 1570 0 . 8 6 0
166 -53 142 -40 32 0.8 1.4 0.2 2.2 1098 57 98 850 1271 1.25 0
273 -55 148 -27 47 0.9 2.7 0.1 1.5 1013 50 88 1 1144 1.22 0
126 -54 44 -39 116 2.1 0.0 0.3 0.6 689 51 136 707 1551 2.06 0
145 -66 40 4 6 113 0.8 0.0 0.1 1.4 1120 44 169 582 2111 2.53 0
101 — 21 -13 147 0.0 0.0 0.3 1.0 641 35 145 545 1075 1.42 0
432 -74 168 -51 172 0.8 5.6 0.3 2.7 955 43 114 624 1555 1.08 0
559 -7 7 575 -80 21 0.0 0.0 0.2 1.8 728 23 - 372 825 1.61 0
144 -55 86 -45 56 1.2 0.0 0.2 1.3 747 84 96 437 1174 1.43 0
1,57 -5^ 38 -54 107 0.5 2.2 0.2 1.2 935 37 90 476 1738 0.69 0
219 -7( 56 -22 225 2.0 0.0 0.2 1.3 765 28 150 743 2069 0.90 0
275 -0 3 6 5 -CM 27 0 7 0.0 0 2 2.3 636 26 69 488 1352 1.33 0
323 -65 60 -21 118 2.4 0.0 0.2 2.4 1203 41 89 631 2379 0.89 0
197 - 3 ‘) 68 - 10 284 0.0 0.0 2.3 2.5 522 57 125 172 887 0.54 0
366 -57 191 o n 4 1 3 l . o 1417.3 2.3 0-2! 23 3 7 136 8 ^ 7 0.90 0
201 <c V< - 37 3.7 07 21 8 ; 941 47 67 159 1258 1.28 0
234 -67 59 -38 106 0.3 0.0 0.1 1.1 603 51 106 539 1290 2.37 0
216 -70 64 -44 1 ! 1 1 o o.O 0 0 1 ' 903 32 138 666 1477 1.89 0
153 -65 46 -25 0.9 0.0 0.1 6.1 635 36 94 597 1546 0
231 -49 lod -4 2.3 07 0.0 1.0 6 0 4 45 100 337 404 1 28 0
350 -64 52 -45 150 0.7 5.1 0.1 3.0 1919 45 123 759 1519 0
137 -59 90 -44 96 3.4 0.0 0.2 4.5 862 49 114 810 1916 1.48 0
293 - 6 5 112 - 35 1.5 0.0 0 4 824 36 95 729 1333 0.69 0
140 -52 87 -43 104 0.7 0.0 0.2 1.7 861 18 75 389 1138 1.57 0
213 -67 96 -48 16,5 2.4 14.9 0.3 2.7 988 30 97 57q 1477 1.66 0
229 -64 177 -41 33 3.8 0.0 0.1 2.7 848 24 51 868 3614 1.18 0
189 -Of 64 -56 170 1.5 0.0 0.1 1.2 820 45 84 1054 1.10 0
267 -5" 145 -48 63 1.6 0.0 0.5 5.7 612 62 7d 681 1192 1.37 0
101 -63 - 40 49 n o 0.0 0.2 1.0 746 34 81 408 649 0.96 0
206 .... 4 io.s 0  2 S 7 o s s 2 830 46 s s SOS 1 2 2 0 1 '■ 0
218 - o n 78 -39 88 1.2 0.0 0.7 5.7 665 30 86 646 1088 1.62 0
164 -67 107 - 35 o s 1.5 n n 0.2 1.9 790 27 53 568 1478 1.11 c
151 - 60 37 -42 46 0.8 0.0 0.2 1.4 760 34 80 563 821 0.72 0
214 -64 26 -3 130 1.7 0.0 0.2 1.2 663 40 89 868 776 0.96 0
172 -37 8,8 -24 14.8 1.4 2.4 3.5 2169 102 180 1821 2377 2.39 0.1
261 -63 93 -31 25 9.0 1.8 0.4 1.5 1379 28 80 396 911 1.55 0.2
73 -46 50 -41 i 07 0.8 0.0 0.1 3 6 769 o- 2 2" 699 1361 2.25 0.2
134 -69 04 -47 20 1 4 8 : : 0.5 2.5 1668 52 327 648 1543 3.24 0.2
169 -48 31 -28 1 s o 2 i 0 . 8 5 l 1145 s o ; s o 4 5 5 1160 7 s 0.2
247 - 5 4 J 4 2 -43 31 15.3 17) 65.3 3.2 1303 19 121 ,580 858 2.00 0.3
142 -64 47 -40 52 11.8 1.5 1.3 2.3 1347 39 240 643 1170 1.92 0.3
265 - 55 116 -29 55 2.5 0.0 0.0 6.6 807 48 117 183 461 1.25 0.5
208 -( ,S 70 -40 1 7 0.0 15 820 51 83 470 1445 2.01 0.5
90 -66 73 -58 183 1.9 0.0 0.4 2.0 746 42 92 592 1774 2.02 0.5
188 -17 86 -3 20.0 1.3 0.9 3.0 175" 32 146 697 1701 2.29 0.6
264 4" 1 3 2 - 24 2 6 10 2 1.5 o o 2.1 1441 34 78 SXO 754 1 M2 1
222 -58 101 -3,5 39 1.1 3.8 0.2 1.2 723 71 108 703 1391 2.10 1.2
401 -69 1 8 1 -52 118 0.3 0.0 0.0 4.2 896 39 64 606 1528 1.99 1.2
207 - 63 65 -30 111 1.3 Q.O 0.3 6.4 820 39 90 550 1223 1.20 1.4
280 - 57 6 1 -42 51 0. 0 0.3 6 62' 4X 116 6 2 6 862 1.09 1.5
19 " -8 s o 4 ~ n. o h ! 3.7 4 os 21 72 644 915 ' 1.5
258 - 45 51 - 26 20 16 5 2.2 1.0 7.6 l!)8S 12 112 4 5 4 1 0 4 0 1.6
173 72 14.6 2.3 0 4 7-5 ! 18. 6 9 247 7 7 6 1085 1.25 1.9
187 -56 73 -23 123 3.5 0.0 0.2 61.0 646 42 81 746 1187 1.80 2
16 -60 -66 3S 12 4 1.9 3.1 1701 22 6 4 8 852 : 2.4
230 -02 105 -55 170 1.7 0.0 0.2 4.9 1055 35 131 10,30 208 0 1.70 2.5
94 -4( 6 3 4 1 30 0 7 1.2 23) 2. 5 1 8 6 0 61 129 914 1435 1.53 2.8
79 1.9 0.0 0.2 3.1 651 38 142 796 1066 1.47 2.9
155 18 14.1 1.9 0.5 2.7 1394 29 73 499 1262 1.43 3
268 7 71 - 4 ) 120 1.7 0.0 o s 2.0 443 28 96 387 1392 1.04 3
125 -65 5< - 4 63 1 .6 2.2 0. 7 s.2 740 79 81 6 M 804 1.29 3
158 -62 79 -62 239 2.6 14.2 0.3 2.1 730 69 116 517 2168 1.02 3
239 -65 81 -48 57 0.0 0.0 0.0 2.5 860 93 75 193 1389 1.06 3.1
301 -61 55 -55 126 0.5 0.0 0.1 2.6 1068 55 68 510 1660 1.49 3.5
171 ■72 135 -.6 1 M87 o n 0 - 0 2 2.8 6 0 7 24 148 445 774 0 9 6 3.5
270 -58 80 -29 3.2 0.0 2.5 4.2 649 56 123 442 741 1.05 3.5
221 -55 0 0 -2 8 i s . 7 1,7 0. 4 2.0 1766 24 106 521 : 0.4 mm 4
249
118 -48 46 -14 104 1.2 0.0 0.2 1.0 1089 69 119 917 2365 0.95
67 -45 13 -28 28 0.6 0.0 0.1 1.0 1069 94 123 630 1089 1.16
206 -48 Ml •38 10(1 0.5 on 11.3 2.3 879 65 70 531 1142 0.96
230 -44 1 19 -37 142 1.5 0.0 0.4 4.9 893 35 147 519 929 0.67
290 -64 153 -42 120 1,3 0.0 Q.3 2.2 653 39 118 455 1289 2.18
256 -"I 70 -43 7- o 1 0 8 0.9 n/a 1030 80 62 626 2787 1.48 4.3
131 54 21.3 3.3 166.8 3.7 1580 44 113 469 925 1.29 4.4
172 -49 75 -28 174 5.9 O.C 65.2 7.9 1077 33 143 193 1513 1.77 4.4
182 I 14 -O 120 73 0.0 Q.O 2.6 456 44 68 370 458 1.58 4.5
79 -59 50 -31 82 50.2 1.2 150.0 4.5 1533 74 86 200 1981 1.30 4.8
118 15 -27 282 1.3 0.0 0.3 0.9 n/a 50 232 811 1187 1.25
185 -(.5 S3 -62 185 n.s 9.0 1.2 0.9 817 72 120 562 1271 1.96
255 -70 X- -40 0.7 0,0 1 1 1.2 776 55 94 623 1311 0.68
147 -65 23 -44 1.8 0.0 0.2 4.8 558 20 n/a 760 1375 2.01
246 -06 129 -30 64 4.0 0.0 0.1 13.9 770 49 94 456 458 2.07
275 -72 122 -38 1.5 O.C 0.5 3.0 649 16 53 756 935 1.25
99 56 7 3 . 0.0 5.6 2.8 799 68 109 215 1579 1.20 5.1
to Z*. -67 174 -45 3.4 0.0 0.1 6.3 573 37 112 474 1237 2.00 5.5
87 -02 215 -42 3.7 0.0 0.3 4.6 886 72 112 486 1011 1.72
21 -84 5 -43 1.1 0.0 0.2 3.8 958 38 92 702 1591 1.26
171 -59 70 -24 791 4.8 0.0 75.4 3.2 852 40 155 148 904 0.96 6.2
314 M 1 0) -4(. (X O.i 7 5 5 7 3 5 InMl 35 iXi 187 920 0.88 6.4
120 54 40 45.(3 3.3 22.7 6.8 1414 71 181 1157 1628 2.29 6.4
130 ;o 0)1 0.0 n 3 7< 3X7 49 166 457 915 1.28 6.5
227 -70 83 -51 53 1.4 0.0 0.2 2.1 785 31 89 539 925 0.98 6.5
258 - 5 9 127 -44 25 14.0 1.7 0.3 7.8 1632 16 60 605 929 1.31 6.9
164 -57 52 -40 151 2.3 0.0 0.1 1.1 628 27 138 1149 2236 1.33
121 -57 89 -36 51 1.6 0.0 0.2 4.0 539 114 151 1168 1567 1.78
93 41 -33 63 1.7 0.0 0.4 2.7 508 38 113 429 470 1.20
139 -o! 7 3 ' : 127 0 3 Ml 02 2 3 1 162 34 91 537 1566 1.77
98 -67 38 -23 73 0.9 0.0 1.1 1.2 586 37 54 551 1269 1.16
115 -4. 48 -26 9.8 2.7 11.8 2.5 907 39 62 143 861 1.49
79 -55 5‘> 6 47 Ml 1 x 1 2 7 M 24 1 15 40X 583 -
211 100 7 71 9.4 0 1 2 n 3 1) 063 15 68 617 1234 1.29
182 -57 58 -44 85 0.7 O.C 0.0 0.6 944 58 145 626 1625 1.40 7.6
93 -59 '■ 22 25 .1, M3 M 1055 18 58 408 823 1.44
217 -5 ( 139 -40 124 0.9 O.C 0.3 1.9 537 51 51 476 1165 1.34
205 -56 39 -37 76 84.2 0.0 176.1 3.0 1201 76 146 180 1263 0.78 8.4
122_  - I -69 341 0.7 0.0 0.2 1.5 1052 37 245 1024 2664 1.90 8.5
200 -65 34 -25 29 O.C 0.0 88.8 2.0 1047 50 127 142 1218 0.57 8.5
172 -56 47 44 5^ 1 1 0.0 0.1 13 867 42 79 485 1240 1.26 8.5
207 -61 70 -48 96 0.6 0.0 0.0 Q.9 1820 70 91 557 1497 0.86 8.5
207 -44 02 -12 154 1.4 16.5 0.1 3.4 617 70 93 563 1123 1.37 8.5
301 "8 -41 34 0.0 ().! M 600 106 o~ 808 3626 2 xn
132 -"1 64 -59 0.8 0.0 0.0 1.0 914 78 32 672 2374 2.53
231 -66 108 -56 0 7 11.8 0.3 1.4 629 55 127 451 1051 1.48
256 00 85 no ,M () 3 2 7. 738 46 i?o 645 r : n
259 -5 9 79 -35 177 1.9 0.0 29.5 5.3 974 69 99 194 1114 1.03 9.5
323 - 100 -4> 79 11 01 0.3 13) 779 57 129 775 1163 O sn 0 5
162 -60 35 -45 234 14.2 0.0 13.7 2.7 1057 34 192 140 1095 1.00 9.7
314 m 1 30 -40 114 0.0 9.9 0.7 915 48 93 192 MS] 0.63 9.X
120 U b 32 -4 64 13.3 1.7 0.4 3.0 1329 56 270 753 1190 2.43 9.8
203 -0 -1" 52 " 7 wl m i I* 0 6 26 i 09 682 1673 i 4 ; in
244 -43 123 -36 0.0 0.0 2.5 8.8 990 40 114 185 1237 1.56 10
241 - ~ 5 1 14 -55 161 0.7 0.0 0.1 0.9 1056 72 104 630 1847 1.38 10
313 -64 1 -6 S3 1 0 0.1 0.1 7 5 847 45 111 735 I4IM 1.27 10
239 -52 174 -32 106 1.1 0.0 0.5 1.2 717 47 148 615 2400 2.16
250
Paraesthesiae
NEUTROPH NEUTRO MONOCYTE MONOCYTE VEGF T N F tt IL-la IL-lb IL-6 sL- sE- sP- slCAM-1 sVCAM-1 vWF
C D llb CD62L C D llb CD62L pg/ml ail p- 'Hi r - ," 1 | ’r  '"1 ng/ml ng/ml ng/ml ng/ml ng/ml HJ/ml paresthcsi
94 -46 52 -41 39 1.2 2.9 1869 61 129 914 1435 1.53 0
181 -49 80 -18 140 0.0 18.6 1097 43 138 168 1160 1.05 C
138 -53 73 -31 0.0 47.4 803 34 129 146 788 0.54 0
184 -59 79 -38 162 0.0 5.4 1261 70 85 544 1770 0.83 0
79 -59 50 -31 82 50.2 1.2 150.0 1533 74 86 200 1981 1.30 0
239 -52 174 -32 106 0.0 0.5 717 47 148 615 2400 2.16 0
180 -52 101 -40 115 0.0 0.0 794 60 160 327 536 0.86 0
301 -63 78 -41 34 0.0 0.1 609 106 97 868 3626 2.50 0
199 -5! 112 -37 86 0.0 0.1 790 26 126 682 1570 0.86 0
203 -6C 93 -42 52 0.0 0.0 620 26 109 682 1673 1.41 0
222 -58 101 -35 39 3.8 0.2 723 71 108 703 1391 2.10 0
273 -55 148 -27 47 2.7 0.1 1013 50 88 713 1144 1.22 0
126 -54 44 -39 116 0.0 0.3 689 51 136 707 1551 2.06 0
185 -65 83 -62 185 9.C 1.2 817 72 120 562 1271 1.96 0
230 -62 105 -55 170 0.0 0.2 1055 35 131 1030 2080 1.70 0
101 -53 21 -13 147 0.0 0.3 641 35 145 545 1075 1.42 0
268 -67 71 -30 120 0.0 0.3 443 28 96 387 1392 1.04 0
93 -59 7 -22 25 O.C 0.3 1055 18 58 408 823 1 44 0
206 -48 111 -38 160 0.0 0.3 879 65 70 531 1142 0.96 0
559 -77 575 -80 21 0.0 0.2 728 23 115 372 825 1 61 0
144 -55 86 -45 56 0.0 0.2 747 84 96 437 1174 1 43 0
93 -38 41 -33 63 0.0 0.4 508 38 113 429 470 1.20 0
401 -69 151 -52 118 0.0 0.0 896 39 64 606 1528 1.99 0
301 -61 55 -55 126 0.0 0.1 1068 55 68 SIC 1660 1 49 0
171 -62 135 -51 357 0.0 0.2 607 24 148 445 774 0.96 0
217 -56 139 -40 124 0.0 0.3 537 51 51 476 1165 1.34 0
230 -44 119 -37 142 0.0 0.4 893 35 147 519 929 0 67 0
299 -64 153 -42 120 0.0 0.3 653 39 118 455 1289 2.18 0
139 -61 73 13 125 0.0 0.2 1162 34 91 537 1566 1 77 0
219 -7( 35 -22 225 0.0 0.2 765 28 150 743 2069 0.90 0
275 -63 55 -60 27 0.0 0.2 636 26 69 488 1352 1.33 0
323 -65 60 -21 118 O.C 0.2 1203 41 89 631 2379 0.89 0
207 -63 65 -3C 111 0.0 0.3 820 39 90 550 1223 1.20 c
200 -65 34 -25 29 O.C 888 1047 5C 127 142 1218 0.57 0
99 56 2 O.C 5.6 799 68 109 215 1579 1.2C 0
366 -57 191 -5C 40 3 0.7 1417.3 1020 23 37 136 877 0.90 c
201 -62 76 -37 0.0 21.8 941 47 67 159 1258 1.28 0
256 -71 70 -43 77 0.8 0.9 1030 80 62 626 2787 1 48 0
234 -67 59 -38 106 0.0 0.1 603 51 106 539 1290 2.37 c
241 -75 114 -55 161 0.0 0.1 1056 72 104 630 1847 1.38 0
255 -76 87 -49 0.0 0.1 776 55 94 623 1311 0.68 0
87 -62 215 -42 0.0 0.3 886 72 112 486 1011 1.72 0
79 0.0 0.2 651 38 142 796 1066 1.47 0
208 -68 79 -49 0.0 0.0 820 51 83 470 1445 2.01 0
153 -65 46 -25 0.0 0.1 635 36 94 597 1546 1.27 0
147 -65 23 -44 0.0 0.2 558 20 n/a 760 1375 2.01 0
207 -61 70 -48 96 0.0 O.C 1820 70 91 557 1497 II 86 0
350 -64 52 -45 150 5.1 0.1 1919 45 123 759 1519 1.25 0
323 -57 160 -40 79 0.0 0.3 779 57 129 775 1163 0.59 0
227 -70 83 -51 53 0.0 0.2 785 31 89 539 925 0.98 0
280 -57 61 -42 51 0.0 0.3 620 48 116 626 862 1.09 0
79 -55 59 -40 4?l 0.0 1.8 718 24 115 408 583 1.08 0
137 -59 90 -44 96 0.0 0.2 862 49 114 810 1916 1 48 0
125 -65 50 -33 63 2.2 0.3 740 79 81 679 804 1 29 0
140 -52 87 -43 104 0.0 0.2 861 18 75 389 1138 1.57 0
213 -67 96 -48 165 14.9 0.3 988 30 97 576 1477 1 66 0
246 -66 129 -30 64 0.0 0.1 770 49 94 456 458 2.07 0
21 -84 5 -43 0.0 0.2 958 38 92 702 1591 1.26 0
79 -41 52 -8 59 0.0 0.3 498 21 72 644 915 1.39 0
229 -64 177 -41 33 0.0 0.1 848 24 51 868 3614 1 18 0
189 -66 64 -56 17C 0.0 0.1 820 45 84 555 1054 1.10 0
90 -66 73 -58 183 0.0 0.4 746 42 92 592 1774 2.02 0
187 -56 73 -23 123 0.0 0.2 646 42 81 746 1187 1.80 0
267 -57 145 -48 63 0.0 0.5 612 62 70 681 1192 1.37 0
211 -55 100 -46 71 0.0 2.0 663 15 68 617 1234 1.29 0
101 -63 58 -40 49 0.0 0.2 746 34 81 408 649 096 0
206 -71 77 -33 105 8.9 0.3 830 46 88 837 1229 1.50 0
218 -60 78 -39 88 0.0 0.7 665 30 86 646 1088 1.62 0
158 -62 79 -62 239 14.2 0.3 730 69 116 517 2168 1.02 0
275 -72 122 -38 0.0 0.5 649 16 53 756 935 1.25 0
164 -67 107 -35 68 0.0 0.2 790 27 53 568 1478 1.11 0
221 -55 96 -28 1 1.7 0.4 1766 24 106 521 1394 1 46 0.1
134 -69 64 -47 29 1 1.4 0.5 1668 52 327 648 1543 3.24 0.1
131 54 2 3.3 166 8 1580 44 113 469 925 1.29 0.1
247 -54 142 -43 31 1 1.9 65.3 1303 19 121 580 858 2.00 0.2
172 -29 88 -24 1 1.4 2.4 2169 102 180 1821 2377 2.39 0.2
251
169 -48 31 -28 15.9 2.C 0.8 3.1 1145 50 180 455 1160 2.15 0.2
264 -47 132 -24 25 10.2 1.5 0.9 2.1 1441 34 78 550 754 1.32 0.3
142 -64 47 -40 52 11.8 1.5 1.3 2.3 1347 39 240 643 1170 1.92 0.3
16 -60 -66 38 12.4 1.9 0.5 3.1 1701 22 112 648 852 1.78 0.3
155 -59 93 -53 34 36.0 1.0 403.0 2.5 873 64 139 168 1205 0.51 0.3
336 -54 204 -44 23 10.7 1.4 1.2 2.2 1726 42 59 601 1039 1.53 0.5
258 -59 127 -44 25 14.0 1.7 0.3 7.8 1632 16 60 605 929 1.31 0.5
205 -56 39 -37 76 84.2 O.C 176.1 3.0 1201 76 146 180 1263 0.78 0.5
120 -46 32 -4 64 13.3 17 0.4 3.0 1329 56 270 753 1190 2.43 0.5
172 -56 47 -44 57 1.1 O.C 0.1 1.3 867 42 79 485 1240 1.26 0.5
185 -51 37 -36 32 21.9 2.1 0.9 2.7 1805 36 102 596 1268 1.26 0.7
188 -17 86 -3 20.0 1.3 0.9 3.0 1757 32 146 697 1701 2.29 0.7
171 -59 70 -24 791 4.8 O.C 75.4 3.2 852 40 155 148 904 0.96 1
2561 -59 66 -29 85 0.6 0.0 0.3 2.2 738 46 126 645 1720 1.25 ;
258 -45 51 -26 29 16.5 2.2 1.6 3.6 1088 12 112 454 1040 2.22 1.4
140 -61 46 -45 60 O.C 0.0 14.0 2.0 1087 15 65 58 1398 0.82 1.5
231 -49 109 -4 2.3 0.0 0.0 1.0 604 45 100 337 404 1.28 1.5
261 -63 93 -31 25 9.0 1.8 0.4 1.5 1379 28 80 396 911 1.55 1.6
145 -66 40 -46 113 0.8 0.0 0.1 1.4 1120 44 169 5821 2111 2.53 2
173 72 14.6 2.3 0.4 3.5 1180 69 247 776 1085 1.25 2
151 -69 37 -42 46 0.8 0.0 0.2 1.4 760 34 80 563 821 0.72 2
239 -65 81 -48 57 0.0 0.0 O.C 2.5 860 93 75 193 1389 1.06 2.5
67 -45 13 -28 28 0.6 0.0 0.1 1.0 1069 94 123 630 1089 1 16 2.5
216 -70 54 -44 111 1.0 0.0 0.0 1.7 903 32 138 666 1477 1 89 2.5
164 -57 52 -40 151 2.3 0.0 0.1 1.1 628 27 138 1149 2236 1.33 3
197 -39 68 -19 284 0.0 O.C 2.3 2.5 522 57 125 172 887 0.54 3.1
118 -48 46 -14 104 1.2 0.0 0.2 1.0 1089 69 119 917 2365 095 3.5
270 -58 80 -29 3.2 0.0 2.5 4.2 649 56 123 442 741 1.05 3.5
259 -59 79 -35 177 1.9 0.0 295 5.3 974 69 99 194 1114 1 03 3.5
293 -65 112 -37 35 1.5 0.0 0.4 3.3 824 36 95 729 1333 069 3.5
162 -60 35 -45 234 14.2 O.C 13.7 2.7 1057 34 192 140 1095 1.00 4
314 -64 139 -46 37 0.0 O.C 255.7 3.5 1064 35 181 187 920 0.88 4.2
120 54 40 45.0 3.3 22.7 6.8 1414 71 181 1157 1628 2.29 4.4
182 114 -32 12C 2.3 O.C O.C 2.6 456 44 68 370 458 1.58 4.5
157 -55 28 -54 107 0.5 2.2 0.2 1.2 935 37 90 476 1738 0.69 4.5
313 -64 1 -6 83 1.0 O.C 0.1 2.5 847 45 111 735 1410 1.27 4.5
73 -46 50 -41 197 0.8 0.0 0.1 3.5 769 65 227 699 1361 2.25 4.8
155 18 14.1 1.9 0.5 2.7 1394 29 73 499 1262 1 43 5
121 -57 89 -36 51 1.6 0.0 0.2 4.0 539 114 151 1168 1567 1 78
115 -46 48 -26 9.8 2.7 11.8 2.5 907 39 62 143 861 1.49 5
132 -71 64 -59 0.8 O.C 0.0 l.C 914 78 32 672 2374 2 53 5
166 -53 142 -40 32 0.8 1.4 0.2 2.2 1098 57 98 850 1271 1.25 5.2
182 -57 58 -44 85 0.7 O.fl 0.0 0.6 944 58 145 626 1625 1 40 5.3
207 -44 92 -12 154 14 16.^ 0.1 3.4 617 70 93 563 1123 1 37 5.5
231 -66 108 -56 0.7 118 0.3 1.4 629 55 127 451 1051 1 48 6
286 -67 174 -45 3.4 0.0 0.1 6.3 573 37 112 474 1237 2.00 6
214 -64 26 -3 130 1.7 0.0 0.2 1.2 663 40 89 868 776 0.96 6
265 -55 116 -29 55 2.5 0.0 0.0 6.6 807 48 117 183 461 1.25 6.5
122 -71 -69 341 0.7 0.0 0.2 1.5 1052 37 245 1024 2664 1.90 7
130 -48 39 -43 101 0.7 0.0 0.3 2.0 387 49 166 457 915 1.28 7
98 -67 38 -23 73 0.9 0.0 1.1 1.2 586 37 54 551 1269 1.16 7
314 -64 139 -46 114 O.C 0.0 9.9 0.7 915 48 93 192 981 0.63 7.2
432 -74 168 -51 172 0.8 5.6 0.3 2.7 955 43 114 624 1555 1.08 7.5
172 -49 75 -28 174 5.9 0.0 65.2 7.9 1077 33 143 193 1513 1.77 9
244 -43 123 -36 O.C 0.0 2.5 8.8 990 40 114 185 1237 1 56 1C
118 -53 13 -27 282 1.3 0.0 0.3 0.9 n/a 50 232 811 1187 1 2 '
252
Oedema
NEUTRO NEUT MONO MONO VEGF TNFal IL- IL-lb IL-6 sL- sE- sP- sICAM sVCA vWF
C D llb CD62L C D llb CD62L De/ml De/ml De/m De/ml De/ml ne/ml ne/ml ne/ml ne/ml ne/ml IlJ/ml edema
336 -54 204 -44 23 10.7 1.4 1.2 2.2 1726 42 59 601 1039 1.53 0
185 -51 37 -36 32 21.9 2.1 0.9 2.7 1805 36 102 596 1268 1.26 0
181 r  -4() 80 -18 146 0.7 0.0 18. (, 1.7 1097 43 138 168 1160 1.05 0
138 -53 73 -31 6.5 0.0 47.4 4.4 803 34 129 140 788 0.54 0
239 -95 81 -48 57 no 0.0 OO 2.5 860 93 5 193 1389 1.06 0
314 -64 -46 37 0.0 no 2' - 52,5 1064 35 181 187 920 0.88 0
314 -64 15') -46 114 on 0.0 9.9 0.7 915 48 93 192 981 0.63 0
. 184 - ^ 3 79 -38 162 1 0.0 5 4_ "I 1261 85 544 1770 0.83 0
118 -4S 46 -14 104 1.2 0.0 0.2 1.0 1089 69 119 917 2365 0.95 0
73 -46 50 -41 197 0.8 0.0 0.1 3.5 769 65 227 699 1361 3.2.5 0
164 -57 52 -40 151 2.3 0.0 0.1 1.1 628 27 138 1149 2236 1.33 0
199 -5! 112 86 on nn o 1 1.0 790 2o 126 682 1570 0.86 Q
203 -42 52 4" 0.0 0,0 1.0 620 7( 109 682 1673 1.41 0
222 -58 .35 o 1.1 3.8 o .2 1.2 723 71 108 703 1391 2.10 0
166 -53 142 -40 32 0.8 1.4 0.2 2.2 1098 57 98 850 1271 1.25 0
126 -54 44 -39 116 2.1 0.0 0.3 0.6 689 51 136 707 1551 2 on 0
130 -48 39 -43 101 0.7 0.0 0.3 2.0 387 49 166 457 915 1.28 0
185 -65 83 -62 185 (1.8 9.0 1.2 on 817 72 120 562 1271 1.96 0
145 -66 40 -46 113 0.8 0.0 0.1 1.4 1120 44 169 582 2111 2.^3 0
121 -57 89 -36 51 ( ' (M 0.2 4.0 539 114 151 1168 1567 1.78 0
268 -67 71 -30 120 1.7 0.0 0.3 2.0 443 28 96 387 1392 1.04 0
206 -48 11. -38 160 0.5 0.0 0.3 2 2 879 (,8 s 5'i 1142 0.96 0
144 -55 86 -46 56 1.2 0.0 0.2 1.3 747 84 90 „ J J 22 1174 1.43 0
93 -38 41 -33 63 1.7 0.0 0.4 2 6 508 38 429 470 1.20 0
171 -62 135 -51 357 no 0.0 0.2 2.8 607 24 148 445 0.96 0
139 -61 73 13 125 0.3 0.0 0.2 2.3 1162 34 91 537 1 506 1.77 0
275 -63 55 -60 27 0.7 0.0 0.2 2 3 636 26 on 488 1 352 1.33 0
200 -65 34 -25 29 0.0 0.0 88.8 2.0 1047 50 127 142 1218 0 5" 0
99 56 23 1 nn 5 6 799 08 109 217 1579 1.20 0
201 -62 76 -37 3.7 0.0 21.8 2.4 941 47 67 159 1258 1.28 0
115 -46 48 -26 9.8 2.6 i 1.8 2 5 007 39 62 861 1.49 0
256 -71 70 -43 77 0.1 0.8 0.9 n/a 1030 80 62 626 2787 1.48 0
234 -67 59 -38 106 0.3 0.0 0.1 1.1 603 51 106 539 1290 2.37 0
132 -71 64 -59 0.8 0 0 0 ( ! ' 914 "8 2r 1'" 2 ' ; 0
255 -76 87 -49 0.7 Q.0 0.1 1.2 776 55 94 623 1 3 1 1 0.68 0
79 1.9 OQ 0.2 3.1 651 38 142 ■9, 1066 1.47 0
208 -49 1 i n n - - 52 7- ' 2 - 83 470 1445 2.01 0
207 -61 70 -48 96 0.6 Q.0 0.0 0.9 1820 70 91 557 1497 0.86 0
227 83 -51 53 1.4 on 0 2 2.1 785 5 ! SO .vo 925 0.98 0
280 -57 (.1 -42 51 2.0 0.0 0.3 5.7 620 48 1 If, (,20 862 1.09 0
137 -59 90 -44 96 3.4 0.0 0.2 4.5 862 49 114 810 1916 1.48 0
125 ' 50 -33 63 1.6 0.3 3.2 740 70 8 1 nV so-; 1.29 0
140 -52 87 -43 104 0.7 0.0 0.2 1.7 861 18 75 389 1138 1.57 0
21 -84 5 -43 1.1 0.0 0.2 3.8 958 38 0 2 702 1591 1.26 0
79 -41 82 -8 59 0.7 0.0 o5 3.7 498 21 72 644 915 1.39 0
207 -44 92 -12 154 1.4 16,5 0.1 3.4 617 70 93 503 1 123 1 7-' 0
267 -57 145 -48 63 1.6 0.0 0.5 5.7 612 62 70 681 1192 1 =7 0
211 -55 100 -46 71 9.4 0.0 2.0 3.0 663 15 68 617 1234 1.29 0
101 -63 58 -40 49 0.0 0.0 0.2 1.0 746 54 81 408 649 0.96 0
206 -71 77 -33 105 0 2 m 0 3 _ 72 85 4o 88 837 1229 1.50 0
275 -72 12? -38 1.5 0.0 0.5 3.0 649 16 53 756 935 1.25 0
164 -67 107 -35 68 1.5 0 0 0.2 1.9 790 27 53 568 1478 1.1 i 0
214 -64 26 -3 130 1.7 Q.Q 0.2 1.2 663 40 89 868 776 0.96 0
16 -60 -66 38 12.4 1 9 0.5 3.1 1701 22 112 648 852 1.78 0.1
169 -48 5. -28 L4-4 .2 0 4S 7 .. on 180 455 1160 2.15 0.2
264 -47 132 -24 25 10.2 1.5 0.9 2.1 1441 34 78 550 7 7..; 1.52 0.3
120 54 40 45.0 3.3 22.7 6.8 1414 71 181 1157 1628 2.29 0.3
87 -62 215 -42 3.7 0 0 0.3 4.6 886 72 112 486 1011 1.72 0.3
142 -(,4 47 -40 52 11.8 1.5 1 .3 2.3 1347 5() 240 0,4 7 1170 1.92 0.4
79 -59 sd -31 82 50.2 1.2 150.0 4.5 IV o 74 86 200 1981 1.30 0.5
247 -54 142 -43 31 15.3 1.9 65.3 3.2 1303 19 121 580 858 2.00 0.6
205 -56 39 -37 76 84.2 0.0 176.1 3.0 1201 76 146 180 1207 0.78 0.7
188 -17 86 -3 20.0 1.3 0.9 3.0 1757 52 146 (,07 1701 0.8
258 -59 127 -44 25 14.0 1,7 0.3 7.8 1632 16 60 605 929 1.31 1
261 -63 93 -31 25 9.0 1.8 0.4 1.5 1379 28 80 390 9 1 1 1.55 1
67 -45 13 -28 28 0.6 0.0 o 1 1.0 ..... - 94 123 O50 1089 1.16 1
131 54 21.3 3-3 166.8 3.7 1580 44 1 1 7 469 925 1.29 1
173 72 14.6 2.3 0.4 3.5 1 ISO no 247 776 108.7 1 1
171 -59 7< - 2 4 791 4 8 n n 75 4 3.2 882 40 157 148 904 0.96 1
229 -64 177 -41 33 3.8 0.0 0 1 2.7 848 24 5i 80S 30 14 1 In 1
118 -53 15 -27 282 1.3 0.0 0.3 0.9 n/a 50 232 811 1187 1.25 1.5
93 -59 7 -22 25 2.0 0.0 0.3 3.0 1055 18 58 408 823 1.44 1.5
299 -64 16' . -42 120 1.3 0.0 0.3 2.2 653 39 1 IV 457 1280 ,  :s 1.5
216 -70 54 -44 111 1.0 nn 0.0 1.7 OD3 52 138 O0( 1477 1.89 1.5
256. -5') 66 - 2 4 85 4( 0.0 ( - 3 2.2 758 4, !2o 645 1720 1.25 1.5
147 _ _._z05 ?■ . -44 1 v 00 >'’ 7 4 8 558 2 0 n/a 760 1375 2.01 1.5
253
151 -69 37 -42 46 0.8 0.0 0.2 1.4 760 34 80 563 821 0.72 1.5
301 -61 55 126 0.5 0.0 0.1 2.6 1068 55 68 510 1660 1.49 2
366 -57 191 4 0 MM 07 ' 141 7 2.3 1020 23 37 136 877 0.90 2
153 -65 2.7 0 . 9 0 . 0 0.1 6.1 635 36 94 597 1546 1.27 2
231 _ . . -4 2.3 0 0 0.0 1.0 604 45 100 337 404 1.28 2
323 -57 160 -12 761 l.i 4 1 0.3 1 9 7 7 9 - 129 775 1163 2
218 -61 7S ’ 88 1.2 0.0 0.7 5.7 665 30 86 646 1088 1.62 2
941 53 -41 36 6 7 1.2 2.9 2.5 1869 61 129 914 1435 1.53 2.1
265 ________22 3 . -26 55 2 7 0.0 6.6 807 48 117 183 461 1.2,5 2.4
270 -58 80 -29 3.2 0.0 2.5 4.2 649 56 123 442 741 1.05 2.5
293 . -65 M2. '■ 35 i 0.0 0.4 3.3 824 36 95 729 1333 0.69 2.5
246 -66 12' - -3f 64 , 0.0 0 1 13 9 770 49 94 456 458 2.07 2.5
162 -60 35 -45 234 14.2 0.0 13.7 2.7 1057 34 192 140 1095 1.00 2.6
134 -69 64l_.. - 4 : 29 1 4 v 1 4 0. 5 2 I66S 52 327 648 1543 9 24 2.7
221 - 55 1 -28 13.7 1.7 0.4 2.0 1766 24 106 521 1394 1.46 3
258 -45 • - 2 < 29 16.5 2.2 1.6 3.6 1088 12 112 454 1040 2.22 3
217 -5( 139 -40 124 0.9 0.0 0.3 1.9 537 51 51 476 1165 1.34 3
323 -65 ni -2 1 118 2.4 0.0 0.2 2.4 1203 41 89 631 2379 0.89 3
350 -64 7 2 -4 7 151 0. 7 7 1 0.1 3.0 1919 45 123 759 i n n . 1.25 3
120 -4. 32 -4 64 13.3 1-7 0.4 3.0 1329 56 270 1190 2.43 3.5
313 -64 1 -6 83 1.0 0.0 0.1 2.5 847 45 111 735 1410 1.27 4
140 -61 4f .. -45 M 0 1. (). 1 4 0 21 1087 15 65 58 1398 0.82 4.5
401 - I -52 118 0.3 0.0 0.0 4.2 896 39 64 606 1528 1.99 4.5
155 1 2 14.1 1.6 0. 5 2.7 1394 29 73 499 1262 1.43 5
273 -55 . _  . 4 7 ■27, 4 ' 0 0 2.7 ^  0.1 1.5 1013 50 88 713 1144 1.22 5
432 ■ T4 I 68 -51 r ? 0.8 5-6 0.3 2.7 955 43 114 624 1555 1.08 5
219 -7i. m -22 22.7 0.0 0.2 1.3 765 28 150 743 2069 0.9Q 5
197 36 68 -19 284 0.0 0.0 2.3 2.5 522 57 125 172 887 0.54 5
231 -66 IDS - 5 6 0. 7 11.8 0.3 1.4 629 55 127 451 1051 1.48 5
213 -48 16.7 2.4 14.9 0. 3 2.7 988 30 97 576 1477 1.66 5
158L ■ ' -62 239 2.6 14.2 0.3 2.1 730 69 116 517 2168 1.02 5
155 -59 n ; -7 7 ''4 46.(1 1.0 4 0 3  0 873 64 139 168 1205 0-51 5.2
182 -57 58 -44 85 0.7 0-0 0.0 0.6 944 58 145 626 1625 1.40 5.4
182 114 -32 120 2.3 0 0 0.0 2.6 456 44 68 370 458 1.58 5.5
559 7 21 0 0 0 0 0 2 1.8 728 23 115 372 825 1.61 5.5
172 -56 47 -44 57 1.1 0.0 0.1 1.3 867 42 79 485 1240 1.26 5.5
79 -55 5:> 47 4 ; 0  0 r- ! i 1 2 718 24 115 408 583 1.08 5.5
101 21 -13 147 0.0 O.o 0.3 1.0 641 35 145 545 1075 1.42 6
207 -63 65 -30 111 1.3 0 0 0.3 6.4 820 39 90 550 1223 1.20 6
286 -67 174 -45 3.4 0.0 ■ 6.3 573 37 112 474 1237 2.00 6
90 -66 73 -58 183 1.9 0 0 0.4 2.0 746 42 92 592 1774 202 6
180 v1 i ii - 4 0 115 1.6 0.0 0.0 1.4 794 60 160 327 536 0.86 6.5
122 -7 1 -69 341 0.7 0.0 0.2 1.5 1052 37 245 1024 2664 1.90 6.5
230 2 105 -55 170 1.7 0 0 0.2 4.9 1055 35 131 1030 2080 1.70 6.5
230 -L i 11- : 142 1.5 0 0 0.4 4.9 893 35 147 519 92^ 0.67 7
98 _ . 2 7 7 7 7 73 0.9 0.0 1.1 1.2 586 37 54 551 1269 1.16 7
241 -75 i 2i -5 5 . 161 6 7' 0 0 0.1 0.9 1056 72 104 630 1847 1.38 7
187 -56 - 23 123 3.5 O.o 0.2 61.0 646 42 81 746 1187 1-90 7
172 -29 88 -24 14.8 14 2.4 3.5 2169 102 180 1821 2377 2.39 7.5
259 5 5 177 1.9 0.0 29.5 5.3 974 69 99 194 1114 1.03 7.5
172 72 . .22 7 7 174 M 6 n o 65 . 2 7.9 1077 33 143 193 1513 1.77 7.5
301 .. -22 ; s -41 34 2 2 0.0 0.1 3.6 609 106 97 868 3626 2.5Q 8
189 -66 . . . . .64 . - 5 6 1 70 : 7 0 0 0.1 1.2 820 45 84 555 1054 1.10 8
239 - 52 174 -32 106 1.1 0.0 0.5 1.2 717 47 148 615 2400 2.16 8.5
244 i 2 : 5 6 0. 0 0 . 0 2.5 8.8 990 40 114 185 1237 1-50 9
. 157 -55 28 . -54 . .. 107 0.5 2.2 0.2 1.2 .. . ‘235 ■- 99 476 9 l).(,9
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a
1001 264 -47 132 -24 25 10.2 1.5 0.9 2.1 1441 34 78 550 754 1.32 0.1 1.4 1 0.3 0.3
1003 94 -46 52 -41 39 9.7 1.2 2.9 2-5 1869 61 129 914 1435 1,53 3.4 3 2.8 0 2.1
1005 247 -54 142 -43 31 15.3 1.9 65.3 3.2 1303 19 121 580 858 2.00 Q.7 2.4 0,3 0.2 0.6
1007 142 -04 47 -40 52 11.8 1.5 1.3 2.3 1347 39 24Q 643 1170 1.92 0,1 0.9 0 3 0.3 0.4
1008 261 -63 93 -51 25 9,0 1 8 0.4 1,5 1379 28 80 396 911 1,55 3 3 2 0.2 1,6 1
1009 221 -55 96 -28 13.7 17 0.4 2.0 1766 24 106 521 1394 1.46 3.3 5.1 4 0.1 3
1010 258 -44 51 -20 29 16.5 2.2 1.6 3.6 1088 12 M2 454 104Q 2 22 4.5 4.9 1.6 1.4 3
1012 265 - 1 10 -29 55 2M 0.0 0.0 6.6 807 48 117 183 461 1.25 2.5 4 0.5 6.5 2.4
1016 138 -53 73 -31 6,5 0.0 47.4 4.4 803 34 129 146 788 0.54 8 7 0 0 0
1018 155 -59 93 -53 34 36-0 1.0 403.0 2.5 873 64 139 168 1205 0.51 5 0 0 0.3 5.2
1019 314 -64 139 -46 37 0.0 0.0 7557 3.5 1064 35 181 187 920 0.88 0 6.4 4.2 0
1020 <14 -04 139 -46 114 0.0 0.0 9.9 0.7 915 48 93 192 981 0.63 5 7 9.8 7.2 0
1021 1 44 -40 7‘> -3 8 162 7.1 0.0 5.4 0.1 1261 70 85 544 1770 0.83 3 4 0 0 0
1023 140 -61 46 -45 60 0,0 0.0 14.0 2.0 1087 15 65 58 1.398 0.82 5.4 4.3 0 1-5 4.5
1024 182 114 -32 120 2.3 0(1 i i d 2M 480 44 OK 370 458 1,58 5 4.5 4 7 5.5
1026 180 -52 101 -40 115 1.6 0.0 0.0 1.4 794 60 160 327 536 0.86 0 0 0 0 6.5
1027 12? -71 -69 341 0,7 0.0 0.2 1,5 1052 37 245 1034 2664 1.90 6 9 8.5 7 6,5
1028 - 40 -14 104 1.2 OO 0.2 1.0 0)59 09 1 19 917 2365 0.95 3 3.5 4 3.5 0
1029 301 '5 78 -41 <4 2.2 0 0 0.1 ono 1Q6 97 SOS «M(, 2.5D 0 6 9 0 8
1030 7 3 -4(, 50 -41 197 0.8 0.0 0.1 3,5 769 65 227 699 1361 2.25 0 4 0.2 4.8 0
1031 142 - 58 -44 85 0 7 0 0 0.0 0 0 944 8 5 145 02 6 1625 1.40 7,5 7.6 7.6 5 ' 5.4
1032 118 -53 15 -27 282 1.3 0.0 0.3 0.9 n/a 50 232 811 1187 1.25 1.8 1.8 5 1.5
1054 - -5! ! ■ ■' 4 ,, ().(, 0 0 " I M 7 911 26 l 3o 157.) 0.86 7 7 5 0 ’ 0
1035 203 -60 93 -42 52 0.7 0.0 0.0 1.0 620 26 109 68? 1673 1.41 1.8 10 0 0
1036 222 101 '5 39 ; 38 0.2 1-2 7 2 ' 71 - -o< 1391 2.10 5.5 7.5 1 2 0 0
1037 -53 142 -40 32 0-8 1-4 0.2 2.2 1098 57 98 850 1271 1.25 0 1 0 5.2 0
1039 67 -45 13 -28 28 0.6 0.0 0.1 1.0 1069 94 123 630 1089 1.16 5 4 4 2-5 1
1040 126 -44 44 -20 116 2.1 0.0 0.3 0.6 689 51 136 707 1551 2.06 0 0 0 0 0
1041 130 -44 39 -43 101 0-7 0 0 0,3 2 0 387 49 166 457 915 128 6-5 5 6-5 7 0
1042 185 -65 83 -6? 185 0.8 9.0 1-2 0.9 817 72 120 ,562 1271 1.96 5 5 5 0 0
1043 144 -66 40 -46 113 0.8 0 0 0.1 1-4 1120 44 169 582 2111 2-53 5 8 0 2 0
1044 230 104 -55 170 1.7 0.0 0.2 4.9 1055 35 131 1030 2Q80 1.70 5 0 2.5 0 6.5
1040 432 -74 168 -51 172 0.8 5.6 0.3 2.7 955 43 114 624 1555 1.08 5 3-5 0 7.5 5
1048 204 71 -3 0 120 1.7 0.0 0.3 2.(1 443 28 96 387 1392 1.04 2 0 3 0 0
1049 93 -59 7 -22 25 2,0 0 0 0,3 3,0 1055 18 58 408 823 1.44 7 0 8 0 1,5
1050 200 -44 Ml -38 160 0.5 0.0 0.3 2,3 879 65 70 531 1142 0 9 6 0 3.5 4 0 0
10,51 559 -77 575 -80 21 0.0 0.0 0.2 1.8 728 23 115 372 825 1.61 0 5 0 0 5-5
1054 v " 28 -54 107 0,5 22 0.2 1.2 935 37 90 476 1738 0-69 0-5 0 4.5
1055 401 -69 151 -52 118 0-3 0 0 0.0 4.2 896 39 64 606 1528 1.99 5 5 1.2 0 4.5
1056 <01 -01 m -55 126 0,5 0.0 0.1 2.6 1068 55 68 510 1660 1.49 3-5 2.5 3-5 0 2
1057 1 71 -03 135 -51 357 0 0 0 0 0.2 2 8 607 24 148 445 774 0-96 2 0 3.5 0 0
1059 2<o -44 ] i 11 — 142 : " (1.0 0 4 4.9 5 9 ; 35 147 519 929 0.67 0 5 4 0 7
1061 1 30 -61 73 13 125 0.3 0.0 0.2 2-3 1162 34 91 537 1566 1.77 4.4 4 7 0 0
1062 210 - o 35 -22 22< : (1.0 0,2 1.3 705 38 150 747 2069 0,90 3 0 0 5
1063 275 -63 55 -60 27 Q.7 0.0 0-2 2-3 636 26 69 488 1352 1.33 0 0 0 0 0
1064 325 ■0 - 60 -21 118 2.4 0 0 0.2 2-4 1203 41 89 631 2379 0.89 0 0 0 0 3
1063 98 -67 38 -23 73 0,9 0 0 1-1 1,2 586 37 54 551 1269 1.16 8 5 7 7 7
1066 207 -63 65 -3(1 111 1.3 0.0 0.3 6.4 820 39 90 550 1223 1.20 3-4 0 1.4 0 6
medi , (,2 -59 78 -40 106 1.16 ft ft 2 915 39 115 550 1311 1 3.4 3.5 1.5 0.0 1.0
Utl 202 -53 113 -29 120 2 1 1 3 10 ,SO 57 141 OS 2 1584 2 5.0 5.0 4.0 3.9 $.0
lq 140 -04 49 10 37 1 0 ft 1 767 25 so 4 70 927 ! <1.1 0.8 0.0 0.0 0.0
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39 185 -51 37 -36 32 21.9 2.1 0.9 2.7 1805 36 102 596 1268 1.26 0.6 2.6 0 0.7 0
53 258 -59 127 -44 25 14.0 1.7 0.3 7.8 1632 16 60 605 929 1.31 6.3 8.2 6.9 0.5 1
63 155 18 14.1 1.9 0.5 2.7 1394 29 73 499 1262 1.43 8.1 4.8 3 5 5
45 205 -56 39 -37 76 84.2 0.0
176.
1 3.0 1201 76 146 180 1263 0.78 1.3 0.3 8.4 0.5 0.7
77 181 -49 80 -18 140 0.7 0.0 18.6 1.7 1097 43 138 168 1160 1.05 0 0 0 0 0
66 239 -65 81 -48 57 0.0 0.0 0.0 2.5 860 93 75 193 1389 1.06 5 5.3 3.1 2.5 0
71 79 -59 50 -31 82 50.2 1.2
150.
0 4.5 1533 74 86 200 1981 1.30 4.5 3.5 4.8 0 0.5
63 239 -52 174 -32 106 1.1 0.0 0.5 1.2 717 47 148 615 2400 2.16 5.5 0 0 8.5
53 164 -57 52 -40 151 2.3 0.0 0.1 1.1 628 27 138 1149 2236 1.33 0 0 7 3 0
57 101 -53 21 -13 147 0.0 0.0 0.3 1.0 641 35 145 545 1075 1.42 5 0 0 6
52 121 -57 89 -36 51 1.6 0.0 0.2 4.0 539 114 151 1168 1567 1.78 7 6.5 7 5 0
41 144 -55 86 -45 56 1.2 0.0 0.2 1.3 747 84 96 437 1174 1.43 0 1.5 0 0 0
70 93 -38 41 -33 63 1.7 0.0 0.4 2.7 508 38 113 429 470 1.20 2 2 7 0 0
49 217 -56 139 -40 124 0.9 0.0 0.3 1.9 537 51 51 476 1165 1.34 3.2 2 8 0 3
63 299 -64 153 -42 120 1.3 0.0 0.3 2.2 653 39 118 455 1289 2.18 3 0 4 0 1.5
n
Me
dia
n 57 181 -56 80 -37 79 1.6 0.0 0.3 2.5 747 43 113 476 1263 1 3.1 2.0 4.4 0.0 0.5
iQ 65 228 -52 108 -32 123 14.1 0.6 0.7 2.9 1298 75 142 600 1478 1 5.4 4.9 7.0 1.6 2.3
LQ 51 132 -59 40 -41 56 1.0 0.0 0.3 1.5 635 35 80 315 1162 1 0.8 0.2 0.8 0.0 0.0
256
C4/C5 SVI
age NEU NEU MONO MONO VEG TNFa IL -la IL -lb IL-6 sL- sE- sP slC sVCA vW symptoms: cm
CD11 CD62 C D llb CD62L pg/ml pg/ml pg/ml pg/ml Pg/ ng/ ng/ ng/ ng/ ng/ml IU/ pain heavi era pare ede
1
59 172 -29 88 -24 14.8 1.4 2.4 3.5 216 102 18 182 2377 2.39 3 6 0 0 8
67 120 -46 32 -4 64 13.3 1.7 0.4 3.0 132 56 27 753 1190 2.43 1 1 10 1 4
42 173 72 14.6 2.3 0.4 3.5 118 69 24 776 1085 1.25 1 0 2 2 1
51 200 -65 34 -25 29 0.0 0.0 88.8 2.0 104 50 12 142 1218 0.57 4 8 9 0 0
60 197 -39 68 -19 284 0.0 0.0 2.3 2.5 522 57 12 172 887 0.54 0 7 0 3 5
74 99 56 23.1 0.0 5.6 2.8 799 68 10 215 1579 1.20 0 0 5 0 0
27 366 -57 191 -50 40 31.9 0.7 1417. 2.3 102 23 37 136 877 0.90 0 0 0 0 2
52 259 -59 79 -35 177 1.9 0.0 29.5 5.3 974 69 99 194 1114 1.03 10 4 10 4 8
53 172 -49 75 -28 174 5.9 0.0 65.2 7.9 107 33 14 193 1513 1.77 7 10 4 9 8
43 115 -46 48 -26 9.8 2.7 11.8 2.5 907 39 62 143 861 1.49 10 5 7 5 0
64 256 -71 70 -43 77 0.1 0.8 0.9 n/a 103 80 62 626 2787 1.48 5 0 4 0 0
61 216 -70 54 -44 111 1.0 0.0 0.0 1.7 903 32 13 666 1477 1.89 3 0 0 3 2
72 255 -76 87 -49 0.7 0.0 0.1 1.2 776 55 94 623 1311 0.68 3 0 5 0 0
60 79 1.9 0.0 0.2 3.1 651 38 14 796 1066 1.47 0 0 3 0 0
67 256 -59 66 -29 85 0.6 0.0 0.3 2.2 738 46 12 645 1720 1.25 5 5 9 1 2
67 208 -68 79 -49 1.3 0.0 0.0 1.5 820 51 83 470 1445 2.01 0 0 1 0 0
41 313 -64 1 -6 83 1.0 0.0 0.1 2.5 847 45 11 735 1410 1.27 0 5 10 5 4
46 323 -57 160 -40 79 1.1 0.0 0.3 1.9 779 57 12 775 1163 0.59 0 0 10 0 2
44 227 -70 83 -51 53 1.4 0.0 0.2 2.1 785 31 89 539 925 0.98 2 2 7 0 0
49 280 -57 61 -42 51 2.0 0.0 0.3 5.7 620 48 11 626 862 1.09 2 1 2 0 0
44 79 -55 59 -40 47 4.1 0.0 1.8 1.2 718 24 11 408 583 1.08 0 5 7 0 6
64 137 -59 90 -44 96 3.4 0.0 0.2 4.5 862 49 11 810 1916 1.48 0 0 0 0 0
68 293 -65 112 -37 35 1.5 0.0 0.4 3.3 824 36 95 729 1333 0.69 0 0 0 4 3
54 125 -65 50 -33 63 1.6 2.2 0.3 3.2 740 79 81 679 804 1.29 0 0 3 0 0
45 140 -52 87 -43 104 0.7 0.0 0.2 1.7 861 18 75 389 1138 1.57 0 3 0 0 0
53 213 -67 96 -48 165 2.4 14.9 0.3 2.7 988 30 97 576 1477 1.66 0 0 0 0 5
48 246 -66 129 -30 64 4.0 0.0 0.1 13.9 770 49 94 456 458 2.07 0 9 5 0 3
66 229 -64 177 -41 33 3.8 0.0 0.1 2.7 848 24 51 868 3614 1.18 0 0 0 0 1
76 90 -66 73 -58 183 1.9 0.0 0.4 2.0 746 42 92 592 1774 2.02 0 0 1 0 6
72 211 -55 100 -46 71 9.4 0.0 2.0 3.0 663 15 68 617 1234 1.29 0 0 7 0 0
41 101 -63 58 -40 49 0.0 0.0 0.2 1.0 746 34 81 408 649 0.96 5 9 0 0 0
54 158 -62 79 -62 239 2.6 14.2 0.3 2.1 730 69 11 517 2168 1.02 0 5 3 0 5
49 275 -72 122 -38 1.5 0.0 0.5 3.0 649 16 53 756 935 1.25 2 3 5 0 0
44 151 -69 37 -42 46 0.8 0.0 0.2 1.4 760 34 80 563 821 0.72 0 0 0 2 2
Med 54 208 -63 75 -40 77 1.9 0.0 0.3 2.5 809 46 98 604 1204 1 0.0 0.6 3.0 0.0 1.3
UQ 66 256 -56 90 -30 107 4.1 0.5 1.9 3.2 957 56 12 734 1504 2 3.0 5.0 6.9 1.8 3.9
LQ 45 140 -66 58 -45 50 1.0 0.0 0.2 2.0 741 32 81 408 896 1 0.0 0.0 0.0 0.0 0.0
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78 188 -17 86 -3 20.0 1.3 0.9 3.0 1757 32 146 697 1701 2.29 5.1 0.5 0.6 0.7 0.8
56 120 54 40 45.0 3.3 22.7 6.8 1414 71 181 1157 1628 2.29 0.2 1.7 6.4 4.4 0.3
38 131 54 21.3 3.3
166.
8 3.7 1580 44 113 469 925 1.29 5 2.7 4.4 0.1 1
65 169 -48 31 -28 15.9 2.0 0.8 3.1 1145 50 180 455 1160 2.15 0.5 0.2 0.2 0.2 0.2
55 162 -60 35 -45 234 14.2 0.0 13.7 2.7 1057 34 192 140 1095 1.00 0.5 4 9.7 4 2.6
80 270 -58 80 -29 3.2 0.0 2.5 4.2 649 56 123 442 741 1.05 0 0 3.5 3.5 2.5
69 171 -59 70 -24 791 4.8 0.0 75.4 3.2 852 40 155 148 904 0.96 0.7 0 6.2 1 1
75 201 -62 76 -37 3.7 0.0 21.8 2.4 941 47 67 159 1258 1.28 0 0 0 0 0
53 244 -43 123 -36 0.0 0.0 2.5 8.8 990 40 114 185 1237 1.56 8.8 1 10 10 9
69 234 -67 59 -38 106 0.3 0.0 0.1 1.1 603 51 106 539 1290 2.37 0 0 0 0 0
22 132 -71 64 -59 0.8 0.0 0.0 1.0 914 78 32 672 2374 2.53 8 8.4 9 5 0
64 241 -75 114 -55 161 0.7 0.0 0.1 0.9 1056 72 104 630 1847 1.38 0 7.5 10 0 7
65 172 -56 47 -44 57 1.1 0.0 0.1 1.3 867 42 79 485 1240 1.26 3 5.4 8.5 0.5 5.5
65 231 -49 109 -4 2.3 0.0 0.0 1.0 604 45 100 337 404 1.28 5 0 0 1.5 2
70 147 -65 23 -44 1.8 0.0 0.2 4.8 558 20 n/a 760 1375 2.01 3 0 5 0 1.5
48 350 -64 52 -45 150 0.7 5.1 0.1 3.0 1919 45 123 759 1519 1.25 0 0 0 0 3
54 125 -65 50 -33 63 1.6 2.2 0.3 3.2 740 79 81 679 804 1.29 0 0 3 0 0
73 21 -84 5 -43 1.1 0.0 0.2 3.8 958 38 92 702 1591 1.26 0 5 6 0 0
72 286 -67 174 -45 3.4 0.0 0.1 6.3 573 37 112 474 1237 2.00 0 0 5.5 6 6
64 79 -41 52 -8 59 0.7 0.0 0.3 3.7 498 21 72 644 915 1.39 0 0 1.5 0 0
29 189 -66 64 -56 170 1.5 0.0 0.1 1.2 820 45 84 555 1054 1.10 0 0 0 0 8
64 207 -44 92 -12 154 1.4 16.5 0.1 3.4 617 70 93 563 1123 1.37 5 5 8.5 5.5 0
71 267 -57 145 -48 63 1.6 0.0 0.5 5.7 612 62 70 681 1192 1.37 0 0 0 0 0
40 206 -71 77 -33 105 0.2 8.9 0.3 3.2 830 46 88 837 1229 1.50 0 0 0 0 0
49 218 -60 78 -39 88 1.2 0.0 0.7 5.7 665 30 86 646 1088 1.62 0 0 0 0 2
39 164 -67 107 -35 68 1.5 0.0 0.2 1.9 790 27 53 568 1478 1.11 0 0 0 0 0
39 214 -64 26 -3 130 1.7 0.0 0.2 1.2 663 40 89 868 776 0.96 1.3 0 0 6 0
Medi
an 64 189 -62 64 -37 106 2 0 0 3 830 45 96 568 1229 1 0.0 0.0 3.0 0.1 0.8
UQ 70 232 -56 89 -28 156 4 2 2 4 1023 54 121 689 1427 2 3.0 2.2 6.3 3.8 2.6
LQ 49 155 -67 51 -45 63 1 0 0 2 633 37 82 462 989 1 0.0 0.0 0.0 0.0 0.0
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40 336 -54 204 -44 23 10.7 1.4 1.2 2.2
172
6 42 59 601
103
9 1.53 2.1 0 0 0.5 0
50 94 -46 52 -41 39 9.7 1.2 2.9 2.5
186
9 61 129 914
143
5 1.53 3.4 3 2.8 0 2.1
53 258 -59 127 -44 25 14.0 1.7 0.3 7.8
163
2 16 60 605 929 1.31 6.3 8.2 6.9 0.5 1
75 142 -64 47 -40 52 11.8 1.5 1.3 2.3
134
7 39 240 643
117
0 1.92 0.1 0.9 0.3 0.3 0.4
67 221 -55 96 -28 13.7 1.7 0.4 2.0
176
6 24 106 521
139
4 1.46 3.3 5.1 4 0.1 3
54 258 -45 51 -26 29 16.5 2.2 1.6 3.6
108
8 12 112 454
104
0 2.22 4.5 4.9 1.6 1.4 3
33 265 -55 116 -29 55 2.5 0.0 0.0 6.6 807 48 117 183 461 1.25 2.5 4 0.5 6.5 2.4
48 16 -60 -66 38 12.4 1.9 0.5 3.1
170
1 22 112 648 852 1.78 2.5 0.2 2.4 0.3 0.1
77 181 -49 80 -18 140 0.7 0.0 18.6 1.7
109
7 43 138 168
116
0 1.05 0 0 0 0 0
71 155 -59 93 -53 34 36.0 1.0
403.
0 2.5 873 64 139 168
120
5 0.51 5 0 0 0.3 5.2
51 314 -64 139 -46 37 0.0 0.0
255.
7 3.5
106
4 35 181 187 920 0.88 0 6.4 4.2 0
27 184 -59 79 -38 162 7.1 0.0 5.4 0.1
126
1 70 85 544
177
0 0.83 3 4 0 0 0
55 140 -61 46 -45 60 0.0 0.0 14.0 2.0
108
7 15 65 58
139
8 0.82 5.4 4.3 0 1.5 4.5
41 180 -52 101 -40 115 1.6 0.0 0.0 1.4 794 60 160 327 536 0.86 0 0 0 0 6.5
40 122 -71 -69 341 0.7 0.0 0.2 1.5
105
2 37 245 1024
266
4 1.90 6 9 8.5 7 6.5
19 118 -48 46 -14 104 1.2 0.0 0.2 1.0
108
9 69 119 917
236
5 0.95 3 3.5 4 3.5 0
70 301 -63 78 -41 34 2.2 0.0 0.1 3.6 609 106 97 868
362
6 2.50 0 6 9 0 8
56 73 -46 50 -41 197 0.8 0.0 0.1 3.5 769 65 227 699
136
1 2.25 0 4 0.2 4.8 0
50 118 -53 15 -27 282 1.3 0.0 0.3 0.9 n/a 50 232 811
118
7 1.25 1.8 1.8 5 1.5
53 164 -57 52 -40 151 2.3 0.0 0.1 1.1 628 27 138 1149
223
6 1.33 0 0 7 3 0
22 199 -51 112 -37 86 0.6 0.0 0.1 1.0 790 26 126 682
157
0 0.86 7 7.5 0 0 0
59 222 -58 101 -35 39 1.1 3.8 0.2 1.2 723 71 108 703
139
1 2.10 5.5 7.5 1.2 0 0
29 166 -53 142 -40 32 0.8 1.4 0.2 2.2
109
8 57 98 850
127
1 1.25 0 1 0 5.2 0
65 130 -48 39 -43 101 0.7 0.0 0.3 2.0 387 49 166 457 915 1.28 6.5 5 6.5 7 0
50 145 -66 40 -46 113 0.8 0.0 0.1 1.4
112
0 44 169 582
211
1 2.53 5 8 0 2 0
53 432 -74 168 -51 172 0.8 5.6 0.3 2.7 955 43 114 624
155
5 1.08 5 3.5 0 7.5 5
52 121 -57 89 -36 51 1.6 0.0 0.2 4.0 539 114 151 1168
156
7 1.78 7 6.5 7 5 0
51 93 -59 7 -22 25 2.0 0.0 0.3 3.0
105
5 18 58 408 823 1.44 7 0 8 0 1.5
41 144 -55 86 -45 56 1.2 0.0 0.2 1.3 747 84 96 437
117
4 1.43 0 1.5 0 0 0
70 93 -38 41 -33 63 1.7 0.0 0.4 2.7 508 38 113 429 470 1.20 2 2 7 0 0
56 171 -62 135 -51 357 0.0 0.0 0.2 2.8 607 24 148 445 774 0.96 2 0 3.5 0 0
259
49 217 -56 139 -40 124 0.9 0.0 0.3 1.9 537 51 51 476
116
5 1.34 3.2 2 8 0 3
26 230 -44 119 -37 142 1.5 0.0 0.4 4.9 893 35 147 519 929 0.67 0 5 4 0 7
63 299 -64 153 -42 120 1.3 0.0 0.3 2.2 653 39 118 455
128
9 2.18 3 0 4 0 1.5
49 139 -61 73 13 125 0.3 0.0 0.2 2.3
116
2 34 91 537
156
6 1.77 4.4 4 7 0 0
61 275 -63 55 -60 27 0.7 0.0 0.2 2.3 636 26 69 488
135
2 1.33 0 0 0 0 0
48 207 -63 65 -30 111 1.3 0.0 0.3 6.4 820 39 90 550
122
3 1.20 3.4 0 1.4 0 6
11 37
Media
n 51 171 -57 80 -40 75 1.3 0.0 0.3 2.3 924 42 117 544
122
3 1.3 3.0 3.0 2.4 0.2 0.1
UQ 59 230 -52 117 -33 129 2.5 1.2 0.5 3.1
110
4 60 148 699
155
5 1.8 5.0 5.0 6.5 3.1 3.0
LQ 41 130 -62 51 -45 37 0.8 0.0 0.2 1.5 706 27 96 445 929 1.1 0.1 0.0 0.0 0.0 0.0
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49 264 -47 132 -24 25 10.2 1.5 0.9 2.1 1441 34 78 550 754 1.32 0.1 1.4 1 0.3 0.3
39 185 -51 37 -36 32 21.9 2.1 0.9 2.7 1805 36 102 596 1268 1.26 0.6 2.6 0 0.7 0
51 247 -54 142 -43 31 15.3 1.9 65.3 3.2 1303 19 121 580 858 2.00 0.7 2.4 0.3 0.2 0.6
55 261 -63 93 -31 25 9.0 1.8 0.4 1.5 1379 28 80 396 911 1.55 3 3.2 0.2 1.6 1
63 155 18 14.1 1.9 0.5 2.7 1394 29 73 499 1262 1.43 8.1 4.8 3 5 5
45 205 -56 39 -37 76 84.2 0.0 176.1 3.0 1201 76 146 180 1263 0.78 1.3 0.3
8.4 0.5 0.7
61 138 -53 73 -31 6.5 0.0 47.4 4.4 803 34 129 146 788 0.54 8 7 0 0 0
66 239 -65 81 -48 57 0.0 0.0 0.0 2.5 860 93 75 193 1389 1.06 5 5.3 3.1 2.5 0
41 314 -64 139 -46 114 0.0 0.0 9.9 0.7 915 48 93 192 981 0.63 5 7 9.8 7.2 0
71 79 -59 50 -31 82 50.2 1.2 150.0 4.5 1533
74 86 200 1981 1.30 4.5 3.5 4.8 0 0.5
39 182 114 -32 120 2.3 0.0 0.0 2.6 456 44 68 370 458 1.58 5 4.5 4.5 5.5
63 239 -52 174 -32 106 1.1 0.0 0.5 1.2 717 47 148 615 2400 2.16 5.5 0 0 8.5
52 182 -57 58 -44 85 0.7 0.0 0.0 0.6 944 58 145 626 1625 1.40 7.5 7.6 7.6 5.3 5.4
55 203 -60 93 -42 52 0.7 0.0 0.0 1.0 620 26 109 682 1673 1.41 1.8 10 0 0
53 273 -55 148 -27 47 0.9 2.7 0.1 1.5 1013 50 88 713 1144 1.22 5 3.5 0 0 5
45 67 -45 13 -28 28 0.6 0.0 0.1 1.0 1069 94 123 630 1089 1.16 5 4 4 2.5 1
69 126 -54 44 -39 116 2.1 0.0 0.3 0.6 689 51 136 707 1551 2.06 0 0 0 0 0
59 185 -65 83 -62 185 0.8 9.0 1.2 0.9 817 72 120 562 1271 1.96 5 5 5 0 0
59 230 -62 105 -55 170 1.7 0.0 0.2 4.9 1055 35 131 1030 2080 1.70 5 0 2.5 0 6.5
57 101 -53 21 -13 147 0.0 0.0 0.3 1.0 641 35 145 545 1075 1.42 5 0 0 6
56 268 -67 71 -30 120 1.7 0.0 0.3 2.0 443 28 96 387 1392 1.04 2 0 3 0 0
61 206 -48 111 -38 160 0.5 0.0 0.3 2.3 879 65 70 531 1142 0.96 0 3.5 4 0 0
41 559 -77 575 -80 21 0.0 0.0 0.2 1.8 728 23 115 372 825 1.61 0 5 0 0 5.5
39 157 -55 28 -54 107 0.5 2.2 0.2 1.2 935 37 90 476 1738 0.69 0.5 0 4.5
56 401 -69 151 -52 118 0.3 0.0 0.0 4.2 896 39 64 606 1528 1.99 5 5 1.2 0 4.5
33 301 -61 55 -55 126 0.5 0.0 0.1 2.6 1068 55 68 510 1660 1.49 3.5 2.5 3.5 0 2
50 219 -70 35 -22 225 2.0 0.0 0.2 1.3 765 28 150 743 2069 0.90 3.5 3 0 0 5
39 323 -65 60 -21 118 2.4 0.0 0.2 2.4 1203 41 89 631 2379 0.89 0 0 0 0 3
46 98 -67 38 -23 73 0.9 0.0 1.1 1.2 586 37 54 551 1269 1.16 8 5 7 7 7
n 29
Media
n 53 206 -59 73 -37 106 1 0 0 2 915 39 96 550
1269 1 4.5 3.5 2.8 0.0 1.0
UQ 59 264 -54 114 -29 120 7 2 1 3 1201 55 129 626 1660 2 5.0 5.0 4.6 2.5 5.1
LQ 45 157 -65 39 -47 50 1 0 0 1 728 34 78 387 1075 1 0.7 1.4 0.0 0.0 0.0
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59 172 -29 88 -24 14.8 1.4 2.4 3.5 2169 102 180 1821 2377 2.39 3.3 6 0.1 0.2 7.5
78 188 -17 86 -3 20.0 1.3 0.9 3.0 1757 32 146 697 1701 2.29 5.1 0.5 0.6 0.7 0.8
56 120 54 40 45.0 3.3 22.7 6.8 1414 71 181 1157 1628 2.29 0.2 1.7 6.4 4.4 0.3
38 131 54 21.3 3.3 166.8 3.7 1580 44 113 469 925 1.29 5 2.7 4.4 0.1 1
42 173 72 14.6 2.3 0.4 3.5 1180 69 247 776 1085 1.25 0.6 0.4 1.9 2 1
60 197 -39 68 -19 284 0.0 0.0 2.3 2.5 522 57 125 172 887 0.54 0 7 0 3.1 5
80 270 -58 80 -29 3.2 0.0 2.5 4.2 649 56 123 442 741 1.05 0 0 3.5 3.5 2.5
69 171 -59 70 -24 791 4.8 0.0 75.4 3.2 852 40 155 148 904 0.96 0.7 0 6.2 1 1
27 366 -57 191 -50 40 31.9 0.7 1417 2.3 1020 23 37 136 877 0.90 0 0 0 0 2
52 259 -59 79 -35 177 1.9 0.0 29.5 5.3 974 69 99 194 1114 1.03 10 3.5 9.5 3.5 7.5
53 244 -43 123 -36 0.0 0.0 2.5 8.8 990 40 114 185 1237 1.56 8.8 1 10 10 9
53 172 -49 75 -28 174 5.9 0.0 65.2 7.9 1077 33 143 193 1513 1.77 6.5 9.7 4.4 9 7.5
43 115 -46 48 -26 9.8 2.7 11.8 2.5 907 39 62 143 861 1.49 10 5 7 5 0
69 234 -67 59 -38 106 0.3 0.0 0.1 1.1 603 51 106 539 1290 2.37 0 0 0 0 0
22 132 -71 64 -59 0.8 0.0 0.0 1.0 914 78 32 672 2374 2.53 8 8.4 9 5 0
61 216 -70 54 -44 111 1.0 0.0 0.0 1.7 903 32 138 666 1477 1.89 3 0 0 2.5 1.5
57 231 -66 108 -56 0.7 11.8 0.3 1.4 629 55 127 451 1051 1.48 5 0 9 6 5
64 241 -75 114 -55 161 0.7 0.0 0.1 0.9 1056 72 104 630 1847 1.38 0 7.5 10 0 7
65 172 -56 47 -44 57 1.1 0.0 0.1 1.3 867 42 79 485 1240 1.26 3 5.4 8.5 0.5 5.5
60 79 1.9 0.0 0.2 3.1 651 38 142 796 1066 1.47 0 0 2.9 0 0
67 208 -68 79 -49 1.3 0.0 0.0 1.5 820 51 83 470 1445 2.01 0 0 0.5 0 0
50 153 -65 46 -25 0.9 0.0 0.1 6.1 635 36 94 597 1546 1.27 0 2.2 0 0 2
37 207 -61 70 -48 96 0.6 0.0 0.0 0.9 1820 70 91 557 1497 0.86 5 4 8.5 0 0
64 137 -59 90 -44 96 3.4 0.0 0.2 4.5 862 49 114 810 1916 1.48 0 0 0 0 0
53 213 -67 96 -48 165 2.4 14.9 0.3 2.7 988 30 97 576 1477 1.66 0 0 0 0 5
73 21 -84 5 -43 1.1 0.0 0.2 3.8 958 38 92 702 1591 1.26 0 5 6 0 0
66 229 -64 177 -41 33 3.8 0.0 0.1 2.7 848 24 51 868 3614 1.18 0 0 0 0 1
29 189 -66 64 -56 170 1.5 0.0 0.1 1.2 820 45 84 555 1054 1.10 0 0 0 0 8
64 207 -44 92 -12 154 1.4 16.5 0.1 3.4 617 70 93 563 1123 1.37 5 5 8.5 5.5 0
76 90 -66 73 -58 183 1.9 0.0 0.4 2.0 746 42 92 592 1774 2.02 0 0 0.5 0 6
54 187 -56 73 -23 123 3.5 0.0 0.2 61.0 646 42 81 746 1187 1.80 3 7 2 0 7
71 267 -57 145 -48 63 1.6 0.0 0.5 5.7 612 62 70 681 1192 1.37 0 0 0 0 0
49 218 -60 78 -39 88 1.2 0.0 0.7 5.7 665 30 86 646 1088 1.62 0 0 0 0 2
n 31
Median 59 193 -59 74 -41 111 1.9 0.0 0.3 3.1 867 44 99 576 1240 1 0.2 0.5 2.0 0.1 1.5
1 0 66 230 -56 90 -26 170 4.8 1.3 2.5 4.5 1020 62 127 697 1591 2 5.0 5.0 7.0 3.5 5.5
LQ 50 166 -66 62 -48 79 1.0 0.0 0.1 1.7 651 38 84 451 1066 1 0.0 0.0 0.0 0.0 0.0
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32 134 -69 64 -47 29 14.8 1.4 0.5 2.5
166
8 52 327 648 1543 3.24 2.1 2.9 0.2 0.1 2.7
65 169 -48 31 -28 15.9 2.0 0.8 3.1
114
5 50 180 455 1160 2.15 0.5 0.2 0.2 0.2 0.2
67 120 -46 32 -4 64 13.3 1.7 0.4 3.0
132
9 56 270 753 1190 2.43 0.7 0.8 9.8 0.5 3.5
51 200 -65 34 -25 29 0.0 0.0 88.8 2.0
104
7 50 127 142 1218 0.57 3.6 8 8.5 0 0
55 162 -60 35 -45 234 14.2 0.0 13.7 2.7
105
7 34 192 140 1095 1.00 0.5 4 9.7 4 2.6
74 99 56 23.1 0.0 5.6 2.8 799 68 109 215 1579 1.20 0 0 5.1 0 0
75 201 -62 76 -37 3.7 0.0 21.8 2.4 941 47 67 159 1258 1.28 0 0 0 0 0
64 256 -71 70 -43 77 0.1 0.8 0.9 n/a
103
0 80 62 626 2787 1.48 5.4 0 4.3 0 0
72 255 -76 87 -49 0.7 0.0 0.1 1.2 776 55 94 623 1311 0.68 3 0 5 0 0
73 87 -62 215 -42 3.7 0.0 0.3 4.6 886 72 112 486 1011 1.72 0 0 6 0 0.3
67 256 -59 66 -29 85 0.6 0.0 0.3 2.2 738 46 126 645 1720 1.25 5.4 5 9 1 1.5
41 313 -64 1 -6 83 1.0 0.0 0.1 2.5 847 45 111 735 1410 1.27 0 5.3 10 4.5 4
65 231 -49 109 -4 2.3 0.0 0.0 1.0 604 45 100 337 404 1.28 5 0 0 1.5 2
70 147 -65 23 -44 1.8 0.0 0.2 4.8 558 20 n/a 760 1375 2.01 3 0 5 0 1.5
48 350 -64 52 -45 150 0.7 5.1 0.1 3.0
191
9 45 123 759 1519 1.25 0 0 0 0 3
46 323 -57 160 -40 79 1.1 0.0 0.3 1.9 779 57 129 775 1163 0.59 0 0 9.5 0 2
44 227 -70 83 -51 53 1.4 0.0 0.2 2.1 785 31 89 539 925 0.98 2 1.5 6.5 0 0
49 280 -57 61 -42 51 2.0 0.0 0.3 5.7 620 48 116 626 862 1.09 2 1.4 1.5 0 0
44 79 -55 59 -40 47 4.1 0.0 1.8 1.2 718 24 115 408 583 1.08 0 5 7 0 5.5
68 293 -65 112 -37 35 1.5 0.0 0.4 3.3 824 36 95 729 1333 0.69 0 0 0 3.5 2.5
54 125 -65 50 -33 63 1.6 2.2 0.3 3.2 740 79 81 679 804 1.29 0 0 3 0 0
45 140 -52 87 -43 104 0.7 0.0 0.2 1.7 861 18 75 389 1138 1.57 0 3 0 0 0
48 246 -66 129 -30 64 4.0 0.0 0.1 13.9 770 49 94 456 458 2.07 0 9 5 0 2.5
72 286 -67 174 -45 3.4 0.0 0.1 6.3 573 37 112 474 1237 2.00 0 0 5.5 6 6
64 79 -41 52 -8 59 0.7 0.0 0.3 3.7 498 21 72 644 915 1.39 0 0 1.5 0 0
72 211 -55 100 -46 71 9.4 0.0 2.0 3.0 663 15 68 617 1234 1.29 0 0 7 0 0
41 101 -63 58 -40 49 0.0 0.0 0.2 1.0 746 34 81 408 649 0.96 5 8.5 0 0 0
40 206 -71 77 -33 105 0.2 8.9 0.3 3.2 830 46 88 837 1229 1.50 0 0 0 0 0
54 158 -62 79 -62 239 2.6 14.2 0.3 2.1 730 69 116 517 2168 1.02 0 5 3 0 5
49 275 -72 122 -38 1.5 0.0 0.5 3.0 649 16 53 756 935 1.25 1.8 2.5 5 0 0
39 164 -67 107 -35 68 1.5 0.0 0.2 1.9 790 27 53 568 1478 1.11 0 0 0 0 0
44 151 -69 37 -42 46 0.8 0.0 0.2 1.4 760 34 80 563 821 0.72 0 0 0 2 1.5
39 214 -64 26 -3 130 1.7 0.0 0.2 1.2 663 40 89 868 776 0.96 1.3 0 0 6 0
n 33
Med
ian 54 201 -64 66 -40 66 2 0 0 3 779 45 98 617 1190 1 0.0 0.0 4.3 0.0 0.2
UQ 67 256 -57 100 -30 90 4 0 1 3 886 52 118 729 1375 1 2.0 3.0 6.5 0.5 2.5
LQ 44 140 -67 50 -44 51 1 0 0 2 718 34 81 455 915 1 0.0 0.0 0.0 0.0 0.0
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Study 2
Total NO
Control C2 C4a C5
Total
NO
Total
NO
Total
NOSerial no Serial no Serial no age sexage sex age sex sex
56.4837.05 44.9 61.99
40.58 51.19 55.1333.12
86.1152.56 49.22 33.9
69.439.99 42.94 59.02
52.0850 m 41.76 51.97 41.24
59.244.31 46.08 44.29
79 m 32.53 40.97 56.99 51.4
20 f 37.64 62.38 46.49
52.96 50.55
56.48 52.76
56.48 49.2 C4b 125.43
42.93 51.19
49.71 45.14
42.93 62.92 54.79in
49.54 53.6 35.31
37.01 50.22
45.64
51.91 61.99
57.87
22.32
50 f 26.83
41.17
39 f 25.07
33.79
55.13Median 42.93 43.92 52.96
64.3049.71 49.89 57.87
51.3040.58 36.21 44.29
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Study 3 & 4
Capillary counts in various stages of CVD and inter-observer analysis
Observer 1 cap evaluable Observer 2 cap evaluable
CO
1 14 14 1 14 10
2 23 15 2 20 14
3 5 5 3 8 5
4 7 7 4 8 8
5 7 6 5 7 6
6 12 9 6 14 11
7 15 12 7 15 10
8 15 13 8 17 13
9 16 15 9 16 15
10 15 13 10 15 13
Median 15 13 15 11
UQ 15 14 16 13
LQ 8 8 10 9
Cl
1 7 7 1 9 7
2 22 14 2 25 13
3 7 7 3 7 6
4 18 12 4 17 12
5 14 10 5 16 9
6 18 11 6 18 10
7 17 15 7 24 15
8 23 15 8 28 15
9 19 11 9 18 11
10 15 14 10 21 14
18 12 18 12
19 14 23 14
14 10 16 9
C2
1 15 11 1 15 11
2 12 9 2 12 9
3 9 8 3 10 8
4 15 11 4 13 9
5 18 11 5 19 11
6 15 8 6 16 8
7 12 7 7 10 7
8 16 13 8 14 12
9 12 6 9 12 6
15 9 13 9
15 11 15 11
12 8 12 8
C3
1 12 7 1 13 7
2 13 9 2 13 11
3 14 11 3 15 11
4 6 4 4 6 4
5 16 12 5 16 12
6 10 7 6 10 7
7 14 10 7 14 11
8 18 11 8 17 10
9 16 11 9 19 11
10 10 10 10 14 10
14 10 14 11
16 11 16 11
11 8 13 8
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C4a
1 8 3 1 9 4
2 12 7 2 12 8
3 15 12 3 20 12
4 10 3 4 10 3
5 8 7 5 8 7
6 11 10 6 11 10
7 7 6 7 7 6
8 10 9 8 10 8
9 7 7 9 7 7
10 14 11 10 14 11
10 7 10 8
12 10 12 10
8 6 8 6
C4b
1 13 9 1 13 10
2 3 3 2 3 3
3 24 12 3 24 13
4 13 10 4 15 10
5 1 15 1 1
6 6 3 6 5 3
7 5 3 7 5 3
8 2 2 8 2 2
9 2 1 9 3 2
10 3 2 10 2 1
4 3 4 3
11 8 11 8
2 2 2 2
C5
1 7 5 1 7 5
2 7 5 2 7 5
3 8 6 3 8 6
4 7 6 4 7 6
5 7 5 5 7 5
6 5 4 6 5 4
7 7 4 7 7 4
8 1 1 8 1 1
9 5 5 9 6 5
10 6 4 10 6 4
7 5 7 5
7 5 7 5
5 4 6 4
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Observer 1: count and capillary loops in various stages of CVD
File name
1_____
2_____
 3________
 4________
5
 9_
10
2_
 3_
 4_
 5_
 6_
 7_
 8_
9__
]_0_
n _
12
13_
14_
16_
17
1_8_
19_
20_
21__
22_
23_
24_
25_
26_
27_
28_
29_
30_
31_
32_
33_
34_
35_
36_
37_
38_
39_
40_
41
Cap
count
Eval
caps
Ji
23
J2
_15
16
15
22
_14
J_7
_23
15
15
12
JJ
_16
12
ill
12
u
J_8
10
_12
_15
10
10
14
13
14
14
11
13
12
12
10
11
Number of loops
10 11 12 13 14 15 med
CO
Cl
C2
C3
lC4a
lC4b
1
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^
42 24 12 5 2 3 5 4 4 7 9 7 5 5 2 5
43 13 10 3 7 2 2 3 6 3 5 3 2 3
44 1 1 15 15
45 6 3 5 10 8 8
46 5 3 5 5 15 5
47 2 2 15 10 13
48 2 1 15 15
49 3 2 15 15 15
50 7 5 15 15 15 15 15 15 C5
51 7 5 15 6 3 3 15 6
52 8 6 5 6 10 15 10 15 10
53 7 6 7 15 11 8 6 12 10
54 7 5 15 4 15 14 14 14
55 5 4 11 15 8 7 10
56 7 4 6 7 15 15 11
57 1 1 11 11
58 5 5 4 6 5 3 6 5
59 6 4 2 2 8 15 5
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Observer 2: count and capillary loops in various stages of CVD
File
Cap
count
Eval
caps 2 3 4 5 6 7 8 9 10 11 12 13 14 15 median
1 14 11 1 1 1 1 1 1 1 1
2 8 8 2 1 1 1
3 7 6 1 1
4 15 10 1 1 1 1 1
5 17 13 1 1 1 2 1 1 1 1 1
6 16 15 1 1 1 1 1 1 1 1 1
7 15 13 1 1 1 2 2 1 1 1 1
8 8 5 1 1
9 20 14 1 1 1 1 1 2 2 3 2 1
10 14 10 1 1 1 1 1 1
11 9 7 1 1 1 1
12 25 13 1 1 1 2 1 1 2 1 1 1
13 7 6 1 1
14 17 12 1 1 1 1 2 2 2 2 1
15 16 9 1 1 1 1 1 1
16 28 15 1 1 1 2 2 1 1 1 1 1 1 1
17 24 15 1 1 1 1 1 1 1 1 1 1 1 1
18 21 14 1 1 1 1 1 2 2 2 1 1 1
19 18 10 1 1 1 1 1 1
20 18 11 1 1 1 1 1 2 2 1
21 16 8 1 1 1 1 1
22 14 12 1 1 1 1 1 1 1 1 1
23 10 8 1 1 1 1 1
24 19 11 1 1 1 1 1 1 1
25 13 9 1 1 1 1 1 1
26 12 9 1 1 2 2
27 10 7 1 1 1
28 15 11 1 1 1 1 1 1 1
29 12 6 1 1 1
30 13 7 1 1 1 1
31 19 11 1 1 1 1 1 1 1 1
32 17 10 1 1 1 1 1 1 1
33 13 11 1 1 1 1 1 1 1 1
34 15 11 1 1 1 1 1 1 1
35 6 4
36 14 11 1 1 1 4 2 3 3 1
37 16 12 1 1 1 1 1 2 2 3 1
38 10 7 1 1 1 1
39 14 10 1 2 3 1 1 1 1 1
40 20 12 4 4 4 3 3 3 2 2 3 5 5 6 4
41 9 4 8 2 4 3 4
42 10 8 2 2 2 1 4 3 3 3 3
43 12 8 4 2 2 3 1 1 1 1 2
44 8 7 2 2 2 4 4 4 7 4
45 10 3 4 7 5 5
46 11 10 2 2 2 2 1 1 1 1 1 1 1
47 14 11 7 3 4 4 1 1 5 2 1 1 1 2
48 7 7 4 4 3 1 3 5 8 4
49 7 6 4 4 3 2 6 7 4
50 15 10 9 2 2 3 2 3 3 3 6 5 3
51 24 13 7 7 9 4 4 5 5 5 5 5 3 2 2 5
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52 5 3 5 6 15 6
53 13 10 4 4 5 5 5 3 3 3 4 3 4
54 1 1 15 15
55 5 3 5 10 8 8
56 3 3 15 6 6 6
57 2 2 16 10 13
58 2 1 15 15
59 3 2 15 20 18
60 6 4 16 2 2 8 5
61 1 1 11 11
62 6 5 7 6 3 5 5
63 4 17 18 6 12
64 6 6 8 12 15 11 10
65 5 15 15 3 6 6
66 5 15 14 15 14 14
67 5 15 15 15 15
68 4 11 8 15 10
69 8 6 20 6 10 10 10
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Capillary loops evaluation between two observers with new proposed classes
median number of loops per evaluable capillary per patient
patient no observer 2 observer 1 observer 2 class observer 1 class
1 1 1 1 1
2 1 1 1 1
3 1 1 class 1= 1-2 1 1
4 1 1 class 2 = 3-5 1 1
5 1 1 class 3 = 6-10 1 1
6 1 1 class 4 = >10 1 1
7 1 1 1 1
8 1 1 1 1
9 1 1 1 1
10 1 1 1 1
1 1 1 1
1 1 1 1
1 1 1 1
11 1 1 1 1 contingency table
12 1 1 1 1
13 1 1 1 1 observer 1
14 1 1 1 1
observe 
r 2 class 1 class 2 class 3 class 4
15 1 1 1 1 class 1 42 1 0 0
16 1 1 1 1 class 2 0 11 1 0
17 1 1 1 1 class 3 0 0 3 0
18 1 1 1 1 class 4 0 0 0 11
19 1 1 1 1
20 1 1 1 1
1 1 1 1
1 1 1 1
1 1 1 1
21 1 1 1 1
22 1 1
23 1 1 1 1
24 1 1 1 1
25 1 1 1 1
26 1 1 1 1
27 1 1 1 1
28 1 1 1 1
29 1 1 1 1
1 1 1 1
1 1 1 1
1 1 1 1
30 1 1 1 1
31 1 1 1 1
33 1 1 1 1
34 1 1
35 1 1 1 1
36 1 1 1 1
37 1 1 1
38 1 1 1 1
39 1 1 1 1
40 1 1 1 1
1 1 1 1
1 1 1 1
1 1 1 1
41 4 4 2 2
42 2 2 1 1
43 4 4 2 2
44 5 5 2 2
45 4 4 2 2
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46
i l  _
22
49
_50 _
21.
_52
_53 _
_54
_55
22.
_60
_61
_63
2d.
JO_
_66
_67
i2.
2d.
_70
1 I
15 15
13 13
15 18
15 15
14 15
15 15
10 10
10 10
14 14
10 10
11 12
11
10 10
11 12
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CV (correlation efficient)
Obs 1 cap evaluable cap evaluable
1 14 M 14 10
2 23 15 20 14
3 5 5 8 5
4 7 7 8 8
5 7 6 7 6
6 12 9 14 11
7 15 12 15 10
8 15 13 17 13
9 16 15 16 15
10 15 13 15 13
11 7 7 9 7
12 22 14 25 13
13 7 7 7 6
14 18 12 17 12
15 14 10 16 9
16 18 11 18 10
17 17 15 24 15
18 23 15 28 15
19 19 11 18 11
20 15 14 21 14
21 15 11 15 11
22 12 9 12 9
23 9 8 10 8
24 15 11 13 9
25 18 11 19 11
26 15 8 16 8
27 12 7 10 7
00 16 13 14 12
29 12 6 12 6
30 12 7 13 7
31 13 9 13 11
32 14 11 15 11
33 6 4 6 4
34 16 12 16 12
35 10 7 10 7
36 14 10 14 11
37 18 11 17 10
38 16 11 19 11
39 10 10 14 10
40 8 3 9 4
41 12 7 12 8
42 15 12 20 12
43 10 3 10 3
44 8 7 8 7
45 11 10 11 10
46 7 6 7 6
47 10 9 10 8
48 7 7 7 7
49 14 11 14 11
50 13 9 13 10
51 3 3 3 3
52 24 12 24 13
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53 13 10 15 10
54 1 1 1 1
55 6 3 5 3
56 5 3 5 3
57 2 2 2 2
58 2 1 3 2
59 3 2 2 1
60 7 5 7 5
61 7 5 7 5
62 8 6 8 6
63 7 6 7 6
64 7 5 7 5
65 5 4 5 4
66 7 4 7 4
67 1 1 1 1
68 5 5 6 5
69 6 4 6 4
mean 11 8 12 8
stdev 6 4 6 4
sqr stdv 31 15 37 14
34 15
sqrt 6 4
CV 0.502 0.471
31.604
CV 0.33 0.32
0.37 0.34
median 12 8 12 8
uiqr 15 11 16 11
liqr 7 5 7 5
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C2/C3 without atypical group
age NE
UT
RO
PHI
LLS
NE
UT
RO
PHI
LLS
MO
NO
CY
TES
MO
NO
CY
TES
VE
GF
VE
GF
TN
Fal
pha
IL-
la
IL-
lb
IL-6 sL-
Sele
ctin
sE-
Sele
ctin
sP-
sele
ctin
slC
AM
-1
sVC
AM
-1
vW
F
symptoms
CD1
lb
CD6
2L
CD1
lb
CD6
2L
Pg/
ml
old Pg/ 
ml
Pg/ 
ml
Pg! 
ml
Pg/
ml
ng/ 
ml
ng/
ml
ng/
ml
ng/
ml
ng/
ml
IU/
ml
pain heav
ines
s
era
mps
pare
sthe
sia
ede
ma
49 264 -47 132 -24 25 25 10.2 1.5 0.9 2.1 144
1
34 78 550 754 1.32 0.1 1.4 1 0.3 0.3
40 336 -54 204 -44 23 23 10.7 1.4 1.2 2.2 172
6
42 59 601 103
9
1.53 2.1 0 0 0.5 0
39 185 -51 37 -36 32 32 21.9 2.1 0.9 2.7 180
5
36 102 596 126
8
1.26 0.6 2.6 0 0.7 0
51 247 -54 142 -43 31 31 15.3 1.9 65.3 3.2 130
3
19 121 580 858 2.00 0.7 2.4 0.3 0.2 0.6
75 142 -64 47 -40 52 52 11.8 1.5 1.3 2.3 134
7
39 240 643 117
0
1.92 0.1 0.9 0.3 0.3 0.4
55 261 -63 93 -31 25 25 9.0 1.8 0.4 1.5 137
9
28 80 396 911 1.55 3 3.2 0.2 1.6 1
33 265 -55 116 -29 55 55 2.5 0.0 0.0 6.6 807 48 117 183 461 1.25 2.5 4 0.5 6.5 2.4
48 16 -60 -66 38 38 12.4 1.9 0.5 3.1 170
1
22 112 648 852 1.78 2.5 0.2 2.4 0.3 0.1
45 205 -56 39 -37 76 76 84.2 0.0 176.
1
3.0 120
1 76
146 180 126
3
0.78 1.3 0.3 8.4 0.5 0.7
77 181 -49 80 -18 140 140 0.7 0.0 18.6 1.7 109
7
43 138 168 116
0
1.05 0 0 0 0 0
61 138 -53 73 -31 12 6.5 0.0 47.4 4.4 803 34 129 146 788 0.54 8 7 0 0 0
66 239 -65 81 -48 57 57 0.0 0.0 0.0 2.5 860 93 75 193 138
9
1.06 5 5.3 3.1 2.5 0
51 314 -64 139 -46 37 37 0.0 0.0 255.
7
3.5 106
4
35 181 187 920 0.88 0 6.4 4.2 0
41 314 -64 139 -46 114 114 0.0 0.0 9.9 0.7 915 48 93 192 981 0.63 5 7 9.8 7.2 0
27 184 -59 79 -38 162 162 7.1 0.0 5.4 0.1 126
1
70 85 544 177
0
0.83 3 4 0 0 0
55 140 -61 46 -45 60 60 0.0 0.0 14.0 2.0 108
7
15 65 58 139
8
0.82 5.4 4.3 0 1.5 4.5
19 118 -48 46 -14 104 104 1.2 0.0 0.2 1.0 108
9
69 119 917 236
5
0.95 3 3.5 4 3.5 0
70 301 -63 78 -41 34 34 2.2 0.0 0.1 3.6 609 106 97 868 362
6
2.50 0 6 9 0 8
56 73 -46 50 -41 197 197 0.8 0.0 0.1 3.5 769 65 227 699 136
1
2.25 0 4 0.2 4.8 0
52 182 -57 58 -44 85 85 0.7 0.0 0.0 0.6 944 58 145 626 162
5
1.40 7.5 7.6 7.6 5.3 5.4
50 118 -53 15 -27 282 282 1.3 0.0 0.3 0.9 n/a 50 232 811 118
7
1.25 1.8 1.8 5 1.5
53 164 -57 52 -40 151 151 2.3 0.0 0.1 1.1 628 27 138 114
9
223
6
1.33 0 0 7 3 0
22 199 -51 112 -37 86 86 0.6 0.0 0.1 1.0 790 26 126 682 157
0
0.86 7 7.5 0 0 0
55 203 -60 93 -42 52 52 0.7 0.0 0.0 1.0 620 26 109 682 167
3
1.41 1.8 10 0 0
59 222 -58 101 -35 39 39 1.1 3.8 0.2 1.2 723 71 108 703 139
1
2.10 5.5 7.5 1.2 0 0
29 166 -53 142 -40 32 32 0.8 1.4 0.2 2.2 109
8
57 98 850 127
1
1.25 0 1 0 5.2 0
45 67 -45 13 -28 28 28 0.6 0.0 0.1 1.0 106
9
94 123 630 108
9
1.16 5 4 4 2.5 1
69 126 -54 44 -39 116 116 2.1 0.0 0.3 0.6 689 51 136 707 155
1
2.06 0 0 0 0 0
65 130 -48 39 -43 101 101 0.7 0.0 0.3 2.0 387 49 166 457 915 1.28 6.5 5 6.5 7 0
59 185 -65 83 -62 185 185 0.8 9.0 1.2 0.9 817 72 120 562 127
1
1.96 5 5 5 0 0
50 145 -66 40 -46 113 113 0.8 0.0 0.1 1.4 112
0
44 169 582 211
1
2.53 5 8 0 2 0
59 230 -62 105 -55 170 170 1.7 0.0 0.2 4.9 105
5
35 131 103
0
208
0
1.70 5 0 2.5 0 6.5
57 101 -53 21 -13 147 147 0.0 0.0 0.3 1.0 641 35 145 545 107 1.42 5 0 0 6
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5
53 432 -74 168 -51 172 172 0.8 5.6 0.3 2.7 955 43 114 624 155
5
1.08 5 3.5 0 7.5 5
52 121 -57 89 -36 51 51 1.6 0.0 0.2 4.0 539 114 151 116
8
156
7
1.78 7 6.5 7 5 0
56 268 -67 71 -30 120 120 1.7 0.0 0.3 2.0 443 28 96 387 139
2
1.04 2 0 3 0 0
51 93 -59 7 -22 25 25 2.0 0.0 0.3 3.0 105
5
18 58 408 823 1.44 7 0 8 0 1.5
61 206 -48 111 -38 160 160 0.5 0.0 0.3 2.3 879 65 70 531 114
2
0.96 0 3.5 4 0 0
41 144 -55 86 -45 56 56 1.2 0.0 0.2 1.3 747 84 96 437 117
4
1.43 0 1.5 0 0 0
70 93 -38 41 -33 63 63 1.7 0.0 0.4 2.7 508 38 113 429 470 1.20 2 2 7 0 0
39 157 -55 28 -54 107 107 0.5 2.2 0.2 1.2 935 37 90 476 173
8
0.69 0.5 0 4.5
33 301 -61 55 -55 126 126 0.5 0.0 0.1 2.6 106
8
55 68 510 166
0
1.49 3.5 2.5 3.5 0 2
56 171 -62 135 -51 357 357 0.0 0.0 0.2 2.8 607 24 148 445 774 0.96 2 0 3.5 0 0
49 217 -56 139 -40 124 124 0.9 0.0 0.3 1.9 537 51 51 476 116
5
1.34 3.2 2 8 0 3
26 230 -44 119 -37 142 142 1.5 0.0 0.4 4.9 893 35 147 519 929 0.67 0 5 4 0 7
63 299 -64 153 -42 120 120 1.3 0.0 0.3 2.2 653 39 118 455 128
9
2.18 3 0 4 0 1.5
49 139 -61 73 13 125 125 0.3 0.0 0.2 2.3 116
2
34 91 537 156
6
1.77 4.4 4 7 0 0
61 275 -63 55 -60 27 27 0.7 0.0 0.2 2.3 636 26 69 488 135
2
1.33 0 0 0 0 0
50 94 -46 52 -41 39 39 9.7 1.2 2.9 2.5 186
9
61 129 914 143
5
1.53 3.4 3 2.8 0 2.1
53 258 -59 127 -44 25 25 14.0 1.7 0.3 7.8 163
2
16 60 605 929 1.31 6.3 8.2 6.9 0.5 1
67 221 -55 96 -28 19 13.7 1.7 0.4 2.0 176
6
24 106 521 139
4
1.46 3.3 5.1 4 0.1 3
54 258 -45 51 -26 29 29 16.5 2.2 1.6 3.6 108
8
12 112 454 104
0
2.22 4.5 4.9 1.6 1.4 3
63 155 18 21 14.1 1.9 0.5 2.7 139
4
29 73 499 126
2
1.43 8.1 4.8 3 5 5
71 155 -59 93 -53 34 34 36.0 1.0 403.
0
2.5 873 64 139 168 120
5
0.51 5 0 0 0.3 5.2
71 79 -59 50 -31 82 82 50.2 1.2 150.
0
4.5 153
3
74 86 200 198
1
1.30 4.5 3.5 4.8 0 0.5
39 182 114 -32 120 120 2.3 0.0 0.0 2.6 456 44 68 370 458 1.58 5 4.5 4.5 5.5
63 239 -52 174 -32 106 106 1.1 0.0 0.5 1.2 717 47 148 615 240
0
2.16 5.5 0 0 8.5
41 180 -52 101 -40 115 115 1.6 0.0 0.0 1.4 794 60 160 327 536 0.86 0 0 0 0 6.5
40 122 -71 -69 341 341 0.7 0.0 0.2 1.5 105
2
37 245 102
4
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4
1.90 6 9 8.5 7 6.5
53 273 -55 148 -27 47 47 0.9 2.7 0.1 1.5 101
3
50 88 713 114
4
1.22 5 3.5 0 0 5
41 559 -77 575 -80 21 21 0.0 0.0 0.2 1.8 728 23 115 372 825 1.61 0 5 0 0 5.5
56 401 -69 151 -52 118 118 0.3 0.0 0.0 4.2 896 39 64 606 152
8
1.99 5 5 1.2 0 4.5
50 219 -70 35 -22 225 225 2.0 0.0 0.2 1.3 765 28 150 743 206
9
0.90 3.5 3 0 0 5
39 323 -65 60 -21 118 118 2.4 0.0 0.2 2.4 120
3
41 89 631 237
9
0.89 0 0 0 0 3
46 98 -67 38 -23 73 73 0.9 0.0 1.1 1.2 586 37 54 551 126
9
1.16 8 5 7 7 7
48 207 -63 65 -30 111 111 1.3 0.0 0.3 6.4 820 39 90 550 122
3
1.20 3.4 0 1.4 0 6
n 66
Me
dian
52 185 -58 79 -40 86 84 1.3 0.0 0.3 2.2 915 40 112 547 126
8
1.32 3.3 3.4 2.5 0.0 0.7
UQ 59 258 -53 116 -30 125 123 5.5 1.3 0.9 3.0 112
0
58 139 646 156
7
1.68 5.0 5.0 5.0 2.5 5.0
LQ 42 139 -63 47 -45 38 35 0.7 0.0 0.2 1 J 723 30 86 431 996 1.04 1 0 0 0 0
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C2/C3 without atypical group
NEUT
ROPH
ILLS
NEUTR
O P I I I L I .
sL-
Selecti
sE-
Sclecti
sP-
selecti sVCA
M-l
MONO
CYTES
MONO
CYTES
slC A 
M -l
sympt
VEGF TNF a  IL -la IL-lb IL-6
heavin p ares  ill
C D llb CD62L C D llb CD62L pg/ml 
 -24  21
: : ■■■■ 
10.2
; _
0 9
__
2T
ng/ml ng/ml 
1441 3.
ng/ml ng/ml
550
ng/ml
754
IU/ml pain 
1.32 OJ
edemacramps
-47 132 1 4 0.3 0.3
336 -54 1726 0.5> 4 -44 10.7 1.4 601 1039 1.53 2.1
185 -51 -36 21.9 0.9 1805 102 5>4. 1268 1.26 0.6 2.6 0.7
247 -54 0.3142 -43 15.3 65.3 1303 121 580 S58 200 2.4 0.2 0.6
1170 0.9 0.3 0.4142 -64 -40 11.8 1347 240 043 1 92 0.1
261 -63 -31 9.0 0.4 1379 396 911 I 55 3.2 1.6
6.5 2.4265 -55 116 -29 2.5 0.0 0.0 807 117 183 461 2.5
0.7205 -56 -37 84 2 0.0 176 1201 146 180 1263 0.78 0.3 8 4 0 5
181 -49 -18 140 0.7 0.0 18.6 1097 138 168 1160 1 05
138 -53 -31 6.5 0 0 47.4 803 129 146 788 0.54
2 5239 -65 -48 0.0 0.0 193 1389 1 06 5.3
0.0 o.o 255 1064 181 187 920 0.88 6.4 4.2314 -64 139 -46
7.2314 -(,4 139 -46 114 0.0 0.0 9 9 915 i 981 0.63 9.8
-59 -38 162 7.1 0 0 5.4 1261 544 1770 0.83184
4.5140 -61 -4.8 0.0 0.0 14 0 1087 1398 0.82 5.4 4.3
3.5118 -48 -14 104 0.0 0.2 1089 119 917 2365 0.95 3.5
2.25 0.2 4 8-46 -41 197 0 8 0.0 0.1 760 227 1361
182 -57 44 0 7 0.0 0.0 044 145 626 1625 I 40 7.5 7.6 7.6 5.3 5.4
n a118 -53 -27 282 1.3 0.0 0.3 232 811 1187 1 25
-57 151 2 1 o o 0.1 628 138 1149 2236 1 33164 -46
199 -51 112 -37 0 6 0.0 0.1 790 126 6-2 1570 0.86 7.5
222 -58 -35 3.8 0 2 723 1 08 703 1391 2.10 5.5 7.5101
5.2166 -53 142 40 0.8 0.2 1098 584 1271 1 25
2.5-45 -28 0.6 0.0 0.1 1069 123 630 1089 1.16
185 185 0.8 817 1271 1 96-6.8 -62 9.0 i: 562
0.8 2.53145 -66 46 113 0.0 0.1 1120 169 582 2111
230 -02 105 -55 r  ■ 1.7 0.0 0.2 1055 131 1030 2080 1 70 2.5 6 5
26.8 -67 -30 120 17 0.0 0.3 443 387 1392 I 04
160___0 5 879 3.5206 -48 111 -38 0.0 0.3 531 1142 0.96
0.5 935 0.5 4 5157 -55 -54 107 2.2 0.2 476 1738
510 3.5 2.5 3 5301 -61 -55 126 0.5 0.0 0.1 1068 1660 1.49
171 774 0.96 3.5-62 135 -51 357 0 0 0.0 0.2 607 145 445
217 -56 476 1165 1.34 3.2139 -40 124 0.9 0.0 0.3 537
-37 0.4 144 519 929 0.67230 119 142 1.5 0.0 893
139 -61 125 0.3 0.0 0.2 1162 537 1566 4.4
275 -63 -60 0.7 0.0 0.2 636 1352 1.33
914 1435 1 53 3.4 2.8-46 -41 9.7 2.9 1869 129
82 6.9 0.52 8 8 .89 127 -44 14 0 0.3 1632 605 929 1.31 6 3
221 -55 96 -28 13.7 0.4 1766 I 521 1394 1.46 3.3 5.1 0.1
2.22 4.5 4 9 I 4258 -45 -26 16.5 2.2 1088 112 454 1040
1.55 0 5 1394 499 1262 1.43 8.1 4.814.1
0.51 0 3155 59 -53 36.0 403 873 139 168 1205
-59 50.2 150 1533 200 1981 1.30 3.5 4 8-31
4 5182 -32 120 2.3 0.0 . . . . 456 370 458 I 58 4.5114
239 -52 174 -32 106 0.0 0.5 717 148 615 2400 2.16
245 1024 2664 8 5 6.5122 -71 -69 341 0.7 0 0 0.2 1052
559 -77 575 0.0 0 0 0.2 728 115 372 825 1.61
1528401 -69 151 -52 118 0.3 0.0 0.0 896 1 99
2069 0.90 3.5219 -70 -22 225 2.0 0.0 0 2 765 150 743
-65 2.4 0.0 0.2 1203 631 2379 0.89323 -21 1 18
-67 -23 0.9 0.0 5v. 551 1269
207 820 550 1223 1 20 3.4-63 30 1 1 1 0.0 0.3
M e d ia
1270 3.5 2.5 0.3 0.7202 -58 -.38 104 1.3 (1.0 0.3 2.2 1052 110 547 1.31 3.4
258 -53 117 2.8 1202 630 1584 1.59 5.0 5.0 4.7 2 . 8 4.5-.30 9.2 1.4 1.2 139
152 -64 -46 0.6 0.0 0.2 1.3 394 1039 0.96
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Atypical group
ag
e
NEU
TR
OP
HIL
LS
NEU
TR
OP
HIL
LS
MO
NO
CYT
ES
MO
NO
CYT
ES
VE
GF TNF a
IL-
la
IL-
lb IL-6
sL-
Selecti
n
sE-
Scle
ctin
sP-
selec
tin
slCA
M -l
sVC
AM-
1 vWF
sympt
oms
CD1
lb
CD6
2L
CD1
lb
CD6
2L
pg/m
1 pg/ml
pg/m
1
pg/m
1
pg/m
1 ng/ml
ng/m
1
ng/m
1
ng/m
1
ng/m
1
lU/m
1 pain
heavin
ess
cram
!,s
pares
thesi
a
ede
ma
48 16 -60 -66 38 12.4 1.9 0.5 3.1 1701 22 112 648 852 1.78 2.5 0.2 2.4 0.3 0.1
41 180 -52 101 -40 115 1.6 0.0 0.0 1.4 794 60 160 327 536 0.86 0 0 0 0 6.5
70 301 -63 78 -41 34 2.2 0.0 0.1 3.6 609 106 97 868 3626 2.50 0 6 9 0 8
55 203 -60 93 -42 52 0.7 0.0 0.0 1.0 620 26 109 682 1673 1.41 1.8 10 0 0
53 273 -55 148 -27 47 0.9 2.7 0.1 1.5 1013 50 88 713 1144 1.22 5 3.5 0 0 5
69 126 -54 44 -39 116 2.1 0.0 0.3 0.6 689 51 136 707 1551 2.06 0 0 0 0 0
65 130 -48 39 -43 101 0.7 0.0 0.3 2.0 387 49 166 457 915 1.28 6.5 5 6.5 7 0
57 101 -53 21 -13 147 0.0 0.0 0.3 1.0 641 35 145 545 1075 1.42 5 0 0 6
53 432 -74 168 -51 172 0.8 5.6 0.3 2.7 955 43 114 624 1555 1.08 5 3.5 0 7.5 5
52 121 -57 89 -36 51 1.6 0.0 0.2 4.0 539 114 151 1168 1567 1.78 7 6.5 7 5 0
51 93 -59 7 -22 25 2.0 0.0 0.3 3.0 1055 18 58 408 823 1.44 7 0 8 0 1.5
41 144 -55 86 -45 56 1.2 0.0 0.2 1.3 747 84 96 437 1174 1.43 0 1.5 0 0 0
70 93 -38 41 -33 63 1.7 0.0 0.4 2.7 508 38 113 429 470 1.20 2 2 7 0 0
63 299 -64 153 -42 120 1.3 0.0 0.3 2.2 653 39 118 455 1289 2.18 3 0 4 0 1.5
n 14 13 14 14 14 12 14 14 14 14
Medi
an 54 137 -56 86 -41 60 1.4 0.0 03 2.1 671 46 114 585 1159 1.4 2.8 1.9 3.2 0.0 0.8
IQ 65 256 -53 101 -34 116 1.9 0.0 03 2.9 915 57 143 701 1554 1.8 5.4 4.6 7.0 0.2 5.0
LQ 51 106 -60 41 -42 48 0.8 0.0 0.1 1.4 612 36 100 442 868 1.2 0.0 0.1 0.0 0.0 0.0
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C2 data to analyse atypical data
iensity no o f loops in cap 1
DO
sup
DO
dep
capillary
one two three four five six seven eight nine ten eleven twelve
nean
loops
m ean
caps
dep
1 dep2 dep3 dep4 dep5 dep6 dep7 dep8 dep9 dep 10 dep 11 dep 12 dep 13 dep 14 dep 15
19
not
done 1 1 1 1 1.0 8.0 1.0 5.0
15 16 1 1 1 1.0 6.0 1 1 1 1 1.0 10.0
22 12 1 1 1 1.0 6.0 1.0 6.0
30 22 1.0 3.0 1.0 6.0
17 25 1.0 3.0 1 1 1 1 1 9.0
17 15 1.0 3.0 1 1 1.0 8.0
1.0 4.0 1.0 2.0
18 16 1 1 1.0 6.0 1 1 4 7.0
9 6 1.0 3.0 1.0 20
12 15 1.3 4.0 1 1 1 1 1.0 10.0
9 17 1.0 3.0 1.0 4.0
30 35 1 1 1 1 1 1 1 2 2 2 1.2 14.0 3 2 1 1 1 2.1 12.0
21 26 1 1 1 1 1 3 2 2 1.3 13.0 1 1 1 1 : 4 ! 1 0
1 ! 1 1 1 1 1 2 ! 1.1 13.0 1 1.0 7.0
1.3 4.0 1 1 1 5 2 2 2 1.5 15.0
1.0 4.0 1 ! 4 7.0
I I 1 1 1.1 9.0 1 1 1 1 3 12.0
27 20 3 2 1 2 2 2.2 10.0 2 2.9 7.0
57 i 3 2 1 2.1 8.0 1.8 4.0
31 2 3 3 2 1 2.2 10.0 4 3 2 5 7 3 3 5 4 2 3 3 5 3.3 190
1 1 1 2 3 2.2 9.0 1 2 2 2 3 3 3 3 3 4 4 5 4 2.7 20.0
51 3 3 2 1 1 1 2.1 10.0 1 1 1 1 2 2 2.1 13.0
4 2 1 3.1 7.0 10 9.0 3.0
6.5 2.0 6.5 2.0
2 : 2 5 3.0 8.0 1 1 1.9 9.0
4.0 4.0 3.3 6.0
4.7 3.0 2.5 6.0
8 4 3 5.2 5.0 2.4 5.0
36 5 s 2 3 3 5 4 5 5 4 5 4 2 3.9 15.0 j 6 5 2 3 3 4 4 5 5 4 3 5 2 t 4 2 18.0
C3 data to analyse atypical data
density no o f loops in cap |
capillary
one two three four five six seven eipht nine ten eleven twelve depl dep2 dep3 dep4 dep5 dep6 dep7 dep8 dep9 dep 10 depl 1
DO DO
sup dep
19 21 1 1 1 1 1 1 1 1 1 1.0 9.0 1 1 1 1.0 4.0
16 16 1 1 1 1.0 3.0 1 1 1 1 1 1.0 7.0
1 1 1 1 1 1.0 8.0 1 1 1 1 1 1 1 2 1.1 11.0
1 1 1 1 1 1 1 1 1.0 11.0 1 1 1 1 1 1 1 1 1 2 1.1 13.0
1 2 2 1 1 1.3 7.0 2 2 2 2 1 1 1 1 1 1 1.3 13.0
2 2 1 1 1 1 1 1 1 1 1 1.2 15.0 3 2 1 1 1 1 1 1 1.5 11.0
1 1 2 1 1.3 4.0 1 2 2 1 1.4 5.0
1 1 1 1 1 1 1 1.0 11.0 4 3 2 2 1 1 1 1 1 1 1.5 13.0
1 1 1 1 1 1.0 9.0 1 1 1 1 1 1 1 1 1 1.0 12.0
1 1 1 1 1.0 7.0 1 1 1 1 2 2 1.4 8.0
20 19 3 1 1 1 1.4 8.0 1 2 3 2 1 4 1 1.8 9.0
24 18 1 1 2 2 1.6 7.0 1 1 1 1 1.0 6.0
22 21 1 1 2 2 1.3 7.0 2 3 1 2 4 2 1 1 2.0 10.0
8 8 1 2 1 1 1.2 5.0 2 3 1 1 2 3 2 3 2 2.1 11.0
10 9 2 2 1 1 1.8 5.0 4 6 4 2 4.7 6.0
1 2 1 1 1 3 2 4 3 3 2 2.1 11.0 1 1 1 3 2 2 2 1 1 1 1 1.5 13.0
1 2 3 4 3 1 5 2 1 1 1 1 3 3 5 2.4 15.0 2 2 2 1 2 3 2 2 1 1 1 5 1.9 13.0
5 3 4 4.0 3.0 3 5 4 4.0 3.0
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Atypical data
density no o f loops in cap
mea
n
loop
No of loops in catI
capi
llary
one two
thre
e
fou
five six
seve
n
eigh nin
ten
eleve
n twelve
dep dep
2
dep
3
dep
4
dep
5
dep
6
dep
7
dep
8
dep
9
depl
0
depl
1
DEP1
2
depl
3
depl
4
depl
5 dep 16
mea
n
loop
mea
i
caps
DO DO
sup dep
27 20 3 3 2 1 1 2 2 2.2
10.
0 3 2 1 1 2.5 6.0
57 1 3 2 1 2.1 8.0 2 1 1.8 4 0
51 3 3 2 1 1 1 2.1
10.
0 3 7 1 1 1 1 1 1 1 2 2 2.1 13.0
4 2 I 3.1 7.0 10 8 9.0 3.0
6.5 2.0 6.5 2 0
2 2 2 5 3.0 8.0 3 2 1 1 1 1 1 1.9 9 0
4.0 4.0 4 4 2 2 3.3 6.0
31 2 3 3 2 1 1 2.2
10.
0 2 1 5 4 3 2 5 7 3 3 5 4 2 3 3 5 3.3 19.0
1 1 1 2 3 2.2 9.0 3 I 2 1 2 2 1 2 3 3 3 3 3 4 4 5 4 2.7 200
36 5 2 3 3 5 4 5 5 4 5 4 2 3.9
15
0 6 6 5 2 3 3 4 4 5 5 4 3 3 2 £ 4.2 18 0
4.7 3.0 2 1 2 2.5 6.0
4 3 5.2 5.0 2 1 2.4 5.0
1 2 3 4 3 1 5 2 1 1 1 1 3 3 5 2.4
15.
0 1 2 2 2 1 2 3 2 2 1 1 1 5 4 5 2.3 15 0
5 3 4 4.0 3.0 3 5 4 4.0 3.0
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Study 5 
PPG
C2 C3 C4a C4b C5
Right Left
Disease
side Right Left Right Left Right Left Right Left
11.5 It 8.3 Right 11.9 10.2 bil 7.7 Right 6.8 Lt.
188 19.3 both 11.6 6.75 bil 16.7 10.5 bil 6.3 It. 10.6 5.66 bil
24.2 rt 6.6 10.3 bil 20.2 6.6 bil 5.2 bil/Right 9.1 14.4 bil
18.5 6.5 bil 21.1 23.8 bil 14.7 13.2 bil 7.75 26.3 bil 6.27 7.93 bil
14.3 7 bil 7.2 6.9 bil 8.2 10.9 bil 8.35 11.5 bil 10.5 rt
14 10.9 bli 7 Lt. 9.1 9.1 bil 9.93 6.4 3.8 6.8 bil
18.3 Left 10.5 10.7 bil bil 8.7 3.15 bil 4.8 9 bil
10 5.3 13.4 Right Right 7.4 8 bil 8.15 rt
22.9 17.8 bil 23.2 21.8 bil/Left 5.1 Right 9.73 8.8 bil 10 lt
11.8 21.2 bil 14.3 27 bil 16.9 5.6 bil 13.7 18.6 bil 20.7 rt
22.9 16.1 bil/Left 5.9 10.9 bil not done Right 12.9 13.5 bil 9.9 12.3 bil
18.8 13.6 bil 25.8 16.3 5.9 5.8 bil 17.1 12.5 bil
21.8 Lt. 15.7 Left 3.93 14.8 bil 13.7 12.1 bil 11.9 11 bil
18.8 14.6 bil 10.5 11 bil 9.73 8.8 bil 19 10.2 bil 8.1 6.8 bil
12 rt 24.1 20.7 bil 7.5 Left 10.6 6.8 bil 6.6 rt
8.36 10 27 12.3 bil 26.3 15.6 11.5 Right 7.2 20.6 bil
29.9 rt 11.7 17.4 bil/Right 6.4 13.2 bil 14.5 Right 6.8 Left
8.03 10.7 bil 8.5 12 bil 00 00
bil/Lef
t 8.4 Left 10.7 5.5 bil/Left
15 13 bil 7.7 7.5 bil 9 bil 15.1 20.1 bil
16.6 rt 7.8 7.2 bil 19.2 16 bil
11.4 11.4 bil 7.6 12.6 bil
17.4 8.5 bil 13.8 12.3 Left 9.2 Left
9 10.3 bil 8.4 Right
5.2 12 bil 9.9 Rt 10.6 10.5 bil
7 14.2 bil
13.9 Lt
15.2 16.8 bil
8.1 3 bil
12 12.5 bil
21.3 27.5 lt
15.2 17.5 bil
8.8 rt
6.4 14.6 bil
17.6 25.9 bil
5.5 Rt
15.7 15.9 bil
17.1 Left
7 9.2 bil
14.8 13.2 bil
14 9.7 bil
18.7 Right
14.6 12.1 rt
8.2 11.9 bil
12.2 Right
4.2 5.5 bil
n 40 37 16 16 17 17 17 14 17 17
Median 14.1 13.0 11.6 12.2 9.4 9.1 9.9 9.6 9.1 9.2
uq 17.8 16.8 21.6 18.2 14.7 12.3 13.7 12.4 10.7 12.6
iq 8.7 10.3 8.5 10.6 7.7 7.5 7.8 8.1 7.2 6.8
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Tonometry
C2 C3 atypical C4 C4a C4b C5
1.68 0.89 1.35 0.66 2.34 0.66 1.02
0.89 1.35 1.42 2.34 1.12 0.36 0.4
1.28 1.42 1.95 1.12 1.68 1.09 1.25
1.39 2.31 1.45 1.68 1.22 1.15 0.4
1.58 1.95 1.16 1.22 0.99 0.83 0.5
1.52 1.16 1.58 0.99 1.48 0.79 0.59
1.32 0.89 0.89 0.36 0.99 1.09 0.66
2.15 1.82 1.82 1.48 0.76 0.96 0.63
1.72 1.62 1.62 0.99 1.58 1.65 1.82
0.96 1.65 1.25 0.76 0.76 1.52 2.58
1.45 3.6 2.21 1.09 1.25 1.65 2.41
1.58 3.56 2.08 1.58 1.62 1.49 1.65
1.02 3.63 3.6 0.76 1.65 1.58 1.52
2.54 2.41 1.98 1.15 1.22 1.16 0.99
1.16 5.31 3.4 1.25 1.52 3.4 1.42
1.72 1.52 2.18 1.62 1.91 0.89 1.29
1.25 3.2 0.83 1.75 1.29 1.52
3.86 2.71 0.79 2.94 0.86 2.51
2.15 1.49 1.65 3.9 2.24
3.2 2.18 1.09 1.52 1.95
2.68 2.44 0.96 2.81 2.11
3.23 2.81 1.22 3.6 0.92
2.21 1.45 1.65 1.68
2.08 1.95 1.52 1.72
2.21 1.65
2.41 1.91
1.98 1.49
3.4 1.75
2.18 1.58
2.84 2.94
3.2 1.16
2.71 3.9
1.49 1.52
2.18 2.81
2.64 3.6
2.44 3.4
2.87 0.89
2.81 1.68
1.45 1.29
1.68 1.72
2.38 0.86
2.38
3.14
1.95
2.24
1.58
2.2 1.7 2.0 1.5 1.6 1.1 1.4
2.6 2.7 2.3 1.7 1.8 1.5 1.9
1.5 1.5 1.5 1.1 1.2 0.9 0.7
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Study 6: Daflon® study: C2
NEUTR
OPHIL
LS
NKUTR
OPHIL
LS
MONOC
YTKS
MONOC
YTKS
VE
GF
VE
GF
TN
Fa
IP
h a
TN
F
IL
l a
IL
l a
IL
l b
IL
l b
IL
- 6
IL
- 6
■ L
S e
l e
c t
i n
sL
Se
l e
c t
i n
sE
S e
l e
c t
i n
sE
S e
l e
c t
i n
SP
s e
l e
c t
i n
SP
s e
l e
c t
i n
s i
CA
M-
1
■ I  
CA 
M- 
1
sV
CA
M-
1
sV
CA
M-
1
vW
F
vW
F
c a p i l  
l a r o s  
c o p y  i
d e n s i
t y
sy m p t
oms
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO DO DO D6
0
DO D6
0
DO D6
0
DO D6
0
DO D6
0
CD
11
b
CD
11
b
CD
62
L
CD
62
L
CD
11
b
CD
11
b
CD
62
L
CD
62
L
pg
/m1
pg
/m1
p g
/m
1
pg
/m1
pg
/m
1
pg
/m1
pg
/m
1
pg
/m1
pg
/m1
pg
/m1
ng
/m
1
ng
/m
1
ng
/m1
ng
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1
ng
/m
1
n g
/m
1
ng
/m
1
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/m
1
n g
/m
1
ng
/m
1
IU
/m
1
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/m
1
su
P i
n e
d e
P
p a
i n
p a
i n
h e
av
i n
e s
s
he
av
i n
e s
s
c r
am
p s
c r
am
p s
p a
r e
S t
h e
s i
a
p a
r e
S t
h e
s i
a
e d
em
a
e d
em
a
26
4
18
1 47 69
13
2
16
0 24 62
25 20 10
.2
11
.7
1 .
5
1 .
9
0 .
9
0 .
7
2 .
1
2 .
3
14
41
13
45
34 32 78 14
6
55
0
51
3
75
4
83
4
1 .
32
1 .
40
19 no
t
do
n e
0 .
1
0 .
1
1 .
4
0 .
1
1 0 .
5
0 .
3
0 .
3
0 .
3
0 .
3
33
6
17
4 54 32
20
4
19
44
-5 23 23 10
.7
33
.9
1 .
4
2 .
7
1 .
2
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34
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37 97
36 19
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2 .
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